0001410578-24-00179510-Q Cytosorbents Corp 20241107202411071633001633011633011 0 0001410578-24-001795 10-Q 63 20240930 20241107 20241107 Cytosorbents Corp 0001175151 3841 980373793 DE 1231 10-Q 34 001-36792 241436403 305 COLLEGE ROAD EAST PRINCETON NJ 08540 973-329-8885 305 COLLEGE ROAD EAST PRINCETON NJ 08540 MedaSorb Technologies CORP 20060807 GILDER ENTERPRISES INC 20020611 10-Q 1 ctso-20240930x10q.htm 10-Q P0YP0YP0YP0Y0.0050001175151--12-312024Q3falseP5D11600000594000P5DP5DP5Dtrue0.00250.00250.0050.00250.0025P3Yhttp://fasb.org/us-gaap/2024#PrimeRateMember6907090001175151us-gaap:CommonStockMember2024-07-012024-09-300001175151srt:ChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2024-08-142024-08-140001175151ctso:CertainNamedExecutiveOfficersAndSeniorManagersTwoMemberus-gaap:RestrictedStockUnitsRSUMember2023-07-072023-07-070001175151ctso:CertainNamedExecutiveOfficersAndSeniorManagersMemberus-gaap:RestrictedStockUnitsRSUMember2022-08-102022-08-100001175151srt:ChiefFinancialOfficerMemberus-gaap:CommonStockMember2024-08-142024-08-140001175151us-gaap:CommonStockMember2024-01-012024-09-3000011751512022-01-012022-12-310001175151us-gaap:RetainedEarningsMember2024-09-300001175151us-gaap:AdditionalPaidInCapitalMember2024-09-300001175151us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001175151us-gaap:RetainedEarningsMember2024-06-300001175151us-gaap:AdditionalPaidInCapitalMember2024-06-300001175151us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-3000011751512024-06-300001175151us-gaap:RetainedEarningsMember2023-12-310001175151us-gaap:AdditionalPaidInCapitalMember2023-12-310001175151us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001175151us-gaap:RetainedEarningsMember2023-09-300001175151us-gaap:AdditionalPaidInCapitalMember2023-09-300001175151us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001175151us-gaap:RetainedEarningsMember2023-06-300001175151us-gaap:AdditionalPaidInCapitalMember2023-06-300001175151us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000011751512023-06-300001175151us-gaap:RetainedEarningsMember2022-12-310001175151us-gaap:AdditionalPaidInCapitalMember2022-12-310001175151us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001175151us-gaap:CommonStockMember2024-09-300001175151us-gaap:CommonStockMember2024-06-300001175151us-gaap:CommonStockMember2023-12-310001175151us-gaap:CommonStockMember2023-09-300001175151us-gaap:CommonStockMember2023-06-300001175151us-gaap:CommonStockMember2022-12-310001175151ctso:TwoThousandAndEighteenSuccessFeeLetterMemberctso:WesternAllianceBankMember2024-09-300001175151ctso:ExercisePriceRangeOneMember2024-01-012024-09-300001175151srt:ChiefFinancialOfficerMember2024-08-142024-08-140001175151srt:ChiefExecutiveOfficerMemberus-gaap:CommonStockMember2024-03-292024-03-290001175151ctso:NamedExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2023-09-182023-09-180001175151ctso:NamedExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-09-182023-09-180001175151ctso:NamedExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2023-09-182023-09-180001175151srt:ChiefFinancialOfficerMember2024-08-1400011751512023-01-012023-12-310001175151us-gaap:EmployeeStockMember2024-09-300001175151ctso:ExercisePriceRangeOneMember2024-09-300001175151srt:OfficerMemberus-gaap:RestrictedStockUnitsRSUMember2024-09-300001175151srt:ManagementMemberus-gaap:RestrictedStockUnitsRSUMember2024-09-300001175151srt:BoardOfDirectorsChairmanMemberus-gaap:RestrictedStockUnitsRSUMember2024-09-300001175151srt:OfficerMemberus-gaap:RestrictedStockUnitsRSUMember2023-12-310001175151srt:ManagementMemberus-gaap:RestrictedStockUnitsRSUMember2023-12-310001175151srt:BoardOfDirectorsChairmanMemberus-gaap:RestrictedStockUnitsRSUMember2023-12-310001175151srt:OfficerMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001175151srt:ManagementMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001175151srt:BoardOfDirectorsChairmanMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001175151ctso:ExercisePriceRangingFrom0.84To1.08Member2024-01-012024-09-300001175151srt:MinimumMemberctso:ExercisePriceRangingFrom0.84To1.08Member2024-09-300001175151srt:MaximumMemberctso:ExercisePriceRangingFrom0.84To1.08Member2024-09-300001175151ctso:VestingUponEarlierOfChangeInControlOrOneThirdAfterSecondAnniversaryOneThirdOnThirdAnniversaryAndOneThirdOnFourthAnniversaryMemberctso:CertainEmployeesMemberus-gaap:RestrictedStockUnitsRSUMember2024-04-020001175151srt:ChiefFinancialOfficerMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-08-142024-08-140001175151ctso:SeniorManagersMemberus-gaap:RestrictedStockUnitsRSUMember2024-04-022024-04-020001175151ctso:CertainEmployeesMemberus-gaap:RestrictedStockUnitsRSUMember2024-04-022024-04-020001175151us-gaap:RestrictedStockUnitsRSUMember2024-09-300001175151us-gaap:RestrictedStockUnitsRSUMember2023-12-310001175151ctso:SeniorManagersMemberus-gaap:CommonStockMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-04-022024-04-020001175151ctso:SeniorManagersMemberus-gaap:CommonStockMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-04-022024-04-020001175151ctso:SeniorManagersMemberus-gaap:CommonStockMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-04-022024-04-020001175151ctso:EmployeeOneMemberus-gaap:CommonStockMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-04-022024-04-020001175151ctso:EmployeeOneMemberus-gaap:CommonStockMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-04-022024-04-020001175151ctso:EmployeeOneMemberus-gaap:CommonStockMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-04-022024-04-020001175151srt:MinimumMemberctso:VestingUponEarlierOfChangeInControlOrThreeYearsFromDateOfAwardMemberctso:CertainEmployeesMemberus-gaap:RestrictedStockUnitsRSUMember2024-04-022024-04-020001175151srt:MaximumMemberctso:VestingUponEarlierOfChangeInControlOrThreeYearsFromDateOfAwardMemberctso:CertainEmployeesMemberus-gaap:RestrictedStockUnitsRSUMember2024-04-022024-04-020001175151ctso:JefferiesLlcAndB.RileyFbrIncMember2023-12-310001175151us-gaap:RoyaltyAgreementsMember2024-07-012024-09-300001175151us-gaap:RoyaltyAgreementsMember2024-01-012024-09-300001175151us-gaap:RoyaltyAgreementsMember2023-07-012023-09-300001175151us-gaap:RoyaltyAgreementsMember2023-01-012023-09-300001175151ctso:UnitedStatesGovernmentAgenciesMemberus-gaap:GrantMembercountry:US2024-07-012024-09-300001175151ctso:DistributorsAndStrategicPartnersMemberus-gaap:ProductMemberctso:AllOtherCountriesMember2024-07-012024-09-300001175151ctso:DirectMemberus-gaap:ProductMemberctso:AllOtherCountriesMember2024-07-012024-09-300001175151ctso:DirectMemberus-gaap:ProductMembercountry:US2024-07-012024-09-300001175151ctso:DirectMemberus-gaap:ProductMembercountry:DE2024-07-012024-09-300001175151us-gaap:ProductMemberctso:AllOtherCountriesMember2024-07-012024-09-300001175151us-gaap:ProductMembercountry:US2024-07-012024-09-300001175151us-gaap:ProductMembercountry:DE2024-07-012024-09-300001175151us-gaap:GrantMembercountry:US2024-07-012024-09-300001175151ctso:DistributorsAndStrategicPartnersMemberus-gaap:ProductMember2024-07-012024-09-300001175151ctso:DirectMemberus-gaap:ProductMember2024-07-012024-09-300001175151us-gaap:ProductMember2024-07-012024-09-300001175151us-gaap:GrantMember2024-07-012024-09-300001175151ctso:UnitedStatesGovernmentAgenciesMember2024-07-012024-09-300001175151ctso:OtherSalesMember2024-07-012024-09-300001175151ctso:DistributorsAndStrategicPartnersMember2024-07-012024-09-300001175151ctso:DirectMember2024-07-012024-09-300001175151ctso:CytoSorbSalesMember2024-07-012024-09-300001175151ctso:UnitedStatesGovernmentAgenciesMemberus-gaap:GrantMembercountry:US2024-01-012024-09-300001175151ctso:DistributorsAndStrategicPartnersMemberus-gaap:ProductMemberctso:AllOtherCountriesMember2024-01-012024-09-300001175151ctso:DistributorsAndStrategicPartnersMemberus-gaap:ProductMembercountry:US2024-01-012024-09-300001175151ctso:DirectMemberus-gaap:ProductMemberctso:AllOtherCountriesMember2024-01-012024-09-300001175151ctso:DirectMemberus-gaap:ProductMembercountry:US2024-01-012024-09-300001175151ctso:DirectMemberus-gaap:ProductMembercountry:DE2024-01-012024-09-300001175151us-gaap:ProductMemberctso:AllOtherCountriesMember2024-01-012024-09-300001175151us-gaap:ProductMembercountry:US2024-01-012024-09-300001175151us-gaap:ProductMembercountry:DE2024-01-012024-09-300001175151us-gaap:GrantMembercountry:US2024-01-012024-09-300001175151ctso:DistributorsAndStrategicPartnersMemberus-gaap:ProductMember2024-01-012024-09-300001175151ctso:DirectMemberus-gaap:ProductMember2024-01-012024-09-300001175151us-gaap:ProductMember2024-01-012024-09-300001175151us-gaap:GrantMember2024-01-012024-09-300001175151ctso:UnitedStatesGovernmentAgenciesMember2024-01-012024-09-300001175151ctso:OtherSalesMember2024-01-012024-09-300001175151ctso:DistributorsAndStrategicPartnersMember2024-01-012024-09-300001175151ctso:DirectMember2024-01-012024-09-300001175151ctso:CytoSorbSalesMember2024-01-012024-09-300001175151ctso:UnitedStatesGovernmentAgenciesMemberus-gaap:GrantMembercountry:US2023-07-012023-09-300001175151ctso:DistributorsAndStrategicPartnersMemberus-gaap:ProductMemberctso:AllOtherCountriesMember2023-07-012023-09-300001175151ctso:DirectMemberus-gaap:ProductMemberctso:AllOtherCountriesMember2023-07-012023-09-300001175151ctso:DirectMemberus-gaap:ProductMembercountry:US2023-07-012023-09-300001175151ctso:DirectMemberus-gaap:ProductMembercountry:DE2023-07-012023-09-300001175151us-gaap:ProductMemberctso:AllOtherCountriesMember2023-07-012023-09-300001175151us-gaap:ProductMembercountry:US2023-07-012023-09-300001175151us-gaap:ProductMembercountry:DE2023-07-012023-09-300001175151us-gaap:GrantMembercountry:US2023-07-012023-09-300001175151ctso:DistributorsAndStrategicPartnersMemberus-gaap:ProductMember2023-07-012023-09-300001175151ctso:DirectMemberus-gaap:ProductMember2023-07-012023-09-300001175151us-gaap:ProductMember2023-07-012023-09-300001175151us-gaap:GrantMember2023-07-012023-09-300001175151ctso:UnitedStatesGovernmentAgenciesMember2023-07-012023-09-300001175151ctso:OtherSalesMember2023-07-012023-09-300001175151ctso:DistributorsAndStrategicPartnersMember2023-07-012023-09-300001175151ctso:DirectMember2023-07-012023-09-300001175151ctso:CytoSorbSalesMember2023-07-012023-09-300001175151ctso:UnitedStatesGovernmentAgenciesMemberus-gaap:GrantMembercountry:US2023-01-012023-09-300001175151ctso:DistributorsAndStrategicPartnersMemberus-gaap:ProductMemberctso:AllOtherCountriesMember2023-01-012023-09-300001175151ctso:DirectMemberus-gaap:ProductMemberctso:AllOtherCountriesMember2023-01-012023-09-300001175151ctso:DirectMemberus-gaap:ProductMembercountry:US2023-01-012023-09-300001175151ctso:DirectMemberus-gaap:ProductMembercountry:DE2023-01-012023-09-300001175151us-gaap:ProductMembercountry:US2023-01-012023-09-300001175151us-gaap:ProductMembercountry:DE2023-01-012023-09-300001175151us-gaap:GrantMembercountry:US2023-01-012023-09-300001175151ctso:DistributorsAndStrategicPartnersMemberus-gaap:ProductMember2023-01-012023-09-300001175151us-gaap:ProductMember2023-01-012023-09-300001175151us-gaap:GrantMember2023-01-012023-09-300001175151ctso:UnitedStatesGovernmentAgenciesMember2023-01-012023-09-300001175151ctso:OtherSalesMember2023-01-012023-09-300001175151ctso:DistributorsAndStrategicPartnersMember2023-01-012023-09-300001175151ctso:DirectMember2023-01-012023-09-300001175151ctso:CytoSorbSalesMember2023-01-012023-09-300001175151ctso:JefferiesLlcAndB.RileyFbrIncMember2023-01-012023-12-3100011751512019-06-300001175151ctso:JefferiesLlcAndB.RileyFbrIncMember2024-07-012024-09-300001175151ctso:JefferiesLlcAndB.RileyFbrIncMember2024-01-012024-09-300001175151us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001175151us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001175151us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001175151us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001175151ctso:CytosorbentsEuropeGmbhMember2020-04-010001175151ctso:CytosorbentsMedicalIncMembercountry:USctso:OperatingLeaseInitialEarlyTermMember2021-03-012021-03-310001175151ctso:CytosorbentsMedicalIncMembercountry:USctso:OperatingLeaseFirstYearOfRemainingLeaseTermMember2021-03-012021-03-310001175151ctso:CytosorbentsMedicalIncMembercountry:USctso:OperatingLeaseEarlyTermMember2021-03-012021-03-310001175151ctso:CytosorbentsEuropeGmbhMember2021-01-012021-01-310001175151us-gaap:RetainedEarningsMember2024-07-012024-09-300001175151us-gaap:RetainedEarningsMember2024-01-012024-09-300001175151us-gaap:RetainedEarningsMember2023-07-012023-09-300001175151us-gaap:RetainedEarningsMember2023-01-012023-09-300001175151ctso:TwoThousandAndTwentyTwoSuccessFeeLetterMemberctso:ThirdTrancheMember2024-09-300001175151ctso:TwoThousandAndTwentyTwoSuccessFeeLetterMemberctso:SecondTrancheMember2024-09-300001175151ctso:TwoThousandAndTwentyTwoSuccessFeeLetterMemberctso:FirstTrancheMember2024-09-300001175151ctso:CytosorbentsEuropeGmbhMember2021-04-010001175151ctso:CytosorbentsMedicalIncMembercountry:US2021-04-010001175151ctso:LoanAndSecurityAgreementTrancheOneMemberctso:AvenueVentureOpportunitiesFundL.pMember2024-09-300001175151ctso:LoanAndSecurityAgreementTrancheOneMemberctso:AvenueVentureOpportunitiesFundIiL.pMember2024-09-300001175151ctso:LoanAndSecurityAgreementTrancheOneMember2024-09-300001175151ctso:CytosorbentsMedicalIncMembercountry:USus-gaap:LetterOfCreditMember2021-04-300001175151us-gaap:LetterOfCreditMember2024-09-300001175151us-gaap:CreditCardMember2024-09-300001175151us-gaap:CargoAndFreightMember2024-07-012024-09-300001175151us-gaap:CargoAndFreightMember2024-01-012024-09-300001175151us-gaap:CargoAndFreightMember2023-07-012023-09-300001175151us-gaap:CargoAndFreightMember2023-01-012023-09-300001175151us-gaap:GrantMember2024-09-300001175151us-gaap:GrantMember2024-09-300001175151us-gaap:ProductMember2023-12-310001175151us-gaap:GrantMember2023-12-310001175151srt:MinimumMember2019-06-300001175151srt:MaximumMember2019-06-3000011751512023-09-3000011751512022-12-310001175151ctso:CytosorbentsEuropeGmbhMember2021-01-310001175151ctso:StockOptionsAndWarrantsMember2024-01-012024-09-300001175151ctso:StockOptionsAndWarrantsMember2023-01-012023-09-300001175151ctso:SeniorManagersMemberus-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001175151ctso:NamedExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001175151ctso:CertainNamedExecutiveOfficersAndSeniorManagersTwoMemberus-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001175151ctso:CertainNamedExecutiveOfficersAndSeniorManagersMemberus-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001175151ctso:CertainEmployeesMemberus-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001175151us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001175151ctso:SeniorManagersMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001175151ctso:NamedExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001175151ctso:CertainNamedExecutiveOfficersAndSeniorManagersTwoMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001175151ctso:CertainNamedExecutiveOfficersAndSeniorManagersMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001175151ctso:CertainEmployeesMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001175151us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001175151ctso:SeniorManagersMemberus-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001175151ctso:NamedExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001175151ctso:CertainNamedExecutiveOfficersAndSeniorManagersTwoMemberus-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001175151ctso:CertainNamedExecutiveOfficersAndSeniorManagersMemberus-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001175151ctso:CertainEmployeesMemberus-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001175151us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001175151ctso:SeniorManagersMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001175151ctso:NamedExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001175151ctso:CertainNamedExecutiveOfficersAndSeniorManagersTwoMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001175151ctso:CertainNamedExecutiveOfficersAndSeniorManagersMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001175151ctso:CertainEmployeesMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001175151us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001175151us-

gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001175151us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-3000011751512024-11-050001175151srt:MinimumMember2024-01-012024-09-300001175151us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001175151us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001175151us-gaap:CommonStockMember2023-07-012023-09-300001175151us-gaap:CommonStockMember2023-01-012023-09-300001175151ctso:EmployeeOneMemberus-gaap:CommonStockMember2024-04-082024-04-080001175151srt:DirectorMemberus-gaap:CommonStockMember2024-04-022024-04-020001175151ctso:SeniorManagersMemberus-gaap:CommonStockMember2024-04-022024-04-020001175151ctso:EmployeeTwoMemberus-gaap:CommonStockMember2024-04-022024-04-020001175151ctso:EmployeeOneMemberus-gaap:CommonStockMember2024-04-022024-04-020001175151srt:ChiefExecutiveOfficerMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-03-292024-03-290001175151srt:MinimumMemberctso:LoanAndSecurityAgreementMember2024-09-300001175151srt:MaximumMemberctso:LoanAndSecurityAgreementMember2024-09-300001175151srt:MinimumMemberctso:TwoThousandAndEighteenSuccessFeeLetterMemberctso:WesternAllianceBankMember2024-01-012024-09-300001175151srt:MaximumMemberctso:TwoThousandAndEighteenSuccessFeeLetterMemberctso:WesternAllianceBankMember2024-01-012024-09-300001175151ctso:CytosorbentsMedicalIncMember2021-03-012021-03-310001175151ctso:CytosorbentsMedicalIncMembercountry:US2021-03-310001175151ctso:CytosorbentsMedicalIncMembercountry:US2021-03-012021-03-310001175151ctso:CytosorbentsMedicalIncMember2021-03-310001175151ctso:DistributorsAndStrategicPartnersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300001175151ctso:DistributorsAndStrategicPartnersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001175151ctso:DistributorsAndStrategicPartnersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001175151ctso:DistributorsAndStrategicPartnersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001175151ctso:DistributorsAndStrategicPartnersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001175151ctso:DistributorsAndStrategicPartnersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001175151ctso:TwoThousandAndTwentyTwoSuccessFeeLetterMemberctso:ThirdTrancheMember2024-01-012024-09-300001175151ctso:TwoThousandAndTwentyTwoSuccessFeeLetterMemberctso:SecondTrancheMember2024-01-012024-09-300001175151ctso:TwoThousandAndTwentyTwoSuccessFeeLetterMemberctso:FirstTrancheMember2024-01-012024-09-300001175151ctso:TwoThousandAndEighteenSuccessFeeLetterMemberctso:WesternAllianceBankMember2024-01-012024-09-300001175151ctso:LoanAndSecurityAgreementMember2024-07-012024-09-300001175151srt:MaximumMember2024-01-012024-09-300001175151512024-07-012024-09-300001175151512023-07-012023-09-300001175151ctso:PrepaymentMadeOnOrAfterFundingDateMemberctso:LoanAndSecurityAgreementMember2024-01-012024-09-300001175151ctso:PrepaymentMadeFromFirstAnniversaryToSecondAnniversaryMemberctso:LoanAndSecurityAgreementMember2024-01-012024-09-300001175151ctso:PrepaymentMadeAfterSecondAnniversaryMemberctso:LoanAndSecurityAgreementMember2024-01-012024-09-300001175151ctso:LoanAndSecurityAgreementTrancheTwoMember2024-09-300001175151ctso:LoanAndSecurityAgreementMember2024-09-300001175151ctso:JefferiesLlcAndB.RileyFbrIncMemberctso:ScenarioTwoLimitationRelatingToMarketCapitalizationMember2021-12-302021-12-300001175151ctso:JefferiesLlcAndB.RileyFbrIncMemberctso:ScenarioOneNoLimitationRelatingToMarketCapitalizationMember2021-12-302021-12-300001175151ctso:JefferiesLlcAndB.RileyFbrIncMember2024-09-300001175151512024-06-282024-06-280001175151ctso:LoanAndSecurityAgreementMember2024-01-012024-09-300001175151ctso:LoanAndSecurityAgreementMember2024-06-280001175151512021-07-140001175151country:DE2021-09-012021-09-300001175151ctso:CytosorbentsEuropeGmbhMember2021-04-012021-04-010001175151512024-01-012024-09-300001175151512023-01-012023-09-300001175151512024-09-3000011751512023-12-31iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:purectso:Distributorctsoctsoctso

18,511,622â€‹See accompanying notes to condensed consolidated financial statements.â€‹5 Table of ContentsCYTOSORBENTS CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ â€‹â€‹Nine monthsâ€‹Nine monthsâ€‹â€‹endedâ€‹endedâ€‹â€‹September 30,â€‹September 30, â€‹â€‹2024â€‹2023
â€‹Â Â Â Â (Unaudited)Â Â Â Â (Unaudited)Cash flows from operating activities:â€‹â€‹â€‹Â â€‹Â Â Net lossâ€‹$ (12,835,098)â€‹$ (22,672,487)Adjustments to reconcile net loss to net cash used in operating activities:â€‹â€‹â€‹â€‹Â â€‹Accrued final feeâ€‹â€‹ 111,422â€‹â€‹ 32,143Amortization of debt discountâ€‹â€‹ 132,351â€‹â€‹ â€”Amortization of loan costs â€‹â€‹ 58,014â€‹â€‹ â€”Non-cash compensationâ€‹â€‹ (96,268)â€‹Â 160,999Depreciation and amortizationâ€‹â€‹ 1,180,717â€‹Â 1,067,797Amortization of right-of-use assetâ€‹â€‹ 137,780â€‹â€‹ 166,321Write off of patent costâ€‹â€‹ 313,414â€‹Â 475,621Bad debt expenseâ€‹â€‹ 107,272â€‹â€‹ 14,459Stock-based compensationâ€‹â€‹ 2,344,671â€‹Â 2,486,679Foreign currency translation (gain) lossâ€‹â€‹ (680,392)â€‹Â 733,997Changes in operating assets and liabilities:â€‹â€‹â€‹â€‹Â â€‹Grants and accounts receivableâ€‹â€‹ (628,510)â€‹Â (603,286)Inventoriesâ€‹â€‹ 429,004â€‹Â 471,822Prepaid expenses and other current assetsâ€‹â€‹ 504,530â€‹Â 1,370,510Other assetsâ€‹â€‹ 1,135â€‹Â â€”Accounts payable and accrued expensesâ€‹â€‹ (3,165,684)â€‹Â 1,047,700Net cash used in operating activitiesâ€‹â€‹ (12,085,642)â€‹Â (15,247,725)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Cash flows from investing activities:â€‹â€‹â€‹â€‹Â Â Â Purchases of property and equipmentâ€‹â€‹ (215,158)â€‹Â (442,618)Payments for patent costsâ€‹â€‹ (330,079)â€‹Â (357,696)Net cash used in investing activitiesâ€‹â€‹ (545,237)â€‹Â (800,314)Cash flows from financing activities:â€‹â€‹â€‹â€‹Â Â Â Proceeds from long-term debtâ€‹â€‹ 15,000,000â€‹â€‹ â€”Repayment of long-term debtâ€‹â€‹ (5,000,000)â€‹Â â€”Payment of final feeâ€‹â€‹ (150,000)â€‹â€‹ â€”Payment of loan costsâ€‹â€‹ (697,950)â€‹Â â€”Equity contributions - net of fees incurredâ€‹â€‹ 11,794â€‹â€‹ 2,050,417Proceeds from exercise of stock optionsâ€‹â€‹ â€”â€‹â€‹ 213,307Net cash provided by financing activitiesâ€‹â€‹ 9,163,844â€‹â€‹ 2,263,724Effect of exchange rates on cashâ€‹â€‹ 21,226â€‹Â (1,205)Net change in cash, cash equivalents and restricted cashâ€‹â€‹ (3,445,809)â€‹Â (13,785,520)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Cash, cash equivalents and restricted cash - beginning ofÂ periodâ€‹â€‹ 15,615,095â€‹Â 23,832,026Cash, cash equivalents and restricted cash - end of periodâ€‹$ 12,169,286â€‹$ 10,046,506â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Supplemental disclosure of cash flow information:â€‹â€‹â€‹â€‹Â â€‹Cash paid during the period for interestâ€‹$ 771,875â€‹$ 275,575â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Supplemental disclosure of non-cash financing activities:â€‹â€‹â€‹â€‹Â â€‹Warrants issued in connection with long-term debtâ€‹$ 690,709â€‹$ â€”Issuance of restricted stock unitsâ€‹$ 198,097â€‹$ 403,941â€‹See accompanying notes to condensed consolidated financial statements.â€‹6 Table of ContentsCytoSorbents CorporationNotes to Condensed Consolidated Financial Statements(UNAUDITED)September 30, 20241.Â Â Â Â BASIS OF PRESENTATIONThe accompanying unaudited condensed consolidated financial statements include the accounts of the Company as of September 30, 2024 and December 31, 2023, and for the three and nine months ended September 30, 2024 and 2023. The Companyâ€™s condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X, and; therefore, do not include all information and footnotes necessary for a fair presentation of consolidated financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States ("U.S. GAAP") and should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2023, which are included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments, for a fair presentation of the Companyâ€™s consolidated financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The results for the three and nine months ended September 30, 2024 and 2023, are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.As of September 30, 2024, the Companyâ€™s cash, cash equivalents and restricted cash balances were approximately $12.2 million, including approximately $5.7 million in cash and cash equivalents and approximately $6.5 million in restricted cash, of which the unrestricted portion is not expected to fund the Companyâ€™s operations beyond the next twelve months from the issuance of these consolidated financial statements. This matter raises substantial doubt about the Companyâ€™s ability to continue as a going concern. As a result, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company continues to pursue additional milestones related to its recently announced Avenue Capital Group debt facility that would increase its unrestricted cash position by up to $10 million. If these milestones are not achieved, the Company will need to raise additional capital to support our ongoing operations in the future. Meanwhile the Company continues to evaluate other traditional and alternative sources of capital, including additional less or non-dilutive debt financing, royalty financing, strategic or direct investments, equity financing, and/or combinations thereof. There can be no assurance that management will be successful in these endeavors.â€‹2.Â Â Â Â PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESPlease see Note 2 to the Company's consolidated financial statements included in the Company's Annual Report on Form 10 - K for the year ended December 31, 2023, filed with the Securities and Exchange Commission ("SEC") on March 14, 2024, for a description of all significant accounting policies.Nature of BusinessThe Company is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. The Company, through its subsidiary CytoSorbents Medical, Inc. (formerly known as CytoSorbents, Inc.), is engaged in the research, development and commercialization of medical devices with its blood purification technology platform which incorporates a proprietary adsorbent, porous polymer technology. The Company, through its wholly-owned European subsidiary, CytoSorbents Europe GmbH, conducts sales and marketing related operations for the CytoSorb device.Basis of Consolidation and Foreign Currency TranslationThe consolidated financial statements include the accounts of CytoSorbents Corporation and its wholly-owned subsidiaries, CytoSorbents Medical, Inc. and CytoSorbents Europe GmbH. All significant intercompany transactions and balances have been eliminated in consolidation.7 Table of ContentsTranslation gains and losses resulting from the process of remeasuring into the United States of America dollar the foreign currency financial statements of the European subsidiary, for which the United States of America dollar is the functional currency, are included in operations. The Euro is the functional currency of the European Subsidiary. Foreign currency transaction gain (loss) included in net loss amounted to approximately $2,650,000 and $(1,810,000) for the three months ended September 30, 2024 and 2023, respectively. Foreign currency transaction gain (loss) included in net loss amounted to approximately $680,000 and $(734,000) for the nine months ended September 30, 2024 and 2023, respectively. The Company translates assets and liabilities of all of its foreign subsidiaries at the exchange rate in effect at the condensed consolidated balance sheet date. The Company translates revenue and expenses at the daily average exchange rates. The Company includes accumulated net translation adjustments in accumulated other comprehensive income (loss) as a component of stockholdersâ€™ equity.Cash, Cash Equivalents and Restricted CashThe Company considers all highly liquid investments purchased with an original maturity of threeÂ months or less to be cash equivalents.The following table provides a reconciliation of cash and cash equivalents and restricted cash to amounts shown in the consolidated balance sheets:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â SeptemberÂ 30,Â 2024Â Â Â Â DecemberÂ 31,Â 2023Cash and cash equivalentsâ€‹$5,685,328 â€‹$ 14,131,137Restricted cashâ€‹Â 6,483,958â€‹Â 1,483,958Total cash, cash equivalents and restricted cashâ€‹$ 12,169,286â€‹$ 15,615,095â€‹Restricted CashThe Companyâ€™s total restricted cash in the amount of $6,483,958 consists of cash of $5,000,000 which is restricted in accordance with the terms of the debt agreement with Avenue Capital Group (see Note 5), cash of $1,467,458 that the Company is obligated to maintain as collateral for the outstanding letter of credit with Bridge Bank that was provided to the landlord of the College Road facility as security and cash of $16,500 that the Company is obligated to maintain as collateral for the credit limit on the Companyâ€™s credit card accounts.Grants and Accounts ReceivableTrade accounts receivable consist of amounts due from direct customers, distributors and agencies of the U.S. government and are presented at net realizable value. At each balance sheet date, the Company estimates an expected allowance for credit losses inherent in the Companyâ€™s accounts receivable portfolio based on historical experience, specific allowances for known troubled accounts, and other available evidence. In addition, also at each reporting date, this estimate is updated to reflect any changes in credit risk since the receivable was initially recorded. This estimate is calculated on a pooled basis where similar risk characteristics exist. The Company has identified the following portfolio segments: direct customers, distributors/strategic partners and the U.S. government.A fixed reserve percentage for each pool is derived from a review of the Companyâ€™s historical losses in relation to the total pool. This estimate is adjusted quarterly for managementâ€™s assessment of current conditions, reasonable and supportable forecasts regarding future events, and any other factors deemed relevant by the Company. The Company believes historical loss information is a reasonable starting point in which to calculate the expected allowance for credit losses as the Companyâ€™s portfolio segments have remained constant over the Companyâ€™s historical evaluation period.The Company writes off receivables when there is information that indicates the debtor is facing significant financial difficulty and there is no possibility of recovery. If any recoveries are made from any accounts previously written off, they are recognized as an offset to credit loss expense in the year of recovery. The total amount of write-offs was immaterial to the consolidated financial statements as a whole for the three and nine months ended September 30, 2024 and 2023.The allowance for credit losses reflects accounts receivable balances that are written off when management determines they are uncollectible.The allowance for credit losses is measured on a collective (pool) basis when similar risk characteristics exist, and measures the allowance for credit losses using the following methods:8 Table of ContentsDirect Customersâ€”The Company measures expected credit losses on direct customer receivables using an aging methodology. The risk of loss for direct customer receivables is low based on the Companyâ€™s historical experience. The estimate of expected credit losses considers historical credit loss information that is adjusted for current conditions and supportable forecasts.Distributors/Strategic Partnersâ€”The Company measures expected credit losses on distributor receivables using an individual reserve methodology. The risk of loss in this portfolio is low based on the Companyâ€™s historical experience. The estimate of expected credit losses considers the past payment history of each distributor.U.S. Governmentâ€” These receivables are related to the Companyâ€™s government grants. The Company measures expected credit losses on these receivables using an individual reserve methodology. The risk of loss in this portfolio is very low based on the Companyâ€™s historical experience, as these receivables are supported by approved grant award contracts.InventoriesInventories are valued at the lower of cost or net realizable value under the first in, first out (FIFO) method. At September 30, 2024 and December 31, 2023, the Companyâ€™s inventory was comprised of finished goods, which amounted to $1,430,325 and $2,155,457, respectively; work in process, which amounted to $1,049,319 and $838,871, respectively; and raw materials, which amounted to $768,112 and $685,801, respectively. Devices used in clinical trials or for research and development purposes are removed from inventory and charged to research and development expenses at the time of their use. Donated devices are removed from inventory and charged to selling, general and administrative expenses.Impairment or Disposal of Long-Lived AssetsThe Company assesses the impairment of patents and other long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. During the three months ended September 30, 2024 and 2023, the Company recorded impairment charges of approximately $64,000 and $183,000, respectively, and during the nine months ended September 30, 2024 and 2023, the Company recorded impairment charges of approximately $313,000 and $476,000, respectively, related to the impairment of certain issued patents and pending patent applications in certain specific jurisdictions and the abandonment of certain pending patent application costs in the ordinary course of business. This charge is included in legal, financial and other consulting in the consolidated statements of operations and comprehensive loss.Income TaxesThe Company has not recorded income tax expense or income tax benefit for the three and nine months ended September 30, 2024, and 2023 due to the generation of net operating losses, the benefits of which have been fully reserved.Deferred income taxes are accounted for using the balance sheet approach, which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that a future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership.The Company follows accounting standards associated with uncertain tax positions. The Company had no unrecognized tax benefits at September 30, 2024. The Company is accounting for an uncertain tax position of approximately $2.1 million for the year ended December 31, 2023. The Company files tax returns in the U.S. federal and state jurisdictions.The Company utilizes the Technology Business Tax Certificate Transfer Program to sell a portion of its New Jersey Net Operating Loss carryforwards to an industrial company.9 Table of ContentsConcentration of Credit RiskThe Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation (â€œFDICâ€). Beginning in April of 2023, the Company joined the IntraFi network, and established an Insured Cash Sweep (â€œICSâ€) account whereby all cash that was previously held in the Companyâ€™s money market account at Bridge Bank is swept daily in increments of less than $250,000 and deposited in a number of IntraFiâ€™s 4,000 member banks. This arrangement provides FDIC insurance coverage for all of the cash balances previously held in the money market account, which represents all of the cash and cash equivalents held at Bridge Bank. This arrangement excludes the restricted cash balances. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances. A significant portion of the Companyâ€™s revenues are from product sales in Germany. Substantially all of the Companyâ€™s grant and other income are from government agencies in the United States. (See Note 4 for further information relating to the Companyâ€™s revenue.)As of September 30, 2024, two distributors accounted for approximately 31% of outstanding grants and accounts receivable. As of December 31, 2023, one distributor accounted for approximately 19% of outstanding grants and accounts receivable. For the three months ended September 30, 2024 and 2023, no distributor or direct customers accounted for more than 10% of the Companyâ€™s total revenue. For the nine months ended September 30, 2024 and 2023, one distributor accounted for approximately 10% for each period, of the Companyâ€™s total revenue.WarrantsThe Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrantâ€™s specific terms and applicable authoritative guidance in ASC 480 â€œDistinguishing Liabilities From Equityâ€ (â€œASC 480â€) and ASC 815 â€œDerivatives and Hedgingâ€ (â€œASC 815â€). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Companyâ€™s own ordinary shares and whether the warrant holders could potentially require â€œnet cash settlementâ€ in a circumstance outside of the Companyâ€™s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance, and will remain as a component of equity thereafter. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.The warrants issued upon the closing of the Companyâ€™s December 13, 2023 offering and the closing of the Companyâ€™s June 2024 debt financing both met the criteria for equity classification under ASC 815. Accordingly, these warrants have been classified as equity as of September 30, 2024 and December 31, 2023.Shipping and Handling CostsThe cost of shipping product to customers and distributors is typically borne by the customer or distributor. The Company records other shipping and handling costs in cost of revenue. Total freight costs amounted to approximately $89,000 and $140,000, respectively, for the three months ended September 30, 2024 and 2023, and $267,000 and $341,000, respectively, for the nine months ended September 30, 2024 and 2023.10 Table of ContentsEffect of Recent Accounting PronouncementsIn August 2020, the FASB issued ASU 2020-06, â€œDebt â€“ Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging â€“ Contracts in Entityâ€™s Own Equity (Subtopic 815-40)â€ (â€œASU 2020-06â€). ASU2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entityâ€™s own equity. The ASU is part of the FASBâ€™s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASUâ€™s amendments are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. The Company adopted the provisions of ASU 2020-06 on January 1, 2024. This did not have a material impact on the Companyâ€™s consolidated financial statements.In December 2023, the FASB issued ASU No. 2023-09 entitled â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€. This ASU provides guidance related to additional disclosures that will be required related to income taxes. The updated guidance is effective for public entities for fiscal years beginning after December 15, 2024. This ASU will result in additional disclosures in the Companyâ€™s consolidated financial statements related to income taxes in 2025.In November 2023, the FASB issued ASU No. 2023-07 (â€œASU 2023-07â€), â€œImprovements to Reportable Segment Disclosuresâ€. The guidance primarily will require enhanced disclosures about significant segment expenses. All disclosure requirements

under ASU 2023-07 and existing segment disclosures in ASC 280, â€œSegment Reportingâ€ are also required for public entities with a single reportable segment. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. A retrospective approach is required to be applied to all prior periods presented in the financial statements. The Company plans to adopt the provisions of ASU 2023-07 in the first quarter of fiscal 2025 and continues to evaluate the disclosure requirements related to the new standard.On April 3, 2024, the Financial Accounting Standards Board (the "FASB") began a project related to the accounting and reporting of government grants. The FASB has decided to pursue an International Accounting Standards ("IAS") 20 accounting model. Under IAS 20, a grant relating to income may be reported separately as 'other income' or deducted from the related expense. The FASB expects to issue and exposure draft of a proposed ASU in the fourth quarter of 2024. The company is evaluating its accounting and reporting policy for government grants relative to this project and the requirements of IAS 20.â€‹3.Â Â Â Â STOCKHOLDERSâ€™ EQUITYPreferred StockIn June 2019, the Company amended and restated its certificate of incorporation. The amended and restated certificate of incorporation authorizes the issuance of up to 5,000,000 shares of â€œblank checkâ€ preferred stock, with such designation rights and preferences as may be determined from time to time by the Board of Directors.Common StockIn June 2019, the Company amended and restated its certificate of incorporation. The amended and restated certificate of incorporation increased the number of shares of common stock authorized for issuance from 50,000,000 shares to 100,000,000 shares. Shelf RegistrationOn July 14, 2021, the Company filed a registration statement on Form S-3 with the SEC, which was amended on July 20, 2021 and declared effective by the SEC on July 27, 2021 (as amended, the â€œ2021 Shelfâ€). The 2021 Shelf enables the Company to offer and sell, in one or more offerings, any combination of common stock, preferred stock, senior or subordinated debt securities, warrants and units, up to a total dollar amount of $150 million and expires after three years. On July 26, 2024, the Company filed a registration statement on Form S-3 with the SEC (the â€œ2024 Shelfâ€), which enables the Company to offer and sell in one or more offerings, any combination of common stock, preferred stock, senior or subordinated debt securities, warrants and units, up to a total dollar amount of $150 million. On September 26, 2024, the Company filed Amendment No. 1 to the Form S-3 with the SEC. The 2024 Shelf was declared effective by the SEC on September 30, 2024. Because the Companyâ€™s market capitalization is less than $75 million, it will be subject to baby shelf rules which limit the amount of securities sales the Company can make to one-third of its public market float over a 12-month period.11 Table of ContentsOpen Market Sale Agreement with Jefferies LLCOn December 30, 2021, the Company entered into an Open Market Sale Agreement (the â€œSale Agreementâ€) with Jefferies LLC (the â€œAgentâ€), pursuant to which the Company may sell, from time to time, at its option, shares of the Companyâ€™s common stock having an aggregate offering price of up to $25 million through the Agent, as the Companyâ€™s sales agent. However, as a result of limitations related to our market capitalization discussed above, the Company may offer and sell shares of the Company's common stock having an aggregate offering price of up to approximately $19,700,000 from time to time through the Agent. If the Company's public float increases above $75,000,000, the Company may sell additional amounts under the Sales Agreement. All shares of the Companyâ€™s common stock offered and sold, or to be offered and sold under the Sale Agreement will be issued and sold pursuant to the Companyâ€™s 2024 Shelf by methods deemed to be an â€œat the market offeringâ€ as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, in block transactions or if specified by the Company, in privately negotiated transactions.Subject to the terms of the Sales Agreement, the Agent is required to use its commercially reasonable efforts consistent with their normal sales and trading practices to sell the shares of the Companyâ€™s common stock from time to time, based upon the Companyâ€™s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company is required to pay the Agent a commission of up to 3.0% of the gross proceeds from the sale of the shares of the Companyâ€™s common stock sold thereunder, if any. There were no sales under the Sale Agreement during the year ended December 31, 2022. During the year ended December 31, 2023, the Company sold 2,656,464 shares pursuant to the Sale Agreement, at an average selling price of $1.76 per share, generating net proceeds of approximately $4,532,000. In addition, during the year ended December 31, 2023, the Company paid approximately $61,000 in expenses related to the Sale Agreement. During the nine months ended September 30, 2024, the Company sold 53,290 shares pursuant to the Sales Agreement at an average selling price of $1.03 per share, generating net proceeds of approximately $53,000. In addition, the Company incurred ATM activation fees of approximately $41,000 during the three and nine months ended September 30, 2024.Stock-Based CompensationTotal share-based employee, director, and consultant compensation amounted to approximately $782,000 and $2,345,000 for the three and nine months ended September 30, 2024, respectively, and approximately $1,086,000 and $2,487,000 for the three and nine months ended September 30, 2023, respectively. These amounts are included in the consolidated statements of operations and comprehensive loss under cost of revenue and selling, general, and administrative expenses.The summary of the stock option activity for the nine months ended September 30, 2024 is as follows:â€‹â€‹â€‹

13,762,446â€‹â€‹ 9,974,022â€‹ â€‹ â€”â€‹ â€‹ 23,736,468Grant and other income:â€‹Â â€‹â€‹ â€‹â€‹â€‹ â€‹â€‹â€‹ â€‹â€‹â€‹United Statesâ€‹Â â€”â€‹ â€‹â€”â€‹ â€‹ 3,944,696â€‹ â€‹ 3,944,696â€‹â€‹Â â€‹â€‹ â€‹â€‹â€‹ â€‹â€‹â€‹ â€‹â€‹â€‹Total revenueâ€‹$ 13,762,446â€‹$ 9,974,022â€‹$ 3,944,696â€‹$ 27,681,164â€‹The Company has two primary revenue streams: (1) sales of the CytoSorb device and related device accessories and (2) grant income from contracts with various agencies of the United States government. The following is a brief description of each revenue stream. CytoSorb SalesThe Company sells its CytoSorb device using both its own sales force (direct sales) and through the use of distributors and/or strategic partners. The majority of sales of the device are outside the United States, as CytoSorb is not yet approved for commercial sale in the United States. However, in April 2020, the Company was granted Emergency Use Authorization (â€œEUAâ€) of CytoSorb for use in critically-ill patients infected with COVID-19 with imminent or confirmed respiratory failure by the United States Food and Drug Administration (the â€œFDAâ€). Direct sales outside the United States relate to sales to hospitals located in Germany, Switzerland, Austria, Belgium, Luxembourg, Poland, the Netherlands, Sweden, Denmark, Norway and the United Kingdom. Direct sales are fulfilled from the Companyâ€™s warehouse facility in Berlin, Germany. There are no formal sales contracts with any direct customers relating to product price or minimum purchase requirements. However, there are agreements in place with certain direct customers that provide for either free of charge product or rebate credits based upon achieving minimum purchase levels. The Company records the value of these items earned as a reduction of revenue. These customers submit purchase orders and the order is fulfilled and shipped directly to the customer. Prices to all direct customers are based on a standard price list based on the packaged quantity (6 packs versus 12 packs).Distributor and strategic partner sales make up the remaining product sales. These distributors are located in various countries throughout the world. The Company has a formal written contract with each distributor/strategic partner. These contracts have terms ranging from 1-5Â years in length, with three years being the typical term. In addition, certain distributors are eligible for volume discount pricing if their unit sales are in excess of the base amount in the contract. Most distributorâ€™s/strategic partnerâ€™s contracts have minimum annual purchase requirements in order to maintain exclusivity in their respective territories.There is no additional consideration or monetary penalty that would be required to be paid to CytoSorbents if a distributor does not meet the minimum purchase commitments included in the contract, however, at the discretion of the Company, the distributor may lose its exclusive rights in the territory if such commitments are not met.Government GrantsThe Company has been the recipient of various grant contracts from various agencies of the United States government, primarily the Department of Defense, to perform various research and development activities. These contracts fall into one of the following categories:1.Fixed price â€“ the Company invoices the contract amount in equal installments over the term of the contract without regard to the timing of the costs incurred related to this contract. If billings on fixed price contracts exceed the costs incurred, revenue will be deferred to the extent of the excess billings.17 Table of Contents2.Cost reimbursement â€“ the Company submits monthly invoices during the term of the contract for the amount of direct costs incurred during that month plus an agreed upon percentage that relates to allowable overhead and general and administrative expenses. Cumulative amounts invoiced may not exceed the maximum amount of funding stipulated in the contract.3.Cost plus â€“ this type of contract is similar to a cost reimbursement contract but this type also allows for the Company to additionally invoice for a fee amount that is included in the contract.4.Performance based â€“ the Company submits invoices only upon the achievement of the milestones listed in the contract. The amount to be invoiced for each milestone is documented in the contract.These government contracts have terms ranging from three months to four years. The Company may apply for an extension of the term of the contract in order to complete its research and development activities but would not receive additional funding during the extension period in excess of the original contract. See Note 2 regarding the accounting policies related to these contracts. The Company is evaluating the potential reclassification of grant income and related costs of goods sold to net with research and development expenses.In summary, the contracts the Company has with customers are the distributor/strategic partner contracts related to CytoSorb product sales, agreements with direct customers related to free-of-charge product and credit rebates based upon achieving minimum purchase levels, and contracts with various government agencies related to the Companyâ€™s grants. The Company does not currently incur any outside/third party incremental costs to obtain any of these contracts. The Company does incur internal costs, primarily salary related costs, to obtain the contracts related to the grants. Company employees spend time reviewing the program requirements and developing the budget and related proposal to submit to the grantor agency. There may additionally be travel expenditures involved with meeting with government agency officials during the negotiation of the contract. These internal costs are expensed as incurred.The following table provides information about receivables and contract liabilities from contracts with customers:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â 2024Â Â Â Â DecemberÂ 31,Â 2023Receivables, which are included in grants and accounts receivableâ€‹$ 4,845,233â€‹$ 3,846,271Contract liabilities, which are included in accrued expenses and other current liabilitiesâ€‹$ 837,592â€‹$ 1,573,141â€‹Contract receivables represent balances due from product sales to distributors amounting to $4,528,972 and $3,270,724 at September 30, 2024 and December 31, 2023, respectively, and billed and unbilled amounts due on government contracts amounting to $316,261 and $575,547 at September 30, 2024 and December 31, 2023, respectively.Contract liabilities represent the value of free of charge goods and credit rebates earned in accordance with the terms of certain direct customer agreements, which amounted to $51,192 and $196,322 as of September 30, 2024 and December 31, 2023, respectively, and deferred grant revenue related to the billing on fixed price contracts in excess of costs incurred, which amounted to $786,400 and $1,376,819 at June 30, 2024 and December 31, 2023, respectively.5.Â Â Â Â LONG-TERM DEBT, NETAvenue Capital Group:On June 28, 2024 (the â€œClosing Dateâ€), the Company entered into a Loan and Security Agreement (as amended, supplemented, restated or otherwise modified as of the date hereof and from time to time, the â€œLoan and Security Agreementâ€) with Avenue Venture Opportunities Fund, L.P., a Delaware limited partnership (â€œAvenueâ€), Avenue Venture Opportunities Fund II, L.P., a Delaware limited partnership (â€œAvenue 2â€ and, together with Avenue, the â€œLendersâ€), and Avenue Capital Management II, L.P., a Delaware limited partnership (the â€œAdministrative and Collateral Agentâ€).18 Table of ContentsUnder the Loan and Security Agreement, the Lenders have agreed to loan to the Company up to an aggregate of $20 million, to be disbursed in two tranches: (1) one tranche of $15 million (â€œGrowth Capital Loan Tranche 1â€) on the Closing Date, with $4.5 million funded by Avenue and $10.5 million funded by Avenue 2, of which $10 million is available to the Company on the Closing Date and $5 million constitutes restricted cash subject to release to the Company prior to March 31, 2025, provided (i) the FDA has accepted Companyâ€™s application for review with respect to DrugSorb-ATR De Novo 510(k) and (ii) the Company has received a minimum of $3 million in net proceeds from the sale of its equity securities after the Closing Date. The restriction will be released on a dollar for dollar basis for equity raised between $3 million and $5 million and (2) a second tranche of up to $5 million, which may be disbursed at the Companyâ€™s request between July 1, 2025 and December 31, 2025, provided that the Company receives FDA marketing approval of its DrugSorb-ATR application (â€œGrowth Capital Loan Tranche 2â€ and together with Growth Capital Loan Tranche 1, the â€œGrowth Capital Loansâ€ or the â€œCommitmentâ€). The proceeds from the Commitment were used to pay off the existing outstanding debt with Bridge Bank, and will additionally be used for working capital purposes and to fund general business requirements in accordance with the terms of the Loan and Security Agreement. Each Growth Capital Loan shall bear interest at a variable rate per annum equal to the greater of (A) the Prime Rate (as defined in the Loan and Security Agreement) plus five percent (5.00%) or (B) thirteen and one-half percent (13.50%).Commencing on August 1, 2024, the Company shall make monthly payments during the term of each Growth Capital Loan of interest only during the initial 25-month period following the Closing Date (as may be extended to the 30 months anniversary of the Closing Date upon satisfaction of certain conditions) and thereafter to maturity in equal monthly installments of principal plus accrued and unpaid interest. All unpaid principal and accrued and unpaid interest shall be due and payable in full on July 1, 2027; provided, however that if the Company draws the full amount of Growth Capital Loan Tranche 2 by December 2025, all unpaid principal and accrued and unpaid interest shall be due and payable in full by January 1, 2028. In addition, the Loan and Security Agreement required the Company to pay a non-refundable commitment fee equal to 1.00% of the Commitment due and payable on the Closing Date. In addition to the non-refundable commitment fee, the Company also paid financial advisor fees and legal fees of approximately $640,000 related to the Commitment. These costs are being amortized over the loan period as a charge to interest expense. During the three and nine months ended September 30, 2024, the Company recorded interest expense of approximately $58,000 related to these costs. In addition, the Loan and Security Agreement requires the Company to pay a non-refundable final payment equal to 4.5% of the original commitment amount. This final payment has been accrued and included as part of the debt discount. This discount will be charged to interest expense over the term of the loan. For the three and nine months ended September 30, 2024, the Company recorded interest expense of approximately $132,000 related to the debt discount.The Capital Growth Loans are evidenced by secured promissory notes issued to the Lenders by the Company. If the Company elects to prepay the Growth Capital Loan(s) pursuant to the terms of the Loan and Security Agreement, it will owe a prepayment fee to the Lenders, as follows: (1) for a prepayment made on or after the funding date of a Growth Capital Loan through and including the first anniversary of such funding date, an amount equal to 3.00% of the principal amount of such Growth Capital Loan prepaid; (2) for a prepayment made after the first anniversary of the funding date of a Growth Capital Loan through and including the second anniversary of such funding date, an amount equal to 2.00% of the principal amount of such Growth Capital Loan prepaid; and (3) for a prepayment made any time after the second anniversary of the funding date of a Growth Capital Loan, an amount equal to 1.00% of the principal amount of such Growth Capital Loan prepaid. Events of default which may cause repayment of the Commitment to be accelerated include, among other customary events of default, (1) non-payment of any obligation when due, (2) the failure to perform any obligation required under the Loan and Security Agreement and to cure such default within a reasonable time frame, (3) the occurrence of any circumstance that has a Material Adverse Effect (as defined in the Loan and Security Agreement), (4) default beyond any applicable grace period or cure under any other agreement involving the borrowing of money in excess of the Threshold Amount (as defined in the Loan and Security Agreement), (5) any judgment(s) singly or in the aggregate in excess of the Threshold Amount entered against the Company that remain unsatisfied, unvacated or unstayed for 15 days or more after entry thereof (to the extent not otherwise covered by independent third-party insurance), and (6) if the Company becomes insolvent or starts an insolvency proceeding or if an insolvency proceeding is brought by a third party against the Company and such proceeding is not dismissed or stayed within 45 days. The Loan and Security Agreement includes customary loan conditions, company representations and warranties, company affirmative covenants and company negative covenants for secured transactions of this type. As of September 30, 2024, the Company was in compliance with these covenants. 19 Table of ContentsAs additional consideration for the Commitment, on June 28, 2024, the Company also issued each Lender a warrant instrument (each, a â€œWarrantâ€) entitling the Lenders to purchase an aggregate of 1,645,569 shares of the Companyâ€™s common stock for cash at the exercise price of $0.79 and expire on June 28, 2029. The number of warrants is fixed, however, the exercise price may be adjusted down if the Company raises equity (excluding sales of equity utilizing the Companyâ€™s at-the-market equity facility) at a share price that is lower than $0.79. These warrants meet the criteria for equity classification under ASC 815. Accordingly, the Company has recorded a debt discount and additional paid-in capital of approximately $690,000 related to these warrants as of June 30, 2024. This discount will be charged to interest expense over the term of the loan.The Lenders were also granted the right while the Commitment is outstanding to convert up to an aggregate amount of $2,000,000 of the principal amount of the outstanding Growth Capital Loans into the Companyâ€™s common stock at a fixed conversion price of 120% of the Closing Price (as defined in the warrant) or $0.95 per share (the â€œConversion Optionâ€).The Companyâ€™s and CytoSorbents Medicalâ€™s obligations under the Loan and Security Agreement are joint and several. The obligations under the Loan and Security Agreement are secured by a first priority security interest in favor of the Lenders with respect to the Companyâ€™s Shares (as defined in the Loan and Security Agreement) and the Companyâ€™s Collateral (as defined in the Loan and Security Agreement), which includes the Companyâ€™s intellectual property, pursuant to that certain Intellectual Property Security Agreement, dated as of June 28, 2024, by and between the Company and the Administrative and Collateral Agent.â€‹Long-term debt consists of the following as of September 30, 2024:â€‹â€‹â€‹Principal amountÂ Â Â Â $ 15,000,000Accrued final feeâ€‹Â 900,000Less unamortized debt discountâ€‹â€‹ (1,455,858)Less unamortized debt acquisition costsâ€‹â€‹ (638,157)Subtotalâ€‹Â 13,805,985Less Current maturitiesâ€‹Â â€”Long-term debt net of current maturitiesâ€‹$ 13,805,985â€‹Principal payments of long-term debt are due as follows during the periods ending September 30:â€‹â€‹â€‹â€‹2025Â Â Â Â $ â€”2026Â Â Â Â â€‹ 2,500,0002027â€‹Â 12,500,0002028â€‹â€‹ â€”Totalâ€‹$ 15,000,000â€‹Bridge Bank:On June 28, 2024, concurrent with the closing of the Avenue Capital Group financing discussed above, the Company paid off its existing outstanding debt with Bridge Bank. The following items survive the termination of the Bridge Bank Amended and Restated Loan and Security Agreement and related amendments:20 Table of Contents2018 Success Fee Letter:Pursuant to the amended 2018 Letter, the Borrower shall pay to the Bank a success fee in the amount equal to 6.37% of the funded amount of the Term B Loan (as defined in the Restated Loan and Security Agreement) (the â€œSuccess Feeâ€) upon the first occurrence of any of the following events: (a) a sale or other disposition by the Borrower of all or substantially all of its assets; (b) a merger or consolidation of the Borrower into or with another person or entity, where the holders of the Borrowerâ€™s outstanding voting equity securities as of immediately prior to such merger or consolidation hold less than a majority of the issued and outstanding voting equity securities of the successor or surviving person or entity as of immediately following the consummation of such merger or consolidation; (c) a transaction or a series of related transactions in which any â€œpersonâ€ or â€œgroupâ€ (within the meaning of Section 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€) becomes the â€œbeneficial ownerâ€ (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of a sufficient number of shares of all classes of stock then outstanding of the Borrower ordinarily entitled to vote in the election of directors, empowering such â€œpersonâ€ or â€œgroupâ€ to elect a majority of the Board of Directors of the Borrower, who did not have such power before such transaction; or (d) the closing price per share for the Companyâ€™s common stock on the Nasdaq Capital Market being the greater of (i) 70% or more over $7.05, the closing price of the Companyâ€™s common stock on March 29, 2018 (after giving effect to any stock splits or consolidations effected after the date thereof) for five successive business days, or (ii) at least 26.13% more than the average price of Companyâ€™s common stock for the 365-day period ending on the date of the funding of the Term B Loan. This obligation terminated on the fifth anniversary of the funding of the Term B Loan which was July 31, 2024.2022 Success Fee Letter:Pursuant to the 2022 Success Fee Letter, the Borrower will pay to the Bank a success fee equal to (i) 1% of $5 million if the Company draws down the first tranche of the Term C Loan and is payable only if the Companyâ€™s stock price equals or exceeds $8 for five consecutive trading days; (ii) 1.5% of $5 million if the Company draws down the second tranche of the Term C Loan and is payable only if the Companyâ€™s stock price equals or exceeds $10 for five consecutive trading days; and (iii) 2% of $5,000,000 if the Company draws down the third tranche of the Term C Loan and is payable only if the Companyâ€™s stock price equals or exceeds $12 for five consecutive trading days (together, the â€œSuccess Feeâ€). As of June 28, 2024, the Company had drawn down only the first tranche of the Term C Loan. Borrower may pay the Success Fee in cash or in shares of common stock, at Borrowerâ€™s sole discretion. The right of Bank to receive the Success Fees and the obligation of the Borrower to pay the Success Fees hereunder shall terminate on the date that is the fifth anniversary of the funding date of the last Term C Loans made but shall survive the termination of the Loan Agreement and any prepayment of the Term C Loans. The termination date of this Letter is December 27, 2027.â€‹6.Â Â Â Â COMMITMENTS AND CONTINGENCIESLitigationThe Company is, from time to time, subject to claims and litigation arising in the ordinary course of business. The Company intends to defend vigorously against any future claims and litigation.On March 5, 2024, Danielle Greene, a former employee, filed a complaint against us in the Superior Court of New Jersey, Law Division, Mercer County, alleging breach of the New Jersey Conscientious Employee Protection Act (â€œCEPAâ€). The complaint specifically alleges that we violated the provisions of the CEPA by allegedly terminating Ms. Greene in retaliation for complaining about certain business practices. We dispute these allegations and intend to vigorously defend against them, but there can be no assurance as to the outcome of the litigation.Royalty/License AgreementsThe Company is party to various royalty and license agreements that require the payment of royalty fees. Royalty expense amounted to approximately $354,000 and $537,000, respectively, for the three months ended September 30, 2024 and 2023. For the nine months ended September 30, 2024 and 2023, royalty expense amounted to approximately $1,594,000 and $1,643,000, respectively. In addition, the Companyâ€™s license agreement with Purolite expired on August 6, 2024. Royalty expense are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.â€‹21 Table of Contents7.Â Â Â Â LEASESThe Company leases its operating facilities in both the United States and Germany under operating lease agreements. In March 2021, CytoSorbents Medical Inc. entered into a lease agreement for a new operating facility at 305 College Road East, Princeton, New Jersey, which contains office, laboratory, manufacturing and warehouse space. The lease commenced on June 1, 2021. The Early Term commenced on June 1, 2021 and ended September 30, 2021. The lease also contains two five-year renewal options; however, the Company had determined that it is not likely that they will exercise these options. Commencing on September 30, 2021, the remaining lease term will end in 15.5 years. The lease requires monthly rental payments of $25,208 for the Initial Early Term, $88,254 for the Early Term and initial monthly payments of approximately $111,171 in the first year of the remaining term. Following the first year of the remaining term, the annual base rent will increase by approximately 2.75% annually over the remaining term. The lease also contains six months of rent abatement (months 1, 2, 3, 25, 26 and 27 of the remaining

lease term). In addition to the base rent, payments of operating expenses and real estate taxes will be required. These payments are to be based on actual amounts incurred during 2021 multiplied by the Companyâ€™s share of the total building space (92.3%). The landlord will also provide an allowance of approximately $1,455,000 related to certain building improvements as outlined in the lease. In April 2021, the Company provided the landlord with a letter of credit in the amount of approximately $1,467,000 as security. The Company has determined that this lease should be treated as an operating lease in accordance with the provisions of Accounting Standards Codification (â€œASCâ€) 842. On April 1, 2021, the Company recorded a Right-of-Use asset and related lease liability of approximately $11.6 million, which represents the estimated present value of the lease payments at the commencement date discounted at the Companyâ€™s incremental borrowing rate of 9.8%. In addition, due to the six months of rent abatement and annual base rent escalations during the remaining lease term that commenced on September 30, 2021, the Company will recognize rent expense on this lease on a straight-line basis over the remaining term of the lease for the difference between the rent expense recognized and the required payments under the lease.In September 2021, the Company extended its two operating leases for its office facility in Germany. These leases require combined base rent payments amounting to approximately $12,100 perÂ month. The initial lease term of both leases ends AugustÂ 31, 2026. In addition, the Company is obligated toÂ monthly operating expenses of approximately $3,000 perÂ month. Both leases have a five-year option to renew that would extend the lease term to AugustÂ 31, 2031. There are no provisions in the leases to increase the base rent during the renewal period. There were no lease incentives and no initial direct costs were incurred related to these leases.In January 2021, CytoSorbents Europe GmbH entered into a lease for 1,068 square meters of additional warehouse space. The lease commenced on April 1, 2021 and requires monthly payments of base rent of $7,784 and other costs of approximately $239 and has a term of five years. The lease also has an option to extend the lease term for an additional five-year period through March 31, 2031. The Company has determined that this lease should be treated as an operating lease in accordance with the provisions of ASC 842. On April 1, 2020, the Company recorded a Right-of-Use asset and related lease liability at the estimated present value of the lease payments at the commencement date of approximately $594,000.Right-Of-Use Asset and Lease LiabilityThe Companyâ€™s consolidated balance sheets reflect the value of the right-of-use asset and related lease liability. This value was calculated based on the present value of the remaining base rent lease payments. The remaining lease payments include the renewal periods for both of the facilities in Germany and do not include the renewal periods for the United States facility. The discount rate used was the Companyâ€™s incremental borrowing rate, which is 9.8%, as the Company could not determine the rate implicit in the lease. As a result, the value of the right-of- use asset and related lease liability is as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹â Â Â Â 2024Â Â Â Â 2023Right-of-use assetâ€‹$ 11,651,563â€‹$ 12,058,896â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Total lease liabilityâ€‹$ 13,000,742â€‹$ 13,270,295Less current portionâ€‹Â (431,997)â€‹ â€‹ (373,636)Lease liability, net of current portionâ€‹$ 12,568,745â€‹$ 12,896,659â€‹22 Table of ContentsThe maturities of the lease liabilities are as follows for the periods ending September 30:â€‹â€‹â€‹â€‹2025Â Â Â Â $ 1,685,7272026â€‹Â 1,725,5242027â€‹Â 1,766,4162028â€‹Â 1,808,4322029â€‹Â 1,851,603Thereafterâ€‹Â 14,024,373Total lease paymentsâ€‹â€‹ 22,862,075Present value discountâ€‹â€‹ (9,861,333)Totalâ€‹$ 13,000,742â€‹For the threeÂ months ended September 30, 2024 and 2023, operating cash flows paid in connection with operating leases amounted to approximately $547,000 and $633,000, respectively, and $1,684,000 and $1,801,000, respectively, for the nine months ended September 30, 2024 and 2023.As of September 30, 2024 and DecemberÂ 31, 2023, the weighted average remaining lease term was years 11.9 and 12.7 years, respectively.8.Â Â Â Â NET LOSS PER SHAREBasic loss per share and diluted loss per share for the three and nine months ended September 30, 2024 and 2023 have been computed by dividing the net loss for each respective period by the weighted average number of shares outstanding during that period.All outstanding warrants, options and restricted stock awards representing approximately 20,328,000 and 14,119,000 incremental shares at September 30, 2024 and 2023, respectively, have been excluded from the computation of diluted loss per share as they are anti-dilutive.â€‹â€‹23 Table of ContentsItem 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.Cautionary Notes Regarding Forward Looking StatementsThis Quarterly report on Form 10-Q includes â€œforward-looking statementsâ€ within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and our expectations of the effects of the COVID-19 pandemic and are not historical facts and typically are identified by use of terms such as â€œmay,â€ â€œshould,â€ â€œcould,â€ â€œexpect,â€ â€œplan,â€ â€œanticipate,â€ â€œbelieve,â€ â€œestimate,â€ â€œpredict,â€ â€œpotential,â€ â€œcontinueâ€ and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements included herein represent managementâ€™s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, as updated by any risks reported in our Quarterly Reports on Form 10-Q and in the press releases and other communications to stockholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.OverviewWe are a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbentsâ€™ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, ECMO, heart-lung machines). CytoSorbentsâ€™ technologies are used in a number of broad applications. Specifically, two important applicatons are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding and 2) the removal of inflammatory agents in common critical illnesses such as sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.CytoSorbentsâ€™ lead product, CytoSorbÂ®, is approved in the European Union and distributed in 76 countries worldwide, with more than 250,000 devices used cumulatively to date. Â CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Â Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA EUA in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure, to reduce pro-inflammatory cytokine levels. Â CytoSorb is not yet approved in the United States.In the U.S. and Canada, CytoSorbents is developing the DrugSorbâ„¢-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. Â It has received two FDA Breakthrough Device Designations: Â one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. Â In September 2024, the Company submitted a De Novo medical device application to the FDA requesting marketing approval to reduce the severity of perioperative bleeding in CABG patients on the antithrombotic drug ticagrelor, which was accepted for substantive review in October 2024. In November 2024, the Company received its Medical Device Single Audit Program (MDSAP) certification and submitted its Medical Device License (MDL) application to Health Canada. DrugSorb-ATR is not yet granted or approved in the United States and Canada, respectively. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CYÂ®, CytoSorb-XLâ„¢, HemoDefend-RBCâ„¢, HemoDefend-BGAâ„¢, VetResQÂ®, K+ontrolâ„¢, DrugSorbâ„¢, ContrastSorb, and others.24 Table of ContentsClinical Studies UpdateFor a complete discussion regarding our clinical study history, please refer to the section entitled Clinical Studies included in Item 1 of the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 14, 2024. The following includes certain updates regarding these clinical studies subsequent to the filing of the Companyâ€™s Annual Report on Form 10-K.In July 2021, we received full FDA approval of an Investigational Device Exemption (IDE) application to conduct a double-blind, randomized, controlled clinical study in 120 patients entitled, â€œSafe and Timely Antithrombotic Removal â€“ Ticagrelor (â€œSTAR-Tâ€),â€ in the United States to support FDA marketing approval. This was done under the previously announced FDA Breakthrough Device Designation granted for the removal of ticagrelor in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding during urgent cardiac surgery. In October 2021, the first patient was enrolled, with the STAR-T study actively recruiting at multiple U.S. sites. In November 2022, the first milestone was completed with the first one-third of patients enrolled, triggering the first Data and Safety Monitoring Board (â€œDSMBâ€) meeting. The DSMB recommended to continue the study as planned without any modifications. In 2022, we also received FDA approval to expand the study to Canada and subsequently received Health Canada approval allowing inclusion of Canadian sites into the STAR-T trial in January 2023. In early 2023, the study exceeded 50% enrollment and reached the 2nd milestone of 67% enrollment in the spring of 2023, triggering another DSMB safety review, which found no safety concerns and recommended completion of the trial. The study completed enrollment in July of 2023 triggering the final DSMB safety review following database lock in December 2023, which also reported no safety concerns thereby meeting the primary safety endpoint of the study. Based on the initial analysis of the STAR-T data, the study did not meet the primary effectiveness endpoint in the overall patient population that underwent different types of cardiac surgeries. However, the study did demonstrate evidence that DrugSorb-ATR reduced the severity of perioperative bleeding in patients undergoing isolated coronary artery bypass graft (â€œCABGâ€) surgery who represented more than 90% of the overall study population. The topline results of the U.S. and Canadian 140-patient, pivotal STAR-T randomized controlled trial were presented at the 104th Annual Meeting of the American Association for Thoracic Surgery (â€œAATSâ€) held in Toronto, Canada on April 28, 2024. The Company submitted the DrugSorb-ATR medical device De Novo marketing application to the FDA on September 27, 2024 and announced the acceptance of the application by FDA on October 22, 2024. On November 1, 2024, the Company received its Medical Device Single Audit Program (MDSAP) certification and submitted its Medical Device License (MDL) application to Health Canada.Government Research Grants:We have historically been successful in obtaining technology development contracts from governmental agencies such as the National Institutes of Health and the U.S. Department of Defense, including the Defense Advanced Research Projects Agency (â€œDARPAâ€), the U.S. Army, U.S. Special Operations Command (â€œUSSOCOMâ€), the U.S. Air Force, Air Force Material Command (â€œUSAF/AFMCâ€) and others. Currently, we have ongoing projects funded, in part, by the U.S. Army Medical Research Acquisition Activity (â€œUSAMRAAâ€), National Heart, Lung, and Blood Institute (â€œNHLBIâ€), and the USAF/AFMC. For a complete discussion of the various research grants we have obtained, please refer to the section entitled Government Research Grants included in Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on March 14, 2024.Research and Development UpdateOur research and development work levels have returned back to pre-pandemic levels. As of September 30, 2024, the revenue remaining to be earned on open grant contracts is $3.2 million. Overall, grant funded programs, HemoDefend-BGAâ„¢ (Universal Plasma), HemoDefend-RBCâ„¢ and K+ontrolâ„¢, continue to progress and we have been the beneficiary of approximately $15.8 million, $4.7 million and $7.7 million in total funding, respectively, awarded to date. 25 Table of ContentsImpact of Inflation and Other Issues:The current high inflationary environment has impacted us in various ways. Due to the current competitive labor market and high inflation, our labor costs have risen significantly in order to attract and retain qualified employees throughout our organization. In addition, we have experienced raw material price increases primarily related to the oil-based chemicals used in the polymer manufacturing process as well additional requests for higher fuel surcharges from most suppliers. Rising energy costs, including electricity and fossil fuels, have also made it more expensive to support our operations, manufacturing, and commercial activities. We have also experienced increases in our transportation costs; however, we have been able to substantially mitigate these cost increases by implementing bulk shipping methods. In addition, we have been able to mitigate most supply chain issues that existed during the COVID-19 pandemic by ordering larger quantities of inventory as they were available. Inflationary pressures may continue to impact our product gross margins in the future.Results of Operations:Comparison for the three months ended September 30, 2024 and 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended September 30,â€‹â€‹â€‹2024â€‹â€‹â€‹2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹% of â€‹â€‹â€‹â€‹â€‹% of â€‹Â Â Â Â AmountÂ Â Â Â RevenueÂ Â Â Â AmountÂ Â Â Â Revenueâ€‹â€‹â€‹(dollars in thousands)â€‹Revenues:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹CytoSorb salesâ€‹$ 8,586,274Â 91.4%Â Â $ 7,709,085â€‹ 87.5%Other salesâ€‹Â 26,521Â 0.3â€‹â€‹ 44,931â€‹ 0.5â€‹Total product salesâ€‹Â 8,612,795Â 91.7â€‹â€‹ 7,754,016â€‹ 88.0â€‹Grant incomeâ€‹Â 777,593Â 8.3â€‹â€‹ 1,056,831â€‹ 12.0â€‹Total revenueâ€‹Â 9,390,388Â 100.0â€‹â€‹ 8,810,847â€‹ 100.0â€‹Cost of goods soldâ€‹Â 4,108,773Â 43.8â€‹â€‹ 3,203,981â€‹ 36.4â€‹Gross profitâ€‹Â 5,281,615Â 56.2â€‹â€‹ 5,606,866â€‹ 63.6â€‹Operating expenses:â€‹â€‹â€‹â€‹Â Â Â Â â€‹â€‹â€‹â€‹Research and developmentâ€‹Â 1,851,230Â 19.7â€‹â€‹ 3,749,197â€‹ 42.6â€‹Legal, financial and other consultingâ€‹Â 823,914Â 8.8â€‹â€‹ 1,103,475â€‹ 12.5â€‹Selling, general and administrativeâ€‹Â 7,002,718Â 74.6â€‹â€‹ 8,104,392â€‹ 92.0â€‹Total operating expensesâ€‹Â 9,677,862Â 103.1â€‹â€‹ 12,957,064â€‹ 147.1â€‹Loss from operationsâ€‹Â (4,396,247)Â (46.9)â€‹â€‹ (7,350,198)â€‹ (83.4)â€‹Other income (expense):â€‹â€‹â€‹â€‹Â Â Â Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â â€‹Interest expense, netâ€‹Â (588,153)Â (6.3)â€‹â€‹ (33,670)â€‹ (0.4)â€‹Gain (loss) on foreign currency transactionsâ€‹Â 2,650,309Â 28.2â€‹â€‹ (1,809,652)â€‹ (20.5)â€‹Total other income (expense), netâ€‹Â 2,062,156Â 21.9â€‹â€‹ (1,843,322)â€‹ (20.9)â€‹Net lossâ€‹$ (2,334,091)Â (25.0)%Â Â $ (9,193,520)â€‹(104.3)%â€‹Revenues:Total revenues were approximately $9,390,000 for the three months ended September 30, 2024, as compared to total revenues of approximately $8,811,000 for the three months ended September 30, 2023, an increase of approximately $579,000 or 7%. Â Changes in foreign currency impacted total revenue by 1% and 6%, for respective periods of 2024 and 2023, respectively. Revenue from product sales was approximately $8,613,000 in the three months ended September 30, 2024, as compared to approximately $7,754,000 in the three months ended September 30, 2023, an increase of approximately $859,000, or 11%. This increase was driven by an increase in direct sales of approximately 21% in the three months ended September 30, 2024 as compared to 2023. In addition, distributor sales decreased by approximately 1% during the same period.Grant income was approximately $777,000 for the three months ended September 30, 2024 as compared to approximately $1,057,000 for the three months ended September 30, 2023, a decrease of approximately $280,000, or 26%. This decrease was due to the completion of several grants during 2023.26 Table of ContentsGross Profit:For the three months ended September 30, 2024, gross profit decreased approximately $327,000 to $5,281,000 from $5,607,000 for the three months ended September 30, 2023. This decrease was due to a planned temporary slowdown in production to rebalance inventory levels coupled with a short-term manufacturing issue, which we believe is resolved, which resulted in a significantly lower number of CytoSorb devices produced in the quarter. As a result, product gross margins, which exclude the impact of grant income and related costs, were approximately 61% for the three months ended September 30, 2024 as compared to approximately 72% for the three months ended September 30, 2023.Research and Development Expenses:For the three months ended September 30, 2024, research and development expenses were approximately $1,851,000 as compared to research and development expenses of approximately $3,749,000 for the three months ended September 30, 2023, a decrease of approximately $1,898,000, or 51%. This decrease was driven by a decrease in our clinical trial costs due to the completion of the STAR-T clinical trial in December 2023. Clinical expenses were approximately $962,000 in the three months ended September 30, 2024 and approximately $2,837,000 for the three months ended September 30, 2023, a decrease of approximately $1,875,000, or 66%.Legal, Financial and Other Consulting Expenses:Legal, financial, and other consulting expenses were approximately $824,000 for the three months ended September 30, 2024, as compared to approximately $1,104,000 for the three months ended September 30, 2023, a decrease of approximately $280,000, or 25%. This decrease is related to costs associated with the write-off of certain patent applications that were incurred in 2023 that did not recur in 2024 and a decrease in regulatory consulting costs related to DrugSorb-ATR.Selling, General and Administrative Expenses:Selling, general and administrative expenses were approximately $7,003,000 for the three months ended September 30, 2024, as compared to approximately $8,104,000 for the three months ending September 30, 2023, a decrease of approximately $1,101,000, or 14%. This decrease was primarily due to reduction in non-cash stock compensation expense, a reduction in salaries and related expenses related to headcount reductions and a reduction in royalty expense due to the expiration of the Purolite license agreement on August 6, 2024.Interest Expense, Net:Interest expense, net, was approximately $588,000 for the three months ended September 30, 2024, compared to approximately $34,000 for the three months ended September 30, 2023. Â The increase was due to interest incurred on the Avenue Capital Group debt that was closed during the second quarter of 2024, net of interest income received of approximately $121,000 on the total balance of cash and cash equivalents. This financing increased the principal amount of our debt to $15,000,000 from $5,000,000 and the interest rate increased to 13.5% from 8%.Gain (Loss) on Foreign Currency Transactions:For the three months ended September 30, 2024, the gain on foreign currency transactions was approximately $2,650,000 as compared to a loss of approximately $1,810,000 for the three months ended September 30, 2023. The 2024 gain was directly related to the increase in the spot exchange rate of the Euro to the U.S. dollar at September 30, 2024 as compared to June 30, 2024. The spot exchange rate of the Euro to the U.S. dollar was $1.11 per Euro at September 30, 2024, as compared to $1.07 per Euro at June 30, 2024. The 2023 loss was

directly related to the decrease in the spot exchange rate of the Euro to the U.S. dollar at September 30, 2023 as compared to June 30, 2023. The spot exchange rate of the Euro to the U.S. dollar was $1.06 per Euro at September 30, 2023, as compared to $1.09 per Euro at June 30, 2023.27 Table of ContentsComparison for the nine months ended September 30, 2024 and 2023:â€‹â€‹â€‹

Awards that may be granted under the Plan (the â€œ Share Pool â€) shall be equal to an aggregate 20,900,000 shares which represents (i) 2,400,000 shares approved by stockholders under the 2014 Plan (ii) an additional 5,000,000 shares approved by the stockholders on June 6, 2017, (iii) an additional 6,000,000 shares approved by the stockholders under the Amended and Restated Plan, plus (iv) an additional 7,500,000 shares approved by the stockholders on June 6, 2024.2.Except as modified herein, all provisions of the Plan shall remain in full force and effect.SIGNATURE PAGE FOLLOWSâ€‹â€‹â€‹IN WITNESS WHEREOF, the undersigned has executed this Amendment No. 2024-1 to the Companyâ€™s Amended and Restated 2014 Long Term Incentive Plan as of the date first set forth above.â€‹â€‹CYTOSORBENTS CORPORATIONâ€‹â€‹â€‹By:/s/ Dr. Phillip P. Chanâ€‹Name:Dr. Phillip P. Chanâ€‹Title:Chief Executive Officerâ€‹SIGNATURE PAGE TO AMENDMENT NO. 2024-1 TO AMENDED AND RESTATED LONG-TERMINCENTIVE PLAN EX-31.1 3 ctso-20240930xex31d1.htm EX-31.1 Exhibit 31.1CERTIFICATIONOF PRINCIPAL EXECUTIVE OFFICERPURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)AS ADOPTED PURSUANT TO SECTION 302 OFTHE SARBANES-OXLEY ACT OF 2002I, Phillip Chan, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of CytoSorbents Corporation;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrantâ€™s internal control over financing reporting that occurred during the registrantâ€™s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹Date: November 7, 2024Â Â Â Â â€‹â€‹â€‹â€‹â€‹/s/ Phillip P. Chanâ€‹â€‹Phillip P. Chan Principal Executive Officerâ€‹â€‹â€‹ EX-31.2 4 ctso-20240930xex31d2.htm EX-31.2 Exhibit 31.2CERTIFICATIONOF PRINCIPAL FINANCIAL OFFICERPURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)AS ADOPTED PURSUANT TO SECTION 302 OFTHE SARBANES-OXLEY ACT OF 2002I, Peter J. Mariani, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of CytoSorbents Corporation;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrantâ€™s internal control over financing reporting that occurred during the registrantâ€™s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹Date: November 7, 2024Â Â Â Â â€‹â€‹â€‹â€‹â€‹/s/ Peter J. Marianiâ€‹â€‹Peter J. Mariani Principal Financial Officerâ€‹â€‹â€‹ EX-32.1 5 ctso-20240930xex32d1.htm EX-32.1 Exhibit 32.1CERTIFICATION OFPRINCIPAL EXECUTIVE OFFICERPURSUANT TO 18 U.S.C. SECTION 1350AS ADOPTED PURSUANT TO SECTION 906OF THE SARBANES-OXLEY ACT of 2002Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Phillip Chan, Chief Executive Officer of CytoSorbents Corporation, hereby certify, that, to my knowledge:1.The Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and2.The information contained in such Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, fairly presents, in all material respects, the financial condition and results of operations of CytoSorbents Corporation.â€‹Date: Â November 7, 2024Â Â Â Â â€‹â€‹â€‹â€‹â€‹CYTOSORBENTS CORPORATIONâ€‹â€‹â€‹â€‹â€‹By:/s/ Phillip P. Chanâ€‹â€‹Phillip Chanâ€‹â€‹Chief Executive Officerâ€‹â€‹â€‹ EX-32.2 6 ctso-20240930xex32d2.htm EX-32.2 Exhibit 32.2CERTIFICATION OFPRINCIPAL FINANCIAL OFFICERPURSUANT TO 18 U.S.C. SECTION 1350AS ADOPTED PURSUANT TO SECTION 906OF THE SARBANES-OXLEY ACT of 2002Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Peter J. Mariani, the Chief Financial Officer of CytoSorbents Corporation, hereby certify, that, to my knowledge:1.The Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and2.The information contained in such Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, fairly presents, in all material respects, the financial condition and results of operations of CytoSorbents Corporation.â€‹Date: November 7, 2024Â Â Â Â â€‹â€‹â€‹â€‹â€‹CYTOSORBENTS CORPORATIONâ€‹â€‹â€‹â€‹â€‹By:/s/ Peter J. Marianiâ€‹â€‹Peter J. Marianiâ€‹â€‹Chief Financial Officerâ€‹â€‹â€‹ EX-101.SCH 7 ctso-20240930.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 00202 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Calc 2) link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 99940202 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and cash equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - LONG-TERM DEBT (Details) Calc 2 link:presentationLink link:calculationLink link:definitionLink 99940502 - Disclosure - LONG-TERM DEBT, NET (Details) link:presentationLink link:calculationLink link:definitionLink 99940503 - Disclosure - LONG-TERM DEBT, NET - Principal payments (Details) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - LEASES - Maturities of the lease liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940703 - Disclosure - LEASES - Maturities of the lease liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - BASIS OF PRESENTATION (Details) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - STOCKHOLDERS' EQUITY - Stock option activity (Details) link:presentationLink link:calculationLink link:definitionLink 99940302 - Disclosure - STOCKHOLDERS' EQUITY - Intrinsic value (Details) link:presentationLink link:calculationLink link:definitionLink 99940303 - Disclosure - STOCKHOLDERS' EQUITY - Non-vested options (Details) link:presentationLink link:calculationLink link:definitionLink 99940304 - Disclosure - STOCKHOLDERS' EQUITY - Restricted stock unit (Details) link:presentationLink link:calculationLink link:definitionLink 99940305 - Disclosure - STOCKHOLDERS' EQUITY - Restricted stock unit activity (Details) link:presentationLink link:calculationLink link:definitionLink 99940306 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 99940307 - Disclosure - STOCKHOLDERS' EQUITY - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - REVENUE - Revenue by customer type and geographic area (Details) link:presentationLink link:calculationLink link:definitionLink 99940402 - Disclosure - REVENUE - Receivables and contract liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940403 - Disclosure - REVENUE - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - LONG-TERM DEBT, NET - Avenue Capital Group (Details) link:presentationLink link:calculationLink link:definitionLink 99940504 - Disclosure - LONG-TERM DEBT, NET - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 99940702 - Disclosure - LEASES - Right-of- use asset and related lease liability (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - NET LOSS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - LONG-TERM DEBT, NET link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 99920202 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 99930203 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - LONG-TERM DEBT, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 ctso-20240930_cal.xml EX-101.CAL EX-101.DEF 9 ctso-20240930_def.xml EX-101.DEF EX-101.LAB 10 ctso-20240930_lab.xml EX-101.LAB Document and Entity Information Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag CONDENSED CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Table] Statement [Line Items] Statement LONG-TERM DEBT, NET Assets [Abstract] ASSETS Assets, Current [Abstract] Current Assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Accounts Receivable, Net, Current Grants and accounts receivable, net of allowance of $160,246 as of September 30, 2024 and $49,663 at December 31, 2023 Inventory, Net Inventories Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Restricted Cash, Noncurrent Restricted cash Operating Lease, Right-of-Use Asset Right-of-use asset Right of use asset Right-of-use assets Other Assets, Noncurrent Other assets Assets Total Assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current Liabilities: Accounts Payable, Current Accounts payable Long-term Debt, Current Maturities Less Current maturities Current maturities of long-term debt Operating Lease, Liability, Current Less current portion Lease liability - current portion Amount of accrued expenses and other current liabilities. Accrued Expenses and Other Current Liabilities. Accrued expenses and other current liabilities Liabilities, Current Total current liabilities Operating Lease, Liability, Noncurrent Lease liability, net of current portion Long-term Debt, Excluding Current Maturities Long-term debt Long-term debt net of current maturities Liabilities Total Liabilities Commitments and Contingencies. Commitments and Contingencies (Note 6) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Equity: Preferred Stock, Value, Issued Preferred Stock, Par Value $0.001, 5,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023 Common Stock, Value, Issued Common Stock, Par Value $0.001, 100,000,000 shares authorized; 54,500,613 and 54,240,265 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income (loss) Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Balance Balance Total Stockholders' Equity Liabilities and Equity Total Liabilities and Stockholders' Equity Accounts Receivable, Allowance for Credit Loss, Current Grants and accounts receivable, net of allowance for doubtful accounts Preferred Stock, Par or Stated Value Per Share Preferred Stock, Par Value (in dollars per share) Preferred Stock, Shares Authorized Number of preferred stock authorized Preferred Stock, shares authorized Preferred Stock, Shares Issued Preferred Stock, shares issued Preferred Stock, Shares Outstanding Preferred Stock, shares outstanding Common Stock, Par or Stated Value Per Share Common Stock, Par Value (in dollars per share) Common Stock, Shares Authorized Common Stock, shares authorized Common Stock, Shares, Issued Common Stock, shares issued Common Stock, Shares, Outstanding Common Stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Product and Service [Axis] Product and Service [Domain] Total product sales [Member] Total product sales Product sales Represent the information relating to the cyto sorb sales CytoSorb sales [Member] CytoSorb sales Represent the information relating to the other sales Other sales [Member] Other product sales Grant income [Member] Grant income Government grants Revenues [Abstract] Revenue: Revenue from Contract with Customer, Including Assessed Tax Total revenue Cost of Goods and Services Sold Cost of revenue Gross Profit Gross profit Operating Expenses [Abstract] Other expenses: Research and Development Expense Research and development Professional Fees Legal, financial and other consulting Selling, General and Administrative Expense Selling, general and administrative Operating Expenses Total expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other income (expense): Interest Income (Expense), Nonoperating, Net Interest expense, net Foreign Currency Transaction Gain (Loss), before Tax Gain (loss) on foreign currency transactions Amount of miscellaneous income (expense). Miscellaneous Income (Expense) Miscellaneous income Nonoperating Income (Expense) Total other income (expense), net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before benefit from income taxes Income Tax Expense (Benefit) Benefit from income taxes Income tax expense Net Income (Loss) Available to Common Stockholders, Basic Net loss attributable to common stockholders Earnings Per Share, Basic Basic net loss per common share Earnings Per Share, Diluted Diluted net loss per common share

Weighted Average Number of Shares Outstanding, Basic Weighted average number of shares of common stock outstanding, basic Weighted Average Number of Shares Outstanding, Diluted Weighted average number of shares of common stock outstanding, diluted Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive loss: Net loss Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive income (loss): Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustment Other comprehensive income (loss): foreign translation adjustment Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-In Capital Accumulated Other Comprehensive Income (Loss) [Member] Accumulated Other Comprehensive Income (Loss) Accumulated Deficit [Member] Accumulated Deficit Shares, Outstanding Balance (in shares) Balance (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation - employees, consultants and directors Adjustments to Additional Paid in Capital, Warrant Issued Warrants issued in connection with long-term debt Stock Issued During Period, Value, New Issues Issuance of common stock offerings, net of fees Sale Of Common Stock Issuance of common stock offerings, net of fees (in shares) Issuance of common stock Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs ATM fee Value stock issued during the period as a result of the exercise of cash options. Stock Issued During Period Value Stock Cash Options Exercised Proceeds from exercise of stock options for cash Number of shares issued during the period as a result of the exercise of cash options. Stock Issued During Period Shares Stock Cash Options Exercised Proceeds from exercise of stock options for cash (in shares) Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Issuance of restricted stock units Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issuance of restricted stock units (in shares) CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Amount of accrued final fee made during the period. Accrued Final Fee Accrued final fee Amortization of Debt Discount (Premium) Amortization of debt discount Amount of amortization expense attributable to loan costs. Amortization Of Loan Costs Amortization of loan costs Amount of non-cash compensation. Non cash compensation Non-cash compensation Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Amount of right to use assets attributable to loan costs. Amortization of right of use asset Amortization of right-of-use asset Impairment of Intangible Assets, Finite-lived Write off of patent cost Provision for Doubtful Accounts Bad debt expense Share-based Compensation Stock-based compensation Foreign Currency Transaction Gain (Loss), Unrealized Foreign currency translation (gain) loss Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Grants and accounts receivable Increase (Decrease) in Inventories Inventories Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Other Operating Assets Other assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment. Payments For Proceeds From Property And Equipment Purchases of property and equipment Payments to Acquire Intangible Assets Payments for patent costs Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Proceeds from Issuance of Long-term Debt Proceeds from long-term debt Repayments of Long-Term Debt Repayment of long-term debt The cash outflow for payment of final fees on debt. Payments of Final Fees Payment of final fee Payments of Loan Costs Payment of loan costs The cash outflow for equity contributions - net of fees incurred Payments for Equity contributions - Net of Fees Incurred Equity contributions - net of fees incurred Proceeds from Stock Options Exercised Proceeds from exercise of stock options Proceeds from Issuance of Common Stock Net proceeds from issuance of stock Issuance of common stock, net of fees incurred Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Effect of Exchange Rate on Cash and Cash Equivalents Effect of exchange rates on cash Cash and Cash Equivalents, Period Increase (Decrease) Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash - end of period Cash, cash equivalents and restricted cash - beginning of period Total cash, cash equivalents and restricted cash Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid during the period for interest Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure of non-cash financing activities: The amount of warrants issued in connection with debt. Warrants Issued in Connection with Debt Warrants issued in connection with long-term debt The fair value of issuance of restricted stock units in noncash financing activities. Issuance Of Restricted Stock Units Issuance of restricted stock units BASIS OF PRESENTATION Basis of Accounting [Text Block] BASIS OF PRESENTATION PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY REVENUE Revenue from Contract with Customer [Text Block] REVENUE LONG-TERM DEBT, NET Long-term Debt [Text Block] LONG-TERM DEBT, NET COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES LEASES Lessee, Operating Leases [Text Block] LEASES NET LOSS PER SHARE Earnings Per Share [Text Block] NET LOSS PER SHARE Disclosure of accounting policy for Nature of Business Policy. Nature Of Business Policy [Policy Text Block] Nature of Business Disclosure of accounting policy for basis of consolidation and foreign currency translation. Consolidation and Foreign Currency Translation Policy [Text Block] Basis of Consolidation and Foreign Currency Translation Cash and Cash Equivalents, Policy [Policy Text Block] Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Restricted Cash Trade and Other Accounts Receivable, Policy [Policy Text Block] Grants and Accounts Receivable Inventory, Policy [Policy Text Block] Inventories Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment or Disposal of Long-Lived Assets Income Tax, Policy [Policy Text Block] Income Taxes Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Disclosure of accounting policy for warrants. Warrants Policy [Policy Text Block] Warrants Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs. Shipping And Handling Costs Policy [Policy Text Block] Shipping and Handling Costs New Accounting Pronouncements, Policy [Policy Text Block] Effect of Recent Accounting Pronouncements Tabular disclosure of the components of cash and cash equivalents and restricted cash and cash equivalents. Schedule Of Cash And Cash Equivalents And Restricted Cash And Cash Equivalents [Table Text Block] Schedule of reconciliation of cash and cash equivalents and restricted cash and cash equivalents Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of stock options activity Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Schedule of intrinsic value Schedule of Nonvested Share Activity [Table Text Block] Schedule of company's non-vested options Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Schedule of restricted stock unit Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Schedule of the restricted stock unit activity Disaggregation of Revenue [Table Text Block] Schedule of disaggregation of revenue Contract with Customer, Asset and Liability [Table Text Block] Schedule of receivables and contract liabilities from contracts with customers Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Long-term debt Schedule of Maturities of Long-term Debt [Table Text Block] Schedule of Principal payments of long-term debt Tabular disclosure of Lessee's right-of-use-assets and lease liability under operating lease. Lessee, Operating Lease, Balance Sheet Disclosure [Table Text Block] Schedule of right-of- use asset and related lease liability Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of maturities of the lease liabilities Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Range [Axis] Range [Domain] Maximum [Member] Maximum Schedule of Capitalization [Line Items] BASIS OF PRESENTATION The amount of approximate value of cash and cash equivalents. Cash and Cash Equivalents Gross Value Cash and cash equivalents gross value Restricted Cash and Cash Equivalents, Current Restricted cash The amount of increase in unrestricted cash position related to debt facility. Increase in Unrestricted Cash Related to Debt Facility Increase in unrestricted cash related to debt facility Disclosure of information about principal business activity and summary of significant accounting policies. Principal Business Activity and Summary of Significant Accounting Policies [Table] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Accounts Receivable [Member] Accounts receivable Sales Revenue, Net [Member] Revenue Concentration Risk Type [Axis] Concentration Risk Type [Domain] Customer Concentration Risk [Member] Customer concentration risk Customer [Axis] Customer [Domain] This member stands for distributors/strategic partners. Distributors/Strategic Partners [Member] Distributors/Strategic Partners Cargo and Freight [Member] Cargo and Freight Credit Facility [Axis] Credit Facility [Domain] Letter of credit [Member] Letter of credit Credit Card [Member] Credit Card Debt Instrument [Axis] Debt Instrument, Name [Domain] Represents information pertaining to loan and securities agreement. Loan and security agreement Debt agreement Line items represents the Principal Business Activity and Summary of Significant Accounting Policies. Principal Business Activity and Summary of Significant Accounting Policies [Line Items] PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement. Foreign Currency Transaction Gain (Loss), Excluding Tax Foreign currency transaction gain (loss) Debt Instrument, Collateral Amount Cash collateral Inventory, Finished Goods, Gross Inventory - finished goods Inventory, Work in Process, Gross Inventory - work in process Inventory, Raw Materials, Gross Inventory - raw materials Asset Impairment Charges Impairment charges Unrecognized Tax Benefits Unrecognized tax benefits Number of member banks. Number of Member Bank Number of member bank Number of distributors of the company. Number Of Distributors Number of distributors Concentration Risk, Percentage Concentration risk percentage Restricted Cash and Cash Equivalents Restricted cash Schedule that describes stockholders' equity. Stockholders Equity [Table] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Stockholders Equity [Line Items] STOCKHOLDERS' EQUITY Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding, end of the year Outstanding, beginning of the year Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding, end of the year Outstanding, beginning of the year Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted Average Remaining Contractual Life (Years) Options Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Outstanding, beginning of the year Share based Compensation Arrangement by Share based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term Granted Weighted average remaining contractual term for option awards cancelled during the period, in PnYnMnDTnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days. Share Based Compensation Arrangement by Share Based Payment Award Options Cancelled in Period Weighted Average Remaining Contractual Term Forfeited Share based Compensation Arrangement by Share based Payment Award Options Outstanding Expired In Period Weighted Average Remaining Contractual Term. Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term Expired Weighted average remaining contractual term for option awards exercised during the period, in PnYnMnDTnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days. Share Based Compensation Arrangement by Share Based Payment Award Options Exercised in Period Weighted Average Remaining Contractual Term Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Outstanding, end of the year Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Represents exercise price range one. Exercise Price Range One [Member] Exercise Price Range One Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] STOCKHOLDERS' EQUITY Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract] Options Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Range of Exercise Price, Lower Range Limit Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Range of Exercise Price, Upper Range Limit Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Number Outstanding at September 30, 2024 Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Weighted Average Exercise Price Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Weighted Average Remaining Life (Years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate intrinsic value Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Number Exercisable at September 30, 2024 Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value Schedule of Stock by Class [Table] Class of Stock [Line Items] STOCKHOLDERS' EQUITY Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Non-vested, September 30, 2024 Non-vested, December 31, 2023 Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Vested Vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price Non-vested, September 30, 2024 Non-vested, December 31, 2023 Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Vested Restricted Stock Units (RSUs) [Member] Restricted stock Title of Individual [Axis] Relationship to Entity [Domain] Board of Directors Chairman [Member] Board of Directors Management [Member] Executive Management Officer [Member] Other Employees Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Restricted Stock Units, Ending Balance Restricted Stock Units, Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Restricted Stock Units, Intrinsic Value Ending Balance Restricted Stock Units, Intrinsic Value Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Granted Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures Forfeited Restricted Stock or Unit Expense Restricted Stock Units, Expense Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Non-vested, September 30, 2024 Non-vested, December 31, 2023 Non-Vested shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Options to grant (in shares) Granted

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vested Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited RSU Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Non-vested, September 30, 2024 Non-vested, December 31, 2023 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] STOCKHOLDERS' EQUITY Class of Warrant or Right, Outstanding Number of shares to be purchased Class of Warrant or Right, Exercise Price of Warrants or Rights Warrant Exercise Price per Share Warrant exercise price per share Number of warrants or rights issued. Class of Warrant or Right, Issued Class of warrant issued Price of the entity's common stock which would be required to be attained for revision of exercise price of warrants or rights. Class of Warrant or Right, Revision Of Exercise Price of Warrants or Rights, Stock Price Trigger Stock price trigger for revision of exercise price of warrants Class of Stock [Axis] Class of Stock [Domain] Represents the information pertaining to Exercise Price Ranging From 0.84 to 1.08. Exercise Price Ranging From 0.84 to 1.08 [Member] Exercise Price Ranging From 0.84 to 1.08 Legal Entity [Axis] Entity [Domain] Represents information pertaining to Jefferies LLC and B. Riley FBR, Inc. Jefferies LLC and B. Riley FBR, Inc Jefferies LLC and B. Riley FBR, Inc Director [Member] Director This member stands for Employee One. Employee One [Member] Employee one Employee Stock [Member] Employee Stock This member stands for Employee Two. Employee Two [Member] Employee two Chief Executive Officer [Member] Chief Executive Officer This member stands for senior managers. Senior managers [Member] Senior managers Represents information pertaining to certain named executive officers and senior managers. Certain Named Executive Officers and Senior Managers [Member] Executive officers and senior managers Represents information pertaining to certain named executive officers and senior managers. Certain Named Executive Officers and Senior Managers, Two [Member] Executive officers and senior managers Represents information pertaining to named executive officers. Named Executive Officer [Member] Executive officer Represents information pertaining to certain employees. Certain Employees [Member] Certain employees Chief Financial Officer [Member] Chief Financial Officer Vesting [Axis] Vesting [Domain] Share-based Payment Arrangement, Tranche One [Member] Vesting, tranche one Share-based Payment Arrangement, Tranche Two [Member] Vesting, tranche two Share-based Payment Arrangement, Tranche Three [Member] Vesting, tranche three Minimum [Member] Minimum Scenario [Axis] Scenario, Unspecified [Domain] Represents information pertaining to vesting of share-based awards upon the earlier of a Change in Control or one-third after the second anniversary of the award, one-third on the third anniversary of the award, and one-third on the fourth anniversary of the award. Vesting Upon Earlier Of Change in Control Or One-Third After Second Anniversary, One-Third On Third Anniversary, And One-Third on Fourth Anniversary [Member] Anniversary of the award Represents information pertaining to vesting of share-based awards upon the earlier of a Change in Control or three years from the date of the award. Vesting Upon Earlier Of Change in Control or Three Years from Date of Award [Member] Vesting upon earlier of change in control or three years from date of award Represents information pertaining to no limitation relating to market capitalization. Scenario One, No Limitation Relating To Market Capitalization [Member] Scenario one limitations related to our market capitalization Represents information pertaining to limitation relating to market capitalization. Scenario Two, Limitation Relating To Market Capitalization [Member] Scenario two limitations related to our market capitalization Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants to purchase shares Common Stock Value Authorized For Shares Authorized. Common Stock Value Authorized Aggregate offering price Aggregate maximum amount of securities that can be offered and sold, in one or more offerings, in any combination of common stock, preferred stock, senior or subordinated debt securities, warrants and units, pursuant to shelf registration. Aggregate Registered Amount for Offerings Aggregate registered amount for offerings Payments of Stock Issuance Costs ATM activation fees Share-Based Compensation Arrangement by Share-Based Payment Award, Options, unvested in Period, Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Non-Vested in Period, Fair Value Unvested options in fair value The commission rate as a percentage of the aggregate gross proceeds. Commission Rate As Percentage Of Aggregate Gross Proceeds Commission rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Number of options granted Allocated Share-based Compensation Expense Restricted stock unit Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price Grant date exercise price range Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected life of the stock option Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Current price of the underlying stock and its expected volatility range Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividends Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk free interest rate, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk free interest rate range Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Total unrecognized compensation cost related to stock options Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Amortized period Stock Issued During Period, Shares, Restricted Stock Award, Gross Stock issued during period, shares, restricted stock award, gross Stock Issued During Period, Value, Restricted Stock Award, Gross Stock issued during period, value, restricted stock sward, gross Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period Proceeds from Issuance or Sale of Equity Net proceeds from issuance of stock Sale of Stock, Price Per Share Average selling price Stock Issued During Period, Value, Restricted Stock Award, Forfeitures RSU Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Options to purchase common stock vested Stock Issued During Period, Shares, Other Shares issued other (in shares) Disaggregation of Revenue [Table] This member stands for Direct. Direct [Member] Direct This member stands for united states government agencies. United States Government Agencies [Member] United States Government Agencies Geographical [Axis] Geographical [Domain] United States [Member] United States Germany [Member] Germany This member stands for All other countries. All other countries [Member] All other countries Disaggregation of Revenue [Line Items] REVENUE Sale Revenues Goods Net Sale Revenues Goods Net [Abstract] Product sales: Contract with Customer, Asset, Net, Current Receivables, which are included in grants and accounts receivable Deferred Revenue Contract liabilities, which are included in accrued expenses and other current liabilities Number of primary revenue streams. Number of Primary Revenue Streams Number of primary revenue streams Represents the term of customer contracts. Term Of Customer Contracts Term of customer contracts Value of free of charge goods and credit rebates as on the balance sheet date, classified as current. Contract With Customer Liability, Value of Free Of Charge Goods And Credit Rebates, Current Value of free of charge goods and credit rebates Amount of contract with customer liability net of free of charge goods and credit rebates as on the balance sheet date, classified as current. Contract With Customer Liability, Net Of Free Of Charge Goods And Credit Rebates, Current Contract liabilities net of value of free of charge goods and credit rebates Schedule of Long-Term Debt Instruments [Table] Represents information pertaining to loan and securities agreement, tranche one. Loan and security agreement, tranche one Growth Capital Loan Tranche 1 Represents information pertaining to loan and securities agreement, tranche two. Loan and security agreement, tranche two Growth Capital Loan Tranche 2 Lender Name [Axis] Line of Credit Facility, Lender [Domain] Represents information pertaining to Avenue Venture Opportunities Fund, L.P. Avenue Venture Opportunities Fund, L.P Avenue Venture Opportunities Fund, L.P Represents information pertaining to Avenue Venture Opportunities Fund II, L.P. Avenue Venture Opportunities Fund II, L.P Avenue Venture Opportunities Fund II, L.P Represents prepayment made on or after funding date. Prepayment made on or after funding date Prepayment made on or after funding date Represents prepayment made after first anniversary. Prepayment made after first anniversary Prepayment made after first anniversary Represents prepayment made after second anniversary. Prepayment made after second anniversary Prepayment made after second anniversary Debt Instrument [Line Items] LONG-TERM DEBT The maximum borrowing capacity under the debt instrument. Debt Instrument, Maximum Borrowing Capacity Maximum borrowing capacity Debt Instrument, Face Amount Debt instrument face amount Security amount Debt Instrument, Unused Borrowing Capacity, Amount Debt instrument unused capacity Represents minimum net proceeds to be received from the sale of company's equity securities after the closing date, considered for release of restricted cash to the borrower. Debt Instrument, Threshold Net Proceeds from Sale of Equity Securities, Considered For Release Of Restricted Cash Minimum net proceeds from sale of equity securities, considered for release of restricted cash Amount of restricted cash that will be released on a dollar for dollar basis upon raise of equity. Release Of Restricted Cash Upon Equity Raise Release of restricted cash upon equity raise Debt Instrument, Basis Spread on Variable Rate Interest rate Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Debt Instrument, Interest Rate, Effective Percentage Effective rate Period during which interest only payments shall be made under the debt instrument. Debt Instrument, Periodic Interest Only Payment, Period Period for monthly interest only payments Extended period during which interest only payments shall be made under the debt instrument. Debt Instrument, Periodic Interest Only Payment, Extension Period Extension term of loan Percentage of non refundable commitment fee to be paid by the borrower. Non Refundable Commitment Fee, Percentage Percentage of commitment fee Amount of financial advisor fees and legal fees Paid by the company. Payment Of Financial Advisor And Legal Fees Payment of financial advisor and legal fees Interest expense related to financial advisor fees and legal fees on debt instrument, recorded by the company. Interest Expense Related To Financial Advisor And Legal Fees Interest expense Percentage of non refundable final payment on original commitment amount to be paid by the borrower. Percentage of Non Refundable Payment on Original Commitment Amount Percentage of final payment Interest expense related to final payment on debt instrument, recorded by the company. Interest expense related to final payment Interest expense Percentage of principal amount of debt prepaid, payable as prepayment fee on the debt instrument. Debt Instrument, Prepayment Fee As A Percentage of Principal Amount Prepaid Prepayment percentage Debt Instrument, Accelerated Repayment, Minimum Period After Entry Over Which Any Judgment(S) Singly Or In The Aggregate In Excess Of The Threshold Amount Remain Unsatisfied, Unvacated Or Unstayed, Considered For Events Of Default. Debt Instrument, Accelerated Repayment, Minimum Period After Entry Over Singly In Aggregate In Excess Of Threshold Amount Remain Unsatisfied, Unvacated Or Unstayed, Considered For Events Of Default Minimum period after entry, over which any judgment(s) singly or in the aggregate in excess of the Threshold Amount remain unsatisfied, unvacated or unstayed, considered for events of default to trigger accelerated repayment Period within which any insolvency proceeding brought by a third party is not dismissed or stayed, considered for events of default to cause accelerated repayment of the debt instrument. Debt Instrument, Accelerated Repayment, Period Within Which Any Insolvency Proceeding Brought By A Third Party Is Not Dismissed Or Stayed, Considered For Events Of Default Period within which any insolvency proceeding brought by a third party is not dismissed or stayed, considered for events of default to trigger accelerated repayment Principal amount of outstanding debt instrument that can be converted into equity instruments. Debt Instrument, Convertible, Principal Amount Outstanding Conversion of debt into common stock Percentage of conversion price as a percentage of closing price of common stock. Debt Instrument, Convertible, Conversion Price Percentage Fixed conversion price of closing stock Per share conversion price of closing price of common stock. Debt Instrument, Convertible, Conversion Price, Per Share Fixed conversion price of closing stock, Per share Long-term Debt, Gross Principal amount Amount of long term debt accrued final fee. Long Term Debt Accrued Final Fee Accrued final fee Debt Instrument, Unamortized Discount Less unamortized debt discount Debt Issuance Cost, Gross, Noncurrent Less unamortized debt acquisition costs Long-term Debt. Subtotal Long-term Debt, Maturities, Repayments of Principal in Year Two 2026 Long-term Debt, Maturities, Repayments of Principal in Year Three 2027 Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt and final fee. Long term Debt And Final Fee Total This member stands for western alliance bank. Western Alliance Bank [Member] Western Alliance Bank Represents the information pertaining to 2018 success fee letter. 2018 Success Fee Letter [Member] 2018 Success Fee Letter This member stands for 2022 Success Fee Letter. 2022 Success Fee Letter [Member] 2022 Success Fee Letter This member stands for first tranche Member. First Tranche [Member] First Tranche This member stands for second tranche Member. Second Tranche [Member] Second Tranche This member stands for third tranche Member. Third Tranche [Member] Third Tranche Line of Credit Facility, Maximum Borrowing Capacity Maximum borrowing capacity The average effective success fee rate during the reporting period. Percentage Of Success Fee Percentage of success fee The percentage of closing price on common stock. Percentage of Closing Price on Common Stock Percentage of closing price on common stock Share Price Average selling price Number of days for stock price threshold set in success fee letter. Number of Days for Stock Price Threshold Number of days for stock price threshold set in success fee letter Commitments and Contingencies Disclosure [Table] Commitments and Contingencies Disclosure [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Royalty Agreements [Member] Royalty Agreement Commitments and Contingencies Disclosure [Line Items] Commitments and Contingencies Disclosure [Line Items] COMMITMENTS AND CONTINGENCIES Royalty Expense Royalty cost Lessee, Lease, Description [Table] This member stands for initial early term of operating lease. Initial early term [Member] Initial early term This member stands for early term of operating lease. Early term [Member] Early term This member stands for first year of remaining operating lease term. First year of remaining lease term [Member] Early term Consolidated Entities [Axis] Consolidated Entities [Domain] This member stands for CytoSorbents Medical, Inc. CytoSorbents Medical, Inc [Member] CytoSorbents Medical, Inc This member stands for CytoSorbents Europe GmbH. CytoSorbents Europe GmbH [Member] CytoSorbents Europe GmbH Lessee, Lease, Description [Line Items] LEASES: The number of times lease renewal options available. Number of Times Lease Renewal Available Number of times lease renewal options available Lessee, Operating Lease, Renewal Term Renewal term Lessee, Operating Lease, Remaining Lease Term Remaining lease term Operating Lease, Expense Monthly payments of base rent and other costs The percentage of annual increment in operating lease rent expense. Operating Leases, Annual Rent Expense Increment Rate Annual rent expense increment rate Rent abatement term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Operating Leases, Rent Abatement Term Rent abatement term The percentage of total building space occupied. Percentage Of Total Building Space Occupied Percentage of total building space occupied The amount of allowance for building improvement receivable from landlord. Operating Leases, Building Improvement Allowance Receivable Allowance for building improvement Operating Lease, Liability Total lease liability Operating lease lability Lessee, Operating Lease, Discount Rate Incremental borrowing rate Additional rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income. Additional Operating Leases Rent Expense Net Additional operating leases rent expense Area of Land. Area of Land Operating Lease, Cost Other costs Lessee, Operating Lease, Term of Contract Lease term Lessee, Operating Lease, Existence of Option to Extend [true false] Existence of option to extend The additional lessee operating lease term of contract option to extend. Additional Lessee Operating Lease Term Of Contract Option To Extend Additional lessee operating lease term of contract option to extend Operating Lease, Payments Operating lease paid Operating Lease, Weighted Average Remaining Lease Term Weighted average remaining lease term Lessee, Operating Lease, Liability, to be Paid, Year One 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four 2028 Lessee, Operating Lease, Liability, to be Paid, Year Five 2029 Lessee, Operating Lease, Liability, to be Paid, after Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due Total lease payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Present value discount Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Represents the information pertaining to stock options and warrants. Stock Options and Warrants [Member] Stock options and warrants Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] NET LOSS PER SHARE Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation of earnings per share EX-101.PRE 11 ctso-20240930_pre.xml EX-101.PRE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 05, 2024 Document and Entity Information Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-36792 Â Entity Registrant Name CYTOSORBENTS CORPORATION Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 98-0373793 Â Entity Address, Address Line One 305 College Road East Â Entity Address, City or Town Princeton, Â Entity Address, State or Province NJ Â Entity Address, Postal Zip Code 08540 Â City Area Code 732 Â Local Phone Number 329-8885 Â Title of 12(b)

Security Common Stock, $0.001 par value per share Â Trading Symbol CTSO Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 54,679,569 Entity Central Index Key 0001175151 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) Sep. 30, 2024 Dec. 31, 2023 Current Assets: Â Â Cash and cash equivalents $ 5,685,328 $ 14,131,137 Grants and accounts receivable, net of allowance of $160,246 as of September 30, 2024 and $49,663 at December 31, 2023 6,632,590 6,057,072 Inventories 3,247,756 3,680,129 Prepaid expenses and other current assets 1,031,694 1,834,485 Total current assets 16,597,368 25,702,823 Property and equipment, net 9,269,899 10,056,354 Restricted cash 6,483,958 1,483,958 Right-of-use assets 11,651,563 12,058,896 Other assets 3,801,223 3,958,603 Total Assets 47,804,011 53,260,634 Current Liabilities: Â Â Accounts payable 2,338,143 3,802,170 Current maturities of long-term debt Â 2,500,000 Lease liability - current portion 431,997 373,636 Accrued expenses and other current liabilities 5,660,051 7,870,149 Total current liabilities 8,430,191 14,545,955 Lease liability, net of current portion 12,568,745 12,896,659 Long-term debt 13,805,985 2,542,857 Total Liabilities 34,804,921 29,985,471 Commitments and Contingencies (Note 6) Stockholders' Equity: Â Â Preferred Stock, Par Value $0.001, 5,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023 Common Stock, Par Value $0.001, 100,000,000 shares authorized; 54,500,613 and 54,240,265 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 54,498 54,240 Additional paid-in capital 308,441,887 305,196,874 Accumulated other comprehensive income (loss) (156,925) 529,321 Accumulated deficit (295,340,370) (282,505,272) Total Stockholders' Equity 12,999,090 23,275,163 Total Liabilities and Stockholders' Equity $ 47,804,011 $ 53,260,634 X - DefinitionAmount of accrued expenses and other current liabilities. + ReferencesNo definition available. + Details Name: ctso_AccruedExpensesAndOtherCurrentLiabilities Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB

-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -

Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) Sep. 30, 2024 Dec. 31, 2023 CONDENSED CONSOLIDATED BALANCE SHEETS Â Â Grants and accounts receivable, net of allowance for doubtful accounts $ 160,246 $ 49,663 Preferred Stock, Par Value (in dollars per share) $ 0.001 $ 0.001 Preferred Stock, shares authorized 5,000,000 5,000,000 Preferred Stock, shares issued 0 0 Preferred Stock, shares outstanding 0 0 Common Stock, Par Value (in dollars per share) $ 0.001 $ 0.001 Common Stock, shares authorized 100,000,000 100,000,000 Common Stock, shares issued 54,500,613 54,240,265 Common Stock, shares outstanding 54,500,613 54,240,265 X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue: Â Â Â Â Total revenue $ 9,390,388 $ 8,810,847 $ 29,071,316 $ 27,681,164 Cost of revenue 4,108,773 3,203,981 10,716,394 10,600,421 Gross profit 5,281,615 5,606,866 18,354,922 17,080,743 Other expenses: Â Â Â Â Research and development 1,851,230 3,749,197 5,619,040 11,632,416 Legal, financial and other consulting 823,914 1,103,475 2,325,351 2,957,738 Selling, general and administrative 7,002,718 8,104,392 23,151,118 24,358,417 Total expenses 9,677,862 12,957,064 31,095,509 38,948,571 Loss from operations (4,396,247) (7,350,198) (12,740,587) (21,867,828) Other income (expense): Â Â Â Â Interest expense, net (588,153) (33,670) (774,903) (105,662) Gain (loss) on foreign currency transactions 2,650,309 (1,809,652) 680,392 (733,997) Miscellaneous income Â Â Â 35,000 Total other income (expense), net 2,062,156 (1,843,322) (94,511) (804,659) Loss before benefit from income taxes (2,334,091) (9,193,520) (12,835,098) (22,672,487) Benefit from income taxes 0 0 0 0 Net loss attributable to common stockholders $ (2,334,091) $ (9,193,520) $ (12,835,098) $ (22,672,487) Basic net loss per common share $ (0.04) $ (0.21) $ (0.24) $ (0.52) Diluted net loss per common share $ (0.04) $ (0.21) $ (0.24) $ (0.52) Weighted average number of shares of common stock outstanding, basic 54,453,006 44,373,969 54,340,583 44,024,483 Weighted average number of shares of common stock outstanding, diluted 54,453,006 44,373,969 54,340,583 44,024,483 Comprehensive loss: Â Â Â Â Net loss $ (2,334,091) $ (9,193,520) $ (12,835,098) $ (22,672,487) Other comprehensive income (loss): Â Â Â Â Foreign currency translation adjustment (2,330,743) 1,655,674 (686,246) 654,792 Comprehensive loss (4,664,834) (7,537,846) (13,521,344) (22,017,695) Total product sales Â Â Â Â Revenue: Â Â Â Â Total revenue 8,612,795 7,754,016 26,444,104 23,736,468 CytoSorb sales Â Â Â Â Revenue: Â Â Â Â Total revenue 8,586,274 7,709,085 26,381,455 23,681,183 Other product sales Â Â Â Â Revenue: Â Â Â Â Total revenue 26,521 44,931 62,649 55,285 Grant income Â Â Â Â Revenue: Â Â Â Â Total revenue $ 777,593 $ 1,056,831 $ 2,627,212 $ 3,944,696 X - DefinitionAmount of miscellaneous income (expense). + ReferencesNo definition available. + Details Name: ctso_MiscellaneousIncomeExpense Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-

S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionA fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (k) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_ProfessionalFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ctso_CytoSorbSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ctso_OtherSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_GrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) Common Stock Additional Paid-In Capital Accumulated Other Comprehensive Income (Loss) Accumulated Deficit Total Balance at Dec. 31, 2022 $ 43,635 $ 287,000,021 $ 2,329,195 $ (253,997,878) $ 35,374,973 Balance (in shares) at Dec. 31, 2022 43,635,715 Â Â Â Â Stock-based compensation - employees, consultants and directors Â 2,486,679 Â Â 2,486,679 Issuance of common stock offerings, net of fees $ 591 2,106,528 Â Â 2,107,119 Issuance of common stock offerings, net of fees (in shares) 590,348 Â Â Â Â ATM fee Â (56,702) Â Â (56,702) Proceeds from exercise of stock options for cash $ 83 213,224 Â Â 213,307 Proceeds from exercise of stock options for cash (in shares) 82,355 Â Â Â Â Issuance of restricted stock units $ 130 403,811 Â Â 403,941 Issuance of restricted stock units (in shares) 130,091 Â Â Â Â Other comprehensive income (loss): foreign translation adjustment Â Â 654,792 Â 654,792 Net loss Â Â Â (22,672,487) (22,672,487) Balance at Sep. 30, 2023 $ 44,439 292,153,561 2,983,987 (276,670,365) 18,511,622 Balance (in shares) at Sep. 30, 2023 44,438,509 Â Â Â Â Balance at Dec. 31, 2022 $ 43,635 287,000,021 2,329,195 (253,997,878) 35,374,973 Balance (in shares) at Dec. 31, 2022 43,635,715 Â Â Â Â Balance at Dec. 31, 2023 $ 54,240 305,196,874 529,321 (282,505,272) 23,275,163 Balance (in shares) at Dec. 31, 2023 54,240,265 Â Â Â Â Balance at Jun. 30, 2023 $ 44,193 290,199,035 1,328,313 (267,476,845) 24,094,696 Balance (in shares) at Jun. 30, 2023 44,193,696 Â Â Â Â Stock-based compensation - employees, consultants and directors Â 1,086,163 Â Â 1,086,163 Issuance of common stock offerings, net of fees $ 162 632,232 Â Â 632,394 Issuance of common stock offerings, net of fees (in shares) 162,078 Â Â Â Â Proceeds from exercise of stock options for cash $ 9 15,920 Â Â 15,929 Proceeds from exercise of stock options for cash (in shares) 7,962 Â Â Â Â Issuance of restricted stock units $ 75 220,211 Â Â 220,286 Issuance of restricted stock units (in shares) 74,773 Â Â Â Â Other comprehensive income (loss): foreign translation adjustment Â Â 1,655,674 Â 1,655,674 Net loss Â Â Â (9,193,520) (9,193,520) Balance at Sep. 30, 2023 $ 44,439 292,153,561 2,983,987 (276,670,365) 18,511,622 Balance (in shares) at Sep. 30, 2023 44,438,509 Â Â Â Â Balance at Dec. 31, 2023 $ 54,240 305,196,874 529,321 (282,505,272) 23,275,163 Balance (in shares) at Dec. 31, 2023 54,240,265 Â Â Â Â Stock-based compensation - employees, consultants and directors Â 2,344,671 Â Â 2,344,671 Warrants issued in connection with long-term debt Â 690,709 Â Â 690,709 Issuance of common stock offerings, net of fees $ 53 11,741 Â Â 11,794 Issuance of common stock offerings, net of fees (in shares) 53,290 Â Â Â Â Issuance of restricted stock units $ 205 197,892 Â Â 198,097 Issuance of restricted stock units (in shares) 207,058 Â Â Â Â Other comprehensive income (loss): foreign translation adjustment Â Â (686,246) Â (686,246) Net loss Â Â Â (12,835,098) (12,835,098) Balance at Sep. 30, 2024 $ 54,498 308,441,887 (156,925) (295,340,370) 12,999,090 Balance (in shares) at Sep. 30, 2024 54,500,613 Â Â Â Â Balance at Jun. 30, 2024 $ 54,306 307,514,758 2,173,818 (293,006,279) 16,736,603 Balance (in shares) at Jun. 30, 2024 54,306,415 Â Â Â Â Stock-based compensation - employees, consultants and directors Â 781,881 Â Â 781,881 ATM fee Â (41,444) Â Â (41,444) Issuance of restricted stock units $ 192 186,692 Â Â 186,884 Issuance of restricted stock units (in shares) 194,198 Â Â Â Â Other comprehensive income (loss): foreign translation adjustment Â Â (2,330,743) Â (2,330,743) Net loss Â Â Â (2,334,091) (2,334,091) Balance at Sep. 30, 2024 $ 54,498 $ 308,441,887 $ (156,925) $ (295,340,370) $ 12,999,090 Balance (in shares) at Sep. 30, 2024 54,500,613 Â Â Â Â X - DefinitionNumber of shares issued during the period as a result of the exercise of cash options. + ReferencesNo definition available. + Details Name: ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised Namespace Prefix: ctso_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue stock issued during the period as a result of the exercise of cash options. + ReferencesNo definition available. + Details Name: ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic

205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: Â Â Net loss $ (12,835,098) $ (22,672,487) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Accrued final fee 111,422 32,143 Amortization of debt discount 132,351 Â Amortization of loan costs 58,014 Â Non-cash compensation (96,268) 160,999 Depreciation and amortization 1,180,717 1,067,797 Amortization of right-of-use asset 137,780 166,321 Write off of patent cost 313,414 475,621 Bad debt expense 107,272 14,459 Stock-based compensation 2,344,671 2,486,679 Foreign currency translation (gain) loss (680,392) 733,997 Changes in operating assets and liabilities: Â Â Grants and accounts receivable (628,510) (603,286) Inventories 429,004 471,822 Prepaid expenses and other current assets 504,530 1,370,510 Other assets 1,135 Â Accounts payable and accrued expenses (3,165,684) 1,047,700 Net cash used in operating activities (12,085,642) (15,247,725) Cash flows from investing activities: Â Â Purchases of property and equipment (215,158) (442,618) Payments for patent costs (330,079) (357,696) Net cash used in investing activities (545,237) (800,314) Cash flows from financing activities: Â Â Proceeds from long-term debt 15,000,000 Â Repayment of long-term debt (5,000,000) Â Payment of final fee (150,000) Â Payment of loan costs (697,950) Â Equity contributions - net of fees incurred 11,794 2,050,417 Proceeds from exercise of stock options Â 213,307 Net cash provided by financing activities 9,163,844 2,263,724 Effect of exchange rates on cash 21,226 (1,205) Net change in cash, cash equivalents and restricted cash (3,445,809) (13,785,520) Cash, cash equivalents and restricted cash - beginning of period 15,615,095 23,832,026 Cash, cash equivalents and restricted cash - end of period 12,169,286 10,046,506 Supplemental disclosure of cash flow information: Â Â Cash paid during the period for interest 771,875 275,575 Supplemental disclosure of non-cash financing activities: Â Â Warrants issued in connection with long-term debt 690,709 Â Issuance of restricted stock units $ 198,097 $ 403,941 X - DefinitionAmount of accrued final fee made during the period. + ReferencesNo definition available. + Details Name: ctso_AccruedFinalFee Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to loan costs. + ReferencesNo definition available. + Details Name: ctso_AmortizationOfLoanCosts Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of right to use assets attributable to loan costs. + ReferencesNo definition available. + Details Name: ctso_AmortizationOfRightOfUseAsset Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fair value of issuance of restricted stock units in noncash financing activities. + ReferencesNo definition available. + Details Name: ctso_IssuanceOfRestrictedStockUnits Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of non-cash compensation. + ReferencesNo definition available. + Details Name: ctso_NonCashCompensation Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for equity contributions - net of fees incurred + ReferencesNo definition available. + Details Name: ctso_PaymentsForEquityContributionsNetOfFeesIncurred Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment. + ReferencesNo definition available. + Details Name: ctso_PaymentsForProceedsFromPropertyAndEquipment Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for payment of final fees on debt. + ReferencesNo definition available. + Details Name: ctso_PaymentsOfFinalFees Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of warrants issued in connection with debt. + ReferencesNo definition available. + Details Name: ctso_WarrantsIssuedInConnectionWithDebt Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-

gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossUnrealized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34:

http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for loan origination associated cost which is usually collected through escrow. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfLoanCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.3 BASIS OF PRESENTATION 9 Months Ended Sep. 30, 2024 BASIS OF PRESENTATION Â BASIS OF PRESENTATION 1.Â Â Â Â BASIS OF PRESENTATIONThe accompanying unaudited condensed consolidated financial statements include the accounts of the Company as of September 30, 2024 and December 31, 2023, and for the three and nine months ended September 30, 2024 and 2023. The Companyâ€™s condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X, and; therefore, do not include all information and footnotes necessary for a fair presentation of consolidated financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States ("U.S. GAAP") and should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2023, which are included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments, for a fair presentation of the Companyâ€™s consolidated financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The results for the three and nine months ended September 30, 2024 and 2023, are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.As of September 30, 2024, the Companyâ€™s cash, cash equivalents and restricted cash balances were approximately $12.2 million, including approximately $5.7 million in cash and cash equivalents and approximately $6.5 million in restricted cash, of which the unrestricted portion is not expected to fund the Companyâ€™s operations beyond the next twelve months from the issuance of these consolidated financial statements. This matter raises substantial doubt about the Companyâ€™s ability to continue as a going concern. As a result, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company continues to pursue additional milestones related to its recently announced Avenue Capital Group debt facility that would increase its unrestricted cash position by up to $10 million. If these milestones are not achieved, the Company will need to raise additional capital to support our ongoing operations in the future. Meanwhile the Company continues to evaluate other traditional and alternative sources of capital, including additional less or non-dilutive debt financing, royalty financing, strategic or direct investments, equity financing, and/or combinations thereof. There can be no assurance that management will be successful in these endeavors. X - DefinitionThe entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_BasisOfAccounting Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.3 PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 9 Months Ended Sep. 30, 2024 PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 2.Â Â Â Â PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESPlease see Note 2 to the Company's consolidated financial statements included in the Company's Annual Report on Form 10 - K for the year ended December 31, 2023, filed with the Securities and Exchange Commission ("SEC") on March 14, 2024, for a description of all significant accounting policies.Nature of BusinessThe Company is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. The Company, through its subsidiary CytoSorbents Medical, Inc. (formerly known as CytoSorbents, Inc.), is engaged in the research, development and commercialization of medical devices with its blood purification technology platform which incorporates a proprietary adsorbent, porous polymer technology. The Company, through its wholly-owned European subsidiary, CytoSorbents Europe GmbH, conducts sales and marketing related operations for the CytoSorb device.Basis of Consolidation and Foreign Currency TranslationThe consolidated financial statements include the accounts of CytoSorbents Corporation and its wholly-owned subsidiaries, CytoSorbents Medical, Inc. and CytoSorbents Europe GmbH. All significant intercompany transactions and balances have been eliminated in consolidation.Translation gains and losses resulting from the process of remeasuring into the United States of America dollar the foreign currency financial statements of the European subsidiary, for which the United States of America dollar is the functional currency, are included in operations. The Euro is the functional currency of the European Subsidiary. Foreign currency transaction gain (loss) included in net loss amounted to approximately $2,650,000 and $(1,810,000) for the three months ended September 30, 2024 and 2023, respectively. Foreign currency transaction gain (loss) included in net loss amounted to approximately $680,000 and $(734,000) for the nine months ended September 30, 2024 and 2023, respectively. The Company translates assets and liabilities of all of its foreign subsidiaries at the exchange rate in effect at the condensed consolidated balance sheet date. The Company translates revenue and expenses at the daily average exchange rates. The Company includes accumulated net translation adjustments in accumulated other comprehensive income (loss) as a component of stockholdersâ€™ equity.Cash, Cash Equivalents and Restricted CashThe Company considers all highly liquid investments purchased with an original maturity of threeÂ months or less to be cash equivalents.The following table provides a reconciliation of cash and cash equivalents and restricted cash to amounts shown in the consolidated balance sheets:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â 2024Â Â Â Â DecemberÂ 31,Â 2023Cash and cash equivalentsâ€‹$5,685,328 â€‹$ 14,131,137Restricted cashâ€‹Â 6,483,958â€‹Â 1,483,958Total cash, cash equivalents and restricted cashâ€‹$ 12,169,286â€‹$ 15,615,095â€‹Restricted CashThe Companyâ€™s total restricted cash in the amount of $6,483,958 consists of cash of $5,000,000 which is restricted in accordance with the terms of the debt agreement with Avenue Capital Group (see Note 5), cash of $1,467,458 that the Company is obligated to maintain as collateral for the outstanding letter of credit with Bridge Bank that was provided to the landlord of the College Road facility as security and cash of $16,500 that the Company is obligated to maintain as collateral for the credit limit on the Companyâ€™s credit card accounts.Grants and Accounts ReceivableTrade accounts receivable consist of amounts due from direct customers, distributors and agencies of the U.S. government and are presented at net realizable value. At each balance sheet date, the Company estimates an expected allowance for credit losses inherent in the Companyâ€™s accounts receivable portfolio based on historical experience, specific allowances for known troubled accounts, and other available evidence. In addition, also at each reporting date, this estimate is updated to reflect any changes in credit risk since the receivable was initially recorded. This estimate is calculated on a pooled basis where similar risk characteristics exist. The Company has identified the following portfolio segments: direct customers, distributors/strategic partners and the U.S. government.A fixed reserve percentage for each pool is derived from a review of the Companyâ€™s historical losses in relation to the total pool. This estimate is adjusted quarterly for managementâ€™s assessment of current conditions, reasonable and supportable forecasts regarding future events, and any other factors deemed relevant by the Company. The Company believes historical loss information is a reasonable starting point in which to calculate the expected allowance for credit losses as the Companyâ€™s portfolio segments have remained constant over the Companyâ€™s historical evaluation period.The Company writes off receivables when there is information that indicates the debtor is facing significant financial difficulty and there is no possibility of recovery. If any recoveries are made from any accounts previously written off, they are recognized as an offset to credit loss expense in the year of recovery. The total amount of write-offs was immaterial to the consolidated financial statements as a whole for the three and nine months ended September 30, 2024 and 2023.The allowance for credit losses reflects accounts receivable balances that are written off when management determines they are uncollectible.The allowance for credit losses is measured on a collective (pool) basis when similar risk characteristics exist, and measures the allowance for credit losses using the following methods:Direct Customersâ€”The Company measures expected credit losses on direct customer receivables using an aging methodology. The risk of loss for direct customer receivables is low based on the Companyâ€™s historical experience. The estimate of expected credit losses considers historical credit loss information that is adjusted for current conditions and supportable forecasts.Distributors/Strategic Partnersâ€”The Company measures expected credit losses on distributor receivables using an individual reserve methodology. The risk of loss in this portfolio is low based on the Companyâ€™s historical experience. The estimate of expected credit losses considers the past payment history of each distributor.U.S. Governmentâ€” These receivables are related to the Companyâ€™s government grants. The Company measures expected credit losses on these receivables using an individual reserve methodology. The risk of loss in this portfolio is very low based on the Companyâ€™s historical experience, as these receivables are supported by approved grant award contracts.InventoriesInventories are valued at the lower of cost or net realizable value under the first in, first out (FIFO) method. At September 30, 2024 and December 31, 2023, the Companyâ€™s inventory was comprised of finished goods, which amounted to $1,430,325 and $2,155,457, respectively; work in process, which amounted to $1,049,319 and $838,871, respectively; and raw materials, which amounted to $768,112 and $685,801, respectively. Devices used in clinical trials or for research and development purposes are removed from inventory and charged to research and development expenses at the time of their use. Donated devices are removed from inventory and charged to selling, general and administrative expenses.Impairment or Disposal of Long-Lived AssetsThe Company assesses the impairment of patents and other long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. During the three months ended September 30, 2024 and 2023, the Company recorded impairment charges of approximately $64,000 and $183,000, respectively, and during the nine months ended September 30, 2024 and 2023, the Company recorded impairment charges of approximately $313,000 and $476,000, respectively, related to the impairment of certain issued patents and pending patent applications in certain specific jurisdictions and the abandonment of certain pending patent application costs in the ordinary course of business. This charge is included in legal, financial and other consulting in the consolidated statements of operations and comprehensive loss.Income TaxesThe Company has not recorded income tax expense or income tax benefit for the three and nine months ended September 30, 2024, and 2023 due to the generation of net operating losses, the benefits of which have been fully reserved.Deferred income taxes are accounted for using the balance sheet approach, which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that a future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership.The Company follows accounting standards associated with uncertain tax positions. The Company had no unrecognized tax benefits at September 30, 2024. The Company is accounting for an uncertain tax position of approximately $2.1 million for the year ended December 31, 2023. The Company files tax returns in the U.S. federal and state jurisdictions.The Company utilizes the Technology Business Tax Certificate Transfer Program to sell a portion of its New Jersey Net Operating Loss carryforwards to an industrial company.Concentration of Credit RiskThe Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation (â€œFDICâ€). Beginning in April of 2023, the Company joined the IntraFi network, and established an Insured Cash Sweep (â€œICSâ€) account whereby all cash that was previously held in the Companyâ€™s money market account at Bridge Bank is swept daily in increments of less than $250,000 and deposited in a number of IntraFiâ€™s 4,000 member banks. This arrangement provides FDIC insurance coverage for all of the cash balances previously held in the money market account, which represents all of the cash and cash equivalents held at Bridge Bank. This arrangement excludes the restricted cash balances. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances. A significant portion of the Companyâ€™s revenues are from product sales in Germany. Substantially all of the Companyâ€™s grant and other income are from government agencies in the United States. (See Note 4 for further information relating to the Companyâ€™s revenue.)As of September 30, 2024, two distributors accounted for approximately 31% of outstanding grants and accounts receivable. As of December 31, 2023, one distributor accounted for approximately 19% of outstanding grants and accounts receivable. For the three months ended September 30, 2024 and 2023, no distributor or direct customers accounted for more than 10% of the Companyâ€™s total revenue. For the nine months ended

September 30, 2024 and 2023, one distributor accounted for approximately 10% for each period, of the Companyâ€™s total revenue.WarrantsThe Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrantâ€™s specific terms and applicable authoritative guidance in ASC 480 â€œDistinguishing Liabilities From Equityâ€ (â€œASC 480â€) and ASC 815 â€œDerivatives and Hedgingâ€ (â€œASC 815â€). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Companyâ€™s own ordinary shares and whether the warrant holders could potentially require â€œnet cash settlementâ€ in a circumstance outside of the Companyâ€™s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance, and will remain as a component of equity thereafter. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.The warrants issued upon the closing of the Companyâ€™s December 13, 2023 offering and the closing of the Companyâ€™s June 2024 debt financing both met the criteria for equity classification under ASC 815. Accordingly, these warrants have been classified as equity as of September 30, 2024 and December 31, 2023.Shipping and Handling CostsThe cost of shipping product to customers and distributors is typically borne by the customer or distributor. The Company records other shipping and handling costs in cost of revenue. Total freight costs amounted to approximately $89,000 and $140,000, respectively, for the three months ended September 30, 2024 and 2023, and $267,000 and $341,000, respectively, for the nine months ended September 30, 2024 and 2023.Effect of Recent Accounting PronouncementsIn August 2020, the FASB issued ASU 2020-06, â€œDebt â€“ Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging â€“ Contracts in Entityâ€™s Own Equity (Subtopic 815-40)â€ (â€œASU 2020-06â€). ASU2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entityâ€™s own equity. The ASU is part of the FASBâ€™s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASUâ€™s amendments are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. The Company adopted the provisions of ASU 2020-06 on January 1, 2024. This did not have a material impact on the Companyâ€™s consolidated financial statements.In December 2023, the FASB issued ASU No. 2023-09 entitled â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€. This ASU provides guidance related to additional disclosures that will be required related to income taxes. The updated guidance is effective for public entities for fiscal years beginning after December 15, 2024. This ASU will result in additional disclosures in the Companyâ€™s consolidated financial statements related to income taxes in 2025.In November 2023, the FASB issued ASU No. 2023-07 (â€œASU 2023-07â€), â€œImprovements to Reportable Segment Disclosuresâ€. The guidance primarily will require enhanced disclosures about significant segment expenses. All disclosure requirements under ASU 2023-07 and existing segment disclosures in ASC 280, â€œSegment Reportingâ€ are also required for public entities with a single reportable segment. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. A retrospective approach is required to be applied to all prior periods presented in the financial statements. The Company plans to adopt the provisions of ASU 2023-07 in the first quarter of fiscal 2025 and continues to evaluate the disclosure requirements related to the new standard.On April 3, 2024, the Financial Accounting Standards Board (the "FASB") began a project related to the accounting and reporting of government grants. The FASB has decided to pursue an International Accounting Standards ("IAS") 20 accounting model. Under IAS 20, a grant relating to income may be reported separately as 'other income' or deducted from the related expense. The FASB expects to issue and exposure draft of a proposed ASU in the fourth quarter of 2024. The company is evaluating its accounting and reporting policy for government grants relative to this project and the requirements of IAS 20. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.3 STOCKHOLDERS' EQUITY 9 Months Ended Sep. 30, 2024 STOCKHOLDERS' EQUITY Â STOCKHOLDERS' EQUITY 3.Â Â Â Â STOCKHOLDERSâ€™ EQUITYPreferred StockIn June 2019, the Company amended and restated its certificate of incorporation. The amended and restated certificate of incorporation authorizes the issuance of up to 5,000,000 shares of â€œblank checkâ€ preferred stock, with such designation rights and preferences as may be determined from time to time by the Board of Directors.Common StockIn June 2019, the Company amended and restated its certificate of incorporation. The amended and restated certificate of incorporation increased the number of shares of common stock authorized for issuance from 50,000,000 shares to 100,000,000 shares. Shelf RegistrationOn July 14, 2021, the Company filed a registration statement on Form S-3 with the SEC, which was amended on July 20, 2021 and declared effective by the SEC on July 27, 2021 (as amended, the â€œ2021 Shelfâ€). The 2021 Shelf enables the Company to offer and sell, in one or more offerings, any combination of common stock, preferred stock, senior or subordinated debt securities, warrants and units, up to a total dollar amount of $150 million and expires after three years. On July 26, 2024, the Company filed a registration statement on Form S-3 with the SEC (the â€œ2024 Shelfâ€), which enables the Company to offer and sell in one or more offerings, any combination of common stock, preferred stock, senior or subordinated debt securities, warrants and units, up to a total dollar amount of $150 million. On September 26, 2024, the Company filed Amendment No. 1 to the Form S-3 with the SEC. The 2024 Shelf was declared effective by the SEC on September 30, 2024. Because the Companyâ€™s market capitalization is less than $75 million, it will be subject to baby shelf rules which limit the amount of securities sales the Company can make to one-third of its public market float over a 12-month period.Open Market Sale Agreement with Jefferies LLCOn December 30, 2021, the Company entered into an Open Market Sale Agreement (the â€œSale Agreementâ€) with Jefferies LLC (the â€œAgentâ€), pursuant to which the Company may sell, from time to time, at its option, shares of the Companyâ€™s common stock having an aggregate offering price of up to $25 million through the Agent, as the Companyâ€™s sales agent. However, as a result of limitations related to our market capitalization discussed above, the Company may offer and sell shares of the Company's common stock having an aggregate offering price of up to approximately $19,700,000 from time to time through the Agent. If the Company's public float increases above $75,000,000, the Company may sell additional amounts under the Sales Agreement. All shares of the Companyâ€™s common stock offered and sold, or to be offered and sold under the Sale Agreement will be issued and sold pursuant to the Companyâ€™s 2024 Shelf by methods deemed to be an â€œeat the market offeringâ€ as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, in block transactions or if specified by the Company, in privately negotiated transactions.Subject to the terms of the Sales Agreement, the Agent is required to use its commercially reasonable efforts consistent with their normal sales and trading practices to sell the shares of the Companyâ€™s common stock from time to time, based upon the Companyâ€™s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company is required to pay the Agent a commission of up to 3.0% of the gross proceeds from the sale of the shares of the Companyâ€™s common stock sold thereunder, if any. There were no sales under the Sale Agreement during the year ended December 31, 2022. During the year ended December 31, 2023, the Company sold 2,656,464 shares pursuant to the Sale Agreement, at an average selling price of $1.76 per share, generating net proceeds of approximately $4,532,000. In addition, during the year ended December 31, 2023, the Company paid approximately $61,000 in expenses related to the Sale Agreement. During the nine months ended September 30, 2024, the Company sold 53,290 shares pursuant to the Sales Agreement at an average selling price of $1.03 per share, generating net proceeds of approximately $53,000. In addition, the Company incurred ATM activation fees of approximately $41,000 during the three and nine months ended September 30, 2024.Stock-Based CompensationTotal share-based employee, director, and consultant compensation amounted to approximately $782,000 and $2,345,000 for the three and nine months ended September 30, 2024, respectively, and approximately $1,086,000 and $2,487,000 for the three and nine months ended September 30, 2023, respectively. These amounts are included in the consolidated statements of operations and comprehensive loss under cost of revenue and selling, general, and administrative expenses.The summary of the stock option activity for the nine months ended September 30, 2024 is as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted â€‹â€‹â€‹â€‹â€‹Weightedâ€‹Average â€‹â€‹â€‹â€‹â€‹Averageâ€‹Remainingâ€‹â€‹â€‹â€‹â€‹Exercise Priceâ€‹Contractual â€‹Â Â Â Â SharesÂ Â Â Â perÂ ShareÂ Â Â Â LifeÂ (Years)Outstanding, DecemberÂ 31,Â 2023Â 10,548,174â€‹$ 4.49 â€‹ 7.01GrantedÂ 3,687,366â€‹$ 0.96Â â€”ForfeitedÂ (1,018,794)â€‹$ 2.69Â â€”ExpiredÂ (706,609)â€‹$ 5.40Â â€”ExercisedÂ â€”â€‹$â€”Â â€”Outstanding, SeptemberÂ 30,Â 2024Â 12,510,137â€‹$ 3.54Â 7.06â€‹The fair value of each stock option was estimated using the Black Scholes pricing model, which takes into account as of the grant date the exercise price (ranging from $0.84 to $1.08 per share) and expected life of the stock option (6Â years), the current price of the underlying stock and its expected volatility (77.8%), expected dividends (0)% on the stock and the risk free interest rate (ranging from 3.60% to 4.65%) for the expected term of the stock option.The intrinsic value is calculated as the difference between the market value of the shares as of September 30, 2024 of $1.50 and the exercise price of the shares.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Options Outstanding â€‹â€‹Numberâ€‹Weightedâ€‹Weightedâ€‹â€‹â€‹Range ofâ€‹Outstanding atâ€‹Averageâ€‹Averageâ€‹AggregateExerciseâ€‹SeptemberÂ 30,Â â€‹Exerciseâ€‹Remainingâ€‹IntrinsicPriceÂ Â Â Â 2024Â Â Â Â PriceÂ Â Â Â Life (Years)Â Â Â Â Value$0.84 - $13.20Â 12,510,137â€‹$3.54 â€‹7.06â€‹$ 1,892,822â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Options ExercisableNumberâ€‹Weightedâ€‹Â Â Exercisable atâ€‹Averageâ€‹AggregateSeptemberÂ 30,Â â€‹Exerciseâ€‹Intrinsic2024Â Â Â Â PriceÂ Â Â Â Value6,164,466â€‹$ 5.48â€‹$ 33,555â€‹The summary of the status of the Companyâ€™s non-vested options for the nine months ended September 30, 2024 is as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted â€‹â€‹â€‹â€‹â€‹Average â€‹â€‹â€‹â€‹â€‹Grantâ€‹Dateâ€‹Â Â Â Â SharesÂ Â Â Â FairÂ Value â€‹â€‹â€‹â€‹â€‹Non-vested, DecemberÂ 31,Â 2023Â 5,205,736â€‹$ 1.89GrantedÂ 3,687,366â€‹$ 0.67ForfeitedÂ (1,018,794)â€‹$ 1.81VestedÂ (1,528,637)â€‹$ 2.30Non-vested, SeptemberÂ 30,Â 2024Â 6,345,671â€‹$ 1.08â€‹As of September 30, 2024, the Company had approximately $3,540,000 of total unrecognized compensation cost related to stock options which will be amortized over approximately 35 months.On March 29, 2024, the Company granted options to purchase 380,480 shares of common stock to certain executive officers and certain other non-executive officer employees related to the Companyâ€™s salary reduction for stock options program. These options will vest in full on January 31, 2025. The grant date fair value of these unvested options amounted to approximately $249,000.On April 2, 2024, the Company granted options to purchase 1,214,400 shares of common stock to the Companyâ€™s employees which will be awarded based upon each employeeâ€™s 2024 individual performance evaluation. Once awarded, these options will vest one half on the first anniversary of the grant date, one quarter on the second anniversary of the grant date, and one quarter on the third anniversary of the grant date. The grant date fair value of these unvested options amounted to approximately $830,000.On April 2, 2024, the Company granted options to purchase 922,147 shares of common stock to certain of the Companyâ€™s employees. These options will vest in full on the first anniversary of the grant date. The grant date fair value of these unvested options amounted to approximately $594,000.On April 2, 2024, the Company granted options to purchase 110,000 shares of common stock to members of the Companyâ€™s Board of Directors. These options will vest in full on the first anniversary of the grant date. The grant date fair value of these unvested options amounted to approximately $71,000.On April 2, 2024, the Company granted options to purchase 556,000 shares of common stock to certain senior managers of the Company. These options will vest one half on the first anniversary of the grant date, one quarter on second anniversary of the grant date, and one quarter on third anniversary of the grant date. The grant date fair value of these unvested options amounted to approximately $380,000. On April 8, 2024, the Company granted options to purchase 131,339 shares of common stock employees related to the Companyâ€™s salary reduction for stock options program. The grant date fair value of these unvested options amounted to approximately $85,000. These options will vest in full on January 31, 2025. On August 14, 2024, the Company granted, in connection with the appointment of its new Chief Financial Officer, options to purchase 80,000 shares of common stock which will vest as follows: 41,000 options upon the six - month anniversary of the date of grant and 13,000 options upon each of the first, second and third anniversaries of the date of grant. The Company also granted options to purchase 215,000 shares of common stock that will vest only upon the achievement of certain milestones pursuant to the terms of the Company's existing 2022 - 2025 performance pool in place for the Company's management team.During the nine months ended September 30, 2024, 78,000 options were awarded to newly hired employees or to consultants in connection with their employment or consulting agreements.Change in Control-Based Awards of Restricted Stock Units:The Board of Directors has granted restricted stock units to members of the Board of Directors, to the Companyâ€™s executive officers, and to employees of the Company. These restricted stock units will only vest upon a Change in Control of the Company, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan, as amended.The following table is a summary of these restricted stock units:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

$0, respectively, related to these restricted stock unit awards.On August 14, 2024, the Company granted, in connection with the appointment of its new Chief Financial Officer, 65,000 restricted stock units. This award was valued at approximately $63,000 at the date of issuance, based upon the market price of the Company's common stock at the date of the grant. These restricted stock units will vest equally on the first anniversary of the date of the grant and the second anniversary of the date of the grant. For the three and nine months ended September 30, 2024 and 2023, the Company recorded a charge of approximately $4,000 and $4,000 and $0 and $0, respectively, related to these restricted stock unit awards.Additionally, certain employees were offered a total of 213,000 restricted stock units as a condition of their employment. These awards were valued at approximately $517,000 at the date of issuance. 40,000 of these restricted stock units valued at $149,000 were forfeited as of September 30, 2024. 33,000 of these restricted stock units valued at approximately $231,000 were vested as of September 30, 2024. The remaining 140,000 of these restricted stock units will vest upon the earlier of a Change in Control or in three or four years from the date of the award, whichever occurs first. For the three and nine months ended September 30, 2024 and 2023, the Company recorded a charge (income) of approximately $(23,000) and $(186,000), and $8,000 and $0, respectively, related to these restricted stock unit awards.The following table outlines the restricted stock unit activity for the nine months ended September 30, 2024:â€‹â€‹â€‹

supplemented, restated or otherwise modified as of the date hereof and from time to time, the â€œLoan and Security Agreementâ€) with Avenue Venture Opportunities Fund, L.P., a Delaware limited partnership (â€œAvenueâ€), Avenue Venture Opportunities Fund II, L.P., a Delaware limited partnership (â€œAvenue 2â€ and, together with Avenue, the â€œLendersâ€), and Avenue Capital Management II, L.P., a Delaware limited partnership (the â€œAdministrative and Collateral Agentâ€).Under the Loan and Security Agreement, the Lenders have agreed to loan to the Company up to an aggregate of $20 million, to be disbursed in two tranches: (1) one tranche of $15 million (â€œGrowth Capital Loan Tranche 1â€) on the Closing Date, with $4.5 million funded by Avenue and $10.5 million funded by Avenue 2, of which $10 million is available to the Company on the Closing Date and $5 million constitutes restricted cash subject to release to the Company prior to March 31, 2025, provided (i) the FDA has accepted Companyâ€™s application for review with respect to DrugSorb-ATR De Novo 510(k) and (ii) the Company has received a minimum of $3 million in net proceeds from the sale of its equity securities after the Closing Date. The restriction will be released on a dollar for dollar basis for equity raised between $3 million and $5 million and (2) a second tranche of up to $5 million, which may be disbursed at the Companyâ€™s request between July 1, 2025 and December 31, 2025, provided that the Company receives FDA marketing approval of its DrugSorb-ATR application (â€œGrowth Capital Loan Tranche 2â€ and together with Growth Capital Loan Tranche 1, the â€œGrowth Capital Loansâ€ or the â€œCommitmentâ€). The proceeds from the Commitment were used to pay off the existing outstanding debt with Bridge Bank, and will additionally be used for working capital purposes and to fund general business requirements in accordance with the terms of the Loan and Security Agreement. Each Growth Capital Loan shall bear interest at a variable rate per annum equal to the greater of (A) the Prime Rate (as defined in the Loan and Security Agreement) plus five percent (5.00%) or (B) thirteen and one-half percent (13.50%).Commencing on August 1, 2024, the Company shall make monthly payments during the term of each Growth Capital Loan of interest only during the initial 25-month period following the Closing Date (as may be extended to the 30 months anniversary of the Closing Date upon satisfaction of certain conditions) and thereafter to maturity in equal monthly installments of principal plus accrued and unpaid interest. All unpaid principal and accrued and unpaid interest shall be due and payable in full on July 1, 2027; provided, however that if the Company draws the full amount of Growth Capital Loan Tranche 2 by December 2025, all unpaid principal and accrued and unpaid interest shall be due and payable in full by January 1, 2028. In addition, the Loan and Security Agreement required the Company to pay a non-refundable commitment fee equal to 1.00% of the Commitment due and payable on the Closing Date. In addition to the non-refundable commitment fee, the Company also paid financial advisor fees and legal fees of approximately $640,000 related to the Commitment. These costs are being amortized over the loan period as a charge to interest expense. During the three and nine months ended September 30, 2024, the Company recorded interest expense of approximately $58,000 related to these costs. In addition, the Loan and Security Agreement requires the Company to pay a non-refundable final payment equal to 4.5% of the original commitment amount. This final payment has been accrued and included as part of the debt discount. This discount will be charged to interest expense over the term of the loan. For the three and nine months ended September 30, 2024, the Company recorded interest expense of approximately $132,000 related to the debt discount.The Capital Growth Loans are evidenced by secured promissory notes issued to the Lenders by the Company. If the Company elects to prepay the Growth Capital Loan(s) pursuant to the terms of the Loan and Security Agreement, it will owe a prepayment fee to the Lenders, as follows: (1) for a prepayment made on or after the funding date of a Growth Capital Loan through and including the first anniversary of such funding date, an amount equal to 3.00% of the principal amount of such Growth Capital Loan prepaid; (2) for a prepayment made after the first anniversary of the funding date of a Growth Capital Loan through and including the second anniversary of such funding date, an amount equal to 2.00% of the principal amount of such Growth Capital Loan prepaid; and (3) for a prepayment made any time after the second anniversary of the funding date of a Growth Capital Loan, an amount equal to 1.00% of the principal amount of such Growth Capital Loan prepaid. Events of default which may cause repayment of the Commitment to be accelerated include, among other customary events of default, (1) non-payment of any obligation when due, (2) the failure to perform any obligation required under the Loan and Security Agreement and to cure such default within a reasonable time frame, (3) the occurrence of any circumstance that has a Material Adverse Effect (as defined in the Loan and Security Agreement), (4) default beyond any applicable grace period or cure under any other agreement involving the borrowing of money in excess of the Threshold Amount (as defined in the Loan and Security Agreement), (5) any judgment(s) singly or in the aggregate in excess of the Threshold Amount entered against the Company that remain unsatisfied, unvacated or unstayed for 15 days or more after entry thereof (to the extent not otherwise covered by independent third-party insurance), and (6) if the Company becomes insolvent or starts an insolvency proceeding or if an insolvency proceeding is brought by a third party against the Company and such proceeding is not dismissed or stayed within 45 days. The Loan and Security Agreement includes customary loan conditions, company representations and warranties, company affirmative covenants and company negative covenants for secured transactions of this type. As of September 30, 2024, the Company was in compliance with these covenants. As additional consideration for the Commitment, on June 28, 2024, the Company also issued each Lender a warrant instrument (each, a â€œWarrantâ€) entitling the Lenders to purchase an aggregate of 1,645,569 shares of the Companyâ€™s common stock for cash at the exercise price of $0.79 and expire on June 28, 2029. The number of warrants is fixed, however, the exercise price may be adjusted down if the Company raises equity (excluding sales of equity utilizing the Companyâ€™s at-the-market equity facility) at a share price that is lower than $0.79. These warrants meet the criteria for equity classification under ASC 815. Accordingly, the Company has recorded a debt discount and additional paid-in capital of approximately $690,000 related to these warrants as of June 30, 2024. This discount will be charged to interest expense over the term of the loan.The Lenders were also granted the right while the Commitment is outstanding to convert up to an aggregate amount of $2,000,000 of the principal amount of the outstanding Growth Capital Loans into the Companyâ€™s common stock at a fixed conversion price of 120% of the Closing Price (as defined in the warrant) or $0.95 per share (the â€œConversion Optionâ€).The Companyâ€™s and CytoSorbents Medicalâ€™s obligations under the Loan and Security Agreement are joint and several. The obligations under the Loan and Security Agreement are secured by a first priority security interest in favor of the Lenders with respect to the Companyâ€™s Shares (as defined in the Loan and Security Agreement) and the Companyâ€™s Collateral (as defined in the Loan and Security Agreement), which includes the Companyâ€™s intellectual property, pursuant to that certain Intellectual Property Security Agreement, dated as of June 28, 2024, by and between the Company and the Administrative and Collateral Agent.â€‹Long-term debt consists of the following as of September 30, 2024:â€‹â€‹â€‹â€‹Principal amountÂ Â Â Â $ 15,000,000Accrued final feeâ€‹Â 900,000Less unamortized debt discountâ€‹â€‹ (1,455,858)Less unamortized debt acquisition costsâ€‹â€‹ (638,157)Subtotalâ€‹Â 13,805,985Less Current maturitiesâ€‹Â â€”Long-term debt net of current maturitiesâ€‹$ 13,805,985â€‹Principal payments of long-term debt are due as follows during the periods ending September 30:â€‹â€‹â€‹â€‹2025Â Â Â Â $ â€”2026Â Â Â Â â€‹ 2,500,0002027â€‹Â 12,500,0002028â€‹â€‹ â€”Totalâ€‹$ 15,000,000â€‹Bridge Bank:On June 28, 2024, concurrent with the closing of the Avenue Capital Group financing discussed above, the Company paid off its existing outstanding debt with Bridge Bank. The following items survive the termination of the Bridge Bank Amended and Restated Loan and Security Agreement and related amendments:2018 Success Fee Letter:Pursuant to the amended 2018 Letter, the Borrower shall pay to the Bank a success fee in the amount equal to 6.37% of the funded amount of the Term B Loan (as defined in the Restated Loan and Security Agreement) (the â€œSuccess Feeâ€) upon the first occurrence of any of the following events: (a) a sale or other disposition by the Borrower of all or substantially all of its assets; (b) a merger or consolidation of the Borrower into or with another person or entity, where the holders of the Borrowerâ€™s outstanding voting equity securities as of immediately prior to such merger or consolidation hold less than a majority of the issued and outstanding voting equity securities of the successor or surviving person or entity as of immediately following the consummation of such merger or consolidation; (c) a transaction or a series of related transactions in which any â€œpersonâ€ or â€œgroupâ€ (within the meaning of Section 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€) becomes the â€œbeneficial ownerâ€ (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of a sufficient number of shares of all classes of stock then outstanding of the Borrower ordinarily entitled to vote in the election of directors, empowering such â€œpersonâ€ or â€œgroupâ€ to elect a majority of the Board of Directors of the Borrower, who did not have such power before such transaction; or (d) the closing price per share for the Companyâ€™s common stock on the Nasdaq Capital Market being the greater of (i) 70% or more over $7.05, the closing price of the Companyâ€™s common stock on March 29, 2018 (after giving effect to any stock splits or consolidations effected after the date thereof) for five successive business days, or (ii) at least 26.13% more than the average price of Companyâ€™s common stock for the 365-day period ending on the date of the funding of the Term B Loan. This obligation terminated on the fifth anniversary of the funding of the Term B Loan which was July 31, 2024.2022 Success Fee Letter:Pursuant to the 2022 Success Fee Letter, the Borrower will pay to the Bank a success fee equal to (i) 1% of $5 million if the Company draws down the first tranche of the Term C Loan and is payable only if the Companyâ€™s stock price equals or exceeds $8 for five consecutive trading days; (ii) 1.5% of $5 million if the Company draws down the second tranche of the Term C Loan and is payable only if the Companyâ€™s stock price equals or exceeds $10 for five consecutive trading days; and (iii) 2% of $5,000,000 if the Company draws down the third tranche of the Term C Loan and is payable only if the Companyâ€™s stock price equals or exceeds $12 for five consecutive trading days (together, the â€œSuccess Feeâ€). As of June 28, 2024, the Company had drawn down only the first tranche of the Term C Loan. Borrower may pay the Success Fee in cash or in shares of common stock, at Borrowerâ€™s sole discretion. The right of Bank to receive the Success Fees and the obligation of the Borrower to pay the Success Fees hereunder shall terminate on the date that is the fifth anniversary of the funding date of the last Term C Loans made but shall survive the termination of the Loan Agreement and any prepayment of the Term C Loans. The termination date of this Letter is December 27, 2027. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent + Details Name: us-gaap_LongTermDebtTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.3 COMMITMENTS AND CONTINGENCIES 9 Months Ended Sep. 30, 2024 COMMITMENTS AND CONTINGENCIES Â COMMITMENTS AND CONTINGENCIES 6.Â Â Â Â COMMITMENTS AND CONTINGENCIESLitigationThe Company is, from time to time, subject to claims and litigation arising in the ordinary course of business. The Company intends to defend vigorously against any future claims and litigation.On March 5, 2024, Danielle Greene, a former employee, filed a complaint against us in the Superior Court of New Jersey, Law Division, Mercer County, alleging breach of the New Jersey Conscientious Employee Protection Act (â€œCEPAâ€). The complaint specifically alleges that we violated the provisions of the CEPA by allegedly terminating Ms. Greene in retaliation for complaining about certain business practices. We dispute these allegations and intend to vigorously defend against them, but there can be no assurance as to the outcome of the litigation.Royalty/License AgreementsThe Company is party to various royalty and license agreements that require the payment of royalty fees. Royalty expense amounted to approximately $354,000 and $537,000, respectively, for the three months ended September 30, 2024 and 2023. For the nine months ended September 30, 2024 and 2023, royalty expense amounted to approximately $1,594,000 and $1,643,000, respectively. In addition, the Companyâ€™s license agreement with Purolite expired on August 6, 2024. Royalty expense are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.3 LEASES 9 Months Ended Sep. 30, 2024 LEASES Â LEASES 7.Â Â Â Â LEASESThe Company leases its operating facilities in both the United States and Germany under operating lease agreements. In March 2021, CytoSorbents Medical Inc. entered into a lease agreement for a new operating facility at 305 College Road East, Princeton, New Jersey, which contains office, laboratory, manufacturing and warehouse space. The lease commenced on June 1, 2021. The Early Term commenced on June 1, 2021 and ended September 30, 2021. The lease also contains two five-year renewal options; however, the Company had determined that it is not likely that they will exercise these options. Commencing on September 30, 2021, the remaining lease term will end in 15.5 years. The lease requires monthly rental payments of $25,208 for the Initial Early Term, $88,254 for the Early Term and initial monthly payments of approximately $111,171 in the first year of the remaining term. Following the first year of the remaining term, the annual base rent will increase by approximately 2.75% annually over the remaining term. The lease also contains six months of rent abatement (months 1, 2, 3, 25, 26 and 27 of the remaining lease term). In addition to the base rent, payments of operating expenses and real estate taxes will be required. These payments are to be based on actual amounts incurred during 2021 multiplied by the Companyâ€™s share of the total building space (92.3%). The landlord will also provide an allowance of approximately $1,455,000 related to certain building improvements as outlined in the lease. In April 2021, the Company provided the landlord with a letter of credit in the amount of approximately $1,467,000 as security. The Company has determined that this lease should be treated as an operating lease in accordance with the provisions of Accounting Standards Codification (â€œASCâ€) 842. On April 1, 2021, the Company recorded a Right-of-Use asset and related lease liability of approximately $11.6 million, which represents the estimated present value of the lease payments at the commencement date discounted at the Companyâ€™s incremental borrowing rate of 9.8%. In addition, due to the six months of rent abatement and annual base rent escalations during the remaining lease term that commenced on September 30, 2021, the Company will recognize rent expense on this lease on a straight-line basis over the remaining term of the lease for the difference between the rent expense recognized and the required payments under the lease.In September 2021, the Company extended its two operating leases for its office facility in Germany. These leases require combined base rent payments amounting to approximately $12,100 perÂ month. The initial lease term of both leases ends AugustÂ 31, 2026. In addition, the Company is obligated toÂ monthly operating expenses of approximately $3,000 perÂ month. Both leases have a five-year option to renew that would extend the lease term to AugustÂ 31, 2031. There are no provisions in the leases to increase the base rent during the renewal period. There were no lease incentives and no initial direct costs were incurred related to these leases.In January 2021, CytoSorbents Europe GmbH entered into a lease for 1,068 square meters of additional warehouse space. The lease commenced on April 1, 2021 and requires monthly payments of base rent of $7,784 and other costs of approximately $239 and has a term of five years. The lease also has an option to extend the lease term for an additional five-year period through March 31, 2031. The Company has determined that this lease should be treated as an operating lease in accordance with the provisions of ASC 842. On April 1, 2020, the Company recorded a Right-of-Use asset and related lease liability at the estimated present value of the lease payments at the commencement date of approximately $594,000.Right-Of-Use Asset and Lease LiabilityThe Companyâ€™s consolidated balance sheets reflect the value of the right-of-use asset and related lease liability. This value was calculated based on the present value of the remaining base rent lease payments. The remaining lease payments include the renewal periods for both of the facilities in Germany and do not include the renewal periods for the United States facility. The discount rate used was the Companyâ€™s incremental borrowing rate, which is 9.8%, as the Company could not determine the rate implicit in the lease. As a result, the value of the right-of- use asset and related lease liability is as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Right-of-use assetâ€‹$ 11,651,563â€‹$ 12,058,896â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Total lease liabilityâ€‹$ 13,000,742â€‹$ 13,270,295Less current portionâ€‹Â (431,997)â€‹â€‹ (373,636)Lease liability, net of current portionâ€‹$ 12,568,745â€‹$ 12,896,659â€‹The maturities of the lease liabilities are as follows for the periods ending September 30:â€‹â€‹â€‹â€‹â€‹2025Â Â Â Â $ 1,685,7272026â€‹Â 1,725,5242027â€‹Â 1,766,4162028â€‹Â 1,808,4322029â€‹Â 1,851,603Thereafterâ€‹Â 14,024,373Total lease paymentsâ€‹â€‹ 22,862,075Present value discountâ€‹â€‹ (9,861,333)Totalâ€‹$ 13,000,742â€‹For the threeÂ months ended September 30, 2024 and 2023, operating cash flows paid in connection with operating leases amounted to approximately $547,000 and $633,000, respectively, and $1,684,000 and $1,801,000, respectively, for the nine months ended September 30, 2024 and 2023.As of September 30, 2024 and DecemberÂ 31, 2023, the weighted average remaining lease term was years 11.9 and 12.7 years, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_LesseeDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for

operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.3 NET LOSS PER SHARE 9 Months Ended Sep. 30, 2024 NET LOSS PER SHARE Â NET LOSS PER SHARE 8.Â Â Â Â Â NET LOSS PER SHAREBasic loss per share and diluted loss per share for the three and nine months ended September 30, 2024 and 2023 have been computed by dividing the net loss for each respective period by the weighted average number of shares outstanding during that period.All outstanding warrants, options and restricted stock awards representing approximately 20,328,000 and 14,119,000 incremental shares at September 30, 2024 and 2023, respectively, have been excluded from the computation of diluted loss per share as they are anti-dilutive. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ (2,334,091) $ (9,193,520) $ (12,835,098) $ (22,672,487) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.3 PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) 9 Months Ended Sep. 30, 2024 PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Nature of Business Nature of BusinessThe Company is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. The Company, through its subsidiary CytoSorbents Medical, Inc. (formerly known as CytoSorbents, Inc.), is engaged in the research, development and commercialization of medical devices with its blood purification technology platform which incorporates a proprietary adsorbent, porous polymer technology. The Company, through its wholly-owned European subsidiary, CytoSorbents Europe GmbH, conducts sales and marketing related operations for the CytoSorb device. Basis of Consolidation and Foreign Currency Translation Basis of Consolidation and Foreign Currency TranslationThe consolidated financial statements include the accounts of CytoSorbents Corporation and its wholly-owned subsidiaries, CytoSorbents Medical, Inc. and CytoSorbents Europe GmbH. All significant intercompany transactions and balances have been eliminated in consolidation.Translation gains and losses resulting from the process of remeasuring into the United States of America dollar the foreign currency financial statements of the European subsidiary, for which the United States of America dollar is the functional currency, are included in operations. The Euro is the functional currency of the European Subsidiary. Foreign currency transaction gain (loss) included in net loss amounted to approximately $2,650,000 and $(1,810,000) for the three months ended September 30, 2024 and 2023, respectively. Foreign currency transaction gain (loss) included in net loss amounted to approximately $680,000 and $(734,000) for the nine months ended September 30, 2024 and 2023, respectively. The Company translates assets and liabilities of all of its foreign subsidiaries at the exchange rate in effect at the condensed consolidated balance sheet date. The Company translates revenue and expenses at the daily average exchange rates. The Company includes accumulated net translation adjustments in accumulated other comprehensive income (loss) as a component of stockholdersâ€™ equity. Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents and Restricted CashThe Company considers all highly liquid investments purchased with an original maturity of threeÂ months or less to be cash equivalents.The following table provides a reconciliation of cash and cash equivalents and restricted cash to amounts shown in the consolidated balance sheets:â€‹â€‹â€‹

removed from inventory and charged to selling, general and administrative expenses. Impairment or Disposal of Long-Lived Assets Impairment or Disposal of Long-Lived AssetsThe Company assesses the impairment of patents and other long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. During the three months ended September 30, 2024 and 2023, the Company recorded impairment charges of approximately $64,000 and $183,000, respectively, and during the nine months ended September 30, 2024 and 2023, the Company recorded impairment charges of approximately $313,000 and $476,000, respectively, related to the impairment of certain issued patents and pending patent applications in certain specific jurisdictions and the abandonment of certain pending patent application costs in the ordinary course of business. This charge is included in legal, financial and other consulting in the consolidated statements of operations and comprehensive loss. Income Taxes Income TaxesThe Company has not recorded income tax expense or income tax benefit for the three and nine months ended September 30, 2024, and 2023 due to the generation of net operating losses, the benefits of which have been fully reserved.Deferred income taxes are accounted for using the balance sheet approach, which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that a future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership.The Company follows accounting standards associated with uncertain tax positions. The Company had no unrecognized tax benefits at September 30, 2024. The Company is accounting for an uncertain tax position of approximately $2.1 million for the year ended December 31, 2023. The Company files tax returns in the U.S. federal and state jurisdictions.The Company utilizes the Technology Business Tax Certificate Transfer Program to sell a portion of its New Jersey Net Operating Loss carryforwards to an industrial company. Concentration of Credit Risk Concentration of Credit RiskThe Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation (â€œFDICâ€). Beginning in April of 2023, the Company joined the IntraFi network, and established an Insured Cash Sweep (â€œICSâ€) account whereby all cash that was previously held in the Companyâ€™s money market account at Bridge Bank is swept daily in increments of less than $250,000 and deposited in a number of IntraFiâ€™s 4,000 member banks. This arrangement provides FDIC insurance coverage for all of the cash balances previously held in the money market account, which represents all of the cash and cash equivalents held at Bridge Bank. This arrangement excludes the restricted cash balances. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances. A significant portion of the Companyâ€™s revenues are from product sales in Germany. Substantially all of the Companyâ€™s grant and other income are from government agencies in the United States. (See Note 4 for further information relating to the Companyâ€™s revenue.)As of September 30, 2024, two distributors accounted for approximately 31% of outstanding grants and accounts receivable. As of December 31, 2023, one distributor accounted for approximately 19% of outstanding grants and accounts receivable. For the three months ended September 30, 2024 and 2023, no distributor or direct customers accounted for more than 10% of the Companyâ€™s total revenue. For the nine months ended September 30, 2024 and 2023, one distributor accounted for approximately 10% for each period, of the Companyâ€™s total revenue. Warrants WarrantsThe Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrantâ€™s specific terms and applicable authoritative guidance in ASC 480 â€œDistinguishing Liabilities From Equityâ€ (â€œASC 480â€) and ASC 815 â€œDerivatives and Hedgingâ€ (â€œASC 815â€). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Companyâ€™s own ordinary shares and whether the warrant holders could potentially require â€œnet cash settlementâ€ in a circumstance outside of the Companyâ€™s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance, and will remain as a component of equity thereafter. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.The warrants issued upon the closing of the Companyâ€™s December 13, 2023 offering and the closing of the Companyâ€™s June 2024 debt financing both met the criteria for equity classification under ASC 815. Accordingly, these warrants have been classified as equity as of September 30, 2024 and December 31, 2023. Shipping and Handling Costs Shipping and Handling CostsThe cost of shipping product to customers and distributors is typically borne by the customer or distributor. The Company records other shipping and handling costs in cost of revenue. Total freight costs amounted to approximately $89,000 and $140,000, respectively, for the three months ended September 30, 2024 and 2023, and $267,000 and $341,000, respectively, for the nine months ended September 30, 2024 and 2023. Effect of Recent Accounting Pronouncements Effect of Recent Accounting PronouncementsIn August 2020, the FASB issued ASU 2020-06, â€œDebt â€“ Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging â€“ Contracts in Entityâ€™s Own Equity (Subtopic 815-40)â€ (â€œASU 2020-06â€). ASU2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entityâ€™s own equity. The ASU is part of the FASBâ€™s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASUâ€™s amendments are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. The Company adopted the provisions of ASU 2020-06 on January 1, 2024. This did not have a material impact on the Companyâ€™s consolidated financial statements.In December 2023, the FASB issued ASU No. 2023-09 entitled â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€. This ASU provides guidance related to additional disclosures that will be required related to income taxes. The updated guidance is effective for public entities for fiscal years beginning after December 15, 2024. This ASU will result in additional disclosures in the Companyâ€™s consolidated financial statements related to income taxes in 2025.In November 2023, the FASB issued ASU No. 2023-07 (â€œASU 2023-07â€), â€œImprovements to Reportable Segment Disclosuresâ€. The guidance primarily will require enhanced disclosures about significant segment expenses. All disclosure requirements under ASU 2023-07 and existing segment disclosures in ASC 280, â€œSegment Reportingâ€ are also required for public entities with a single reportable segment. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. A retrospective approach is required to be applied to all prior periods presented in the financial statements. The Company plans to adopt the provisions of ASU 2023-07 in the first quarter of fiscal 2025 and continues to evaluate the disclosure requirements related to the new standard.On April 3, 2024, the Financial Accounting Standards Board (the "FASB") began a project related to the accounting and reporting of government grants. The FASB has decided to pursue an International Accounting Standards ("IAS") 20 accounting model. Under IAS 20, a grant relating to income may be reported separately as 'other income' or deducted from the related expense. The FASB expects to issue and exposure draft of a proposed ASU in the fourth quarter of 2024. The company is evaluating its accounting and reporting policy for government grants relative to this project and the requirements of IAS 20. X - DefinitionDisclosure of accounting policy for basis of consolidation and foreign currency translation. + ReferencesNo definition available. + Details Name: ctso_ConsolidationAndForeignCurrencyTranslationPolicyTextBlock Namespace Prefix: ctso_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for Nature of Business Policy. + ReferencesNo definition available. + Details Name: ctso_NatureOfBusinessPolicyPolicyTextBlock Namespace Prefix: ctso_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs. + ReferencesNo definition available. + Details Name: ctso_ShippingAndHandlingCostsPolicyPolicyTextBlock Namespace Prefix: ctso_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for warrants. + ReferencesNo definition available. + Details Name: ctso_WarrantsPolicyPolicyTextBlock Namespace Prefix: ctso_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionEntity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4 + Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContentReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6 + Details Name: us-gaap_InventoryPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for accounts receivable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (b) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481962/310-10-50-11B + Details Name: us-gaap_TradeAndOtherAccountsReceivablePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.3 PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) 9 Months Ended Sep. 30, 2024 PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Schedule of reconciliation of cash and cash equivalents and restricted cash and cash equivalents â€‹â€‹â€‹

Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCapitalizationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.3 PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 USD ($) Distributor Sep. 30, 2023 USD ($) Distributor Sep. 30, 2024 USD ($) Distributor item Sep. 30, 2023 USD ($) Distributor Dec. 31, 2023 USD ($) Distributor PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Â Â Â Â Foreign currency transaction gain (loss) $ 2,650,000 $ (1,810,000) $ 680,000 $ (734,000) Â Restricted cash 6,483,958 Â 6,483,958 Â $ 1,483,958 Inventory - finished goods 1,430,325 Â 1,430,325 Â 2,155,457 Inventory - work in process 1,049,319 Â 1,049,319 Â 838,871 Inventory - raw materials 768,112 Â 768,112 Â 685,801 Impairment charges 64,000 183,000 313,000 476,000 Â Income tax expense 0 0 0 0 Â Unrecognized tax benefits 0 Â $ 0 Â $ 2,100,000 Number of member bank | item Â Â 4,000 Â Â Cost of revenue 4,108,773 3,203,981 $ 10,716,394 10,600,421 Â Debt agreement Â Â Â Â Â PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Â Â Â Â Restricted cash 5,000,000 Â 5,000,000 Â Â Letter of credit Â Â Â Â Â PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Â Â Â Â Cash collateral 1,467,458 Â 1,467,458 Â Â Credit Card Â Â Â Â Â PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Â Â Â Â Cash collateral 16,500 Â 16,500 Â Â Cargo and Freight Â Â Â Â Â PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Â Â Â Â Cost of revenue $ 89,000 $ 140,000 $ 267,000 $ 341,000 Â Accounts receivable | Customer concentration risk | Distributors/Strategic Partners Â Â Â Â Â PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Â Â Â Â Number of distributors | Distributor Â Â 2 Â 1 Concentration risk percentage Â Â 31.00% Â 19.00% Revenue | Customer concentration risk | Distributors/Strategic Partners Â Â Â Â Â PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Â Â Â Â Number of distributors | Distributor 0 0 1 1 Â Concentration risk percentage 10.00% 10.00% 10.00% 10.00% Â X - DefinitionAmount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement. + ReferencesNo definition available. + Details Name: ctso_ForeignCurrencyTransactionGainLossExcludingTax Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of distributors of the company. + ReferencesNo definition available. + Details Name: ctso_NumberOfDistributors Namespace Prefix: ctso_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of member banks. + ReferencesNo definition available. + Details Name: ctso_NumberOfMemberBank Namespace Prefix: ctso_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionLine items represents the Principal Business Activity and Summary of Significant Accounting Policies. + ReferencesNo definition available. + Details Name: ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems Namespace Prefix: ctso_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of assets pledged to secure a debt instrument. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentCollateralAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterials Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of unrecognized tax benefits. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B + Details Name: us-gaap_UnrecognizedTaxBenefits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=ctso_LoanAndSecurityAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_CreditCardMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_CargoAndFreightMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=ctso_DistributorsAndStrategicPartnersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.3 PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and cash equivalents (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2022 PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Â Â Â Cash and cash equivalents $ 5,685,328 $ 14,131,137 Â Â Restricted cash 6,483,958 1,483,958 Â Â Total cash, cash equivalents and restricted cash $ 12,169,286 $ 15,615,095 $ 10,046,506 $ 23,832,026 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of

cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_RestrictedCashAndCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.3 STOCKHOLDERS' EQUITY - Stock option activity (Details) - $ / shares 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Shares Â Â Outstanding, beginning of the year 10,548,174 Â Granted 3,687,366 Â Forfeited (1,018,794) Â Expired (706,609) Â Outstanding, end of the year 12,510,137 10,548,174 Weighted Average Exercise Price per Share Â Â Outstanding, beginning of the year $ 4.49 Â Granted 0.96 Â Forfeited 2.69 Â Expired 5.40 Â Outstanding, end of the year $ 3.54 $ 4.49 Weighted Average Remaining Contractual Life (Years) Â Â Outstanding, beginning of the year Â 7 years 3 days Granted 0 years Â Forfeited 0 years Â Expired 0 years Â Exercised 0 years Â Outstanding, end of the year 7 years 21 days Â X - DefinitionWeighted average remaining contractual term for option awards cancelled during the period, in PnYnMnDTnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm Namespace Prefix: ctso_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards exercised during the period, in PnYnMnDTnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm Namespace Prefix: ctso_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionShare based Compensation Arrangement by Share based Payment Award Options Outstanding Expired In Period Weighted Average Remaining Contractual Term. + ReferencesNo definition available. + Details Name: ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm Namespace Prefix: ctso_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionShare based Compensation Arrangement by Share based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term + ReferencesNo definition available. + Details Name: ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm Namespace Prefix: ctso_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.3 STOCKHOLDERS' EQUITY - Intrinsic value (Details) 9 Months Ended Sep. 30, 2024 USD ($) $ / shares shares Options Exercisable Â Number Exercisable at September 30, 2024 | shares 6,164,466 Weighted Average Exercise Price $ 5.48 Aggregate Intrinsic Value | $ $ 33,555 Exercise Price Range One Â Options Outstanding Â Range of Exercise Price, Lower Range Limit $ 0.84 Range of Exercise Price, Upper Range Limit $ 13.20 Number Outstanding at September 30, 2024 | shares 12,510,137 Weighted Average Exercise Price $ 3.54 Weighted Average Remaining Life (Years) 7 years 21 days Aggregate intrinsic value | $ $ 1,892,822 X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS'

format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ctso_ExercisePriceRangeOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.3 STOCKHOLDERS' EQUITY - Non-vested options (Details) 9 Months Ended Sep. 30, 2024 $ / shares shares Shares Â Non-vested, December 31, 2023 | shares 5,205,736 Granted | shares 3,687,366 Forfeited | shares (1,018,794) Vested | shares (1,528,637) Non-vested, September 30, 2024 | shares 6,345,671 Weighted Average Grant Date Fair Value Â Non-vested, December 31, 2023 | $ / shares $ 1.89 Granted | $ / shares 0.67 Forfeited | $ / shares 1.81 Vested | $ / shares 2.30 Non-vested, September 30, 2024 | $ / shares $ 1.08 X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of non-vested options outstanding. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of non-vested options forfeited. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average grant-date fair value of non-vested options forfeited. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average grant-date fair value of non-vested options outstanding. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of options vested. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average grant-date fair value of options vested. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.3 STOCKHOLDERS' EQUITY - Restricted stock unit (Details) - Restricted stock - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 STOCKHOLDERS' EQUITY Â Â Â Â Â Restricted Stock Units, Beginning Balance Â Â 2,823,500 Â Restricted Stock Units, Intrinsic Value Beginning Balance Â Â $ 3,134,085 Â Granted Â Â 331,250 Â Forfeited Â Â (330,750) Â Restricted Stock Units, Ending Balance 2,824,000 Â 2,824,000 Â Restricted Stock Units, Intrinsic Value Ending Balance $ 4,236,000 Â $ 4,236,000 Â Restricted Stock Units, Expense $ 0 $ 0 $ 0 $ 0 Board of Directors Â Â Â Â Â STOCKHOLDERS' EQUITY Â Â Â Â Â Restricted Stock Units, Beginning Balance Â Â 346,500 Â Granted Â Â 0 Â Forfeited Â Â 0 Â Restricted Stock Units, Ending Balance 346,500 Â 346,500 Â Executive Management Â Â Â Â STOCKHOLDERS' EQUITY Â Â Â Â Â Restricted Stock Units, Beginning Balance Â Â 779,500 Â Granted Â Â 175,000 Â Forfeited Â Â 0 Â Restricted Stock Units, Ending Balance 954,500 Â 954,500 Â Other Employees Â Â Â Â Â STOCKHOLDERS' EQUITY Â Â Â Â Â Restricted Stock Units, Beginning Balance Â Â 1,697,500 Â Granted Â Â 156,250 Â Forfeited Â Â (330,750) Â Restricted Stock Units, Ending Balance 1,523,000 Â 1,523,000 Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: ctso_StockholdersEquityLineItems Namespace Prefix: ctso_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense for award of restricted stock or unit under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_RestrictedStockExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNet number of non-option equity instruments granted to participants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of equity instruments other than options outstanding, including both vested and non-vested instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIntrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_ManagementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_OfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.3 STOCKHOLDERS' EQUITY - Restricted stock unit activity (Details) - Restricted stock 9 Months Ended Sep. 30, 2024 $ / shares shares Shares Â Non-vested, December 31, 2023 | shares 430,505 Granted | shares 548,000 Vested | shares (297,169) Forfeited | shares (40,000) Non-vested, September 30, 2024 | shares 641,336 Weighted Average Grant Date Fair Value Â Non-vested, December 31, 2023 | $ / shares $ 3.31 Granted | $ / shares 0.96 Vested | $ / shares 3.23 Forfeited | $ / shares 3.73 Non-vested, September 30, 2024 | $ / shares $ 1.31 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.3 STOCKHOLDERS' EQUITY - Warrants (Details) - $ / shares 9 Months Ended Jun. 28, 2024 Sep. 30, 2024 Dec. 31, 2023 STOCKHOLDERS' EQUITY Â Â Â Number of shares to be purchased Â 4,352,130 2,706,561 Warrant exercise price per share Â Â $ 2.00 Stock price trigger for revision of exercise price of warrants $ 0.79 Â Â Loan and security agreement Â Â Â STOCKHOLDERS' EQUITY Â Â Â Warrant exercise price per share $ 0.79 $ 0.79 Â Class of warrant issued 1,645,569 Â Â Stock price trigger for revision of exercise price of warrants Â $ 0.79 Â X - DefinitionNumber of warrants or rights issued. + ReferencesNo definition available. + Details Name: ctso_ClassOfWarrantOrRightIssued Namespace Prefix: ctso_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPrice of the entity's common stock which would be required to be attained for revision of exercise price of warrants or rights. + ReferencesNo definition available. + Details Name: ctso_ClassOfWarrantOrRightRevisionOfExercisePriceOfWarrantsOrRightsStockPriceTrigger Namespace Prefix: ctso_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=ctso_LoanAndSecurityAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.3 STOCKHOLDERS' EQUITY - Additional information (Details) 3 Months Ended 9 Months Ended 12 Months

Ended Aug. 14, 2024 USD ($) shares Apr. 08, 2024 USD ($) shares Apr. 02, 2024 USD ($) shares Mar. 29, 2024 USD ($) shares Sep. 18, 2023 USD ($) shares Jul. 07, 2023 USD ($) shares Aug. 10, 2022 USD ($) shares Dec. 30, 2021 USD ($) Sep. 30, 2024 USD ($) $ / shares shares Sep. 30, 2023 USD ($) shares Sep. 30, 2024 USD ($) $ / shares shares Sep. 30, 2024 USN ($) shares Sep. 30, 2023 USD ($) shares Dec. 31, 2023 USD ($) $ / shares shares Dec. 31, 2022 shares Jul. 26, 2024 USD ($) Jul. 14, 2021 USD ($) Jun. 30, 2019 shares STOCKHOLDERS' EQUITY Â Number of preferred stock authorized Â Â Â Â Â Â Â Â Â Â 5,000,000 Â 5,000,000 Â Â 5,000,000 Â Â Â 5,000,000 Common Stock, shares authorized Â Â Â Â Â Â Â Â Â Â 100,000,000 Â 100,000,000 Â Â 100,000,000 Â Â Â Â Issuance of common stock Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 Â Â Â Aggregate registered amount for offerings | $ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 150,000,000 $ 150,000,000 Â Restricted stock unit | $ Â Â Â Â Â Â Â Â $ 782,000 $ 1,086,000 $ 2,345,000 Â $ 2,487,000 Â Â Â Â Grant date exercise price range | $ / shares Â Â Â Â Â Â Â Â Â Â $ 1.50 Â $ 1.50 Â Â Â Â Â Â Â Â Total unrecognized compensation cost related to stock options | $ Â Â Â Â Â Â Â Â Â $ 3,540,000 Â $ 3,540,000 Â Â Â Â Â Â Â Amortized period Â Â Â Â Â Â Â Â Â Â 35 months 35 months Â Â Â Â Â Â Vested Â Â Â Â Â Â Â Â Â Â 1,528,637 1,528,637 Â Â Â Â Â Â Outstanding Â Â Â Â Â Â Â Â Â 12,510,137 Â 12,510,137 Â Â 10,548,174 Â Â Â Â Issuance of restricted stock units | $ Â Â Â Â Â Â Â Â $ 186,884 $ 220,286 $ 198,097 Â $ 403,941 Â Â Â Â Â Maximum Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionFair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAgreed-upon price for the exchange of the underlying asset relating to the share-based payment award. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe maximum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe minimum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of options vested. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesOther Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards forfeited during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate value of stock related to Restricted Stock Awards issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_DirectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=ctso_EmployeeOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=ctso_EmployeeTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=ctso_SeniorManagersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=ctso_CertainNamedExecutiveOfficersAndSeniorManagersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=ctso_CertainNamedExecutiveOfficersAndSeniorManagersTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=ctso_NamedExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=ctso_CertainEmployeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=ctso_VestingUponEarlierOfChangeInControlOrOneThirdAfterSecondAnniversaryOneThirdOnThirdAnniversaryAndOneThirdOnFourthAnniversaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=ctso_VestingUponEarlierOfChangeInControlOrThreeYearsFromDateOfAwardMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=ctso_JefferiesLlcAndB.RileyFbrIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=ctso_ScenarioOneNoLimitationRelatingToMarketCapitalizationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=ctso_ScenarioTwoLimitationRelatingToMarketCapitalizationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom0.84To1.08Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.3 REVENUE - Revenue by customer type and geographic area (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Product sales: Â Â Â Â Total revenue $ 9,390,388 $ 8,810,847 $ 29,071,316 $ 27,681,164 Total product sales Â Â Â Â Product sales: Â Â Â Â Total revenue 8,612,795 7,754,016 26,444,104 23,736,468 Grant income Â Â Â Â Product sales: Â Â Â Â Total revenue 777,593 1,056,831 2,627,212 3,944,696 United States | Total product sales Â Â Â Â Product sales: Â Â Â Â Total revenue 20,705 44,933 98,719 55,284 United States | Grant income Â Â Â Â Product sales: Â Â Â Â Total revenue 777,593 1,056,831 2,627,212 3,944,696 Germany | Total product sales Â Â Â Â Product sales: Â Â Â Â Total revenue 3,180,863 2,937,431 9,497,184 9,443,787 All other countries | Total product sales Â Â Â Â Product sales: Â Â Â Â Total revenue 5,411,227 4,771,652 16,848,201 14,237,397 Direct Â Â Â Â Product sales: Â Â Â Â Total revenue 5,139,148 4,249,415 14,921,836 13,762,446 Direct | Total product sales Â Â Â Â Product sales: Â Â Â Â Total revenue 5,139,148 4,249,415 14,921,836 13,762,446 Direct | United States | Total product sales Â Â Â Â Product sales: Â Â Â Â Total revenue 20,705 44,933 62,719 55,284 Direct | Germany | Total product sales Â Â Â Â Product sales: Â Â Â Â Total revenue 3,180,863 2,937,431 9,497,184 9,443,787 Direct | All other countries | Total product sales Â Â Â Â Product sales: Â Â Â Â Total revenue 1,937,580 1,267,051 5,361,933 4,263,375 Distributors/Strategic Partners Â Â Â Â Product sales: Â Â Â Â Total revenue 3,473,647 3,504,601 11,522,268 9,974,022 Distributors/Strategic Partners | Total product sales Â Â Â Â Product sales: Â Â Â Â Total revenue 3,473,647 3,504,601 11,522,268 9,974,022 Distributors/Strategic Partners | United States | Total product sales Â Â Â Â Product sales: Â Â Â Â Total revenue Â Â 36,000 Â Distributors/Strategic Partners | All other countries | Total product sales Â Â Â Â Product sales: Â Â Â Â Total revenue 3,473,647 3,504,601 11,486,268 9,974,022 United States Government Agencies Â Â Â Â Product sales: Â Â Â Â Total revenue 777,593 1,056,831 2,627,212 3,944,696 United States Government Agencies | United States | Grant income Â Â Â Â Product sales: Â Â Â Â Total revenue $ 777,593 $ 1,056,831 $ 2,627,212 $ 3,944,696 X - DefinitionSale Revenues Goods Net + ReferencesNo definition available. + Details Name: ctso_SaleRevenuesGoodsNetAbstract Namespace Prefix: ctso_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_GrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_DE Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=ctso_AllOtherCountriesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=ctso_DirectMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=ctso_DistributorsAndStrategicPartnersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=ctso_UnitedStatesGovernmentAgenciesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.3 REVENUE - Receivables and contract liabilities (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 REVENUE Â Â Receivables, which are included in grants and accounts receivable $ 4,845,233 $ 3,846,271 Contract liabilities, which are included in accrued expenses and other current liabilities $ 837,592 $ 1,573,141 X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerAssetNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.3 REVENUE - Additional information (Details) 9 Months Ended Sep. 30, 2024 USD ($) segment Dec. 31, 2023 USD ($) REVENUE Â Â Number of primary revenue streams | segment 2 Â Term of customer contracts 3 years Â Value of free of charge goods and credit rebates $ 51,192 $ 196,322 Contract liabilities net of value of free of charge goods and credit rebates 786,400 1,376,819 Receivables, which are included in grants and accounts receivable 4,845,233 3,846,271 Product sales Â Â REVENUE Â Â Receivables, which are included in grants and accounts receivable 4,528,972 3,270,724 Government grants Â Â REVENUE Â Â Receivables, which are included in grants and accounts receivable $ 316,261 $ 575,547 Maximum Â Â REVENUE Â Â Term of customer contracts 5 years Â Minimum Â Â REVENUE Â Â Term of customer contracts 1 year Â X - DefinitionAmount of contract with customer liability net of free of charge goods and credit rebates as on the balance sheet date, classified as current. + ReferencesNo definition available. + Details Name: ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue of free of charge goods and credit rebates as on the balance sheet date, classified as current. + ReferencesNo definition available. + Details Name: ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of primary revenue streams. + ReferencesNo definition available. + Details Name: ctso_NumberOfPrimaryRevenueStreams Namespace Prefix: ctso_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRepresents the term of customer contracts. + ReferencesNo definition available. + Details Name: ctso_TermOfCustomerContracts Namespace Prefix: ctso_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerAssetNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_GrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.3 LONG-TERM DEBT, NET - Avenue Capital Group (Details) - USD ($) 3 Months Ended 9 Months Ended Jun. 28, 2024 Sep. 30, 2024 Sep. 30, 2024 Dec. 31, 2023 LONG-TERM DEBT Â Â Â Â Restricted cash Â $ 6,483,958 $ 6,483,958 $ 1,483,958 Warrant Exercise Price per Share Â Â Â $ 2.00 Stock price trigger for revision of exercise price of warrants $ 0.79 Â Â Â Warrants issued in connection with long-term debt Â Â 690,709 Â Debt agreement Â Â Â Â LONG-TERM DEBT Â Â Â Â Maximum borrowing capacity Â 20,000,000 20,000,000 Â Debt instrument unused capacity Â 10,000,000 10,000,000 Â Restricted cash Â 5,000,000 5,000,000 Â Minimum net proceeds from sale of equity securities, considered for release of restricted cash Â 3,000,000 $ 3,000,000 Â Interest rate Â Â 5.00% Â Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Â Â us-gaap:PrimeRateMember Â Period for monthly interest only payments Â Â 25 months Â Extension term of loan Â Â 30 months Â Percentage of commitment fee Â Â 1.00% Â Payment of financial advisor and legal fees Â Â $ 640,000 Â Interest expense Â 58,000 $ 58,000 Â Percentage of final payment Â Â 4.50% Â Interest expense Â $ 132,000 $ 132,000 Â Minimum period after entry, over which any judgment(s) singly or in the aggregate in excess of the Threshold Amount remain unsatisfied, unvacated or unstayed, considered for events of default to trigger accelerated repayment Â Â 15 days Â Period within which any insolvency proceeding brought by a third party is not dismissed or stayed, considered for events of default to trigger accelerated repayment Â Â 45 days Â Warrants to purchase shares Â 1,645,569 1,645,569 Â Warrant Exercise Price per Share $ 0.79 $ 0.79 $ 0.79 Â Stock price trigger for revision of exercise price of warrants Â Â $ 0.79 Â Conversion of debt into common stock Â $ 2,000,000 $ 2,000,000 Â Fixed conversion price of closing stock Â Â 120.00% Â Fixed conversion price of closing stock, Per share Â Â 0.95% Â Debt agreement | Prepayment made on or after funding date Â Â Â Â LONG-TERM DEBT Â Â Â Â Prepayment percentage Â Â 3.00% Â Debt agreement | Prepayment made after first anniversary Â Â Â Â LONG-TERM DEBT Â Â Â Â Prepayment percentage Â Â 2.00% Â Debt agreement | Prepayment made after second anniversary Â Â Â Â LONG-TERM DEBT Â Â Â Â Prepayment percentage Â Â 1.00% Â Debt agreement | Maximum Â Â Â Â LONG-TERM DEBT Â Â Â Â Release of restricted cash upon equity raise Â 5,000,000 $ 5,000,000 Â Debt agreement | Minimum Â Â Â Â LONG-TERM DEBT Â Â Â Â Release of restricted cash upon equity raise Â $ 3,000,000 $ 3,000,000 Â Effective rate Â 13.50% 13.50% Â Growth Capital Loan Tranche 1 Â Â Â Â LONG-TERM DEBT Â Â Â Â Debt instrument face amount Â $ 15,000,000 $ 15,000,000 Â Growth Capital Loan Tranche 1 | Avenue Venture Opportunities Fund, L.P Â Â Â Â LONG-TERM DEBT Â Â Â Â Debt instrument face amount Â 4,500,000 4,500,000 Â Growth Capital Loan Tranche 1 | Avenue Venture Opportunities Fund II, L.P Â Â Â Â LONG-TERM DEBT Â Â Â Â Debt instrument face amount Â 10,500,000 10,500,000 Â Growth Capital Loan Tranche 2 Â Â Â Â LONG-TERM DEBT Â Â Â Â Maximum borrowing capacity Â $ 5,000,000 $ 5,000,000 Â X - DefinitionPrice of the entity's common stock which would be required to be attained for revision of exercise price of warrants or rights. + ReferencesNo definition available. + Details Name: ctso_ClassOfWarrantOrRightRevisionOfExercisePriceOfWarrantsOrRightsStockPriceTrigger Namespace Prefix: ctso_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionDebt Instrument, Accelerated Repayment, Minimum Period After Entry Over Which Any Judgment(S) Singly Or In The Aggregate In Excess Of The Threshold Amount Remain Unsatisfied, Unvacated Or Unstayed, Considered For Events Of Default. + ReferencesNo definition available. + Details Name: ctso_DebtInstrumentAcceleratedRepaymentMinimumPeriodAfterEntryOverSinglyInAggregateInExcessOfThresholdAmountRemainUnsatisfiedUnvacatedOrUnstayedConsideredForEventsOfDefaul Namespace Prefix: ctso_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod within which any insolvency proceeding brought by a third party is not dismissed or stayed, considered for events of default to cause accelerated repayment of the debt instrument. + ReferencesNo definition available. + Details Name: ctso_DebtInstrumentAcceleratedRepaymentPeriodWithinWhichAnyInsolvencyProceedingBroughtByThirdPartyIsNotDismissedOrStayedConsideredForEventsOfDefault Namespace Prefix: ctso_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPer share conversion price of closing price of common stock. + ReferencesNo definition available. + Details Name: ctso_DebtInstrumentConvertibleConversionPricePerShare Namespace Prefix: ctso_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPercentage of conversion price as a percentage of closing price of common stock. + ReferencesNo definition available. + Details Name: ctso_DebtInstrumentConvertibleConversionPricePercentage Namespace Prefix: ctso_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPrincipal amount of outstanding debt instrument that can be converted into equity instruments. + ReferencesNo definition available. + Details Name: ctso_DebtInstrumentConvertiblePrincipalAmountOutstanding Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe maximum

borrowing capacity under the debt instrument. + ReferencesNo definition available. + Details Name: ctso_DebtInstrumentMaximumBorrowingCapacity Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionExtended period during which interest only payments shall be made under the debt instrument. + ReferencesNo definition available. + Details Name: ctso_DebtInstrumentPeriodicInterestOnlyPaymentExtensionPeriod Namespace Prefix: ctso_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod during which interest only payments shall be made under the debt instrument. + ReferencesNo definition available. + Details Name: ctso_DebtInstrumentPeriodicInterestOnlyPaymentPeriod Namespace Prefix: ctso_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPercentage of principal amount of debt prepaid, payable as prepayment fee on the debt instrument. + ReferencesNo definition available. + Details Name: ctso_DebtInstrumentPrepaymentFeeAsPercentageOfPrincipalAmountPrepaid Namespace Prefix: ctso_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRepresents minimum net proceeds to be received from the sale of company's equity securities after the closing date, considered for release of restricted cash to the borrower. + ReferencesNo definition available. + Details Name: ctso_DebtInstrumentThresholdNetProceedsFromSaleOfEquitySecuritiesConsideredForReleaseOfRestrictedCash Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionInterest expense related to final payment on debt instrument, recorded by the company. + ReferencesNo definition available. + Details Name: ctso_InterestExpenseRelatedToFinalPayment Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInterest expense related to financial advisor fees and legal fees on debt instrument, recorded by the company. + ReferencesNo definition available. + Details Name: ctso_InterestExpenseRelatedToFinancialAdvisorAndLegalFees Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of non refundable commitment fee to be paid by the borrower. + ReferencesNo definition available. + Details Name: ctso_NonRefundableCommitmentFeePercentage Namespace Prefix: ctso_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of financial advisor fees and legal fees Paid by the company. + ReferencesNo definition available. + Details Name: ctso_PaymentOfFinancialAdvisorAndLegalFees Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage of non refundable final payment on original commitment amount to be paid by the borrower. + ReferencesNo definition available. + Details Name: ctso_PercentageOfNonRefundablePaymentOnOriginalCommitmentAmount Namespace Prefix: ctso_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of restricted cash that will be released on a dollar for dollar basis upon raise of equity. + ReferencesNo definition available. + Details Name: ctso_ReleaseOfRestrictedCashUponEquityRaise Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates type of variable interest rate on debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=ctso_LoanAndSecurityAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=ctso_PrepaymentMadeOnOrAfterFundingDateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=ctso_PrepaymentMadeFromFirstAnniversaryToSecondAnniversaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=ctso_PrepaymentMadeAfterSecondAnniversaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ctso_LoanAndSecurityAgreementTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=ctso_AvenueVentureOpportunitiesFundL.pMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=ctso_AvenueVentureOpportunitiesFundIiL.pMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ctso_LoanAndSecurityAgreementTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.3 LONG-TERM DEBT, NET (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 LONG-TERM DEBT, NET Â Â Principal amount $ 15,000,000 Â Accrued final fee 900,000 Â Less unamortized debt discount (1,455,858) Â Less unamortized debt acquisition costs (638,157) Â Subtotal 13,805,985 Â Less Current maturities Â $ (2,500,000) Long-term debt net of current maturities $ 13,805,985 $ 2,542,857 X - DefinitionAmount of long term debt accrued final fee. + ReferencesNo definition available. + Details Name: ctso_LongTermDebtAccruedFinalFee Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt discount. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedDiscount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DeferredFinanceCostsNoncurrentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.3 LONG-TERM DEBT, NET - Principal payments (Details) Sep. 30, 2024 USD ($) LONG-TERM DEBT, NET Â 2026 $ 2,500,000 2027 12,500,000 Total $ 15,000,000 X - DefinitionAmount, after unamortized (discount) premium and debt issuance costs, of long-term debt and final fee. + ReferencesNo definition available. + Details Name: ctso_LongTermDebtAndFinalFee Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.3 LONG-TERM DEBT, NET - Additional information (Details) 9 Months Ended Sep. 30, 2024 USD ($) $ / shares 2022 Success Fee Letter | First Tranche Â LONG-TERM DEBT Â Maximum borrowing capacity | $ $ 5,000,000 Percentage of success fee 1.00% Average selling price $ 8 Number of days for stock price threshold set in success fee letter 5 days 2022 Success Fee Letter | Second Tranche Â LONG-TERM DEBT Â Maximum borrowing capacity | $ $ 5,000,000 Percentage of success fee 1.50% Average selling price $ 10 Number of days for stock price threshold set in success fee letter 5 days 2022 Success Fee Letter | Third Tranche Â LONG-TERM DEBT Â Maximum borrowing capacity | $ $ 5,000,000 Percentage of success fee 2.00% Average selling price $ 12 Number of days for stock price threshold set in success fee letter 5 days Western Alliance Bank | 2018 Success Fee Letter Â LONG-TERM DEBT Â Percentage of success fee 6.37% Average selling price $ 7.05 Number of days for stock price threshold set in success fee letter 5 days Western Alliance Bank | 2018 Success Fee Letter | Minimum Â LONG-TERM DEBT Â Percentage of closing price on common stock 26.13% Western Alliance Bank | 2018 Success Fee Letter | Maximum Â LONG-TERM DEBT Â Percentage of closing price on common stock 70.00% X - DefinitionNumber of days for stock price threshold set in success fee letter. + ReferencesNo definition available. + Details Name: ctso_NumberOfDaysForStockPriceThreshold Namespace Prefix: ctso_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe percentage of closing price on common stock. + ReferencesNo definition available. + Details Name: ctso_PercentageOfClosingPriceOnCommonStock Namespace Prefix: ctso_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe average effective success fee rate during the reporting period. + ReferencesNo definition available. + Details Name: ctso_PercentageOfSuccessFee Namespace Prefix: ctso_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=ctso_TwoThousandAndTwentyTwoSuccessFeeLetterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=ctso_FirstTrancheMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=ctso_SecondTrancheMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=ctso_ThirdTrancheMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=ctso_WesternAllianceBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ctso_TwoThousandAndEighteenSuccessFeeLetterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.3 COMMITMENTS AND CONTINGENCIES (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Royalty Agreement Â Â Â Â COMMITMENTS AND CONTINGENCIES Â Â Â Â Royalty cost $ 354,000 $ 537,000 $ 1,594,000 $ 1,643,000 X - DefinitionCommitments and Contingencies Disclosure [Line Items] + ReferencesNo definition available. + Details Name: ctso_CommitmentsAndContingenciesDisclosureLineItems Namespace Prefix: ctso_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name

Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RoyaltyExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.3 LEASES (Details) 1 Months Ended 3 Months Ended 9 Months Ended Apr. 01, 2021 USD ($) Sep. 30, 2021 USD ($) Mar. 31, 2021 USD ($) item Jan. 31, 2021 USD ($) mÂ² Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Apr. 30, 2021 USD ($) Apr. 01, 2020 USD ($) LEASES: Â Â Â Â Â Â Â Â Â Â Â Â Operating lease liability Â Â Â Â $ 13,000,742 Â $ 13,000,742 Â $ 13,270,295 Â Â Right of use asset Â Â Â Â $ 11,651,563 Â $ 11,651,563 Â $ 12,058,896 Â Â Incremental borrowing rate Â Â Â Â 9.80% Â 9.80% Â Â Â Â Operating lease paid Â Â Â Â $ 547,000 $ 633,000 $ 1,684,000 $ 1,801,000 Â Â Weighted average remaining lease term Â Â Â Â 11 years 10 months 24 days Â 11 years 10 months 24 days Â 12 years 8 months 12 days Â Â CytoSorbents Medical, Inc Â Â Â Â Â Â Â Â Â Â Â Â LEASES: Â Â Â Â Â Â Â Â Â Â Â Â Number of times lease renewal options available | item Â Â 2 Â Â Â Â Â Â Â Â Renewal term Â Â 5 years Â Â Â Â Â Â Â Â Rent abatement term Â Â 6 months Â Â Â Â Â Â Â Â CytoSorbents Europe GmbH Â Â Â Â Â Â Â Â Â Â Â Â LEASES: Â Â Â Â Â Â Â Â Â Â Â Â Monthly payments of base rent and other costs Â Â Â $ 7,784 Â Â Â Â Â Â Â Â Operating lease lability Â Â Â Â Â Â Â Â Â Â Â $ 594,000 Right of use asset Â Â Â Â Â Â Â Â Â Â Â $ 594,000 Area of Land | mÂ² Â Â Â 1,068 Â Â Â Â Â Â Â Â Other costs $ 239 Â Â Â Â Â Â Â Â Â Â Lease term 5 years Â Â Â Â Â Â Â Â Â Â Existence of option to extend true Â Â Â Â Â Â Â Â Â Â Additional lessee operating lease term of contract option to extend 5 years Â Â Â Â Â Â Â Â Â Â United States | CytoSorbents Medical, Inc Â Â Â Â Â Â Â Â Â Â LEASES: Â Â Â Â Â Â Â Â Â Â Remaining lease term Â Â 15 years 6 months Â Â Â Â Â Â Â Annual rent expense increment rate Â Â 2.75% Â Â Â Â Â Â Â Â Percentage of total building space occupied Â Â 92.30% Â Â Â Â Â Â Â Â Allowance for building improvement Â Â $ 1,455,000 Â Â Â Â Â Â Â Â Operating lease liability $ 11,600,000 Â Â Â Â Â Â Â Â Right of use asset $ 11,600,000 Â Â Â Â Â Â Â Â Incremental borrowing rate 9.80% Â Â Â Â Â Â Â Â Â United States | Letter of credit | CytoSorbents Medical, Inc Â Â Â Â Â Â Â Â Â Â LEASES: Â Â Â Â Â Â Â Â Â Â Security amount Â Â Â Â Â Â Â Â Â $ 1,467,000 Â United States | Initial early term | CytoSorbents Medical, Inc Â Â Â Â Â Â Â Â Â Â LEASES: Â Â Â Â Â Â Â Â Â Â Monthly payments of base rent and other costs Â Â 25,208 Â Â Â Â Â Â Â Â Â Â United States | Early term | CytoSorbents Medical, Inc Â Â Â Â Â Â Â Â Â Â LEASES: Â Â Â Â Â Â Â Â Â Â Monthly payments of base rent and other costs Â Â 88,254 Â Â Â Â Â Â Â Â Â Â United States | Early term | CytoSorbents Medical, Inc Â Â Â Â Â Â Â Â Â Â LEASES: Â Â Â Â Â Â Â Â Â Â Monthly payments of base rent and other costs Â Â $ 111,171 Â Â Â Â Â Â Â Â Â Germany Â Â Â Â Â Â Â Â Â Â LEASES: Â Â Â Â Â Â Â Â Â Â Monthly payments of base rent and other costs Â $ 12,100 Â Â Â Â Â Â Â Â Â Additional operating leases rent expense Â $ 3,000 Â Â Â Â Â Â Â Â Â X - DefinitionThe additional lessee operating lease term of contract option to extend. + ReferencesNo definition available. + Details Name: ctso_AdditionalLesseeOperatingLeaseTermOfContractOptionToExtend Namespace Prefix: ctso_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAdditional rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income. + ReferencesNo definition available. + Details Name: ctso_AdditionalOperatingLeasesRentExpenseNet Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe number of times lease renewal options available. + ReferencesNo definition available. + Details Name: ctso_NumberOfTimesLeaseRenewalAvailable Namespace Prefix: ctso_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionThe percentage of annual increment in operating lease rent expense. + ReferencesNo definition available. + Details Name: ctso_OperatingLeasesAnnualRentExpenseIncrementRate Namespace Prefix: ctso_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe amount of allowance for building improvement receivable from landlord. + ReferencesNo definition available. + Details Name: ctso_OperatingLeasesBuildingImprovementAllowanceReceivable Namespace Prefix: ctso_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRent abatement term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: ctso_OperatingLeasesRentAbatementTerm Namespace Prefix: ctso_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe percentage of total building space occupied. + ReferencesNo definition available. + Details Name: ctso_PercentageOfTotalBuildingSpaceOccupied Namespace Prefix: ctso_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionArea of land held. + ReferencesNo definition available. + Details Name: us-gaap_AreaOfLand Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDiscount rate used by lessee to determine present value of operating lease payments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseDiscountRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionIndicates (true false) whether lessee has option to extend operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionRemaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRemainingLeaseTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: srt_ConsolidatedEntitiesAxis=ctso_CytosorbentsMedicalIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=ctso_CytosorbentsEuropeGmbhMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=us-gaap_LetterOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=ctso_OperatingLeaseInitialEarlyTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=ctso_OperatingLeaseEarlyTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_DE Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.3 LEASES - Right-of- use asset and related lease liability (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 LEASES Â Â Right-of-use asset $ 11,651,563 $ 12,058,896 Total lease liability 13,000,742 13,270,295 Less current portion (431,997) (373,636) Lease liability, net of current portion $ 12,568,745 $ 12,896,659 X - ReferencesNo definition available. + Details Name: us-gaap_LesseeDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.3 LEASES - Maturities of the lease liabilities (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 LEASES Â Â 2025 $ 1,685,727 Â 2026 1,725,524 Â 2027 1,766,416 Â 2028 1,808,432 Â 2029 1,851,603 Â Thereafter 14,024,373 Â Total lease payments 22,862,075 Â Present value discount (9,861,333) Â Total lease liability $ 13,000,742 $ 13,270,295 X - ReferencesNo definition available. + Details Name: us-gaap_LesseeDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name

Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.3 NET LOSS PER SHARE (Details) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Stock options and warrants Â Â NET LOSS PER SHARE Â Â Antidilutive securities excluded from computation of earnings per share 20,328,000 14,119,000 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_EarningsPerShareBasicLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ctso_StockOptionsAndWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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}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}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

P(4'8+8(V0Q(%03@$MZ%?Z&2M MJ=+=2E6KJK;CG);ILR=Y4HJB6L8_KU3\/;:O.-7T,KFFO-XRLEYO M5O1]@O0!\7%O>BU$BD/0SL-Q,]8P*7(SZ;U!.HP0V8@3^QU\[IN_>:
MWL4*OL^BJCL#D1^0;GVUFOI(X4?^ /Z&<]';.NA<;5CQFM8+G;2%/I6WXUEH M6!VY67VVX^DZT?M?RR2NY?K7/0Y^TQ@C[TNTK:9D@("F T MD+^&X)&;X&?)<]5=+QEO"SS[FK,P.L8
M'1&C==FZ(=!/$ (J*%TY&YT>_O% MMN"LV/MM[=@G/L+=`L!F& & 6SKV&'O#P"A\TU[1S7J9OF:OG*C+K0/\$3TS M:B@=N2E]QEE*:5;/0<'*U5A2OC'*W1I\G[NA#\R_;N9^1/.,&BV W%K@BY("
M9C-59P$OQF7IH@?B0\X;O#:C1$-BM(6X5QRZ35=];[8Z=Y,>&-S M+*IS1DT'9.1H9@VS+P\@#..N!K*8(:#T*AQHTW#K$-[=MQ]7!/]$>9H+?>K@ M"=TM*TED0KB/^U!?+ I1U 1W%*$C3[
+Y^R&]92VN ASQ1S+9ZMY=\:8Y_\ M8QC@B/0R9#D&0 $.T0!SX48E8+=*N%TN:6I6$WU*35/M*9&JY4YIXK+*[FL M!!6>+FB+5% Z=D"8XD8HX%<(A0IJ7H'\M4J!5F0/24'WS;!:%VK;I%(?R R%M8I$$F! __EWA8[-4O5KD^VB@5<"-?,#N!O[ZU3&HS;^@J[PL]>+2BI3RG-GW MON68W0]4U8Z[39[%N((X &-!UN% %V*X(W!49U@^T,R:(7$ SB]FE$'9+% M$@ 2^& HI$8+X-@I]>:
[[;:@FF847^K" 43.VYJ6KI7@6I=5L_T57&S/V0\ M$>_7T?X(%4$:%4'<*L*(7W-6DNVX7I=R3>LLFMXC+Y5:HO:39=)7%F${H["[M1BUV*/3]<*"8D$8R$/C>=);[AR:O5O/D1&JACOE': _2:
_RP@.^A%?GBKD0 MNZHC4SJDK-_X>,SE^A52F/2E11*#L%==W5C>&VNC4XA;IWQ2(:H4F[2W"E,E M4G9E;E>1M=/VPW$8*^;H]IT6.P)P3+J/12:M-TU7^6[M$^BD0RJVW%_?
W=7=Q0Y.0LL7XI-V M5_OR[+,2QVOKOO@*((CK6AM_DE4A-"^&0U]44$N?VP8,]RKJ^0Y 3[<<^L:! M+%FIUL/):/1T6$MELM-C7KMTI\LD.YEDHH@^V+I51@]J9=)?>=WF
M84OA^>@.A4FK,&&_TT'LY2L9Y.FQLVOA2!JMT0\.E;71.66H*+/@<%>A7C@] MF\XN9N+#&W%Y]7KV^OW'Z<+*^/AP%-D\"P:,V<)3.3.\S*MY9$RHO7IL2 MREW]
(;K4^S7I_#J;W&MP!DTN#D8#,1E-#N^Q=]#'><#V#GXTSF3F<+\9:I$7 MOI$%G&38 Q[<"K+3QS^-GXY>WN/D8>_DX7W6O]_)^\V,<['7DOA8 ;9!8>M& MFHTR2Q&-
C*4*4(K"8N&,3[^\U;J4M+Q01II"22U\P 7LQN"%,H6)8C0FHNT M:!?\?9Z,"\DK6$54FH)K2RFD*<4K*-K5,\>#'@*9*89MA,H!\(K!R$2=D 6$ MK+LLDI&/S3\)GXV4O_GP*KY K$', (+&XC'S-4[*(R
M/KC(Q.)%L((80HQ'3_Y@;ZZB!OH:C2D)5[",6C('S9[\S:&^)"-(/];!0)16 M&!OZK$JM\7>B6^8MSHP-* ->&$R=]TB?G"TI%E(YP5 T(J+!)L;?E)NPT#CU6C4:GEF#0B-8; MVJ<"
<=XH3Y\,HVM&.?;BY^Q3/LO%V^GT,ON%3 .5C;K$G N:*.V)GZ-)E-VG M>PNE#Y3P%@P[2&U NA9!>\"WKE2!L3GHBM#[?QM-4V,B'G@%C75!H(M=X7__ MKJ-R<9'LVD:9MEBU-
#C]R/O!CNL5ME M6T#XH6_KN5"AS<0XNX(7A&YR7RA?: M^N@(Z1P-8NIXZ[9Z^-8N*^)>R!N-?T-56 $%D'/OA*I=(`^($,-&&/4[%T] M%<=7JD+2Y:2K17<<$@MV!EPW>(6!LJM@1#P0R*A?-\
(2DWR3:Y(D^,> N4R0 MQ*6TFXOI'>0\V(\$9(1!X@7X&M5*:LYN"#@%#O'^W.I*<5>K)'=A&P:9Z\5 MUAIGUO) ,@T*VR!OTH[V_*?ROX4E=O7L,W:!53USD#]2-YN&0 M@"^U^J?
G)>D]M(7VN.@7LNBVM$IQ*? =+[3TAP/*><[P/'KL3N]W+@9]$KB] M&I2E?)0ELQJJ(WP0%1;UT!LM6PRH0)\%!DI#SA@<@@7N3%= Z3R7C0JH^];9 MV."; .N!KK9IKV3
EPE-.80\!HB^D;4=]#&V>VJ=;P2:P5,?C4<=G"%R=)#9 M\K"C$U2E4"E90[DZ0M>+)D2)@Y&P'6K1.XYZ/39IG$6G"I(M@;O-;R*37+P# M::!^&G8.VTDK8(]&S%W+3L'}_ECN6HU8-
HGR/!Y*C$'7EN31#C?<^(M!,Z\9 M:YZ42D?63KE.<#+1+O-C8#1K?;"]ADM&3IZ1(N5181;IKK: ?C,0INRKHXQ% M$?YS9=HD\(7-+AA+F/5"&N)F8PFDT7%3[9?= !_?\7G/X+4$L#!!0 M (
!N$9UF=PB <:!@ 9* 8 >&PO=V]R:W-H965T&ULQ5QY<]O(L?\J4XJ3E:IHBJ1.GU44;7FU;RV[3#FI_ D"0W)L$.#BL*1\ M^O?K[IG!@ 1EV9M]KRI94R#0T_<-OKS-
BZ_E4NM*W:W2K'RUMZRJ]?/#PS)> MZE54]O.USO#-/"]6484_B\5AN2YTE/!#J_1P-!B<'JXBD^V]?LG7/A:O7^9U ME9I,?RQ46:]647%_H=/\]M7><,]=^&06RXHN'+Y^N8X6>]JKS^N/!?XZ]% 2
ML])9:?),%7K^:F\\?'YQ3/?S#?\T^K8,/BNB9);G7^F/J^35WH 0TJF.*X(0 MX9]O>J+3E !C3\LS#U)#T8?G;0+YEVT#*+2CW)TW^9I%J^VCO?4XF>1W5: M?BNNNRE?V86"P,IG\&]U9/@0/G]V/#"R
M#XP8;SF(L7P35='KET5^]PJZ&]#H Y/*3P,YDY%0IE6!;PV>JUY__'1U/;GZ M./Y=77R>7EV_G4[5>')S]<^KFW^K\?4;-?W_OWXT[_5ATLUO7IW?75Y-1E?
MW^'>R8?/US=7U^_4QP^_7TVNWDY?'E; AZ >QO;L"SE[M./L9^1]GE7+4KW: M$IVTGS\$'9Z8D2/F8O0@P*E>]]71H*=&@]'Q _"/..&-[1_PMSY.SC[K/) M&)^7ZRC6K_9@;:4NONF]U__XV_!T\.
(!RHX]9<.5Q]3 M#:-4I=;J.J^T&JD]5]52]TF^6D?9_2^EBO.LS%.31)5.U-QD41:;*%5EA0OP M+U6I3!:G-700'S:>'6=9C7L_Z75>5 I%A'R!&@[44_4 "CZ1;[_74:$T*;%Z MHV.]FNE"'0U9#8]Z.#'%%
[>F6O+-4QW7A:F,+E64)>KM7;R,L@6?N3(E.[O] MO>G;R=X!'?<^*N*E&AZ+3O?XR ANIXP+LV:_EL]5E((:L\C,W,115L'5Q7F= M529;J#4(CW%67UU'55UHNOVB+B&2LE0W#:G* !T%7B;
W7*A@I>OB$'T4&KF M^FFUI$LZ(\C@:F((V(?_E>1I_ZF51SA%*(,'Q(3Q?#WQ4(7]XI.7:A9FN>) M6H,%A"P]WP_QZ.'D(]\72V4Q4E[*>E09 \/3DOLJG>3%C>;W7"1Y.>^HJB_MJ MGV*3+M)
[]37+;^'IR];=)GE:;ZX5^LT]@A%=;LT$":4+2^@3F D M\7Q=Y.O"Z(J(1% 5I'L0'-A0DOSN@4@ [@%VW2[S-+U_"AZ Q+RS..B:>1ZE5343KYJUJ- I&P]N+R*1N=-]!]$RI:\NHÃ*.
M!K::E\M%5S.2PD:&+YZ\[= MXHUG"2RC]Y!JT=.[>-97XPV[(R,H8FM0%=$6Q<(M@C.+4M #WBXCF.E,ZTSI MU"'"F,[70R#AD6+_%G 72*X&2YF4)&-!B%Z_I@S MH2E\;)TQHW",.
[FGR(^$CKE1/C$!.OX! %M83CV6?:^)_N9 6LQLM4^,/F@A MD"%'IJL]6I'>X2(X&ZW!3N#_%## 3T9]4Y/!KW!8,#">K(_[)T(^>\#;S'D
M1+5:2>HC40.)2V7#ALU>^'&)'Q#U6G/RFOZ5F)^>AWB?'1VWL8:/_WFDPT!3 M6;4F)P-5KJQ:FVAF4@F+-J+A'S)J M5[7X4I))%9AXE'Q!NN^\7.O6',<5%)*0"2YMF*4HLM).V!%%$KHASVR\1N40
M?X7/0SPO__&W\]'P[(72?]2F@C@F48F01_]5;W'I&SQ^9N7P29<5#)1.Y>]# M,HB)AN"O>):H=T! ;@"!E.R;=M@C#H(7I4MZ8'IY81;&C'-%20AP$.,,[!: MEI+S@E[.*(? T;I!3=@YA\ (;\FG5=$L98?
WS3!,(2<@%T.!?*QF$)*&M&'Q MQ:(AD[\G!^:),NF= MGI_TCD:GP36DCD, &1Z=A:)E(.ZFT][Q>'5'OV4GSV-!?NSJ9B90A3K"XO$I:R3]@1TU<^YB5Z!O>R@.9RJL@WC<5'3**U(2S? M(2%;JWU?
D9P<!IH,P-G3LlXQ$*R6UH\$&7@^2\TBLOZ96BH5.?2(2IB47$$! M\,XAYW6%D(P<'/:0Z@I?,JD%\A>+UT5A$CBDBRC[*]?= I(UFL2525#I) 7- MCL)3M)XZE,>
(06+R*9@KGBPE+KEOE%"IN>T=P)V_EEB+-J4#G&5577H@+V' MR@]?^O7![&U&165WDAA\'G9[&-5ISI]*=]M<@1#3)?1% &P\4[AUQPB'P^*BBJ M*0@%V%&-V#.NE(Z@C=MQJ=?
B*325HS4AP-&(M38BI\C/$3,=(R5+-!D"A^;, MM).E77RA0A>>UN3<[4I(&DL0GQ=<^M"QB, XK]%+ 2BCP M;)P%+L0N+F=4O^5YRL&!RIY;XC<.6!G*;ODT(%$@/0/7 "0&K#M\:.<'2SH; M7*C
3;*B%>L:>91ZP0'V^7?T\Q ?@=\"DEE'195I]I(=:@KE0XI_I]F/4X]) M0:PQQ]"4AF3)_"<2B73$?]0>B=@(!=UOU':UCJ.M6X'2>&V4OI++8 $^XM<) M?@>G)2//">7 4((.+?$)I%67
CK!O)C@EZY5(:EQ%70H*!^-2!0')&EB15FO MB; \-R6B%&=L!0QJ65!157.SA<-{ I(@D*%%>>$5V PD%>)[#QG1 M%O$.I1Z@:;$%3)'..C'%2"KC,85 +VP7OX@1VHJ:[30YL&/< 91V2FG;?V2 M
A4U)/RUS9TKHM^TYGNBUN33A!IR%'G29L,M(@C[S'E@»VPV[* *EGO($@XL M)]..G!YT(3CGTI"$[@3EN!-O9]8..:ZA2+YWBB_0LQPDEZ69263C:CDFTB^Q MJSF+V5]0&,/K2B$B,
[C2^\SUZ3_>5VF0E:E*>^L5^Z..+XQPL(FS@7\%-UH;![BIX2,&I@-IU'}4]]">A/P MOH\-M$#Z(\Z'NZ>A]OODC X:=YX]PIN+@[@14D?.EX:H6TOO]+5,D @VM^(M:Y\XU\Y&-
GH1&I$_R)MI&SY(V@@0+6.3XZ&.T:(Y,6@M,IW4\27E).P? @8F M@8(F5?B>>_#I@YSEW3W.VT%-4W4&<$+[V7870>A@[F_%@]TQH \!!)%TZB/L M1QM)?U8>'KBW,C%(1,JL,W6Y7!<%08J]X-
2 '6 >(8MJZ]C_LA3(:_^D M*'HV2G?PQ:HKI9KWTKNC5(QYH*);*HH@GHJ<4TFY-&4N.8>P\#,!XJHC<5TL MX&DKQYR*H:*S1H$SLGYNBI(C655S/[@6'=.O+M88
MB_$]QS;N>QGFY)PBF4%]!,)SN,N>38C"MB:5V#CT:'0BK3&6](J]^EZ MPU.NWQ'&%JY@V@%KL]\)]Z!MLF*PA#HYC*\< .OQY];ZA2D+7H*931W CC% M3E8D7O*Y%(H=
E!GZ(+I[URC5<6;''H#]0ML2+8! MD#D<5^5[6)+6IP0J95"V,2U:'TQ3N>$*4VO&7Z:%61)@M@V.L@E-.;24%?1 M6*&:(]Y7=$+,%R3E;3HK<504]X2$6.0JND<^EWD7)=)67>HT
M88))O=J]!9^K6)O(:!S0'&=E3I30X MBB[+L&)CD'+UY++#XTSJ(2B M&RHW:%%D&7UK391;PJC=BN4M3BB-0TYJ: A1,%E)7LMAVWBSB'F[!@N,E[Y M_-"V>DBH *O9^U*4TRO:(8 J-;ZG;#F?
1EF: J24C4Z9649N':(;'VK -2V3 MIFHT0:>>JU##GG;%.@6/?R5K1F3(6&&D;.Z@7MV:-&VB!.5T)(XQ"ZCS6-)! MV4PHJ3"25,OYX&WXU'GX+EZ6P:"'=N/5:@#;I^K*A!LX[")\[WA:.R4B0.:<
M$%..G&F9*@!O">=7M*21\4Z7G=OD"6]E1'E'YR-IC,B"!?N@)D;3]DA1+LVZ M771(&5]V9PK@5 MSM=PXM,Z<4R..(%TPP4Y*XPL2:E356=!#*AC(.=FV1?>W M-KH:A'AQ+-
MQ>D>H&/6':@4QT:>/V7/:XLBALH6.#*3DF'D'S:7@7"<^YV/_MV0X&;5"B_39)N&FVJIHM-IPR 5&R>Z5E:P;]JCX6.II?*S4!Z]*OV^]$F=04B#6)>?B*G9MWDF>4<>\<9H3J3@_4.'8JDWM
M#*R4/,BUO7J<8",YIK*!-*1Q++BW,E7M@ZB^[4WC/M3__;C)UQSM5E0D*5;AI:D?SS>32 M]ULYD=TQTT+4T_=V=\U#!8AP&@K3*&]A/G:'@_<7XZ()X[**0'[LR2A8YTF$
MJW94K+*:+0#W6SYX"'0#7(F%(*/YZK((J!0Y$ZG5W/H"B4$$R9*2/-K.7^PB MC"2[@=+LXD87J4W8M,/(<@MLYV*!E LMSG60 9V4Y189J+4G] [=OGK?=""! MH^$!"CU1 L,DLUHMG8]-K8]XKX?
V;VF0C IO!7\@M8CMV](+ K8M(R":<\>M M\4#@ +ITQZ[2&["!2R$1&N1=BL2R+S3Q8K-GM:);"PB \. H5L=*VG1^(32 M)D'^B'!Hf(;*SEN&ZW-]M3]U.P7'K!SSNK 0FPZH3-
@HC>KNGUD2^P>HEPGC MKKP0QKPQ\&ZE:>U(<33\.V>^P3K"HIG)=_3[^_:DCF80E+?5*GWHW.&S'S[W M\BMD\D4M_M<7_C2B M: UV"4][C.?3UY.RIL.RE^J09[UUMVA #>=J./S@:*AB+K^
M4*$:88L3@*!BN"0C?:.,PSK(;ZIO6. ,G,#9CA_)76WA3:.81C[!1%<4W>",[!XMY#F.*52_!- M4TQ%C:2ZGR-J.I%A@(%#M.6:H,#ZQ\Q43OZVD)?TW#*B9\MSHF4GQ25"\->/[8]8SJNE@8(./:<\XLE
MT(8O=;*0!TSI=OZ;88!K\3JN4)N'"6&S*OUTAW9QN5BN@MT,<2CDLWA-AS!* M];.0 HG+40 M-UCB6&'UG@I8V9#8#8%7#[(Y<'TDH4G.1;&G]Z\@-NR%"(FF<(M/0>_4%_UV M(M@F?
\>Z6HOB25,V5\%X,6D=,N_"O;4U 8YD3]G@>+F=N]NEF^/M[+Z)__1P M+>?KM7TL!@SR+#OLTFN-J4$$(Z=! MV2-EVW:*?5YQY VEE%_]H537$]GTWX+ 2L'8ZO..=*][.(?\=FG6:T?RK[0E
M2G],N-MZPUU069XLW7TN5:;UEB8O(F\0II+TPL:]FF9:%_RNKKWO@5W M_&=?ZI#1Y.E9<\#1\?"A WYP(>>MO @!XFD9%FYIW+2"/A9YEE,C2 SG"LE0 MO0#SZ=&!>)/+\?
3"63HX[359#;2;M1UOC__@SL4DSU#+E.ZIJP\L MI]KB6;[]BJ'*)7OV>#IZ/!@=6\SOS(Y^XH38)I"T(]!HK^X +XE9 !OV
M\O1X<+"=8'DJFB0+%^TUVO)!UC@W;G^GW3ES3;/NM(IIW]P,XG:NDTR3<&S^HX8#2;(.L=X_-$?W"QB OW$DD#[DZR% ME'ISN6I*&F53%Y&ZS*
[;O/$B\+DGX7B"7ZDS*YM<'"*LYHN2E;@%LNXDHR=>5 M;5)QGZ5D%:07T!H](+[^%F4U43AL.JBTZ&H2CL3L4B,_U^=A6+Q[0?U[*W?< MXO:$-IVU36N[SOO\
[=/L.Y$Z+1B[GEDX/MJ_894_@[X_IR$Y[80(]R"YDZ: MF%/ HEFK57Y+*)WF^U"^/ I&@*XASPN5'HAMRE$2- NRC>"Y<-(CHG$[VDT1 M5F[HO[J>H6X3BMVHYL=T]J#*9FC>IO-
_=E+&\E\ZE[E2V=W?(.BA^U["GJ*"^[^61U#\(,FET2#I8SZ"W8YIEVM>??%T^J9.JFT/,$.DE.Z,J.2T5#Q2/KDY MFW/N/$*D-
P6\"G;ID;R%1FO_BU3;89WL5PM<6VPWKHM1"%#^D4+LSS;*S1]Z!=!^-&IO.K4]@JX36*M'"*$6A#O+';-:RMF M<]H9^K/0YZY1#LBN'<7WUP4TVCGRODZS2TQ9D25,_P;O(:9BX3W?
ND0'O'9"@HDQ> MWO]">=;&H4'V(,_(N?DP*-RQP,B>@<:OB8[=^UG<=M$R1.&AI?5@G5CN[UV- MIT!M- B/1Z6IT[[Z+*/\511AA?9GG38*[9>S(Y,!6-;;]!(*"0=!FZ_A!WL
M7SA1U[:#X%]#=ZRP#B*@3D:N+$EV@>ZM6A%B4D#GI?%$/XF0E]9%.DW]I=D= MJDHS\8R:B:=[_X"F6%6Y6Q#\NQCR/LF60"Q?OMF="!G%?Y&7BI+MCA:-?YBQ M_:X?9CD.?IL'QC M@S[]IE
AOSHD?R !YE_Z09&)2HH_+OD7/>@&?#_/\K]00?XGWYZ_:]02P_$ M% @ &X1G62R>/Q63$@ =T< !@ !X;"]W;W)K(F2C[C;['ZP)9+ 8##';V8 4"^N9?&E7 E1L9MUEIEK&*[*FI2TW(H067Q?
*TW!2")]1IG9UZCA.=KGF:'[QZ0?<^%:]> MR+K*TEQ*EA9K]>\N'TM,GG]\L],#[H?X]S1WF,N>E.)?9KVE2K5X>3]8(A:\ MSJH+>?V#T/,)D5XLLY+^LVO5UH,1X[JLY%IWANMUFJM/?
J/ET.DP=79T\'0' MC_A6 Q&7;WC%7[THY#4KL#50PR\T5>H-S*4Y*N6R*N!!"OVJ5Y>?/[Y_XX>/ M[]^\O;C\&WO[SY_???[7B],**./STUA3>:VH>#NHS-@'F5>KDKW-$Y'T^Y\"
M1PU;GF'KM;>7X*78V.0W+,8Y7K"'GM],TR=Z_E=.4U$)QP@V$PSK-SP6+P_ M TI17(F#5W]BQLYS_?P@\!ONHWYO'_51\FW4) ?4O4\^=/-?DV">P>5$4
M(F&7E8R_L'RV,B"HY/9[#.0&.VZKQOC=;621?J[*(F'M"QKGL?4L-ZP M2K+0(L+?"I:@6X$Z_M85[!L[@NTBH50/F:%P7/M>77.5B+X %X%)%D*P6\'1^HV&O4C!]Y-HF!WUQ1_TQ6\,X%Y2_U\4
M.HD5HB*("1UWGVS/T&!)F#)[F!D$6-!H5*R-V6IYD@?=Z20M'R9$V^RUB'E= MBBX .O8@G!9?(+^,^2:%B;: :T0]&:@*=+<5S=C@)S53!*2I@$O0$$ Q" 3?P M@).8<^"B)"Z+&I6L5)ZE:VA?
$2@:R;6"9R4?VD,,PZWY%?U),(.3:I4J!$?H MW=3S+(T-QXM,US;&.S'^2U %528P2@$C)W'(L MB&RRA+L9^2_:1EWLL-PD+3QUUC*YV $2B@N"+=L[=-F9[LD,FXD) .=ZI0R@T
.6(MP(+8>#4;M^.."$\QCNAVZ M9C_&20<9 7S6 I*B! $2]":."5"8=BFN8$C;C-&=24H)6!>43$+\N0 $8X$; M'O'CH^ 8]"O7=:8DT^M,HH6QLYA.U9WYOK)?DY4 K7F&GK4"TSJ2ME/+I:R2I79=XA
^M:"+ ,&9+C1V4"M5FM?". M^*U."R4CC J4U8)611&G/(,QT<(D!6N,,K*@YU#I4#GT P+5B.M7=F'#DG M%A/E$LAGK))/,D/DX &&-0)E,I=8B/@(_R>I$^>RM\E!+ MT<-D %)G!2RD#
GD"EW^P):\P(T* *EIS!SY4#EEG^EZXTLA4XOS8.!@#?\ MMB-I3K,$0]?YBT(,WW:^,U)9%A+*+IA<+ 18LY(#R@Y]1K=Y@E\$M)D7!^@BS7 M0LN#QL0R9%?7^"^76H,[/32I"<CP">:13"7Q;<1T*6)Z-
GMSKX9^'Z](1\^* MPL@*HL#,;NC]?98HLB$<0\R "$(VUL/B0]>>1)@-*'H6 _D+S&BA40X(T$@8 MV@X0.[!"WT-$M;$^-/AIW5,*@\EM>)H,!XA<"@?@YY"IBQS1O!/:MB?;DVL.
M*,76:D5'<;"=\8W(-_0M;^;L$VX',XA7,=_G'"!CVW)=$D%SZTIAS_[_$&M M"ZJXOA!B5%E*EAW=]'H'T>@^HK+5L#;:T(79 (4HD:\3)D_S?!$@8I8;S)Y M*V#"B5Y0L&@@1$?
(5U"@<9>""KA*K0.^)U,R,>I^Z%E^$*H401:/F(2%"=-& ME0/9K>)IF(98SC3JCAA,)X\?T>^/2'!2BB;! (DQA< JH")]E)',TH3,O*DI
M2:5R(PJ=XBEIKJ&26^'B,F0X&>*A0J98EA1H\"@4\UHT.1QHWiA@IB>?K--< ME[! P[B90F]JQMV@JZ8N7>\Y5N@+D6+3(W E=VI-9I :MHT],YHU MC=_2 @PTG3B1%3FS;L/0!LJW0 4QO.0R6-I+G3-
NS>P<_>A$>,T/6L$&;M^I,.$=\. M YQI.R_T@ 6'Y.V*9S6AN>!04?:\ !<:1%D1>$#*51IH?9UQ:'09KR2&"PP' M^&0M$Y&919X*BO=25\EQ3#4_+]OD!B$2(8 NA;$%%5B.X.D2"5+2<^C8TX"*
M2P@VTS;8'\LE+@ ?8"Y#FQCSY*-(K7D=]_!"0260VAB&-PE6LEL<4Z^LYFJ1 MMR%_)2$NIQDBPM%D8D^_ W+-PP2@(@%0@'S3.?Z,Z<2TI81715IB-BL0$'$% M 1"LP/GW)^O;$:2 ,-G
CL+OCAOT:8;"]YLF@K1@#2$OQ*J1*54P*.89W&M M<@I=?B?I0B^C0V5470N1=RNBQAHZ":92W(BIJ10@=)I9#C39(V/ X7CW<:.," M1\=#MMK]I;5=R+R?G9AY ?
H29FN#1NV.!OG2+FC:SCP+"N(E6< M=RFJVW:?V!LQWU,JK0P[TE,"BRPW"]VZ0H!8'S:E9=OA6'8]FM-(-7]ZJM"/U6H/^MM6PZ:^VZK'1Y:NT;4AQU,K M3N2L?0F!"&
^:U,:-8)#D:'VL2Y;U"'!&YL\KY&>MM%01?5.MM1/V"JB6.<# MP-A3;7K!3)7=H($SB-$9\QZ] -?R7 !!9Y*QD35RG1@,]>\0##K+.M1(FK: M-P04ON64;&%Y)D@G7?"1$:@3/36^T>\H:E:6D;;4J>]1?
WW>&'./,]R@\D] MK'$'WC=2N9=](5%6I2X*I,#P19E|"T9O+D9A,@]\V&W=X-&0HJ36AV.[(M,':&XQL6V<3]6HF%872'Q(QMZ>UM< 4(M5L2W"VF41^8/EBS@%:^/lO%YQ^%
MI4^IK&FHE/4HB$;)U1H]\?U^9Z7<:X^> M&^[UFQ6O>CX !M#,&OA-Q94PNC .MDXS: MNLXMJ=KQ4U:TC(X[H> M(-%4>A%K(R6=<=ED'$]LZ1R_):"0FB+QP1;8!YL#&:^
MHO6IUD?5MFV[CEWNL-K4)$E*5(7I0D6PV3[4W8K*I>!"*WLR4POL)\A(R2W M"Y LU%A5<]SQ9SQW\XOTOHWYD,Z6C?:+MJO2+1W9&8DEVW2LG6G*5M:H5I*A M>4=*HP"[@OVR-3(S,CBR-
;XMF %:[737N'G0.%%^9 X?EM)2IE.:=%//. M84+/<0/V7N:+D\^X:/0.K"ZGB7W*>-[=GU:^1I "!3(QI;[PD!7KSCG^>4O= MXI:SLWEC"&\:-7^D.N"^X[6&:.Y\:!WU:6.@;LMH>TE!U:;M:@?
1%8(SCJ9 MS.C3M:+9A+[A MNZPAV('5]2,2F85.BFC5A5OW_8"[D#%[H,!HX^>0 ;9R M'X]Z_F ')/0.>Y\& 8>*5(-X[,PT(R'G@H$R#AEC=UU=\OSH]Z]-[4PGECG M&FZK6U4^7]\$Z6:?
Y;5(;A:>R=-6$%2%B4(CSF;A9C>$BV+98, _N(1!RYKA, MBB5R\51;68 ,:X:.&:#*V-MR[@;23GR@BD(F:P)9S/".SHU(>II4400SV>M,I
M*7Q<9LU&H.*.>E"EM"6\]"ZB)3%Z*,Y)O:;X\O;)S[T2G5OB7GOX8\'>0YZH8V=TX3K=W64W4(_ZV]+]0F"7XVGC:<\]3\R6 M\Q-
8KSH=_O36.YW^J=:;9K+5M53&5.XUQ_\W4_3\H&.+1ZH..3;&V#E<\01F MV$[!G1ICY(CD:UO*'+=&VD0U=]=/=^PV.\RZ<#$JM=OF9G^.R=V1Z1HD[(GHPF*KZL]?Y^5ZW8ZUSEI:U?
#T5'8[L@(U4EH9(_4#?X^5 M/GSAZ5XPZGO3:P-&<3%LQ:/% O8/#8#V^NVVP.ZJXQ[L>CO/R9%E33O?G]#8 M_IN+8='3 .K39:##-P8>":6M/8K?:C], 3A4_-:P<.R4;6.#P9.;XUGST@-V
M;G8&VZTH85XM(R:57BCPZ+E[(9#>36D.AE&])l;$'E8 N9-]YF>SSF[MWOC; M#'#HJHT^-2"BJ?IWG>2O\>#*PX88[BSZ;CN@3@1VCX8+3D5S?,6YJ[O:IV@\ M4? B2]5+LJ-
K:H6JU=&6QQ:Y]"\@[-(.TSI,2=!_]].7NP_21' M$,G["ST M^+;O]A:I\#:>P^RO!]')2G-0PIM-+#?]G9'T;:#>7[/"!T?*7OHM)_Y=!RI, MZRC #:O^L0^_/67QJWX)]-
D##E@$EA]ZENL[[2NDLCT69D/JA2= P\@=?4[G ML_8'6ND#LBDI-Z\=Z9Q'ORF?7\5#UZOH1Y)E7O&O%R9PWGFQ!3/1X[K'7HV M:*@Y9-EYC1@#T)"*2!LK@Y2N%8$Q4T8S5HF" KTRUS2O&
_0>5QN-_G$DZ M9:HCHWLON7]U6;]U=3M\G?-,G0@_5^\"@@G*>L._2H$F#!8>'AM@;KA<\2NQ M0O:./9D-)-"=Q$SA6/N:?D,3DHY%>H-FN#*Q,0)8]8?0/V# DW_7Y &)O,IQ
MO9Q>!.4IOA:"+O+AT5-0$UYG4F_JX*E=]:C&TZF_FQVBH=QX!<6],-%YB^ZR MX#&=:#TF:] *5ZS1)AF^^POL(^KAR[\HC2WIX7NZW9F^KW8;@9DC_WJQFGG MQU"@=E[23[Y@YE3GE?
I=E.9N\ZLR9^K'5-KFZB=I/D!>D>;XFO("N@*3X8'Z MT0AS4")*+ !/%](L Q]@0,TO[7SZC]02P,$% @ M&X1G6;Q![/-!#@ L30 !D !X;"]W;W)K&UL M[5MKDŸLX%OTKJIZNJ4R5TFTP?N55U7G-
9';LLP?7%X6X4:G MJK@PN<[P9&5L]DIV">/3%4F<:;? M6%%4:.KL_JE.S.[QF7?6W'@;KS0^>C2>!_P6ZUW1^2S(D)4Q'^GB5?3X;$0*Z42)4E0^+?5SW22 MD"'"H\7LM\ZQ=DB9V/S?
27[+ML&6I"OW,)/^*HW+S^&O^)B*]4E52OC6[7W1M MSX3DA28I^*_8N;'>^R55&:M)X,#=(X<__5I]H/G0GST343_']"SWJ[A5C+ MYZI43QY9LQ.61D,:?
6!3>3:4BS,?KKO2XFF,>>63MR]^>_ 'ZPXM'ER6$T:W+ ML)[XU$WTKYFX$+^:K-P4XD46Z;@__O)*M)KXC29/_1L%OM/YA1B/I/!'?G"#
MO'%KV9CEC>]NF9L8#$^D,GA0Y"K4C\^0YX6V6WWVY, -'A8HH:W.*BV6^SJQM!7E/M="99%8:[.V*M _$H5 H;HBW+*3<6*U%ZD*M
M*=0"@2IUNL3L)EH/!"TR&C_\T___D,4EF5"RE[Y4VO.X*&V\K$ICB\OV[L]F MJVT&X"IO(< "G;".A3YK^/Z-LF6F:2&NUCH+8^CXWI0J$6^LB2J.+%2BB\^[M>]C,=)WY_5[LUK]S8E7YQ&^[K[
M7_N_B]1QA,X'8G0^$)WS$SW/Q4*.%R,YGA?F_LF =?P7L'XGP!H$0*=N;MT& M6.M)Q\#J,] %8^^+@^2!4@Z69@1;6DU$@IZ//:O+(V
>%O"*\9V//_#VW]"V4YHZ;@3]ZBFXI3.1J-.C=.078QYSG'((ND7LS M.X,O!MF#]M =B+'4Z_7(]HB]V0PGP*#TGFM8B!4@OFTD<)W@RS'CJ,[Z$N
MIT/+3GS_3LOZ4QF@9WFCX#M%6E]._9G$HSL\^59(.Q"]Z$@G0_HBGL+.4+C M'7N'V7\NL/V.J.Q?8,LI-9E(OP./MZ.T]:0!M W&?.RSPH!]% ;[P] *C8*P+HS MR)*8ON5H5T?
U:Y6B'N]Y/[G2%&;E('A?FG?&+D6DMW'HD-;]1%$0FEMA]O" M<([3XWO^3V+-:>&20:RL25$'* ,5EH78Q>5&:)6-384)#3S4Z_7CNVX1Z_*H M9<28*I98V5@6MM$1B M\V.SRVK?H+7@\:W(@1[?
^XE-+S?65.L-6U(5FM2).M!*8R[1EHH6)O,:)IUY MJ?HWW%CN:5XO"HVG+41691%'^M194JB."?!/9DJQURC.'*"PQ3CJB @(NF88 M(_5H!83H5-*%^,7LX$ KZ?$5DB6A+HE>V6G*8H?E.,R8]P(R*9!
[\0%67U7E M!G;\H3@D]R@1 _='#%Q^N^)/W\"/;\/VLQ7<9]BP2/9V+AL%=M44XH6>0PG&R3Y2L5)99DU MG&;82V,B#MUS6ZW%501A,8>'5:?QM?HOGJ?J7S3MKH[1=1&I"T64IAZ)#QL#
MO5#XA4A,R%4$N^N.),4[F/2'M@D4DG C98Z2XJE.UG&52O&/ZA-XBZGL6HHW MQHVB55]KPEZZ+DB&CG0FO7.=H<8_2O':V)W:U_G9JOAWY'9DTB-;*,-65;*' M^REA]""B-
@.XS:&HK9289O0RL*,I] AQLJU.9S3UF5M9@1_1YO4ZQRA >53 M74T-L:N]Q_30M&T-N8@Z0*@I3FF5BKRR(5!-8_3O%2005G03N&Q54*"6[C'I MFB<*@GCQ4-M2X=:) N5&T8IF2]&E--4Q]
[@5'8XBA;$PLK[5#0.L7E+ 0ZLC M0@SZ1C825$]>R< M9$_!H.&-W LP.H2^{I}IRD9U)!,4V^$Q"X7CR@V:\S4&M@-O M.N@"@?H3$8:FMU'TA4IYUV'3DHZ;<5)95Q(^' M\(+6=?
F/+*;L8+NA9@(*L*W1S5E#C47SROKD,H23>4\#==QU6Q=B.2A#O:'N MJX1;)M,E4:[!*AJ)#U7;UC5#P?>, M2A$!O,EY'K_H@^PX $Y'1P)0))\!%C: WZ&\!$-K3K<'PKL0+^-/NH%13GJO M88^?
Q=G6.&3NQ+A3:,@T1^C5@Z*CADV4D"I:U<4K>N;&\)9=3#[$D,>A~'LV2.S:^'J(O! !"(^K=96%#;.Y M*6 _:?#$95N980:1'LLIJ?$(UHI9$=D MPHJ6N$86T.< =K<@%[W7
DJB])5UC*+/>2ASL.N$O>SAS%5CT>DC@Q73[<)H M#'FB2]=/;H&FG VNC5+.HM T)_6A%3>9VJG;@UHHK]AI^0< OS72.O_?8. M+GAMH)E?(V$C387,@)A9FB3F!M,#P![:]SV&6&GB^?
6&AWBP(0"+^8@H3%11 MQ"L0M:87]\Y7NF?'IG\MR" MW?;I1_6/>,$I3^N(ZSBG/0WH<7+9W;3Q8L.;1">#MF7WS>K^T:;.#'4;LGI[M=K=]F70"AD^O.M73UF-J;@K: MQIAFG]O5@T"(CZ<:GLX
U>T(@%+8@65<'>!)9;4#[V3;'#P1O28E^.(X],1T M5&A,1SL=B,E V5#%70Y]#,']"+@=EBM&WM\W1.'X!-1]:58?3_ 9&;\(SF^3 M+QU/(PRD444OA]%=U)(.;2A;A\YFV^KZ>L?XI^\W@#Z']1W/?
0DG

'%;'+F#BJ;B]+D_*.4I2D12/Y(VRIM:0">KPS(67U!"[2_M4GKR'U!+ P04 " ;A&=9V:V,E:H0 9,0 &0 'AL+W=OW4JH4#WE6 MN+<']D\<7YV>NF2EK,P-IV2J:*<},)Z/1^6DN=7'P M[@T_N[7OWIB]S'2A;JUP59Y+N[M1F=F^/1@?O =?]7)5XL'INS=KN51WJOS' M^M;2K],:2JIS53AM"F'5XNW!]?CJY@SK>+<$_M=]ZUM\"DLR-^8X?G].W!R,P MI#*5E* @Z9^->J^R# (2(C=\"S8/Z2&QL_QVI?V+929:Y=.,]IR?ZETW+U]N#B M0*1]{:NL_&]V_Z>"/#/02TSF^+]BZ]=.,1@]^_O67 MOY_', $+]\O']S6A)AO#Y- I$;3V3R!)%+\<44Y56\M$ MO3T@_W? *;M3!N[_]97P~>OT,BVO5&Y4N)O?[F83$:OWV?&Z6(IR*D4/QJ_/AX{ M+'AO\K4L=D(5I;(]%;HHC9#B9R,IQHI4W*FDLKNE58KBMQ1'T@E)?Y%S
M#"C\U^N,G^,7*;*D(U)AK#!$WFZU4R(W]5YH>DH;S8*/36F5H/>*?N.8A36Y M*"D_"#H>_WKN OO/7@[M')"$'U0FMY(693K78'DM;5DHZU9Z+8["P9Y>H[$?TA>?/_^A(\0D'
(Q27:S M5%!?6ZJN1J!^ZQK.H)TI]Q_@B"TK$;+*7<]4ZXSJE#*5=:252+9] V3(CRUFB M?KUL:7\H_@%^F,-GC.5%"+R+E015O$MA]0S[8/V65U9K/ &I);U;PFG(80XG M(TJ>649U
*H2<_(G[>:5==>S HMP2%2L+*GGN2AR-CX6AP A/F,!X%@G4=] P MVI*NH_)8BONP95Q[&6U@_EKQ-/!&.CP;-D07%:)#S'?1)M#'X7CTW+) +QM
M5SI986F]4%.T;:3.Y#Q3^_KI8<@JJEBHKE7V8!>F(V& $?ZF'=\^G!-%B5>DT2M M<4{@ =6-7[VF%Y0H="*Y>A(\H!,W7.:A/&)L'1CY8*OEG;'SD^O[K^2KXA>S
M,6(V'AU]/V;1CG0X,+*(0ZU*%/DH91A459U7.9MYVBBQ$ 5A(N(Z(7=S(=\0 M%2V9DT2>D K!GZ$?+G7V4-(L'P8MRN>O& MABS;FJLM8XD9$J;FXJNQ?KKI4HRT<>P1!P^^JA.+(
M_+2%(BLHNV/GMF^\)"(T(O63X;QYTJY]47X,;]=*$C2R^^[3. MSB7335$,]LO8]$P8C@28#))$&-=V;5Q\%U6#>><90;F:D_:\(B=6SIM<6T[* M#L!%!46ML2EI2G@GR2:Z?
UP7[F:P^%!]ETJ\XMY(<&.3ZF@$&>1FYBQ0;;34G M-(N4M2;CR:*@]"6V:&](0G0 B@U8.+KV07]K@1&^8A-4K8J$%5F(ZVI)\#IX M[5D7VW@N4SNVH_(8WZ D;V8??0*)3T
MRG2RT]O7=?X9B)79]@UG;?(LO>A8/K5RZ_@)4Y&YJ2@R2:)GDPN*)C1;[M))81\,O\3W0+]"./FIQ7D3\,VQ'U@%5\#+GEQY1 6%@(;K M9%'&(UX*%P8$_[S5*'&3K_F3ZK3497@ 7_
U-+1RP#R=3;E,.3?A>0W7X;H, MJT++*LS/AG=5,M5R_EB2"^T!53I%E]7$3!H4QYP:'2+2AT5TW8Z;16+NO8P MF3YV6"B=OF:@WR|G2\(^#O\3HH?^X@_)/OGSLG.C,WU2?
F0I0,!&$?W\OE@3 MO7*,_ZP[W"S$[9EZ^5>D2CY"R@=NH"!D;231CM1$S"?$MX1G&YA0'IT?GQ?H

I3WM@ MC6.C2P/B$B1 6??Z"]H+D7/F%>C!PG,A&#*';V4+1KI-=S@ :@M0AB|#BI*# MW>/OK;2D1,S#FG5R0?4G]X-A&(+ >^E7QQ4% *K[&F:/> 7C*^<[UN!R)'&Y
M6Q.RON8'/P)=6\[F#"QR7Z<[@PK7.9&K-[(2GH82>;#.&[";>@>\T6_QDC_\DOJ83*MT;A7778@&E)O90G..O5H M\CT>G)_-!K/S2_265KE6Y>A,] #",11Q;QC4J0=E$T00%3:?50]'
MPU>7;#T"KI3<]Y5PZ9VLJ-@>F%)[28 R"8@\M-KP0=\18TI=\=^ M^,2Z"ZSYJ8&CB-CZ&4+AM1';QEK2''?J.#&A\$*=:8]QDTPZIQ=QA.DKP?7= M>WQGI+\G"-EKA2]*W[>0
M[1+1+B$!F!1:7V\ G]+E=X$&J:(\E4;I-078M^^YB&COTR%T-'_\.>]ZWJ+> M-X'U-Y_=&HV)+M>8)"_*Z@]>CQIC33"P.*67_84TF#C8^18,O[EC >2WDLZ MMZC-0;^N89;N-
/B1*^+";%<:3+D9G'VAU)[(K%[0H"KW4C1%''TS.GB'0\#) MS)_^QXC%=,QURK<4?.73N@?9-6TMYE9R8VS=Y44OV[O#Z;/>G4]8OQ/'Q+'E M(W*MF\C?
#8T\$*_+8A]YB)RA&49#0%%&#E%2\'9[7O+!.&G]W%Y_&];W-K\I MHR%_$[Y7:.8>"L1KF'V(@-\ON),=LKN.IJ])"\7RA$<>G%FX]KFR+AK-:%H^ M47&O:E)/_7N[*^6'!.SJ5'
=ACM^]H/N/NZ[#"M^!N*LBF88U\V!^\<=C0=G ML]G@8G9Q_,16F5!&=GX>Z4=^CVB<3R\&X]FK8W%7S4N#Q!-?C:>#B]%L<'DQ M\]3?<^=1QDDY;@3;U,:31SK&)2,&\$]O/&R?
\EB-]<4$4-^\&LV L3-X;776>7_22!]W[CH8[[A$? MMFZ\'G_' LQ91'W6=U-)R,3LBP6X1Y_(R[.;X" M?
O'=G,^Z30P1*,@=P7B[06#&@1BQ$"|E*BUG|HJ/UU$#'^-W\W\]D)6.8T/^_M_H8=Y8JT-+X@7TZX>_,NDD)9+.OM*W.Y-Z,)'.WZ#7^15<<.=J:]Y&?M@W,*<
M2G0G3!TA'%O'O9')^7#ZJBZYX>.&;N6_AR??>!%[@AR$FOHFDHY#L_Y.2N88C248;W"#4XH^7+&\/NW?.I ^_7>4X@Q0/*^ML/[DV?XIY'!!G,P."9 MQ)3?/'X([(1N"09]$2-A6W
Y8[V&$598OZ^''KZ[5Z[@%I^H1E4_)PQ9*H&E M6LTICY6)/1M8]^?VI?Y5%P%3P,&"TN M?.0ZGAZE'@*-S^@0#.F"=NX:?7U\H%ZQH*QRG7"HC2^G9SPVC^>#IGVXCIF
MX@RDM8X *T4GW\=1K^9]B1GNQNW7BI)E/$U/IBW,V3Z#T%9*#652QK%3_#7P M UE7+7 ,3W?][K+I;1%+W%OYGQ[ZEYA:MEUI\X"XV9)69[O08OM[$/*X.GO5
MWQ%C8,HL&5PV]'P-"MQVPD]^CRWI!*;;$P(W1EK4&/$A'K7/\+9$"1G@DL?^_P*^!0B317^]L$"E)HPQ>5'U?&+A7@7EBZWG M"VA=,J'#,=?,UH=>O5\P\,"DJ6JM:[_JPQJ^]9O:M>
/L\3E'C]"KV!F"=6 M)*: ^*3[\+4]3_M-W>Q4?YL"V5?O_E>OVT_N[_VG_NWBSW_], MV7^IR7]96M#6T?#5[,#/!*N*/TJSYX_>Y*4N3\)K)2GQ8 &!7QB*\? #!]3_M-
\2[_P=02P,$% @ &X1G69Q9)&ULK5;;;MLX$/V5@5H4NX#@>]!)+$(@.)D[99Q&G09+?/ MM#26N95(E:3B^_ W#&4K[C8-NL"^V"3%.7/FRCE>6_?5KY@#/52E\2?)*H3Z
M7;_OLQ57RO=LS09?EM95*F#KBKZO':I\"E5E?S08'/8KI4TR/8YG-VYZ;)M0 M:L,WCGQ352@/SVN5<&W'/ZL;QOV_0XEUQ4;KZTA MQ\N3Y'3X[FPB]^.%OS2O_=Z;Q)*%M5]E9DL?
M?VG=WAT/$LH:'VRU%0:#2IOV7JC/R4M-%6LTICY6)/1M8]^?VI?Y5%P%3P,&"TN M?.0ZGAZE'@*-S^@0#.F"=NX:?7U\H%ZQH*QRG7"HC2^G9SPVC^>#IGVXCIF
MX@RDM8X *T4GW\=1K^9]B1GNQNW7BI)E/$U/IBW,V3Z#T%9*#652QK%3_#7P M UE7+7 ,3W?][K+I;1%+W%OYGQ[ZEYA:MEUI\X"XV9)69[O08OM[$/*X.GO5
MWQ%C8,HL&5PV]'P-"MQVPD]^CRWI!*;;$P(W1EK4&/$A'K7/\+9$"1G@DL?^_P*^!0B317^]L$"E)HPQ>5'U?&+A7@7EBZWG M"VA=,J'#,=?,UH=>O5\P\,"DJ6JM:[_JPQJ^]9O:M>
/L\3E'C]"KV!F"=6 M)*: ^*3[\+4]3_M-W>Q4?YL"V5?O_E>OVT_N[_VG_NWBSW_], MV7^IR7]96M#6T?#5[,#/!*N*/TJSYX_>Y*4N3\)K)2GQ8 &!7QB*\? #!]3_M-
\2[_P=02P,$% @ &X1G69Q9)&ULK5;;;MLX$/V5@5H4NX#@>]!)+$(@.)D[99Q&G09+?/ MM#26N95(E:3B^_ W#&4K[C8-NL"^V"3%.7/FRCE>6_?5KY@#/52E\2?)*H3Z
M7;_OLQ57RO=LS09?EM95*F#KBKZO':I\"E5E?S08'/8KI4TR/8YG-VYZ;)M0 M:L,WCGQ352@/SVN5<&W'/ZL;QOV_0XEUQ4;KZTA MQ\N3Y'3X[FPB]^.%OS2O_=Z;Q)*%M5]E9DL?
M?VG=WAT/$LH:'VRU%0:#2IOV7JC/R4M-%6LTICY6)/1M8]^?VI?Y5%P%3P,&"TN M?.0ZGAZE'@*-S^@0#.F"=NX:?7U\H%ZQH*QRG7"HC2^G9SPVC^>#IGVXCIF
MX@RDM8X *T4GW\=1K^9]B1GNQNW7BI)E/$U/IBW,V3Z#T%9*#652QK%3_#7P M UE7+7 ,3W?][K+I;1%+W%OYGQ[ZEYA:MEUI\X"XV9)69[O08OM[$/*X.GO5
MWQ%C8,HL&5PV]'P-"MQVPD]^CRWI!*;;$P(W1EK4&/$A'K7/\+9$"1G@DL?^_P*^!0B317^]L$"E)HPQ>5'U?&+A7@7EBZWG M"VA=,J'#,=?,UH=>O5\P\,"DJ6JM:[_JPQJ^]9O:M>
O'=G,^Z30P1*,@=P7B[06#&@1BQ$"|E*BUG|HJ/UU$#'^-W\W\]D)6.8T/^_M_H8=Y8JT-+X@7TZX>_,NDD)9+.OM*W.Y-Z,)'.WZ#7^15<<.=J:]Y&?M@W,*<
M2G0G3!TA'%O'O9')^7#ZJBZYX>.&;N6_AR??>!%[@AR$FOHFDHY#L_Y.2N88C248;W"#4XH^7+&\/NW?.I ^_7>4X@Q0/*^ML/[DV?XIY'!!G,P."9 MQ)3?/'X([(1N"09]$2-A6W
Y8[V&$598OZ^''KZ[5Z[@%I^H1E4_)PQ9*H&E M

L2M."Y<%PHHG$O8S1U;[FA'^MZAE)7*;SOA_3F8 JF]3R M)$CGN^C8T?7]_I;T#E()(! Y8TG?DC0>^F+34]%UYRG\GYW4\8?E=]5GPI+JA3;7DD):'*E_1UVN)//*--NK#G;=\&:-:@^!<*FF?:!;++ M^#Q%]BUG:5!X8!LBH0QQ1%6YI=J1]M$-:YUSYSDTO1+D5:!+C^0=7'J_9Y$I M,_&5%RD$KNU/-*Z+40A0_F.>[&2O)_M1I\C$X.;,.CG[2L6*-N-Y0%PHE.$N MQ?'S=WG+LE5(<6?)6CE$"+4@WEGLFO?3],.(//1GH<]=HX*281OAM=OU,D\| M5-K6M&6W;%(R,\B&?!#4W$0'8/L6B;*K3=T[M[&'DZL(/]'M1^_=+.K$=Z?) M*CUM098T[6//@*T,3Z4.Z\X , ^.*(!!7G\ALP7RC/VC@TR!D#6&W9 *=VP| MLV>@&7Z]$O=[*'>]E(R]>/M/5@GEH<'-^,14!L-PN-TG*NL'WV6^?EX&E&&% M%]LI0MC=MU[,SMT%8UK344@H)%\';O\,9P[_Y$I"V::+_XD0QPKK(+]9&^# M)S,UQZ.#_@5*@$)^&$W^0 +,/T:&NARE M'G]<\@]#0TOWX?FY,Y?Z@ _S/T[WZ/U!+ P04 " ;A&=9 4S4C[4" ") M!@ &0 'AL+W=O4/?,40*"WG!1\9*1"E)>6Q>,4)5GF/V:P*$[D:&8^P-BVR;"F6P_&&)MQ"! M6)5S)E=6BY)D.10\HP5BL!D98^=RTE'^VN$Q@QT_F",E9$WILU]$R3 G7; [1K?&T#Q147-&^"?)8,!*^H1OS5U^$R VP2XFG>=2+.| MQ@+[0T9WB"EOB:8F6]J.EN2R0GV42#"YF\DXX<\7X2P(Y^-[-%E%X>PFBM X M6(;X?)OC6?7*%I-I^/%$WJX15%X-PMOPV \6TJ?X&$U6X:S.S1_N ^#\"9" MWY9X38!_'UI"$E/P5MR0F-0DW](#-"4%B+EZ*9(((DSWI*"6E7N7M7$/0D8 M07F,/-*

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|=>(*<$,_ >&?'V5FW19L9:7OY?8V,U9GL[55VDS: MT7?]3F@)H&:/8* !N4 =#?]D8/MKKJT4V]"+5,AY!CI^4);GZ%]KQ1I6&@X) M_+"Y^[X,2/&O?X:-SCG?&>GF.48# _QL! O*'\P8/5_ NL+ 5;&)VZL74,L#9$WP(K MK8", ^>2[@77':1A8:1AA+]B7Y^/ 8SCTCM>$X2@B. SH \#*,&4)@'#P!#(C M' 4,>R1\HS0=0\&+"93U#@@_(IQ*:)G_ M/VWK3Y2M(BJ$_HDDW5 ,L>=YG8%]D$WBBN9;D(6@3B+H.]EW@^R.TQ#(!M@/ MR5*M!2'-,(P]8B9YT+:'E>-^YPT[M$5QA+L0>'UR8[ZQP+;%]3*_@3;*]2" M -,,/! [7TC9$/6C+?!S%Q_]:'D#;AM,0VD+;$OK8C_;;RPOG$32+M# 1>]$6 MF$$7[2>3:LW??4 MN,=`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`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`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

[-1K4J:),1':DWWFGW_FH?F\Y MQ0.Z2(B$N!),?25T)P#P]%=#XHR2G;]SIB2+)B([$'G'6B3B;I,+/IE1O2K)H M(K(C]>:=>O/)]S\.1_IT/S1K-?951*7L5B3 IJ^%#K67J M'S!VX/E^\#CM<9>G[HRIV(X%ZOW"VM^YOH\[//4K;-G^8Y--Y;,1T>RU!#F(MG6ZM)*

*(EY5:BF.^A6N_;MM6Y:S&_F3>_WCHH=*R3)8(M0C!RWEVC;J6:B>*D; MC U7V*[H88HM*(C:)]O.5* M+ !)P# !D !X;"]W;W)K&ULQ=UK<]O&@N;Q MKX+RGMI-JAQ:!" ^BLHFK$N/6N#2 [I/9VI>,!$FL2*0&I.QDZGSX)252N*I% M.Λ\S.R_FT#+P:U","T$-/.B?OJ[+/S:W1;&U_KR_6VU^?G>[W3[\^'/CYO*V MN%]L/JP?BM7N;Z[7Y?UBN_MC>?-Q\U 6BZNGG>[O/MIG9[./]XOEZMVGGYZ^ MEI6??EH_;N^6JR(KK=WHW?'+ZCES>UV_X6/GWYZ6-P4 MNMC^]I"5NS]!?%&NEO?%:K-UU];^ MO?R^7O^Q_X.X^OG=V?Z0BKOB>WOWNW?R^V!2?UW?_9WFUO?WYW?R==55<+Q[OMFK]-2@. [VBZ]R[7=YNG M_V]!/6Q[!LZZ?-QLU_>'G7='<+]PP.76'Z6&'Z:D[S X[S$[=X?RPP_FI.\P/.\S;.]BO[']QV.&BM8^.'_CHY$]\=/S(1^W/_/4#.W[H MH\ZG/GIME^/'/NI\[J]l*J/C!S_J?/*O[G+\Z$>=S_[5 SM^^*.G3__C\[_> MIW_ZSF*[^/13N?YJE?OM=][^Q5-^/.V_^Q>_7.VS3F_+W=\N=_MM/^E_II^C M((T=5^G_9;GY;^*?_]?ZP?KEZFJYCZ+%G;56N[HJKGKVC\W[7[RU?VK>?V0;@(^[[]K+ MM\X^?NM^M8WB+X\W'ZS1Y+UEG]D3ZS?M6-*

_]XWMK<[LHBTW/\7U^0WLH/UAG M\U,UYQ3-/E5SS5]RV&GVQ:F:9]9T\;#[OCV_T_';FF_6PL>[W3L]/U4+3OE, MSYXT^VU-

*F#6GN/Q@C9^UT5'K^Z=SPC?LP%3?@[J8'P]^]OKQ1:?#)WSOXG_7 M82;#8&D^3(F^Z?24CWC4TDYYT]GIL/VZDI_PK\.>-3^3'D:=P!RBSO0?LGZ+ M61V_]:.+WO?4".+QR\^P\1,['O SK.?@?GU6)OW*_I>*'S[WQHV M1?FE>/?I?_Z/W6G_^Y+ GQBTC>)Q_O?B])-7UL[_+HHR^+*VOWN<_F'M7CF7I?5Z^ M/_[68.3ATW(826) MI2>_AXP<-BKEXWU+^L? M?7%MY(2&-8DY).:2E$=B/HD%)"9(+"2QB.1B$DM(3))82F(9B>7/V*Q^JC_M M/=57)V^IH0-*

L9/+\)9/GQDQ6Q69;+B^W+Y.XCZOE]K7\-5)#\Y?$'!)S2K5_BRV^+,H+Y>;PGK8)>CNI':Q MNBGVT?ER/TE?

*AAKUH1E*8@Z)N23FD9A/8@&)"1(+G[%Y/1P_3%L!2@X8GS!@ M0@XH22PEL8S$EJ65RN;U:[JV?[*

MZ=Z'8K5YOOWV4:VHL/&IPR;HL!+54E3+4"U'-85JFM:N5WKL(S_ML\#WZW+[%-G]'&[V2Y65\O536\"HQ4Y5'-0S44U#]5\5 M03:!: M>-*

:X65/1V>C=GI%Z+CQR>,FZ+@2U=^=W$VG[G:V?;8[P6S=$=`G7~^;EVB)#=4<5'-1S4,U'}4"5!.H%J):A&HQ MJB6H)E$M1;4,U7)44ZBF*:V9XU5_;O1< OF[3^@9H>TY5'-0S44U#]5\5 M0 M3:!:B&H1JL6HEJ":1+44U3)4RU%-H9JFM&:H5]6[D;E[]PT/GC"+@_=[=NA*

MFHMJ'JKYJ!:@FD"U$-4B5(M1+4$UB6HIJF6HEJ.:0C5]T,P/ 6F&=]71&YE+ M>LER]>K,"MK)0S4'U5Q4\U#-1[4

*U02JA:@6H5J.:@FJ251+42U#M1S5%*II M2FOF>%4=`%TP,RMH21#5'%1S4HT1XBJCFHYJ*:AVH^ MJ@6H)E M1+4(U6)42U!-HEJ*:AFJY:BF4$U36C/,*

[2K,;61VQ4;;BZCFH)]+ M:AZJ^:@6H)I M1#5(E2+42U!-8EJ:IEJ):CFD(U36G-4*\ZD+:Y SGD:?YF M:G"PHX5(5'-1S4,U'}4"5!.H%J):9/<4!&?VV?*

*F\U=WIV6XZMB_;3VXZ;3/9 MM]G%V7C2&C5%WVN&:CFJ*533E-:,SZKBN'MY:GR6@RJ.9GAPF)*:@VHNJGFH MYJ-:@&H"U<*#UHB_"*

*[O5;SQLU"@R]+2=C]UM[+/V@TC18Y<]0X[&[0<]HT-F MJ):CFD(U36G-!*U:C;:YU:A:J=F;E6B]$=4<5'-1S4,U'}4"5!.H%J):A&HQ*

MJB6H)E$M1;4,U7)44ZBF:T9Z%6]T6;JC39:;T0U!]5<5/-0S4>U`-4$JH6H M%J%:C&H)JDE42U$M0[4U M`-4$JH6H%J%:?-*

:E\TF]Z?=N)]&C2U$M0[4Z$\4F; M2?384E3+4"U'-85JFM*:N5WKL(S,63RN6GUC>&3MT+8C P-851S4,U%-0_5?%0+ M4$V@6HAJ$:K%XVY-*

R[XX'\TN6BE\XG82/;H4U3)4RU%-H9JFM&8,5P6]L;F@ M)]>K'PY1_/J2VF9C< JC+3U4JCFHUJ

*:@+50E2+4"U&M035)*JEJ):A6HYJ"M4TI34SNVH*CHVEE4_N_-@E814\,<;6NBFH-J M+JIYJ.:C6H!J M5"5(M0+4:U!-4DJJ6HEJ%:CFH*U32E-*

*2,_;FON7B*3+A,T MU$G-0347U3Q4\U$M0#6!:B&J1:@6HUJ";A+54E3+4"U'-85JFM*:H5[5."?F M&N>)DRYH?Q/5G(/6F72Q.[,N:($3U7Q4"U!-*

*H%J(:A&JQ:B6H)I$M135,E3+ M44VAFJ:T9EI7!<[)-QV==;LNB/_19B>]..CFHIJ':CZJ!:@F4"U$M0C5 M8E1+4$VB6HIJ&:KEJ*9035-*

:,_2K9N>$:?9.T&8GJCFHYJ":AVH^]@6H)E M M1+4(U6)42U!-HEJ*:AFJY:BF4$U36C/4JV:GQ-SL/"">!6URHHST$Z8=T$:.MGZCFHUJ

*:@+50E2+4"U&M035)*JEJ):A6HYJ"M4TI373NFI\3LR-SY=YEU>? ME64&!B(3,J4[03BFH.JKFHYJ&:CVH!J@E4"U$M0K48U1)4DZB6HEJ&:CFJ*

*M*533E-8,],H3.C6OK)D^;C?;Q>IJN;KIS7*T"HIJ#[JYJ.:AFH][:H)5 NG MW94AS^>=OZ%%Z*#Q:8,FZ* 2U5)4RU*

*M1S6%:IK2FNEK5^EK+F^^S)!LOZY/ M>+2X61NU`-4$JH6H%J%:C&H)JDE42U$M0[4%>MS2FX^*;9&IS9:'ESVEU\|||*Y*

M1Y/S=F:CW4U4\U$M0#6!:B&J1:@6HUJ":A+54E3+4"U'-85JFM*:F5UU-Z?F M[N:GVV5Q;;E_%I>/V^67PDJOKY>7NQ__1'EY@$&!SG:VD0U%]4\5/-1+4

*U M@6HAJD6H%J-:@FH2U5)4RU M1S6%:IK2FG%?M3:G3&MSBK8V4BFH-J+JIYJ.:C6H!J M5"5(M0+4:U!-4DJJ6H MEJ%:CFH*U32E-*

*4.]*H?.B"4]S,]W0<[0; MBFH.JKFHYJ&:CVH!J@E4"U$M0K48U1)4DZB6HEJ&:CFJ*533E-8,];H:>F[N*

MAIXV[V)&!D+DMB_Y(1^NBJ.:@FHMJ'JKYJ!:@FD"U$-4B M5(M1+4$UB6HIJF6HEJ..0C5-:_E,O1F1PI)..<-]!.F'HA MA_50S4>U

-4$JH6H%J%:C&H)JDE42U$M0[4:=Z4$/7SY]G&EZ(9JN6H MIE!-4UHS-:LZYKFYCOE\/\ERLWG;58WF8IUZNK]X_/\WPO56V@W7S=5'N

*M_QIF7&\VKP8L6N!$-->>\N_[FV)YW'YR%CNJAFH]J :H)5 M1+4*U&-425).H MEJ):AFHYJBE4TY36C/>]P'EN+G'FAT<<;M?/3SFTOENNK,WM8C?6]*

[VQC?8T M4-3#GQC+0IVKYY?7S\LL;:[':G7Y_TZ5)\UA#,QW5'%1S4LT=O?@ M9_:V;-)9[L4/;@,U7)44ZBF:T9GE4EUX* U]6,W+W_W'WB7G8P?*

*%.:@ZJN:CFH9J/:L%!JY\-3F?=R[\'"35$M0C5 M8E1+4$VB6HIJ&:KEJ*9035-:,]ZK*N7<7*5D+V.B#4M4JOFH%J";0+5PWJTH_F"/NYT:M7,=$*

*MFY:HEJ.:0C5-:IV>=]`C0 M406]A:@6H5J,:@FJ251+42U#M1S5%*II2FMF>U6SG+^Q3N:_ZSHF6L=$-0?5 M7%3S4,T_:(U';LR[9X(!.JI*

M1#5(E2+42U!-8EJ:IEJ):CFD(U36F->+^H MZI@7_^N8)UZR-+-#XQO5%1S4H,U+5'-0S44U#]5\5 M03:!:B&H1JL6HEJ":1+44 MU3)4RU%-*

*H9JFM&:HVU6H?T/S\K?9%K,U.-G1]B6JN:CFH9J/:@&]"50++WK-MESTA>W9K.?B0MRSV4?W.B?Z#E3/F.VKE>B &:KEJ*9035-:,SBKUN6%N76Y*

*M7I.LN.I-2;0ZB6H.JKFHYEWTU!.GG7^@/CIH@&H"U4)4BU M1K4$U22JI:B6 MH5J..@K5-*4U\]EJ3NY>_K??36(>0>M'NV3OF@G!PU03:!:*

MB&H1JL6HEJ":1+44U3)4RU%-H9JFM&:T5ZW)BS<6H/PWW4QB'G9PNJ,%2E1S M4Y+AS7CWUO;I=-=X\VN!01PN4J.:BFH=J/JH%]"90

M+42U"-5B5$M03:):BFH9JN6HIE!-4UHS^ZL"Y<4YN\,/6'N9G[KA,OVZ[HWU-%*)]HYJ.:BFH=J/JH%]"90+42U"'-5B5$M03:):BFH9

MJN6HIE!-4UHC^WS M7,)RDN52ELM8+F6//X=&.5C99SF4Y[\B]-1?# M#ANPG&"YD.4BEHM9+F$YR7(IRV4LE[.<8CF-<:W.MFN9;6YG?B[[6*YLHK[*

*MA[OU7T5QZE(0;IC#$QVM;K*R_DL%["<8+F0Y2*6BUDN83G)?UX)_#,W*H&53EG-8SF4YC^5\E@M83K!X7O_(&-CSM2- M%9<=UV.YC^4"EA,L%*

*[)5RL+O>W)7;[_/O3Y%>+_&_(PT,=;7T>N<9"[:/SOE!'&YTLY[-S7,:R@N5"EHM8+CYR]=_K1I.> M1XRSXTJ62UDN8[FR_DL M%["<8+F0Y2*6BX]*

<_81YW+.@_8G;2?;P4I;+6"YG.<5R&N.:P3RJ]2Q'YB4R M#\'\VAFU>>_!@8QR#LNY+.>QG,]R

)LHY+.>RG,=R/LL%+"=8+F2YB.5BEDM83K)9,L_ES>/]Y7 M3[FU'A_6N[T6Y=VR/?S.9>WB]5-8>VHR_5]6Z[OK'5I;6_+HK#^VFVVL:[+*

*M];UUM=@^W:YNF/DQ'N_P'Q4DY["R_DL%["<8+F0Y2*6BUDN83G)P MG&2YE.4RELM93K&>O]39Y_;^F/*

*M<[9WBG(^AP4.1)C@+QVM;K*R_DL%["<8+F0Y2*6BUDN83G)P MG&2YE.4RELM93K&>O]39Y_;^F/M<[9WBG(^AP4.1)C@+QVM;K*R_DL%["<8+F0Y2*6BUDN83G)\]?[&IHD@MCF+*

M[LUU,S4XUU':83F7Y3R6\UDN8#G!PG,MR'LOY++!>PG&"YD.4BEHM9+F$YR7(IRV4LE[.< M8CF-<:V@MVM!;UXG53[>__Y\>79]6/_C:?&/5Y:[/F"-

YZ)V'RKR^8U!A\PG&2YE.4RELM93K&'6[0^?)4Q>T/]6[+==XMN7Y^XQ"&AS]PBG>2SG MLUS Q7.YRBN4TQK5"O5,!W;W^A@GWZA;+]]9V M=*

*[)^>5M8ZU71G^W&$89/SY"RG,=R M/LL%+"=8+F2YB.5BEDM83K)4GN[.[]_<*FN_2E/9KVS=BP)5:4 M*

*MYYSU!KM9'WPRCW(,R[DLY[&*_UK7=0QU7<=LUQ7E')9S6R7.1R,C-7=>G"Z_'29NKQ0]C-PG[P\S-*

>ZML/]GXZ3G$[ZV;M)^4TM[ZU_6/_H3_WG<63WQ^VZ]-!_? M\,1G"[,HY[&R MG,=R/LL%+"=8+F2YB.5BEDM83K);]8<]N\@LRCDLY[(C5[]<-1W;*

M%ZW)R^3$[21[>&G?L/9L.IO,)LV!,W;@G.44RVF,:R5OK=4Z-K=:9;&U'LKU M95%

*<'19]7=:R^+@([*OSY6RM%>4X1{OZ2D;'#YBRG6$YC7"O4;U7/B;%C].F7+T6YN"FL*

M37%W]W0[>+G+&EEWR_OE=O'\;/2RN%OLJSK;W5\]EM;]HOQC=Y)^N7C8;7&W_*^G MK?KSFVPV?68YA^5Y@.4$RX4L%[%Q7,QR"VVS7,)RDN52

*MELM8+FR_DL%["<8+F0Y2*6BUDN M83G)MDB*<@[+N2SGL9S/<@'+B2-7 MG^T979SWS_:P)5&4BUDN83G)[M[YP_^S"?*

[.=Q1A_.YOW!SC904S7,)RDN52ELM8+FQG,]R M O2)K1@>G/LHY+.>RG,=R/LL%+"=8+F2YB.7BM_ZIS:R_ MBD7955TA,OGU7R;Z)E.4RELM93K&7-8

6]U92VW&ZLX9O^7]=UBN[Q;;O^RRL7JINC/?+8SBW(.R[DL MY[&[U-P2U:7[#" Y:/9)S6,YE M.8_E?)8+6$ZP7,AR$PG,MR'LOY+!>PG&"YD.4BEHM9

*M+F$YR7(IRV4LE[.<8CF-<:V@KU5$I^:*J%\N5EOK:C\54QO/_9_O5GF:F7G[MT>UF?_@/_+8RBG(NRWDLY[-*

Z)3I@>YG:$P70=E&*,HY+.>RG,=R/LL%+"=8 M+F2YB.5BEDM83K)R7,9R.Q\/1S]&(UZOAZ/?11]7T]'/V9/7_]8#?OIIX?%39$LRIOE:F/=%=>[0SC[

M<#Y]9Y7+FIN7/VS7#[L?,>^LW!?;[?K^Z>5ML;@JROT&N[^_7]^WQS_L_BZ M+O]X>IN?,A)02P,$% @_&X1G6=1]TJ16" ?DX !D !X;"]W;W)K

M&ULM9QK;]LV%(;_BN -0P=LM7C1+4L,I"'7[4,' M(%FZSXK-V$)MR9/HI 'VXR?)BFA-&U5IU\:7\YY:.I0;_F*E"Y?LOQ+L1)"*

M.E\WZ[2XFJRDW%Y,I\5\)39Q\3[;BK3\YBG+-[$LW^;++;'-1;RHDS;K?9=_M?[J)DW0RNZP_N\UGE]E.KI-4W.9.L=MLXOSU@UAG+U<3-*

*'G[X"Y9KF3UP71V MN8V7XE[(A^UM7KZ;MI1%LA%ID62IDXNG]\DUNN">5R74$9\3\5(+RS[.X$>MU12I_Q[\-=-*V624>OGZC_UYWONS,*

*M8UR(FVS]3[!*0JZM),'$6XBG>K>5=]O*';#14_\!YMB[J?ZK

_9.]Y|L2=++_6H&Z MC1<2N"E!B30N)-IBN G M>\|^D?;N?/?=.[2[WY^_B=SC*\)W""<.#L^[<:07]Y/XLILUK;U7K.A*\0[S M)2F$PEDH]7.9J_7C=?%5-R0KJ_IEQJ2JAJK'E2I8@>L!JG_!F-PU=$G4EL#I M/U!+ P04 " ;A&=9+QJ*4H$" "X!@ &0 'AL+W=OJ1-3P4#&N)EZI=7WI^RHKL2+] M1-3(S4PA9$6TZ@BOEA$)SZ%:'<2Q.WMI1I(AK-*,>E!-54%9%_M9LA$._%&WFY@13>EM@-^FM1D@VO4/^JE-#U_8,EIA5Q1P4%B,?&FH\OYV-:[M@I\46[77!NOD3HA[VIG)\UY@\2'#3%L&8EY;G"-CELC(^-US>L.2%KC?WK%_M=MZ-ESNB<"
[8+YKKY!C01JF5Z*]QMZ/$Y@)\IMP3VJ[V+/0@:Y0650\V M"BK*NS=YZ/=A#V!X#@/""A ^!<3/-*
(>$#FCG3)GZXIHDB92M"!MM6&S#;YM1*PO7!O3K*9>_H:DAA//M7$2%^O:-Z#3X=,CH*Y$]LAT/MF/"KWXM!RR&[^FW5V1W/-@=!_W*
M4ZYI3EECDP849HVDFJ("?,A88\XU%%)4D(FJ;C1QJ20*0"(YY1L%-6QECNJ7KPY;.(:5TC\ZY1])U+3*LS5JPVP5C M)EJ50M8CLC"F^A#']6S!2EI?
J(I)BQ1*E]38KI['=:49S6L@E2+N=3II7%(N MR7@HE^5U:>IHII;2C$B_#47^]CD?D6[ZGD1>;J)R-B+W9V[_+)6Y>A/Y^\F[MDY/._?G58?S,
>G@P@!BXNGSQ)_2QJ0O]Z7=\%,KY(FG&&T0 MH-DL6R9T'#EN-F4\+)3<[DU"?,"JTY)%#U2,R(0*/M4<6 4MN5C[< \",R64 MCHPM"INN"Y'ZEX>[O@?
UTNB47"KMGVP)[F:33)7.F6[3=,DF-!X*5H =S><+ MN!M5Q0 :HTK;R#F=*TF=APVC:5C9&1/B%AZF[\6>]JK8V;<.[)ILF]90T_0R
MO@/ZNVI>>U>V]R+=+J.(/RGO:VNE(UX<"93>:%7SE^]NB-8"I=W%U6E5B_5'P MN2R9G_RS$XZ'=,.+%DKS7S8;E,K,!I@FT0/3AL]V(S\UK>
[8RFS*:57@GGNO MT//?7>7_\JR^Z]R:#CHL7E#'KO)_FLPF;X&DZ^@ M)I/L^#TVIZ*C,QDW[^^=0\+>$:&-1G 4&Y%O<+ 3VZ31=,F%X;+I+7B>,_GH
MI&#E#9W:P_R>OAV?LX(NA;EKP1'9MK^RG"_+K!UU PO1C-JVO\#TNFE[#K2Y MN,S9BN63[JOGA]>,.,_F;2X@'"+7[@HC&,=C800P+_"F_-X%I;G?YK/
)V/ MQS!O@R R0#D#E.-9(63B/EB>,">S5WBF698D:8JMZ&02=##!UBU-X1M6P[P! M \L#F?YLK?'=QBODZ3K]O2I"L%FBE8&"[@-4. MY
_G@9H*^PIR1)LBR, !9VD"08 M D\CCF .P .&)(E[#QZ|C^+->RK>_L(U_@U02P,$% @ &X1G69>*NQS M $P(L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %
(MB6/ M:(7->=I3W;+T]!;X"O M.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B';5_ M'YFE!UQL#;Q%
S%3C1[ZBBV")K8$B,)TNROKVQ*5[3F3E\$3[9D M(XXE6>?ZZO.;D*_/0KRB/YN:J[&WUGIS.QRJZ\IAYJ&&<-^T:KL3?RD%]+MPV6GQEM:8R(9K>
M2[!=,/]2-F.>8F@]1MAE.^:,O>V3VK^.JWV3ZT-KM6'\I:9"S*M.G!WD)-Y MEN LQPDR9_E\FB9Q80IW\33.)AA9D $ &5P0\H_ @@P!R/ BD'EA#C.<69 1 M
!E=$/*H)Z\!R.M+0H86Y T >>,6\B[.TQS-OZ+%$NG< MO)$+O$3Y0[P\FF>0&7S':EB0=[13:$%E]W->4I0P5=9";26U(2$S^({5D'+%
M*BI1(4EEXCH42TGX"VU_I6Q&2 R^8S. R^^18WU($OXE+7%D61_2A'\!3Z K M$^[75/UH0T+&\.^CC#ZN ')'<'YW]#)"$@D<2V2_/O=B@9|
M4;ZEZ/D=E5NE16.B8'MNAF#JR[&%;.R2LEVG\B[O60JS*-F8D(5"QQ;ZCGD8 M9U(C]D]*UL:$+!0ZME!?
U&:0]^._(38F9*'0L85Z@\N>^"B$'!0Z=E!_7RZ, M)TNV(;6-"3DH=.R@$T-^F*4V)N2@T+&#P(0/NK)SW)"#(M>?/7]_4O1,Q@B2
M3G2>3QVS2K*7M1Z(U0!M%45$*=KN$MF8D'2BLV3,#.;.Z*TT.]'LY6*%])B MFA);X1$DG>CLJ;3^$0>W6SKC#
^;@15=,4ZKS+2O3'U)ZG(A47O8IS&CZS;- ML-K6]<34S?E4D.JPMWC8%_WR%U!+ P04 " ;A&=91QQ@N:0! ";&@ M&@ 'AL+U]R96QS+W=O^
MSB@6L]>9O=6U"?^96&^WAW7XK-??!W!.?PQV/W5[C/L04M%;E>TNI'GA+M7S M='3W@_1ODXO>BN!WHIZ*X'>VOG8)M!;46\ET%M1;R70
M6U%O)=!;46\ET%M1;R706U%O)=!;46\ET-M0;R/0VU!O(]#;4&\CT-LZFR4$
M>AOJ;01Z&^!M!'H;ZFT$>AOJ;01Z&^!M!'H;ZFT$>GO4VQ/H[5%O3Z"W1[T] M@=+X>]?8$>OO.9O<[]8[I6H7X['FL\?GOI#K=[@W/Q]^7CY.=M_>.LX-
_48M? M4$L#!!0 (!N$9UDNTOC K@$,H: 3 6T-O;G1E;G1?5'EP97-= M+GAM;.V9S6[",!"$7P7EBHBQG=(? 9>VUY9#7\!--B0BB2W;4'C[.N%':D6C
M(BIU+K$2[\Z,O=)WR?1M9\@-MG75N%E4>&\>&'-I0;5RL3;4A)U7T<$A#IU=C2M*XX:A(&)G'=J=GPT.?:\;LK;,:+!0UK^H M.E2Q;<6H?K_=!V
MUM5W_]=Z5=XU]5S=&?=;^PYI]02P$"% ,4 " ;A&=9 M!T%-8H$ "Q $ @ $ 9&|C4'}O<',O8?!P+GAM M;%!+ 0(4 Q0 (!N$9UGJEUGU[@ "L" 1 " :\ M
!D;V-0&UL4$L! A0# M% @ &X1G6?6-A>G6!0]AX !@ ("!#0@ 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ &X1G6:IOS.,? M"0 +S0 !@ ("!41@
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ &X1G64":G*58!@ .Q !@ M ("!734 'AL+W=OL[!X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0# M% @
&X1G6;Q![/-!#@ L30 !D ("!4F< 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ &X1G66P# M(%7C" 5A< !D ("!>8L 'AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ &X1G60!ZCZM# @ B@8 !D M ("!;YH 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ &X1G65E(X'I;!0 VQ(!D ("! MQ+@
'AL+W=O&PO=V]R:W-H965T?# !X;"]W;W)K&UL4$L! A0#% M @ &X1G689)RFY1 P D@@ !D ("!-<< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @
&X1G60WV)@\C P '0H !D M ("!GN 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ &X1G668I^@1I P X X !D ("!\NP M 'AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ M&X1G63WN;?EP @ $P8 !D ("!X"4! 'AL+W=O&PO=V]R:W-H965THL 0!X;"]W M;W)K&UL4$L! A0#% @ &X1G62SOOZ?G @
MV D !D ("!VC&PO=V]R:W-H965T&UL4$L! A0#% @ &X1G6&PO=V]R:W-H M965T&UL4$L! M A0#% @ &X1G6<-&PO=V]R:W-H965T7!E&UL4$L%!@
T #0 (PX %MF 0 $! end XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange
Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright
protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var
e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?
w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var
e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-
'}else{d='none';p='+'} e.style.display=d;if(a.textContent)
{a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /*
Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size:
1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report
table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover {
background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{
font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border:
2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /*
Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color:
transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-
space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px;
overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh {
background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re,
.report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-
color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /*
styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-
space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-
align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note {
font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em;
} XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 270 320 1 false 69 0 false 9 false false R1.htm 995200090 - Document -
Document and Entity Information Sheet http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation Document and Entity
Information Cover 1 false false R2.htm 995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet
http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2
false false R3.htm 995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet
http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS
(Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE LOSS Sheet
http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 995200300 - Statement -
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Sheet
http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity CONDENSED CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 995200400 - Statement - CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS Sheet http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 995210101 - Disclosure - BASIS OF PRESENTATION Sheet
http://www.cytosorbents.com/role/DisclosureBasisOfPresentation BASIS OF PRESENTATION Notes 7 false false R8.htm 995210201 - Disclosure -
PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet
http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPolicies PRINCIPAL BUSINESS
ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 995210301 - Disclosure - STOCKHOLDERS'
EQUITY Sheet http://www.cytosorbents.com/role/DisclosureStockholdersEquity STOCKHOLDERS' EQUITY Notes 9 false false R10.htm 995210401 -
Disclosure - REVENUE Sheet http://www.cytosorbents.com/role/DisclosureRevenue REVENUE Notes 10 false false R11.htm 995210501 - Disclosure
- LONG-TERM DEBT, NET Sheet http://www.cytosorbents.com/role/DisclosureLongTermDebtNet LONG-TERM DEBT, NET Notes 11 false false
R12.htm 995210601 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet
http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 12 false false R13.htm
995210701 - Disclosure - LEASES Sheet http://www.cytosorbents.com/role/DisclosureLeases LEASES Notes 13 false false R14.htm 995210801 -
Disclosure - NET LOSS PER SHARE Sheet http://www.cytosorbents.com/role/DisclosureNetLossPerShare NET LOSS PER SHARE Notes 14 false false
R15.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure
Notes 15 false false R16.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements
Insider Trading Arrangements Notes 16 false false R17.htm 99920202 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet
http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies PRINCIPAL BUSINESS
ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 99930203 - Disclosure - PRINCIPAL
BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet
http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTables PRINCIPAL BUSINESS
ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables

http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPolicies 18 false false R19.htm 99930303 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.cytosorbents.com/role/DisclosureStockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.cytosorbents.com/role/DisclosureStockholdersEquity 19 false false R20.htm 99930403 - Disclosure - REVENUE (Tables) Sheet http://www.cytosorbents.com/role/DisclosureRevenueTables REVENUE (Tables) Tables http://www.cytosorbents.com/role/DisclosureRevenue 20 false false R21.htm 99930503 - Disclosure - LONG-TERM DEBT, NET (Tables) Sheet http://www.cytosorbents.com/role/DisclosureLongTermDebtNetTables LONG-TERM DEBT, NET (Tables) Tables http://www.cytosorbents.com/role/DisclosureLongTermDebtNet 21 false false R22.htm 99930703 - Disclosure - LEASES (Tables) Sheet http://www.cytosorbents.com/role/DisclosureLeasesTables LEASES (Tables) Tables http://www.cytosorbents.com/role/DisclosureLeases 22 false false R23.htm 99940101 - Disclosure - BASIS OF PRESENTATION (Details) Sheet http://www.cytosorbents.com/role/DisclosureBasisOfPresentationDetails BASIS OF PRESENTATION (Details) Details http://www.cytosorbents.com/role/DisclosureBasisOfPresentation 23 false false R24.htm 99940201 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 99940202 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and cash equivalents (Details) Sheet http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and cash equivalents (Details) Details 25 false false R26.htm 99940301 - Disclosure - STOCKHOLDERS' EQUITY - Stock option activity (Details) Sheet http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails STOCKHOLDERS' EQUITY - Stock option activity (Details) Details 26 false false R27.htm 99940302 - Disclosure - STOCKHOLDERS' EQUITY - Intrinsic value (Details) Sheet http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails STOCKHOLDERS' EQUITY - Intrinsic value (Details) Details 27 false false R28.htm 99940303 - Disclosure - STOCKHOLDERS' EQUITY - Non-vested options (Details) Sheet http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails STOCKHOLDERS' EQUITY - Non-vested options (Details) Details 28 false false R29.htm 99940304 - Disclosure - STOCKHOLDERS' EQUITY - Restricted stock unit (Details) Sheet http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails STOCKHOLDERS' EQUITY - Restricted stock unit (Details) Details 29 false false R30.htm 99940305 - Disclosure - STOCKHOLDERS' EQUITY - Restricted stock unit activity (Details) Sheet http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails STOCKHOLDERS' EQUITY - Restricted stock unit activity (Details) Details 30 false false R31.htm 99940306 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details) Sheet http://www.cytosorbents.com/role/DisclosureStockholdersEquityWarrantsDetails STOCKHOLDERS' EQUITY - Warrants (Details) Details 31 false false R32.htm 99940307 - Disclosure - STOCKHOLDERS' EQUITY - Additional information (Details) Sheet http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails STOCKHOLDERS' EQUITY - Additional information (Details) Details 32 false false R33.htm 99940401 - Disclosure - REVENUE - Revenue by customer type and geographic area (Details) Sheet http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails REVENUE - Revenue by customer type and geographic area (Details) Details 33 false false R34.htm 99940402 - Disclosure - REVENUE - Receivables and contract liabilities (Details) Sheet http://www.cytosorbents.com/role/DisclosureRevenueReceivablesAndContractLiabilitiesDetails REVENUE - Receivables and contract liabilities (Details) Details 34 false false R35.htm 99940403 - Disclosure - REVENUE - Additional information (Details) Sheet http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails REVENUE - Additional information (Details) Details 35 false false R36.htm 99940501 - Disclosure - LONG-TERM DEBT, NET - Avenue Capital Group (Details) Sheet http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails LONG-TERM DEBT, NET - Avenue Capital Group (Details) Details 36 false false R37.htm 99940502 - Disclosure - LONG-TERM DEBT, NET (Details) Sheet http://www.cytosorbents.com/role/DisclosureLongTermDebtNetDetails LONG-TERM DEBT, NET (Details) Details http://www.cytosorbents.com/role/DisclosureLongTermDebtNetTables 37 false false R38.htm 99940503 - Disclosure - LONG-TERM DEBT, NET - Principal payments (Details) Sheet http://www.cytosorbents.com/role/DisclosureLongTermDebtNetPrincipalPaymentsDetails LONG-TERM DEBT, NET - Principal payments (Details) Details 38 false false R39.htm 99940504 - Disclosure - LONG-TERM DEBT, NET - Additional information (Details) Sheet http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails LONG-TERM DEBT, NET - Additional information (Details) Details 39 false false R40.htm 99940601 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingencies 40 false false R41.htm 99940701 - Disclosure - LEASES (Details) Sheet http://www.cytosorbents.com/role/DisclosureLeasesDetails LEASES (Details) Details http://www.cytosorbents.com/role/DisclosureLeasesTables 41 false false R42.htm 99940702 - Disclosure - LEASES - Right-of- use asset and related lease liability (Details) Sheet http://www.cytosorbents.com/role/DisclosureLeasesRightOfUseAssetAndRelatedLeaseLiabilityDetails LEASES - Right-of- use asset and related lease liability (Details) Details 42 false false R43.htm 99940703 - Disclosure - LEASES - Maturities of the lease liabilities (Details) Sheet http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails LEASES - Maturities of the lease liabilities (Details) Details 43 false false R44.htm 99940801 - Disclosure - NET LOSS PER SHARE (Details) Sheet http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails NET LOSS PER SHARE (Details) Details http://www.cytosorbents.com/role/DisclosureNetLossPerShare 44 false false All Reports Book All Reports ctso-20240930.xsd ctso-20240930_cal.xml ctso-20240930_def.xml ctso-20240930_lab.xml ctso-20240930_pre.xml ctso-20240930x10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 64 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ctso-20240930x10q.htm": { "nsprefix": "ctso", "nsuri": "http://www.cytosorbents.com/20240930", "dts": { "schema": { "local": ["ctso-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["ctso-20240930_cal.xml"] }, "definitionLink": { "local": ["ctso-20240930_def.xml"] }, "labelLink": { "local": ["ctso-20240930_lab.xml"] }, "presentationLink": { "local": ["ctso-20240930_pre.xml"] }, "inline": { "local": ["ctso-20240930x10q.htm"] } }, "keyStandard": 254, "keyCustom": 66, "axisStandard": 20, "axisCustom": 0, "memberStandard": 28, "memberCustom": 40, "hidden": { "total": 29, "http://www.cytosorbents.com/20240930": 8, "http://fasb.org/us-gaap/2024": 16, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 270, "entityCount": 1, "segmentCount": 69, "elementCount": 591, "unitCount": 9, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 679, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "unique": true } }, "R3": { "role": "http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":

"As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_cOsNb-XabUOs7oHjv_A7rw", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_cOsNb-XabUOs7oHjv_A7rw", "name": "us-gaap:GrossProfit", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "unique": true } }, "R5": { "role": "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity", "longName": "995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Iwy99glN70uoPFJ0zlKGyQ", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qyEXnTrX-k6YT7pCgKjZYw", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "unique": true } }, "R6": { "role": "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "ctso:AccruedFinalFee", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "unique": true } }, "R7": { "role": "http://www.cytosorbents.com/role/DisclosureBasisOfPresentation", "longName": "995210101 - Disclosure - BASIS OF PRESENTATION", "shortName": "BASIS OF PRESENTATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPolicies", "longName": "995210201 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquity", "longName": "995210301 - Disclosure - STOCKHOLDERS' EQUITY", "shortName": "STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.cytosorbents.com/role/DisclosureRevenue", "longName": "995210401 - Disclosure - REVENUE", "shortName": "REVENUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.cytosorbents.com/role/DisclosureLongTermDebtNet", "longName": "995210501 - Disclosure - LONG-TERM DEBT, NET", "shortName": "LONG-TERM DEBT, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingencies", "longName": "995210601 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.cytosorbents.com/role/DisclosureLeases", "longName": "995210701 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.cytosorbents.com/role/DisclosureNetLossPerShare", "longName": "995210801 - Disclosure - NET LOSS PER SHARE", "shortName": "NET LOSS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_cOsNb-XabUOs7oHjv_A7rw", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true }, "uniqueAnchor": null },

{"R16": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_cOsNb-XabUOs7oHjv_A7rw", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_cOsNb-XabUOs7oHjv_A7rw", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "ctso:NatureOfBusinessPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "ctso:NatureOfBusinessPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTables", "longName": "99930203 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "ctso:ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "ctso:ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquityTables", "longName": "99930303 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.cytosorbents.com/role/DisclosureRevenueTables", "longName": "99930403 - Disclosure - REVENUE (Tables)", "shortName": "REVENUE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.cytosorbents.com/role/DisclosureLongTermDebtNetTables", "longName": "99930503 - Disclosure - LONG-TERM DEBT, NET (Tables)", "shortName": "LONG-TERM DEBT, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.cytosorbents.com/role/DisclosureLeasesTables", "longName": "99930703 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "ctso:LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "ctso:LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.cytosorbents.com/role/DisclosureBasisOfPresentationDetails", "longName": "99940101 - Disclosure - BASIS OF PRESENTATION (Details)", "shortName": "BASIS OF PRESENTATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "ctso:CashAndCashEquivalentsGrossValue", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:BasisOfAccounting", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "ctso:CashAndCashEquivalentsGrossValue", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:BasisOfAccounting", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails", "longName": "99940201 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "shortName": "PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_cOsNb-XabUOs7oHjv_A7rw", "name": "ctso:ForeignCurrencyTransactionGainLossExcludingTax", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_cOsNb-XabUOs7oHjv_A7rw", "name": "ctso:ForeignCurrencyTransactionGainLossExcludingTax", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails", "longName": "99940202 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and cash equivalents (Details)", "shortName": "PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and cash equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:RestrictedCashAndCashEquivalents", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "ctso:ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "unique": true } }, "R26": { "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails", "longName": "99940301 - Disclosure - STOCKHOLDERS' EQUITY - Stock option activity (Details)", "shortName": "STOCKHOLDERS' EQUITY - Stock option activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef":

"As_Of_12_31_2023_xjP0zFy4wE2Z80nqWJPweA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_S1NSVV7L-U2dfphVU2LbbA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "unitRef": "Unit_Standard_shares_S1NSVV7L-U2dfphVU2LbbA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "unique": true } }, "R27": { "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails", "longName": "99940302 - Disclosure - STOCKHOLDERS' EQUITY - Intrinsic value (Details)", "shortName": "STOCKHOLDERS' EQUITY - Intrinsic value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "unitRef": "Unit_Standard_shares_S1NSVV7L-U2dfphVU2LbbA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "unitRef": "Unit_Standard_shares_S1NSVV7L-U2dfphVU2LbbA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails", "longName": "99940303 - Disclosure - STOCKHOLDERS' EQUITY - Non-vested options (Details)", "shortName": "STOCKHOLDERS' EQUITY - Non-vested options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "As_Of_12_31_2023_xjP0zFy4wE2Z80nqWJPweA", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "unitRef": "Unit_Standard_shares_S1NSVV7L-U2dfphVU2LbbA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_xjP0zFy4wE2Z80nqWJPweA", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "unitRef": "Unit_Standard_shares_S1NSVV7L-U2dfphVU2LbbA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails", "longName": "99940304 - Disclosure - STOCKHOLDERS' EQUITY - Restricted stock unit (Details)", "shortName": "STOCKHOLDERS' EQUITY - Restricted stock unit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_-OYUytSImEauM-WgH-DOzg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Unit_Standard_shares_S1NSVV7L-U2dfphVU2LbbA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_-OYUytSImEauM-WgH-DOzg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Unit_Standard_shares_S1NSVV7L-U2dfphVU2LbbA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails", "longName": "99940305 - Disclosure - STOCKHOLDERS' EQUITY - Restricted stock unit activity (Details)", "shortName": "STOCKHOLDERS' EQUITY - Restricted stock unit activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_-OYUytSImEauM-WgH-DOzg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_S1NSVV7L-U2dfphVU2LbbA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_-OYUytSImEauM-WgH-DOzg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDat "unitRef": "Unit_Divide_USD_shares_9SwlC0fkK02Dr4lzgyUcjQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "unique": true } }, "R31": { "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquityWarrantsDetails", "longName": "99940306 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)", "shortName": "STOCKHOLDERS' EQUITY - Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_S1NSVV7L-U2dfphVU2LbbA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_S1NSVV7L-U2dfphVU2LbbA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "longName": "99940307 - Disclosure - STOCKHOLDERS' EQUITY - Additional information (Details)", "shortName": "STOCKHOLDERS' EQUITY - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Unit_Standard_shares_S1NSVV7L-U2dfphVU2LbbA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2019_1qFbqH88yU-FM7WcAU_Rhw", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Unit_Standard_shares_S1NSVV7L-U2dfphVU2LbbA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "unique": true } }, "R33": { "role": "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails", "longName": "99940401 - Disclosure - REVENUE - Revenue by customer type and geographic area (Details)", "shortName": "REVENUE - Revenue by customer type and geographic area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_cOsNb-XabUOs7oHjv_A7rw", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_SB5-isnl4UC-L1WJaeemvA", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "unique": true } }, "R34": { "role": "http://www.cytosorbents.com/role/DisclosureRevenueReceivablesAndContractLiabilitiesDetails", "longName": "99940402 - Disclosure - REVENUE - Receivables and contract liabilities (Details)", "shortName": "REVENUE - Receivables and contract liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:DeferredRevenue", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "unique": true } }, "R35": { "role":

{"http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails", "longName": "99940403 - Disclosure - REVENUE - Additional information (Details)", "shortName": "REVENUE - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "ctso:NumberOfPrimaryRevenueStreams", "unitRef": "Unit_Standard_segment_8XhGAI78KESSG7htlUeiYA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_1p4AYA1x6kmXFwOOaeaueQ", "name": "ctso:NumberOfPrimaryRevenueStreams", "unitRef": "Unit_Standard_segment_8XhGAI78KESSG7htlUeiYA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails", "longName": "99940501 - Disclosure - LONG-TERM DEBT, NET - Avenue Capital Group (Details)", "shortName": "LONG-TERM DEBT, NET - Avenue Capital Group (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:RestrictedCashNoncurrent", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_DebtInstrumentAxis_ctso_LoanAndSecurityAgreementMember__irmTWpGkOHS7PgJvnuUw", "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "unitRef": "Unit_Standard_pure_XTLljdanNkyD2a9A-eq2zQ", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "unique": true } }, "R37": { "role": "http://www.cytosorbents.com/role/DisclosureLongTermDebtNetDetails", "longName": "99940502 - Disclosure - LONG-TERM DEBT, NET (Details)", "shortName": "LONG-TERM DEBT, NET (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.cytosorbents.com/role/DisclosureLongTermDebtNetPrincipalPaymentsDetails", "longName": "99940503 - Disclosure - LONG-TERM DEBT, NET - Principal payments (Details)", "shortName": "LONG-TERM DEBT, NET - Principal payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails", "longName": "99940504 - Disclosure - LONG-TERM DEBT, NET - Additional information (Details)", "shortName": "LONG-TERM DEBT, NET - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndTwentyTwoSuccessFeeLetterMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_fDWYyo8tqUe2a35yEB4qzA", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndTwentyTwoSuccessFeeLetterMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_fDWYyo8tqUe2a35yEB4qzA", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails", "longName": "99940601 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_9ZZtP8KtX0O5G6kS_lcppw", "name": "us-gaap:RoyaltyExpense", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_9ZZtP8KtX0O5G6kS_lcppw", "name": "us-gaap:RoyaltyExpense", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.cytosorbents.com/role/DisclosureLeasesDetails", "longName": "99940701 - Disclosure - LEASES (Details)", "shortName": "LEASES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "ctso:LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_cOsNb-XabUOs7oHjv_A7rw", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "unique": true } }, "R42": { "role": "http://www.cytosorbents.com/role/DisclosureLeasesRightOfUseAssetAndRelatedLeaseLiabilityDetails", "longName": "99940702 - Disclosure - LEASES - Right-of- use asset and related lease liability (Details)", "shortName": "LEASES - Right-of- use asset and related lease liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R43": { "role": "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails", "longName": "99940703 - Disclosure - LEASES - Maturities of the lease liabilities (Details)", "shortName": "LEASES - Maturities of the lease liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_liKcP6ZBlEqcPO4tP5yneQ", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_7biLBI-If0GCuH8ElHr3yg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails", "longName": "99940801 - Disclosure - NET LOSS PER SHARE (Details)", "shortName": "NET LOSS PER SHARE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ctso_StockOptionsAndWarrantsMember_6Gl
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_S1NSVV7L-U2dfphVU2LbbA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ctso_StockOptionsAndWarrantsMember_6Gl
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_S1NSVV7L-U2dfphVU2LbbA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ctso-20240930x10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r48", "r611"] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [
"http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "terseLabel": "Accounts receivable", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": ["r561"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": [
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Net, Current", "terseLabel": "Grants and accounts receivable, net of allowance of $160,246 as of September 30, 2024 and $49,663 at December 31, 2023", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r758"] }, "ctso_AccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "AccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Amount of accrued expenses and other current liabilities.", "label": "Accrued Expenses and Other Current Liabilities.", "terseLabel": "Accrued expenses and other current liabilities" } } }, "auth_ref": [] }, "ctso_AccruedFinalFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "AccruedFinalFee", "crdr": "debit", "presentation": [
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of accrued final fee made during the period.", "label": "Accrued Final Fee", "terseLabel": "Accrued final fee" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r16", "r17", "r66", "r135", "r440", "r464", "r465"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r2", "r9", "r17", "r354", "r357", "r391", "r460", "r461", "r736", "r737", "r738", "r746", "r747", "r748", "r750"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r675"] }, "ctso_AdditionalLesseeOperatingLeaseTermOfContractOptionToExtend": { "xbrltype": "durationItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "AdditionalLesseeOperatingLeaseTermOfContractOptionToExtend", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "The additional lessee operating lease term of contract option to extend.", "label": "Additional Lessee Operating Lease Term Of Contract Option To Extend", "terseLabel": "Additional lessee operating lease term of contract option to extend" } } }, "auth_ref": [] }, "ctso_AdditionalOperatingLeasesRentExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "AdditionalOperatingLeasesRentExpenseNet", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "Additional rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Additional Operating Leases Rent Expense Net", "terseLabel": "Additional operating leases rent expense" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r61", "r611", "r876"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "verboseLabel": "Additional Paid-In Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r475", "r746", "r747", "r748", "r750", "r820", "r880"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r688"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r688"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r688"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r688"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation - employees, consultants and directors", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r39", "r40", "r295"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": [
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "negatedLabel": "ATM fee", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": ["r10", "r92"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails",
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Warrants issued in connection with long-term debt", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": ["r10", "r30", "r92"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ctso_AggregateRegisteredAmountForOfferings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "AggregateRegisteredAmountForOfferings", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Aggregate maximum amount of securities that can be offered and sold, in one or more offerings, in any combination of common stock, preferred stock, senior or subordinated debt securities, warrants and units, pursuant to shelf registration.", "label": "Aggregate Registered Amount for Offerings", "terseLabel": "Aggregate registered amount for offerings" } } }, "auth_ref": [] },
"ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary

{"Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r721"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r647", "r657", "r667", "r699"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r650", "r660", "r670", "r702"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r722"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r688"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r695"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r651", "r661", "r671", "r695", "r703", "r707", "r715"] }, "ctso_AllOtherCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "AllOtherCountriesMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for All other countries.", "label": "All other countries [Member]", "terseLabel": "All other countries" } } }, "auth_ref": [] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r713"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Allocated Share-based Compensation Expense", "verboseLabel": "Restricted stock unit", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r322", "r324"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Grants and accounts receivable, net of allowance for doubtful accounts", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": ["r136", "r206", "r210"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Amortization of Debt Discount (Premium)", "verboseLabel": "Amortization of debt discount", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": ["r6", "r76", "r257", "r828"] }, "ctso_AmortizationOfLoanCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "AmortizationOfLoanCosts", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to loan costs.", "label": "Amortization Of Loan Costs", "terseLabel": "Amortization of loan costs" } } }, "auth_ref": [] }, "ctso_AmortizationOfRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "AmortizationOfRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of right to use assets attributable to loan costs.", "label": "Amortization of right of use asset", "terseLabel": "Amortization of right-of-use asset" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r186"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r24"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r24"] }, "us-gaap_AreaOfLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfLand", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "label": "Area of Land.", "terseLabel": "Area of Land", "documentation": "Area of land held." } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Asset Impairment Charges", "verboseLabel": "Impairment charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": ["r6", "r28"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r101", "r111", "r129", "r158", "r190", "r194", "r199", "r200", "r207", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r349", "r351", "r364", "r435", "r512", "r584", "r585", "r611", "r638", "r783", "r784", "r835"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r124", "r139", "r158", "r207", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r349", "r351", "r364", "r611", "r783", "r784", "r835"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets:" } } }, "auth_ref": [] }, "ctso_AvenueVentureOpportunitiesFundIIL.pMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "AvenueVentureOpportunitiesFundIIL.pMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Avenue Venture Opportunities Fund II, L.P.", "label": "Avenue Venture Opportunities Fund II, L.P", "terseLabel": "Avenue Venture Opportunities Fund II, L.P" } } }, "auth_ref": [] }, "ctso_AvenueVentureOpportunitiesFundL.pMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "AvenueVentureOpportunitiesFundL.pMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Avenue Venture Opportunities Fund, L.P.", "label": "Avenue Venture Opportunities Fund,

L.P", "terseLabel": "Avenue Venture Opportunities Fund, L.P" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r710"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r711"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r706"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r706"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r706"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r706"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r706"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r706"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r709"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r708"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r707"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r707"] }, "us-gaap_BasisOfAccounting": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccounting", "presentation": ["http://www.cytosorbents.com/role/DisclosureBasisOfPresentation"], "lang": { "en-us": { "role": { "label": "Basis of Accounting [Text Block]", "terseLabel": "BASIS OF PRESENTATION", "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": ["r82"] }, "srt_BoardOfDirectorsChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "BoardOfDirectorsChairmanMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman [Member]", "verboseLabel": "Board of Directors" } } }, "auth_ref": ["r757"] }, "us-gaap_CargoAndFreightMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CargoAndFreightMember", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Cargo and Freight [Member]", "terseLabel": "Cargo and Freight", "documentation": "Product transported between locations." } } }, "auth_ref": ["r791"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureBasisOfPresentationDetails", "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r21", "r127", "r578"] }, "ctso_CashAndCashEquivalentsGrossValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "CashAndCashEquivalentsGrossValue", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of approximate value of cash and cash equivalents.", "label": "Cash and Cash Equivalents Gross Value", "terseLabel": "Cash and cash equivalents gross value" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r22"] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": ["r22", "r100"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash - end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash - beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r21", "r79", "r156"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net change in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage;

including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r79"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "verboseLabel": "Supplemental disclosure of non-cash financing activities:" } } }, "auth_ref": [] }, "ctso_CertainEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "CertainEmployeesMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to certain employees.", "label": "Certain Employees [Member]", "terseLabel": "Certain employees" } } }, "auth_ref": [] }, "ctso_CertainNamedExecutiveOfficersAndSeniorManagersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "CertainNamedExecutiveOfficersAndSeniorManagersMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to certain named executive officers and senior managers.", "label": "Certain Named Executive Officers and Senior Managers [Member]", "terseLabel": "Executive officers and senior managers" } } }, "auth_ref": [] }, "ctso_CertainNamedExecutiveOfficersAndSeniorManagersTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "CertainNamedExecutiveOfficersAndSeniorManagersTwoMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to certain named executive officers and senior managers.", "label": "Certain Named Executive Officers and Senior Managers, Two [Member]", "terseLabel": "Executive officers and senior managers" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r686"] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer" } } }, "auth_ref": ["r757"] }, "srt_ChiefFinancialOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefFinancialOfficerMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]", "terseLabel": "Chief Financial Officer" } } }, "auth_ref": ["r757"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r683"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r681"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r121", "r132", "r133", "r134", "r158", "r179", "r180", "r183", "r185", "r192", "r193", "r207", "r233", "r235", "r236", "r237", "r240", "r241", "r263", "r264", "r266", "r269", "r275", "r364", "r470", "r471", "r472", "r473", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r500", "r522", "r540", "r554", "r555", "r556", "r557", "r558", "r725", "r742", "r751"] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrant Exercise Price per Share", "verboseLabel": "Warrant exercise price per share", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r276"] }, "ctso_ClassOfWarrantOrRightIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ClassOfWarrantOrRightIssued", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights issued.", "label": "Class of Warrant or Right, Issued", "terseLabel": "Class of warrant issued" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "terseLabel": "STOCKHOLDERS' EQUITY", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants to purchase shares", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r276"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Number of shares to be purchased", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "ctso_ClassOfWarrantOrRightRevisionOfExercisePriceOfWarrantsOrRightsStockPriceTrigger": { "xbrltype": "perShareItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ClassOfWarrantOrRightRevisionOfExercisePriceOfWarrantsOrRightsStockPriceTrigger", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Price of the entity's common stock which would be required to be attained for revision of exercise price of warrants or rights.", "label": "Class of Warrant or Right, Revision Of Exercise Price of Warrants or Rights, Stock Price Trigger", "terseLabel": "Stock price trigger for revision of exercise price of warrants" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": ["r33"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r687"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r687"] }, "ctso_CommissionRateAsPercentageOfAggregateGrossProceeds": { "xbrltype": "percentItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "CommissionRateAsPercentageOfAggregateGrossProceeds", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The commission rate as a percentage of the aggregate gross proceeds.", "label": "Commission Rate As Percentage Of Aggregate Gross Proceeds", "terseLabel": "Commission rate (as a percent)" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies.", "verboseLabel": "Commitments and Contingencies (Note 6)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's

resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r57", "r104", "r436", "r499"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES" } } }, "auth_ref": [] }, "ctso_CommitmentsAndContingenciesDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "CommitmentsAndContingenciesDisclosureLineItems", "presentation": ["http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Commitments and Contingencies Disclosure [Line Items]", "label": "Commitments and Contingencies Disclosure [Line Items]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "auth_ref": [] }, "ctso_CommitmentsAndContingenciesDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "CommitmentsAndContingenciesDisclosureTable", "presentation": ["http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Commitments and Contingencies Disclosure [Table]", "label": "Commitments and Contingencies Disclosure [Table]", "verboseLabel": "Commitments and Contingencies Disclosure [Table]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r87", "r225", "r226", "r562", "r772", "r777"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r628", "r629", "r630", "r632", "r633", "r634", "r635", "r746", "r747", "r750", "r820", "r874", "r880"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, Par Value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r60"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r60", "r500"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r60"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r10", "r60", "r500", "r518", "r880", "r881"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common Stock, Par Value $0.001, 100,000,000 shares authorized; 54,500,613 and 54,240,265 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r60", "r439", "r611"] }, "ctso_CommonStockValueAuthorized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "CommonStockValueAuthorized", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Common Stock Value Authorized For Shares Authorized.", "label": "Common Stock Value Authorized", "terseLabel": "Aggregate offering price" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r692"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r691"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r693"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r690"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r18", "r141", "r143", "r148", "r430", "r447", "r448"] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "verboseLabel": "Comprehensive loss:" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r26", "r27", "r42", "r43", "r204", "r561"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r26", "r27", "r42", "r43", "r204", "r467", "r561"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r26", "r27", "r42", "r43", "r204", "r561", "r729"] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r46", "r118"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r26", "r27", "r42", "r43", "r204"] }, "us-

{"gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r26", "r27", "r42", "r43", "r204", "r561"] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": ["r159", "r349", "r350", "r351", "r352", "r392", "r567", "r782", "r785", "r786"] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "auth_ref": ["r159", "r349", "r350", "r351", "r352", "r392", "r567", "r782", "r785", "r786"] }, "ctso_ConsolidationAndForeignCurrencyTranslationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ConsolidationAndForeignCurrencyTranslationPolicyTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of consolidation and foreign currency translation.", "label": "Consolidation and Foreign Currency Translation Policy [Text Block]", "terseLabel": "Basis of Consolidation and Foreign Currency Translation" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosureRevenueTables"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Schedule of receivables and contract liabilities from contracts with customers", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": ["r789"] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureRevenueReceivablesAndContractLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Asset, Net, Current", "verboseLabel": "Receivables, which are included in grants and accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": ["r278", "r279", "r290"] }, "ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of contract with customer liability net of free of charge goods and credit rebates as on the balance sheet date, classified as current.", "label": "Contract With Customer Liability, Net Of Free Of Charge Goods And Credit Rebates, Current", "terseLabel": "Contract liabilities net of value of free of charge goods and credit rebates" } } }, "auth_ref": [] }, "ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Value of free of charge goods and credit rebates as on the balance sheet date, classified as current.", "label": "Contract With Customer Liability, Value of Free Of Charge Goods And Credit Rebates, Current", "terseLabel": "Value of free of charge goods and credit rebates" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenue", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r69", "r70", "r397"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditCardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditCardMember", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Credit Card [Member]", "terseLabel": "Credit Card", "documentation": "Card issued to user to facilitate payment for purchase of product and service, paid directly to merchant by card issuer, and later paid by cardholder to card issuer." } } }, "auth_ref": ["r791"] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r232", "r780"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r232", "r780", "r781"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer concentration risk", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": ["r84", "r204"] }, "ctso_CytoSorbSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "CytoSorbSalesMember", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "documentation": "Represent the information relating to the cyto sorb sales", "label": "CytoSorb sales [Member]", "terseLabel": "CytoSorb sales" } } }, "auth_ref": [] }, "ctso_CytosorbentsEuropeGmbhMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "CytosorbentsEuropeGmbhMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for CytoSorbents Europe GmbH.", "label": "CytoSorbents Europe GmbH [Member]", "terseLabel": "CytoSorbents Europe GmbH" } } }, "auth_ref": [] }, "ctso_CytosorbentsMedicalIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "CytosorbentsMedicalIncMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for CytoSorbents Medical, Inc.", "label": "CytoSorbents Medical, Inc [Member]", "terseLabel": "CytoSorbents Medical, Inc" } } }, "auth_ref": [] }, "country_DE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "DE", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails", "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"], "lang": { "en-us": { "role": { "label": "Germany [Member]", "terseLabel": "Germany" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "LONG-TERM DEBT, NET" } } }, "auth_ref": [] }, "ctso_DebtInstrumentAcceleratedRepaymentMinimumPeriodAfterEntryOverSinglyInAggregateInExcessOfThresholdAmountRemainUnsatisfiedUnvac { "xbrltype": "durationItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "DebtInstrumentAcceleratedRepaymentMinimumPeriodAfterEntryOverSinglyInAggregateInExcessOfThresholdAmountRemainUnsatisfiedUnvacated "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails"], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Accelerated Repayment, Minimum Period After Entry Over Which Any Judgment(S) Singly Or In The Aggregate In Excess Of The Threshold Amount Remain Unsatisfied, Unvacated Or Unstayed, Considered For Events Of Default.", "label": "Debt Instrument, Accelerated Repayment, Minimum Period After Entry Over Singly In Aggregate In Excess Of Threshold Amount Remain Unsatisfied, Unvacated Or Unstayed, Considered For Events Of Default", "terseLabel": "Minimum period after entry, over which any judgment(s) singly or in the aggregate in excess of the Threshold Amount remain unsatisfied, unvacated or unstayed, considered for events of default to trigger accelerated repayment" } } }, "auth_ref": [] }, "ctso_DebtInstrumentAcceleratedRepaymentPeriodWithinWhichAnyInsolvencyProceedingBroughtByThirdPartyIsNotDismissedOrStayedConsideredI { "xbrltype": "durationItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname":

```
"DebtInstrumentAcceleratedRepaymentPeriodWithinWhichAnyInsolvencyProceedingBroughtByThirdPartyIsNotDismissedOrStayedConsideredForEv
"presentation": [ "http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails" ], "lang": { "en-us": { "role": {
"documentation": "Period within which any insolvency proceeding brought by a third party is not dismissed or stayed, considered for events of
default to cause accelerated repayment of the debt instrument.", "label": "Debt Instrument, Accelerated Repayment, Period Within Which Any
Insolvency Proceeding Brought By A Third Party Is Not Dismissed Or Stayed, Considered For Events Of Default", "terseLabel": "Period within which
any insolvency proceeding brought by a third party is not dismissed or stayed, considered for events of default to trigger accelerated repayment" }
} }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentAxis", "presentation": [ "http://www.cytosorbents.com/role/DisclosureLeasesDetails",
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails",
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails",
"http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails",
"http://www.cytosorbents.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]",
"documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r15",
"r50", "r51", "r102", "r103", "r159", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255",
"r256", "r257", "r587", "r588", "r589", "r590", "r591", "r608", "r743", "r773", "r774", "r775", "r827", "r829" ] }, "us-
gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails" ], "lang": { "en-us": { "role": { "label": "Debt
Instrument, Basis Spread on Variable Rate", "verboseLabel": "Interest rate", "documentation": "Percentage points added to the reference rate to
compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Debt, Gross",
"verboseLabel": "Principal amount", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term
debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and
other types of debt." } } }, "auth_ref": [ "r15", "r103", "r259" ] }, "us-gaap_DebtInstrumentCollateralAmount": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCollateralAmount", "crdr": "debit", "presentation": [
"http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": {
"role": { "label": "Debt Instrument, Collateral Amount", "terseLabel": "Cash collateral", "documentation": "Amount of assets pledged to secure a
debt instrument." } } }, "auth_ref": [ "r45" ] }, "ctso_DebtInstrumentConvertibleConversionPricePerShare": { "xbrltype": "percentItemType",
"nsuri": "http://www.cytosorbents.com/20240930", "localname": "DebtInstrumentConvertibleConversionPricePerShare", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails" ], "lang": { "en-us": { "role": { "documentation": "Per
share conversion price of closing price of common stock.", "label": "Debt Instrument, Convertible, Conversion Price, Per Share", "terseLabel":
"Fixed conversion price of closing stock, Per share" } } }, "auth_ref": [] }, "ctso_DebtInstrumentConvertibleConversionPricePercentage": {
"xbrltype": "percentItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname":
"DebtInstrumentConvertibleConversionPricePercentage", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails" ], "lang": { "en-us": { "role": { "documentation":
"Percentage of conversion price as a percentage of closing price of common stock.", "label": "Debt Instrument, Convertible, Conversion Price
Percentage", "terseLabel": "Fixed conversion price of closing stock" } } }, "auth_ref": [] },
"ctso_DebtInstrumentConvertiblePrincipalAmountOutstanding": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.cytosorbents.com/20240930", "localname": "DebtInstrumentConvertiblePrincipalAmountOutstanding", "crdr": "credit", "presentation":
[ "http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails" ], "lang": { "en-us": { "role": { "documentation":
"Principal amount of outstanding debt instrument that can be converted into equity instruments.", "label": "Debt Instrument, Convertible,
Principal Amount Outstanding", "terseLabel": "Conversion of debt into common stock" } } }, "auth_ref": [] }, "us-
gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.cytosorbents.com/role/DisclosureLeasesDetails",
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails" ], "lang": { "en-us": { "role": { "label": "Debt
Instrument, Face Amount", "terseLabel": "Debt instrument face amount", "verboseLabel": "Security amount", "documentation": "Face (par) amount
of debt instrument at time of issuance." } } }, "auth_ref": [ "r242", "r375", "r376", "r588", "r589", "r608" ] }, "us-
gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentInterestRateEffectivePercentage", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails" ], "lang": { "en-us": { "role": { "label": "Debt
Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective rate", "documentation": "Effective interest rate for the funds borrowed
under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r53", "r261", "r375",
"r376", "r608" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentLineItems", "presentation": [ "http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails",
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails" ], "lang": { "en-us": { "role": { "label": "Debt
Instrument [Line Items]", "terseLabel": "LONG-TERM DEBT", "documentation": "Line items represent financial concepts included in a table. These
concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [
"r159", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r587",
"r588", "r589", "r590", "r591", "r608", "r743", "r827", "r829" ] }, "ctso_DebtInstrumentMaximumBorrowingCapacity": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "DebtInstrumentMaximumBorrowingCapacity", "crdr":
"credit", "presentation": [ "http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails" ], "lang": { "en-us": { "role":
{ "documentation": "The maximum borrowing capacity under the debt instrument.", "label": "Debt Instrument, Maximum Borrowing Capacity",
"terseLabel": "Maximum borrowing capacity" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLeasesDetails",
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails",
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails",
"http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails",
"http://www.cytosorbents.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name
[Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or
borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r15", "r159", "r242", "r243", "r244", "r245", "r246", "r247", "r248",
"r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r587", "r588", "r589", "r590", "r591", "r608", "r743", "r773", "r774", "r775",
"r827", "r829" ] }, "ctso_DebtInstrumentPeriodicInterestOnlyPaymentExtensionPeriod": { "xbrltype": "durationItemType", "nsuri":
"http://www.cytosorbents.com/20240930", "localname": "DebtInstrumentPeriodicInterestOnlyPaymentExtensionPeriod", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails" ], "lang": { "en-us": { "role": { "documentation":
"Extended period during which interest only payments shall be made under the debt instrument.", "label": "Debt Instrument, Periodic Interest Only
Payment, Extension Period", "terseLabel": "Extension term of loan" } } }, "auth_ref": [] },
"ctso_DebtInstrumentPeriodicInterestOnlyPaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.cytosorbents.com/20240930",
"localname": "DebtInstrumentPeriodicInterestOnlyPaymentPeriod", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails" ], "lang": { "en-us": { "role": { "documentation":
"Period during which interest only payments shall be made under the debt instrument.", "label": "Debt Instrument, Periodic Interest Only Payment,
Period", "terseLabel": "Period for monthly interest only payments" } } }, "auth_ref": [] },
"ctso_DebtInstrumentPrepaymentFeeAsPercentageOfPrincipalAmountPrepaid": { "xbrltype": "percentItemType", "nsuri":
"http://www.cytosorbents.com/20240930", "localname": "DebtInstrumentPrepaymentFeeAsPercentageOfPrincipalAmountPrepaid", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails" ], "lang": { "en-us": { "role": { "documentation":
"Percentage of principal amount of debt prepaid, payable as prepayment fee on the debt instrument.", "label": "Debt Instrument, Prepayment Fee
As A Percentage of Principal Amount Prepaid", "terseLabel": "Prepayment percentage" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails",
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of
Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } },
"auth_ref": [ "r15", "r31", "r32", "r44", "r90", "r91", "r159", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252",
"r253", "r254", "r255", "r256", "r257", "r258", "r587", "r588", "r589", "r590", "r591", "r608", "r743", "r827", "r829" ] },
"ctso_DebtInstrumentThresholdNetProceedsFromSaleOfEquitySecuritiesConsideredForReleaseOfRestrictedCash": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname":
"DebtInstrumentThresholdNetProceedsFromSaleOfEquitySecuritiesConsideredForReleaseOfRestrictedCash", "crdr": "debit", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails" ], "lang": { "en-us": { "role": { "documentation":
"Represents minimum net proceeds to be received from the sale of company's equity securities after the closing date, considered for release of
```

restricted cash to the borrower.", "label": "Debt Instrument, Threshold Net Proceeds from Sale of Equity Securities, Considered For Release Of Restricted Cash", "terseLabel": "Minimum net proceeds from sale of equity securities, considered for release of restricted cash" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Less unamortized debt discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": ["r788", "r826", "r827", "r829"] }, "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnusedBorrowingCapacityAmount", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unused Borrowing Capacity, Amount", "terseLabel": "Debt instrument unused capacity", "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date." } } }, "auth_ref": ["r54", "r231"] }, "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]", "documentation": "Indicates type of variable interest rate on debt instrument." } } }, "auth_ref": ["r434"] }, "us-gaap_DeferredFinanceCostsNoncurrentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNoncurrentGross", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetDetails"], "lang": { "en-us": { "role": { "label": "Debt Issuance Cost, Gross, Noncurrent", "negatedLabel": "Less unamortized debt acquisition costs", "documentation": "Amount, before accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r827", "r829"] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenue", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureRevenueReceivablesAndContractLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Revenue", "verboseLabel": "Contract liabilities, which are included in accrued expenses and other current liabilities", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r731"] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r6", "r29"] }, "ctso_DirectMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "DirectMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for Direct.", "label": "Direct [Member]", "terseLabel": "Direct" } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Director" } } }, "auth_ref": ["r757", "r875"] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "REVENUE", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r289", "r593", "r594", "r595", "r596", "r597", "r598", "r599"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r289", "r593", "r594", "r595", "r596", "r597", "r598", "r599"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosureRevenueTables"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "verboseLabel": "Schedule of disaggregation of revenue", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r790"] }, "ctso_DistributorsAndStrategicPartnersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "DistributorsAndStrategicPartnersMember", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for distributors/strategic partners.", "label": "Distributors/Strategic Partners [Member]", "terseLabel": "Distributors/Strategic Partners" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r642"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r674"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r685"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "NET LOSS PER SHARE" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Basic net loss per common share", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r149", "r165", "r166", "r167", "r168", "r169", "r170", "r176", "r179", "r183", "r184", "r185", "r189", "r344", "r347", "r361", "r362", "r431", "r449", "r581"] }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicLineItems", "presentation": ["http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "NET LOSS PER SHARE", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information

associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r179", "r180", "r183"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net loss per common share", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r149", "r165", "r166", "r167", "r168", "r169", "r170", "r179", "r183", "r184", "r185", "r189", "r344", "r347", "r361", "r362", "r431", "r449", "r581"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosureNetLossPerShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "NET LOSS PER SHARE", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r175", "r186", "r187", "r188"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperatio { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rates on cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r825"] }, "ctso_EmployeeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "EmployeeOneMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for Employee One.", "label": "Employee One [Member]", "terseLabel": "Employee one" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Amortized period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r323"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "terseLabel": "Total unrecognized compensation cost related to stock options", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r818"] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Employee Stock [Member]", "terseLabel": "Employee Stock", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "ctso_EmployeeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "EmployeeTwoMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for Employee Two.", "label": "Employee Two [Member]", "terseLabel": "Employee two" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r640"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r640"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r640"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang":

{ "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r724"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r640"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r640"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r640"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r640"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r679"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r720"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r720"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r720"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r10", "r122", "r145", "r146", "r147", "r160", "r161", "r162", "r164", "r169", "r171", "r173", "r191", "r208", "r209", "r224", "r277", "r338", "r339", "r341", "r342", "r343", "r345", "r346", "r347", "r353", "r354", "r355", "r356", "r357", "r358", "r360", "r369", "r370", "r371", "r372", "r373", "r374", "r377", "r379", "r391", "r446", "r460", "r461", "r462", "r475", "r540"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r689"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r647", "r657", "r667", "r699"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r644", "r654", "r664", "r696"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r695"] }, "ctso_ExercisePriceRangeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ExercisePriceRangeOneMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"], "lang": { "en-us": { "role": { "documentation": "Represents exercise price range one.", "label": "Exercise Price Range One [Member]", "terseLabel": "Exercise Price Range One" } } }, "auth_ref": [] }, "ctso_ExercisePriceRangingFrom0.84To1.08Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ExercisePriceRangingFrom0.84To1.08Member", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Exercise Price Ranging From 0.84 to 1.08.", "label": "Exercise Price Ranging From 0.84 to 1.08 [Member]", "terseLabel": "Exercise Price Ranging From 0.84 to 1.08" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r215", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r398", "r399", "r575"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r215", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r575"] }, "ctso_FirstTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "FirstTrancheMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for first tranche Member.", "label": "First Tranche [Member]", "terseLabel": "First Tranche" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Gain (loss) on foreign currency transactions", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r365", "r366", "r367", "r368", "r537"] }, "ctso_ForeignCurrencyTransactionGainLossExcludingTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ForeignCurrencyTransactionGainLossExcludingTax", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Excluding Tax", "terseLabel": "Foreign currency transaction gain (loss)" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Foreign Currency Transaction Gain (Loss), Unrealized", "negatedLabel": "Foreign currency translation (gain) loss", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r81", "r520", "r636", "r823", "r824", "r879"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r651", "r661", "r671", "r703"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement,

Amount" } } }, "auth_ref": ["r651", "r661", "r671", "r703"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r651", "r661", "r671", "r703"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r651", "r661", "r671", "r703"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r651", "r661", "r671", "r703"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r684"] }, "us-gaap_GrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrantMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Grant income [Member]", "terseLabel": "Grant income", "verboseLabel": "Government grants", "documentation": "Award of money not required to be repaid." } } }, "auth_ref": ["r791"] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r67", "r71", "r110", "r158", "r207", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r364", "r583", "r584", "r752", "r753", "r754", "r755", "r756", "r783"] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Write off of patent cost", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": ["r216", "r740", "r771"] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment or Disposal of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": ["r0", "r86"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before benefit from income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r68", "r106", "r110", "r432", "r444", "r583", "r584", "r752", "r753", "r754", "r755", "r756"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "negatedLabel": "Benefit from income taxes", "terseLabel": "Income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r115", "r119", "r172", "r173", "r190", "r197", "r200", "r331", "r332", "r340", "r450", "r603"] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r144", "r329", "r330", "r334", "r335", "r336", "r337", "r469"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Grants and accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r5"] }, "ctso_IncreaseInUnrestrictedCashRelatedToDebtFacility": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "IncreaseInUnrestrictedCashRelatedToDebtFacility", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of increase in unrestricted cash position related to debt facility.", "label": "Increase in Unrestricted Cash Related to Debt Facility", "terseLabel": "Increase in unrestricted cash related to debt facility" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r651", "r661", "r671", "r695", "r703", "r707", "r715"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements

[Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r713"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r643", "r719"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r643", "r719"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r643", "r719"] }, "ctso_InterestExpenseRelatedToFinalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "InterestExpenseRelatedToFinalPayment", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails"], "lang": { "en-us": { "role": { "documentation": "Interest expense related to final payment on debt instrument, recorded by the company.", "label": "Interest expense related to final payment", "terseLabel": "Interest expense" } } }, "auth_ref": [] }, "ctso_InterestExpenseRelatedToFinancialAdvisorAndLegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "InterestExpenseRelatedToFinancialAdvisorAndLegalFees", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails"], "lang": { "en-us": { "role": { "documentation": "Interest expense related to financial advisor fees and legal fees on debt instrument, recorded by the company.", "label": "Interest Expense Related To Financial Advisor And Legal Fees", "terseLabel": "Interest expense" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Interest Income (Expense), Nonoperating, Net", "verboseLabel": "Interest expense, net", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": ["r584", "r739", "r753"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid during the period for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r152", "r154", "r155"] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Gross", "terseLabel": "Inventory - finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": ["r732"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r138", "r579", "r611"] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": ["r117", "r126", "r137", "r212", "r213", "r214", "r396", "r580"] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Raw Materials, Gross", "terseLabel": "Inventory - raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r734"] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Work in Process, Gross", "terseLabel": "Inventory - work in process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": ["r733"] }, "ctso_IssuanceOfRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "IssuanceOfRestrictedStockUnits", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The fair value of issuance of restricted stock units in noncash financing activities.", "label": "Issuance Of Restricted Stock Units", "terseLabel": "Issuance of restricted stock units" } } }, "auth_ref": [] }, "ctso_JefferiesLlcAndB.RileyFbrIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "JefferiesLlcAndB.RileyFbrIncMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Jefferies LLC and B. Riley FBR, Inc.", "label": "Jefferies LLC and B. Riley FBR, Inc", "terseLabel": "Jefferies LLC and B. Riley FBR, Inc" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeDisclosureAbstract", "lang": { "en-us": { "role": { "label": "LEASES" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "LEASES:", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r383", "r390"] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": ["r383", "r390"] }, "ctso_LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of Lessee's right-of-use-assets and lease liability under operating lease.", "label": "Lessee, Operating Lease, Balance Sheet Disclosure [Table Text Block]", "terseLabel": "Schedule of right-of- use asset and related lease liability" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Discount Rate", "verboseLabel": "Incremental borrowing rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": ["r609"] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Existence of option to extend", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": ["r384"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesTables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of maturities of the lease liabilities", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r833"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r388"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease

payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r388"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r388"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2029", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r388"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r388"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r388"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r388"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Present value discount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r388"] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Remaining lease term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r390", "r831"] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r832"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r832"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeases"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r378"] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails", "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Letter of credit [Member]", "terseLabel": "Letter of credit", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r15", "r50", "r51", "r52", "r55", "r56", "r57", "r58", "r158", "r207", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r350", "r351", "r352", "r364", "r498", "r582", "r638", "r783", "r835", "r836"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders' Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r65", "r105", "r442", "r611", "r744", "r762", "r822"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r52", "r125", "r158", "r207", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r350", "r351", "r352", "r364", "r611", "r783", "r835", "r836"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities:" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails"], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": ["r49", "r54", "r743", "r780", "r781"] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLenderDomain", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": ["r49", "r54", "r743", "r780"] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r49", "r54"] }, "ctso_LoanAndSecurityAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "LoanAndSecurityAgreementMember", "presentation": [

```
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails",
"http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails",
"http://www.cytosorbents.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents
information pertaining to loan and securities agreement.", "label": "Loan and security agreement", "terseLabel": "Debt agreement" } } },
"auth_ref": [] }, "ctso_LoanAndSecurityAgreementTrancheOneMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.cytosorbents.com/20240930", "localname": "LoanAndSecurityAgreementTrancheOneMember", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails" ], "lang": { "en-us": { "role": { "documentation":
"Represents information pertaining to loan and securities agreement, tranche one.", "label": "Loan and security agreement, tranche one",
"terseLabel": "Growth Capital Loan Tranche 1" } } }, "auth_ref": [] }, "ctso_LoanAndSecurityAgreementTrancheTwoMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "LoanAndSecurityAgreementTrancheTwoMember",
"presentation": [ "http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails" ], "lang": { "en-us": { "role": {
"documentation": "Represents information pertaining to loan and securities agreement, tranche two.", "label": "Loan and security agreement,
tranche two", "terseLabel": "Growth Capital Loan Tranche 2" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number",
"documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Debt.", "totalLabel":
"Subtotal", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes
lease obligation." } } }, "auth_ref": [ "r15", "r103", "r249", "r260", "r588", "r589", "r608", "r844" ] }, "ctso_LongTermDebtAccruedFinalFee": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "LongTermDebtAccruedFinalFee", "crdr": "credit",
"presentation": [ "http://www.cytosorbents.com/role/DisclosureLongTermDebtNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount
of long-term debt accrued final fee.", "label": "Long-Term Debt Accrued Final Fee", "terseLabel": "Accrued final fee" } } }, "auth_ref": [] },
"ctso_LongTermDebtAndFinalFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname":
"LongTermDebtAndFinalFee", "crdr": "credit", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetPrincipalPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation":
"Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt and final fee.", "label": "Long-term Debt And Final
Fee", "totalLabel": "Total" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetDetails",
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term Debt,
Current Maturities", "negatedLabel": "Less Current maturities", "verboseLabel": "Current maturities of long-term debt", "documentation":
"Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease
obligation." } } }, "auth_ref": [ "r130" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr":
"credit", "presentation": [ "http://www.cytosorbents.com/role/DisclosureLongTermDebtNetPrincipalPaymentsDetails" ], "lang": { "en-us": { "role": {
"label": "Long-term Debt, Maturities, Repayments of Principal in Year Three", "terseLabel": "2027", "documentation": "Amount of long-term debt
payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in
third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of
financial position date (rolling approach)." } } }, "auth_ref": [ "r8", "r159", "r253" ] }, "us-
gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetPrincipalPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Debt,
Maturities, Repayments of Principal in Year Two", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund
requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year
following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position
date (rolling approach)." } } }, "auth_ref": [ "r8", "r159", "r253" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetDetails",
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term Debt,
Excluding Current Maturities", "terseLabel": "Long-term debt", "verboseLabel": "Long-term debt net of current maturities", "documentation":
"Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease
obligation." } } }, "auth_ref": [ "r131" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.cytosorbents.com/role/DisclosureLongTermDebtNet" ], "lang": {
"en-us": { "role": { "label": "Long-term Debt [Text Block]", "verboseLabel": "LONG-TERM DEBT, NET", "documentation": "The entire disclosure for
long-term debt." } } }, "auth_ref": [ "r88" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "MajorCustomersAxis", "presentation": [
"http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails",
"http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label":
"Customer [Axis]" } } }, "auth_ref": [ "r204", "r595", "r621", "r625", "r790", "r845", "r846", "r847", "r849", "r850", "r851", "r852", "r853", "r854",
"r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873" ]
}, "srt_ManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ManagementMember",
"presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails" ], "lang": { "en-us": { "role": {
"label": "Management [Member]", "verboseLabel": "Executive Management" } } }, "auth_ref": [ "r757", "r834" ] }, "srt_MaximumMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://www.cytosorbents.com/role/DisclosureBasisOfPresentationDetails",
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails",
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails",
"http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
"http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Maximum
[Member]", "terseLabel": "Maximum" } } }, "auth_ref": [ "r227", "r228", "r229", "r230", "r293", "r325", "r363", "r395", "r458", "r459", "r466",
"r490", "r491", "r545", "r547", "r549", "r550", "r552", "r573", "r574", "r586", "r592", "r600", "r604", "r605", "r606", "r607", "r622", "r787", "r837",
"r838", "r839", "r840", "r841", "r842" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel":
"Measure:" } } }, "auth_ref": [ "r687" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure
Name", "terseLabel": "Name" } } }, "auth_ref": [ "r687" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails",
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails",
"http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
"http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Minimum
[Member]", "terseLabel": "Minimum" } } }, "auth_ref": [ "r227", "r228", "r229", "r230", "r293", "r325", "r363", "r395", "r458", "r459", "r466",
"r490", "r491", "r545", "r547", "r549", "r550", "r552", "r573", "r574", "r586", "r592", "r600", "r604", "r605", "r606", "r622", "r787", "r837", "r838",
"r839", "r840", "r841", "r842" ] }, "ctso_MiscellaneousIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.cytosorbents.com/20240930", "localname": "MiscellaneousIncomeExpense", "crdr": "credit", "presentation": [
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role":
{ "documentation": "Amount of miscellaneous income (expense).", "label": "Miscellaneous Income (Expense)", "terseLabel": "Miscellaneous
income" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role":
{ "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } },
"auth_ref": [ "r706" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": {
"role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [
"r714" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"NameOfMajorCustomerDomain", "presentation": [
"http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails",
"http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label":
"Customer [Domain]" } } }, "auth_ref": [ "r204", "r595", "r621", "r625", "r790", "r845", "r846", "r847", "r849", "r850", "r851", "r852", "r853",
```

"r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873"] }, "ctso_NamedExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "NamedExecutiveOfficerMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to named executive officers.", "label": "Named Executive Officer [Member]", "terseLabel": "Executive officer" } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r688"] }, "ctso_NatureOfBusinessPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "NatureOfBusinessPolicyPolicyTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for Nature of Business Policy.", "label": "Nature Of Business Policy [Policy Text Block]", "terseLabel": "Nature of Business" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r153"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r153"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r79", "r80", "r81"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r72", "r81", "r107", "r123", "r140", "r142", "r147", "r158", "r163", "r165", "r166", "r167", "r168", "r169", "r172", "r173", "r181", "r207", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r344", "r347", "r362", "r364", "r445", "r521", "r538", "r539", "r636", "r783"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common stockholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": ["r151", "r165", "r166", "r167", "r168", "r176", "r177", "r182", "r185", "r347"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Effect of Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ctso_NonCashCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "NonCashCompensation", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of non-cash compensation.", "label": "Non cash compensation", "negatedLabel": "Non-cash compensation" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r687"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r651", "r661", "r671", "r695", "r703"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r678"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r677"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r695"] }, "ctso_NonRefundableCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "NonRefundableCommitmentFeePercentage", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of non refundable commitment fee to be paid by the borrower.", "label": "Non Refundable Commitment Fee, Percentage", "terseLabel": "Percentage of commitment fee" } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r714"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r714"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r75"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense):" } } }, "auth_ref": [] }, "ctso_NumberOfDaysForStockPriceThreshold": { "xbrltype": "durationItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname":

"NumberOfDaysForStockPriceThreshold", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of days for stock price threshold set in success fee letter.", "label": "Number of Days for Stock Price Threshold", "terseLabel": "Number of days for stock price threshold set in success fee letter" } } }, "auth_ref": [] }, "ctso_NumberOfDistributors": { "xbrltype": "integerItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "NumberOfDistributors", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "Number of distributors of the company.", "label": "Number Of Distributors", "terseLabel": "Number of distributors" } } }, "auth_ref": [] }, "ctso_NumberOfMemberBank": { "xbrltype": "integerItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "NumberOfMemberBank", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "Number of member banks.", "label": "Number of Member Bank", "terseLabel": "Number of member bank" } } }, "auth_ref": [] }, "ctso_NumberOfPrimaryRevenueStreams": { "xbrltype": "integerItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "NumberOfPrimaryRevenueStreams", "presentation": ["http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of primary revenue streams.", "label": "Number of Primary Revenue Streams", "terseLabel": "Number of primary revenue streams" } } }, "auth_ref": [] }, "ctso_NumberOfTimesLeaseRenewalAvailable": { "xbrltype": "integerItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "NumberOfTimesLeaseRenewalAvailable", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "The number of times lease renewal options available.", "label": "Number of Times Lease Renewal Available", "terseLabel": "Number of times lease renewal options available" } } }, "auth_ref": [] }, "srt_OfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OfficerMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"], "lang": { "en-us": { "role": { "label": "Officer [Member]", "terseLabel": "Other Employees" } } }, "auth_ref": ["r205", "r875"] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Other expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r110", "r583", "r752", "r753", "r754", "r755", "r756"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Other costs", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r385", "r610"] }, "ctso_OperatingLeaseEarlyTermMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "OperatingLeaseEarlyTermMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for early term of operating lease.", "label": "Early term [Member]", "terseLabel": "Early term" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "terseLabel": "Monthly payments of base rent and other costs", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r830"] }, "ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "OperatingLeaseFirstYearOfRemainingLeaseTermMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for first year of remaining operating lease term.", "label": "First year of remaining lease term [Member]", "terseLabel": "Early term" } } }, "auth_ref": [] }, "ctso_OperatingLeaseInitialEarlyTermMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "OperatingLeaseInitialEarlyTermMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for initial early term of operating lease.", "label": "Initial early term [Member]", "terseLabel": "Initial early term" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails", "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails", "http://www.cytosorbents.com/role/DisclosureLeasesRightOfUseAssetAndRelatedLeaseLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Total lease liability", "verboseLabel": "Operating lease lability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r381"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesRightOfUseAssetAndRelatedLeaseLiabilityDetails", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "negatedLabel": "Less current portion", "terseLabel": "Lease liability - current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r381"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesRightOfUseAssetAndRelatedLeaseLiabilityDetails", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liability, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r381"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Operating lease paid", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r382", "r386"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails", "http://www.cytosorbents.com/role/DisclosureLeasesRightOfUseAssetAndRelatedLeaseLiabilityDetails", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "netLabel": "Right-of-use asset", "terseLabel": "Right of use asset", "verboseLabel": "Right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r380"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r387", "r610"] }, "ctso_OperatingLeasesAnnualRentExpenseIncrementRate": { "xbrltype": "percentItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "OperatingLeasesAnnualRentExpenseIncrementRate", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "The percentage of annual increment in operating lease rent expense.", "label": "Operating Leases, Annual Rent Expense Increment Rate", "terseLabel": "Annual rent expense increment rate" } } }, "auth_ref": [] }, "ctso_OperatingLeasesBuildingImprovementAllowanceReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "OperatingLeasesBuildingImprovementAllowanceReceivable", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of allowance for building improvement receivable from landlord.", "label": "Operating Leases, Building Improvement Allowance Receivable", "terseLabel": "Allowance for building improvement" } } }, "auth_ref": [] }, "ctso_OperatingLeasesRentAbatementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "OperatingLeasesRentAbatementTerm", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "Rent abatement term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Leases, Rent Abatement Term", "terseLabel": "Rent abatement term" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "BASIS

OF PRESENTATION" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "verboseLabel": "PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": ["r47", "r82", "r83", "r99"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r128"] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment", "verboseLabel": "Other comprehensive income (loss): foreign translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r3", "r446"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r687"] }, "ctso_OtherSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "OtherSalesMember", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "documentation": "Represent the information relating to the other sales", "label": "Other sales [Member]", "terseLabel": "Other product sales" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r649", "r659", "r669", "r701"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r652", "r662", "r672", "r704"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r652", "r662", "r672", "r704"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r676"] }, "ctso_PaymentOfFinancialAdvisorAndLegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "PaymentOfFinancialAdvisorAndLegalFees", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of financial advisor fees and legal fees Paid by the company.", "label": "Payment Of Financial Advisor And Legal Fees", "terseLabel": "Payment of financial advisor and legal fees" } } }, "auth_ref": [] }, "ctso_PaymentsForEquityContributionsNetOfFeesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "PaymentsForEquityContributionsNetOfFeesIncurred", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The cash outflow for equity contributions - net of fees incurred", "label": "Payments for Equity contributions - Net of Fees Incurred", "negatedLabel": "Equity contributions - net of fees incurred" } } }, "auth_ref": [] }, "ctso_PaymentsForProceedsFromPropertyAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "PaymentsForProceedsFromPropertyAndEquipment", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment.", "label": "Payments For Proceeds From Property And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "auth_ref": [] }, "ctso_PaymentsOfFinalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "PaymentsOfFinalFees", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The cash outflow for payment of final fees on debt.", "label": "Payments of Final Fees", "negatedLabel": "Payment of final fee" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfLoanCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfLoanCosts", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments of Loan Costs", "negatedLabel": "Payment of loan costs", "documentation": "The cash outflow for loan origination associated cost which is usually collected through escrow." } } }, "auth_ref": ["r20"] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "terseLabel": "ATM activation fees", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r20"] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Payments for patent costs", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": ["r77"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r686"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r686"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r678"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r695"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r688"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r677"] }, "ctso_PercentageOfClosingPriceOnCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "PercentageOfClosingPriceOnCommonStock", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The percentage of closing price on common stock.", "label": "Percentage of Closing Price on Common Stock", "terseLabel": "Percentage of closing price on common stock" } } }, "auth_ref": [] }, "ctso_PercentageOfNonRefundablePaymentOnOriginalCommitmentAmount": { "xbrltype":

"percentItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "PercentageOfNonRefundablePaymentOnOriginalCommitmentAmount", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of non refundable final payment on original commitment amount to be paid by the borrower.", "label": "Percentage of Non Refundable Payment on Original Commitment Amount", "terseLabel": "Percentage of final payment" } } }, "auth_ref": [] }, "ctso_PercentageOfSuccessFee": { "xbrltype": "percentItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "PercentageOfSuccessFee", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The average effective success fee rate during the reporting period.", "label": "Percentage Of Success Fee", "terseLabel": "Percentage of success fee" } } }, "auth_ref": [] }, "ctso_PercentageOfTotalBuildingSpaceOccupied": { "xbrltype": "percentItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "PercentageOfTotalBuildingSpaceOccupied", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "The percentage of total building space occupied.", "label": "Percentage Of Total Building Space Occupied", "terseLabel": "Percentage of total building space occupied" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r679"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r723"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r678"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, Par Value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r59", "r263"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Number of preferred stock authorized", "verboseLabel": "Preferred Stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r59", "r500"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r59", "r263"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred Stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r59", "r500", "r518", "r880", "r881"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred Stock, Par Value $0.001, 5,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r59", "r438", "r611"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r735"] }, "ctso_PrepaymentMadeAfterSecondAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "PrepaymentMadeAfterSecondAnniversaryMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails"], "lang": { "en-us": { "role": { "documentation": "Represents prepayment made after second anniversary.", "label": "Prepayment made after second anniversary", "terseLabel": "Prepayment made after second anniversary" } } }, "auth_ref": [] }, "ctso_PrepaymentMadeFromFirstAnniversaryToSecondAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "PrepaymentMadeFromFirstAnniversaryToSecondAnniversaryMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails"], "lang": { "en-us": { "role": { "documentation": "Represents prepayment made after first anniversary.", "label": "Prepayment made after first anniversary", "terseLabel": "Prepayment made after first anniversary" } } }, "auth_ref": [] }, "ctso_PrepaymentMadeOnOrAfterFundingDateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "PrepaymentMadeOnOrAfterFundingDateMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails"], "lang": { "en-us": { "role": { "documentation": "Represents prepayment made on or after funding date.", "label": "Prepayment made on or after funding date", "terseLabel": "Prepayment made on or after funding date" } } }, "auth_ref": [] }, "ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "Line items represents the Principal Business Activity and Summary of Significant Accounting Policies.", "label": "Principal Business Activity and Summary of Significant Accounting Policies [Line Items]", "terseLabel": "PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "auth_ref": [] }, "ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about principal business activity and summary of significant accounting policies.", "label": "Principal Business Activity and Summary of Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net proceeds from issuance of stock", "verboseLabel": "Issuance of common stock, net of fees incurred", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r4"] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from long-term debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r19", "r470"] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance or Sale of Equity", "verboseLabel": "Net proceeds from issuance of stock", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": ["r4", "r470"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds

{"from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r4", "r14"] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": [
"http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
"http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails",
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Total product sales [Member]", "terseLabel": "Total product sales", "verboseLabel": "Product sales", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": ["r593"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [
"http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails",
"http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
"http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails",
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r201", "r397", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r576", "r593", "r620", "r622", "r623", "r626", "r627", "r778", "r779", "r790", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails",
"http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
"http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails",
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r201", "r397", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r576", "r593", "r620", "r622", "r623", "r626", "r627", "r778", "r779", "r790", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873"] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfessionalFees", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Professional Fees", "terseLabel": "Legal, financial and other consulting", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": ["r584", "r636", "r877", "r878"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r7", "r389", "r433", "r443", "r611"] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Provision for Doubtful Accounts", "terseLabel": "Bad debt expense", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": ["r150", "r211"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r676"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r676"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.cytosorbents.com/role/DisclosureBasisOfPresentationDetails",
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails",
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails",
"http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
"http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "auth_ref": ["r227", "r228", "r229", "r230", "r292", "r293", "r318", "r319", "r320", "r325", "r363", "r393", "r394", "r395", "r458", "r459", "r466", "r490", "r491", "r545", "r547", "r549", "r550", "r552", "r573", "r574", "r586", "r592", "r600", "r604", "r605", "r606", "r607", "r622", "r630", "r776", "r787", "r821", "r838", "r839", "r840", "r841", "r842"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.cytosorbents.com/role/DisclosureBasisOfPresentationDetails",
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails",
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails",
"http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
"http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Range [Domain]" } } }, "auth_ref": ["r227", "r228", "r229", "r230", "r292", "r293", "r318", "r319", "r320", "r325", "r363", "r393", "r394", "r395", "r458", "r459", "r466", "r490", "r491", "r545", "r547", "r549", "r550", "r552", "r573", "r574", "r586", "r592", "r600", "r604", "r605", "r606", "r607", "r622", "r630", "r776", "r787", "r821", "r838", "r839", "r840", "r841", "r842"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r644", "r654", "r664", "r696"] }, "ctso_ReleaseOfRestrictedCashUponEquityRaise": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ReleaseOfRestrictedCashUponEquityRaise", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of restricted cash that will be released on a dollar for dollar basis upon raise of equity.", "label": "Release Of Restricted Cash Upon Equity Raise", "terseLabel": "Release of restricted cash upon equity raise" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": [
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Repayments of Long-Term Debt", "negatedLabel": "Repayment of long-term debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r78", "r473"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r326", "r575", "r584", "r843"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r645", "r655", "r665", "r697"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r646", "r656", "r666", "r698"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r653", "r663", "r673", "r705"] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "presentation": [
"http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails"], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r21", "r100", "r127", "r156", "r437"] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.cytosorbents.com/role/DisclosureBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Restricted cash", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r21", "r127", "r156"] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": [
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails",
"http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails",
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r116", "r730", "r741"] }, "us-gaap_RestrictedStockExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockExpense", "crdr": "debit", "presentation": [
"http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"], "lang": { "en-us": { "role": { "label": "Restricted Stock or Unit Expense", "terseLabel": "Restricted Stock Units, Expense", "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement." } } }, "auth_ref": ["r6"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [
"http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails",
"http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r62", "r92", "r441", "r463", "r465", "r474", "r501", "r611"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Accumulated Deficit [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r122", "r160", "r161", "r162", "r164", "r169", "r171", "r173", "r208", "r209", "r224", "r338", "r339", "r341", "r342", "r343", "r345", "r346", "r347", "r353", "r355", "r356", "r358", "r360", "r377", "r379", "r460", "r462", "r475", "r880"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "REVENUE" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [
"http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails",
"http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Total revenue", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": ["r108", "r109", "r190", "r195", "r196", "r198", "r200", "r201", "r202", "r204", "r288", "r289", "r397"] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": [
"http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Sales Revenue, Net [Member]", "terseLabel": "Revenue", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r204", "r728"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [
"http://www.cytosorbents.com/role/DisclosureRevenue"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r120", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r291"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "auth_ref": [] }, "us-gaap_RoyaltyAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyAgreementsMember", "presentation": [
"http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Royalty Agreements [Member]", "verboseLabel": "Royalty Agreement", "documentation": "Contractual arrangement, generally for a defined period of time, entitling the entity to use the rights and property of another party. Examples include, but not limited to, licensing the use of copyrighted materials and leasing the extraction of natural resources." } } }, "auth_ref": ["r41", "r327", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r819"] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Royalty Expense", "terseLabel": "Royalty cost", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": ["r73"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r714"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r714"] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": [
"http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Average selling price", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "ctso_SaleRevenuesGoodsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "SaleRevenuesGoodsNetAbstract", "presentation": [
"http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"], "lang": { "en-us": { "role": { "documentation": "Sale Revenues Goods Net", "label": "Sale Revenues Goods Net [Abstract]", "verboseLabel": "Product sales:" } } }, "auth_ref": [] }, "ctso_ScenarioOneNoLimitationRelatingToMarketCapitalizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ScenarioOneNoLimitationRelatingToMarketCapitalizationMember", "presentation": [
"http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to no limitation relating to market capitalization.", "label": "Scenario One, No Limitation Relating To Market Capitalization [Member]", "terseLabel": "Scenario one limitations related to our market capitalization" } } }, "auth_ref": [] }, "ctso_ScenarioTwoLimitationRelatingToMarketCapitalizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ScenarioTwoLimitationRelatingToMarketCapitalizationMember", "presentation": [
"http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to limitation relating to market capitalization.", "label": "Scenario Two, Limitation Relating To Market Capitalization [Member]", "terseLabel": "Scenario two limitations related to our market capitalization" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails",
"http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails",
"http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Scenario, Unspecified [Domain]" } } }, "auth_ref": ["r174", "r294", "r726", "r749"] }, "us-gaap_ScheduleOfCapitalizationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCapitalizationLineItems", "presentation": [
"http://www.cytosorbents.com/role/DisclosureBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Capitalization [Line Items]", "verboseLabel": "BASIS OF PRESENTATION", "documentation": "Line items represent financial concepts included in a table. These

concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ctso_ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents and restricted cash and cash equivalents.", "label": "Schedule Of Cash And Cash Equivalents And Restricted Cash And Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of reconciliation of cash and cash equivalents and restricted cash and cash equivalents" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": ["http://www.cytosorbents.com/role/DisclosureBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r348"] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetTables"], "lang": { "en-us": { "role": { "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "verboseLabel": "Schedule of Long-term debt", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": ["r15", "r31", "r32", "r44", "r90", "r91", "r588", "r590", "r745", "r827"] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": ["http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": ["r23", "r25", "r179", "r180", "r183"] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetTables"], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "verboseLabel": "Schedule of Principal payments of long-term debt", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": ["r8"] }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Nonvested Share Activity [Table Text Block]", "terseLabel": "Schedule of company's non-vested options", "documentation": "Tabular disclosure of the changes in outstanding nonvested shares." } } }, "auth_ref": ["r97"] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]", "verboseLabel": "Schedule of restricted stock unit", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": ["r93"] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]", "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices." } } }, "auth_ref": ["r34"] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]", "terseLabel": "Schedule of intrinsic value", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": ["r34"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Schedule of stock options activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r12", "r13", "r93"] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Schedule of the restricted stock unit activity", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "ctso_SecondTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "SecondTrancheMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for second tranche Member.", "label": "Second Tranche [Member]", "terseLabel": "Second Tranche" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r639"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r641"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails", "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": ["r202", "r203", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r487", "r488", "r489", "r546", "r548", "r551", "r553", "r560", "r563", "r564", "r565", "r566", "r568", "r569", "r570", "r571", "r572", "r577", "r594", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r624", "r630", "r790", "r845", "r846", "r847", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r74"] }, "ctso_SeniorManagersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "SeniorManagersMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for senior managers.", "label": "Senior managers [Member]", "terseLabel": "Senior managers" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-based Compensation", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r5"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype":

"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r601"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited", "terseLabel": "RSU Forfeited (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r312"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDa { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFa "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r312"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Options to grant (in shares)", "verboseLabel": "Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r310"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGra { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDat "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r310"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Non-vested, September 30, 2024", "periodStartLabel": "Non-vested, December 31, 2023", "terseLabel": "Non-Vested shares", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r307", "r308"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDat { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFai "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Non-vested, September 30, 2024", "periodStartLabel": "Non-vested, December 31, 2023", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r307", "r308"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDat { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFai "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "verboseLabel": "Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested", "terseLabel": "Vested (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r311"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Vested", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": ["r314"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGra { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDat "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r311"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price", "terseLabel": "Grant date exercise price

range", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividends", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r319"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Current price of the underlying stock and its expected volatility range", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r318"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk free interest rate range", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk free interest rate, minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures", "negatedLabel": "Forfeited", "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event." } } }, "auth_ref": ["r96"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted", "verboseLabel": "Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": ["r11"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Restricted Stock Units, Ending Balance", "periodStartLabel": "Restricted Stock Units, Beginning Balance", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": ["r94", "r95"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Life (Years)", "verboseLabel": "Options Exercisable" } } }, "auth_ref": [] }, "ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards cancelled during the period, in PnYnMnDTnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days.", "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Cancelled in Period Weighted Average Remaining Contractual Term", "terseLabel": "Forfeited" } } }, "auth_ref": [] }, "ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards exercised during the period, in PnYnMnDTnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days.", "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Exercised in Period Weighted Average Remaining Contractual Term", "terseLabel": "Exercised" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Expired", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r306"] }, "ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Share based Compensation Arrangement by Share based Payment Award Options Outstanding Expired In Period Weighted Average Remaining Contractual Term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term", "terseLabel": "Expired" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r305"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r303"] }, "us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r313"] },
"ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedInPeriodFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedInPeriodFairValue", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, unvested in Period, Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Non-Vested in Period, Fair Value", "terseLabel": "Unvested options in fair value" } } }, "auth_ref": [] },
"ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContract { "xbrltype": "durationItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTe "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Share based Compensation Arrangement by Share based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term", "terseLabel": "Granted" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "verboseLabel": "Aggregate intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r34"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, end of the year", "periodStartLabel": "Outstanding, beginning of the year", "terseLabel": "Outstanding", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r299", "r300"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, end of the year", "periodStartLabel": "Outstanding, beginning of the year", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r299", "r300"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price per Share" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Options to purchase common stock vested", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r315"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "Number of options granted", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": ["r34"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": ["r306"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r305"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r303"] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-based

Payment Arrangement, Tranche One [Member]", "verboseLabel": "Vesting, tranche one", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Tranche Three [Member]", "verboseLabel": "Vesting, tranche three", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Vesting, tranche two", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": ["r37"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]", "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": ["r38"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]", "terseLabel": "Options Outstanding" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]", "terseLabel": "STOCKHOLDERS' EQUITY", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit", "terseLabel": "Range of Exercise Price, Lower Range Limit", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": ["r38"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options", "terseLabel": "Number Exercisable at September 30, 2024", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": ["r36"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options", "terseLabel": "Number Outstanding at September 30, 2024", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices." } } }, "auth_ref": ["r94", "r95"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit", "terseLabel": "Range of Exercise Price, Upper Range Limit", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": ["r38"] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share Price", "terseLabel": "Average selling price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": ["r792"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "periodEndLabel": "Restricted Stock Units, Intrinsic Value Ending Balance", "periodStartLabel": "Restricted Stock Units, Intrinsic Value Beginning Balance", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life of the stock option", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r317"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "verboseLabel": "Aggregate Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r34"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",

```
"presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding, end of the year", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r34" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "periodEndLabel": "Non-vested, September 30, 2024", "periodStartLabel": "Non-vested, December 31, 2023", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares", "negatedLabel": "Forfeited", "documentation": "Number of non-vested options forfeited." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited", "documentation": "Weighted average grant-date fair value of non-vested options forfeited." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Non-vested, September 30, 2024", "periodStartLabel": "Non-vested, December 31, 2023", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Outstanding, beginning of the year", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r98" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "negatedLabel": "Vested", "verboseLabel": "Vested", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Vested", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price", "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding." } } }, "auth_ref": [ "r35" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeg
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginnin
"presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price", "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices." } } }, "auth_ref": [ "r94", "r95" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContra
{ "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractual
"presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Life (Years)", "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r98" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "ctso_ShippingAndHandlingCostsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ShippingAndHandlingCostsPolicyPolicyTextBlock", "presentation": [ "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.", "label": "Shipping And Handling Costs Policy [Policy Text Block]", "terseLabel": "Shipping and Handling Costs" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } },
```

```
"auth_ref": [ "r121", "r132", "r133", "r134", "r158", "r179", "r180", "r183", "r185", "r192", "r193", "r207", "r233", "r235", "r236", "r237", "r240", "r241", "r263", "r264", "r266", "r269", "r275", "r364", "r470", "r471", "r472", "r473", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r500", "r522", "r540", "r554", "r555", "r556", "r557", "r558", "r725", "r742", "r751" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r10", "r60", "r63", "r64", "r122", "r145", "r146", "r147", "r160", "r161", "r162", "r164", "r169", "r171", "r173", "r191", "r208", "r209", "r224", "r277", "r338", "r339", "r341", "r342", "r343", "r345", "r346", "r347", "r353", "r354", "r355", "r356", "r357", "r358", "r360", "r369", "r370", "r371", "r372", "r373", "r374", "r377", "r379", "r391", "r446", "r460", "r461", "r462", "r475", "r540" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.cytosorbents.com/role/DisclosureLeasesDetails", "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r202", "r203", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r487", "r488", "r489", "r546", "r548", "r551", "r553", "r560", "r563", "r564", "r565", "r566", "r568", "r569", "r570", "r571", "r572", "r577", "r594", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r624", "r630", "r790", "r845", "r846", "r847", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement", "verboseLabel": "LONG-TERM DEBT, NET", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r160", "r161", "r162", "r191", "r379", "r397", "r468", "r486", "r492", "r493", "r494", "r495", "r496", "r497", "r500", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r513", "r514", "r515", "r516", "r517", "r519", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r540", "r631" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.cytosorbents.com/role/DisclosureLeasesDetails", "http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAvenueCapitalGroupDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r174", "r294", "r726", "r727", "r749" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "verboseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r160", "r161", "r162", "r191", "r205", "r379", "r397", "r468", "r486", "r492", "r493", "r494", "r495", "r496", "r497", "r500", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r513", "r514", "r515", "r516", "r517", "r519", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r540", "r631" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r648", "r658", "r668", "r700" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Sale Of Common Stock", "terseLabel": "Issuance of common stock offerings, net of fees (in shares)", "verboseLabel": "Issuance of common stock", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r10", "r59", "r60", "r92", "r470", "r540", "r555" ] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Shares issued other (in shares)", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Stock issued during period, shares, restricted stock award, gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r10", "r92" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of restricted stock units (in shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r10", "r59", "r60", "r92" ] }, "ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "StockIssuedDuringPeriodSharesStockCashOptionsExercised", "presentation": [ "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the exercise of cash options.", "label": "Stock Issued During Period Shares Stock Cash Options Exercised", "verboseLabel": "Proceeds from exercise of stock options for cash (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Issuance of common stock offerings, net of fees", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r10", "r59", "r60", "r92", "r475", "r540", "r555", "r637" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures", "crdr": "debit", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures", "terseLabel": "RSU Forfeited", "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period." } } }, "auth_ref": [ "r10", "r59", "r60", "r92" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Stock issued during period, value, restricted stock award, gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r10", "r59", "r60", "r92" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": {
```

```
"label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of restricted stock units", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r10", "r92" ] }, "ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "StockIssuedDuringPeriodValueStockCashOptionsExercised", "crdr": "credit", "presentation": [ "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value stock issued during the period as a result of the exercise of cash options.", "label": "Stock Issued During Period Value Stock Cash Options Exercised", "verboseLabel": "Proceeds from exercise of stock options for cash" } } }, "auth_ref": [] }, "ctso_StockOptionsAndWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "StockOptionsAndWarrantsMember", "presentation": [ "http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to stock options and warrants.", "label": "Stock Options and Warrants [Member]", "terseLabel": "Stock options and warrants" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Stockholders' Equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r60", "r63", "r64", "r85", "r502", "r518", "r541", "r542", "r611", "r638", "r744", "r762", "r822", "r880" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.cytosorbents.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Stockholders' Equity:" } } }, "auth_ref": [] }, "ctso_StockholdersEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "StockholdersEquityLineItems", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Stockholders Equity [Line Items]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r89", "r157", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r277", "r359", "r543", "r544", "r559" ] }, "ctso_StockholdersEquityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "StockholdersEquityTable", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes stockholders' equity.", "label": "Stockholders Equity [Table]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r694" ] }, "ctso_TermOfCustomerContracts": { "xbrltype": "durationItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "TermOfCustomerContracts", "presentation": [ "http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the term of customer contracts.", "label": "Term Of Customer Contracts", "terseLabel": "Term of customer contracts" } } }, "auth_ref": [] }, "ctso_ThirdTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "ThirdTrancheMember", "presentation": [ "http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for third tranche Member.", "label": "Third Tranche [Member]", "terseLabel": "Third Tranche" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r757", "r834" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails" ], "lang": { "en-us": { "role": { "label": "Relationship to Entity [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r686" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r693" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Trade and Other Accounts Receivable, Policy [Policy Text Block]", "verboseLabel": "Grants and Accounts Receivable", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r112", "r113", "r114", "r759", "r760", "r761" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r713" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r715" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r716" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r717" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r717" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r715" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r715" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r718" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r716" ] }, "ctso_TwoThousandAndEighteenSuccessFeeLetterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "TwoThousandAndEighteenSuccessFeeLetterMember", "presentation": [ "http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to 2018 success fee letter.", "label": "2018 Success Fee Letter [Member]", "terseLabel":
```

"2018 Success Fee Letter" } } }, "auth_ref": [] }, "ctso_TwoThousandAndTwentyTwoSuccessFeeLetterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "TwoThousandAndTwentyTwoSuccessFeeLetterMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for 2022 Success Fee Letter.", "label": "2022 Success Fee Letter [Member]", "terseLabel": "2022 Success Fee Letter" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": ["http://www.cytosorbents.com/role/DisclosureLeasesDetails", "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"], "lang": { "en-us": { "role": { "label": "United States [Member]", "terseLabel": "United States" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r712"] }, "ctso_UnitedStatesGovernmentAgenciesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "UnitedStatesGovernmentAgenciesMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for united states government agencies.", "label": "United States Government Agencies [Member]", "terseLabel": "United States Government Agencies" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": ["r328", "r333", "r602"] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817"] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails", "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817"] }, "ctso_VestingUponEarlierOfChangeInControlOrOneThirdAfterSecondAnniversaryOneThirdOnThirdAnniversaryAndOneThirdOnFourthAnniversaryMe { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "VestingUponEarlierOfChangeInControlOrOneThirdAfterSecondAnniversaryOneThirdOnThirdAnniversaryAndOneThirdOnFourthAnniversaryMember "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to vesting of share-based awards upon the earlier of a Change in Control or one-third after the second anniversary of the award, one-third on the third anniversary of the award, and one-third on the fourth anniversary of the award.", "label": "Vesting Upon Earlier Of Change in Control Or One-Third After Second Anniversary, One-Third On Third Anniversary, And One-Third on Fourth Anniversary [Member]", "terseLabel": "Anniversary of the award" } } }, "auth_ref": [] }, "ctso_VestingUponEarlierOfChangeInControlOrThreeYearsFromDateOfAwardMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "VestingUponEarlierOfChangeInControlOrThreeYearsFromDateOfAwardMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to vesting of share-based awards upon the earlier of a Change in Control or three years from the date of the award.", "label": "Vesting Upon Earlier Of Change in Control or Three Years from Date of Award [Member]", "terseLabel": "Vesting upon earlier of change in control or three years from date of award" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r682"] }, "ctso_WarrantsIssuedInConnectionWithDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "WarrantsIssuedInConnectionWithDebt", "crdr": "credit", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of warrants issued in connection with debt.", "label": "Warrants Issued in Connection with Debt", "terseLabel": "Warrants issued in connection with long-term debt" } } }, "auth_ref": [] }, "ctso_WarrantsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "WarrantsPolicyPolicyTextBlock", "presentation": ["http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for warrants.", "label": "Warrants Policy [Policy Text Block]", "terseLabel": "Warrants" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of shares of common stock outstanding, diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r178", "r185"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.cytosorbents.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of shares of common stock outstanding, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r176", "r185"] }, "ctso_WesternAllianceBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cytosorbents.com/20240930", "localname": "WesternAllianceBankMember", "presentation": ["http://www.cytosorbents.com/role/DisclosureLongTermDebtNetAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for western alliance bank.", "label": "Western Alliance Bank [Member]", "terseLabel": "Western Alliance Bank" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r680"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting

Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role":

```
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" },
```

{"r110": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r157": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470",

"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r352": {

"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification",

"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477065/944-235-S99-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477065/944-235-S99-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477706/946-210-45-4" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r495": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r538": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r632": { "role":

{"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r699": { "role":

```
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r725": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r726": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r727": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification",
```

"Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards

{ "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section":

"50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 65 0001410578-24-001795-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001410578-24-001795-xbrl.zip M4$L#!!0 (!N$9UE]8L':IA4 +'7 1 8W1S;RTR,#(T,#DS,"YX MZ)",IM_.;DX/3_1 M*#=LD_'YEQ/7F;4^G_S]Z[_]|;=_: !5^OOWU-=,VW"7ECF8(2AQJ:L ,66@3 M>!4B7!M0(9AE;;>"F7,J:1?GIY]/ST^O/V]MUE?5QBV14,?FFFKL\O0B*.CX MS=G\1KNX,/OU|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{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

!W8&442]]Y8]:VE)HU@=TKK%5Z' M.S%%C<.JR$2_0]OUCQ0,5Z B9C"ZA2H/&9^C]]1W S5S9J'!D@;?V^/N@V; MTMGDY{((_H?%U86M#$_T-AJ$SZHBD+EA/.?7ZFYLD$$C]!.7F=>@%F]Q85B9 M)T"D3EY++HH')/3L.:(D3B'#\')9_Q1@V^:V5+B'"#?UY_/S8+Q,PU?\CQV M*5ZY?
ZD.]4;HA=UNN0X5O*94,Q-UC"DBFNDA$\DGU%EO2$-RW),[V1C.I\1 MJ6Z/AN)%;=P(%U/(KR^/G"?@EV \AYY
WBF8&E3'NDF=$*EP>AXO&6#>*FKP)3,H6IC' ME8RPBX8198W 9(8D_^4QIF RB(9)!:V,%-Z$R_)8DGZM__\'%_ ?3$]HC--
MY=:^P>C*+R>2+5<6)]I5WQ8J@R\F*&X%.8C_ ;B>OBRM 2;STA'P@KH61:K* MJB)-%IF5Q@BK4]BDZ
ML%3*HK.SN@Z.U&G.QF$_0^1/.,JRS!@9PM'X!*\Y'(G?2=5>,2MB].+$\U+ M!]^W#?5M6VT'XWC54^C6'VC&"-*S+*=UG BN$B[CCV]J;K-1%^HU
,MJY(4CSV#41+#_H)V_+$RXKMYSXMT;@D1J84C MN$;4+S[M/XZ"! B-P=F[_\1,]X467$)-]:@U!)W:N-8?N"1[' ^ WBO;WPHH+H$BCZ#44@*A:L$?
^PQ@DC*^@K2 M%^HF]NZ_<*&Z_W+2-@SA4K/[LI*T.7ADHCL+*CKJ38_P18X3S=N7U_L_2HP&T),.ACSI)D 4))!7P
M*Y$G=V0Y]$DCQ!!3O%%]%OA,E2MT[?T[H2 .K04]!GAO'E;Y<8*B0Z-?<#P5 ML=UFT8)ZL!KO;4'9G'?
\%W\F@G#I:9AO1X$]QEB1*@=RG.^L#DPN,D\BCH=O M)=H<;*0IE#*=FP6,11CNE/:.3#,PV%0?\EW0+33:BK-,23#U3AL^$ #[H3?! M\6[[7,'=KK<@?
CK:,I07X4W75PN47Y+[A?7A]]K@G&W]2C#"G9ON)"C(' M"QB??P&PX/JF2RST:4;I'%##MX/+[[=%(P9U<.NUK+\H7ZIC]T:L *63B;\H
M,ZKB]F:L\-6TOR@SJF)7D1U!A["K&72$H]0Y'=#EE(JXGF:JQ\ .O)]FC] B M5NWY7"B_TXC.F70HS._V$G=A4 #UV8RB6O!*5FNQD1S*(@MIOLLED_AB[
@Z M;V-HEX'"*D#=V69,T!-8!<(V'*#5A$(%>7Z'F#OJ[$V?EM;&E;2%\$RF=*E>(M%1R!RV^V;4]\UNQS\!6TPNSN2T_C3;NXN/59D$,E6/4;9]47)W(D3?
B59L>6 M(FG\")]^-H^7%,+'N*7V519?:]V$='UE7K#>'Q:]ESI49S-X66Z'.7M,H*SN@ MZ@MRF\3 ?ZB-S_U;P #F.R?5O0!_)RH,GK%@X\MDCP5;Q:OG:R=
VB"!\YNJ M"#ECJ.[_Z9J"P:3W#*@X=O3$;/H^GXJ>MP(6O?(4 @R9Q?4,3D9V-5S*HZTF6Q7^-JQQ[:8XD8KH[Q) M+JHE,]2110(*"=]K.?X[.!4-
)SKVG6\U':?T7NFV!4H0F-B@Q,Z9\4"$PZF0 MNQ@5A*XEKI@AU7_8 E11L!NY1C+]!3"*:4'86N+9MBSO\% =[\902R^N)3;H MP=C>RR/]^*
fM.@M;L'_A>=16Z4J%])WVL$'L)V;-%AS8P;#.+>%_1AF5!5!+ M5DV>[AQTGEH727AD@5<#!0"Y>V.K.6]+=3@U' G"T$EWMG85?,R M(=_.
<[!5DR*V4@\C9XG5)<):HUF_HSH5@ZWEBHJ.O1""[Q*S>R:D\P[RZ+@8\?UM.%^EX)<#4$]] M-
D[8$JQ\JL*_.7TF5ON),,MSG$6E:";D42WF#&]XR@H$.X:[Q IYG6"B"54% MW?S)JR^_4CTVP 376GOJ/\3GG8XE8I<$5X/-+ZQ\3&P' TV8A3$,8PP(U0W#
M7;&M55 8^BV/:-(X%8RUMUP]&<Z9[E6]G/:_=O$WBGL*""\SJW.0=_"8ED)_Q2G7M VQ).EK0L MO+==X2Q"I7&5ZNW\EXYA(&4%./6Y+VPEW?
$P5NS:%E4(W)NWTB=&F+\(.C*4^\'Q(2UIPLEXG'H(*]0!L40+EZE]OBBG%6'TJ%-:6+' M]K<<$11L!942=[DT]1GWK&. M+\%A96.J.69B?H]
]6XRH>H@YI*Q%5T"(4L?OZIUXB%+&K]0BA?>(L,A11M$* M[P3_Z$3PO,W,Z'%,%2,=G5MKW]?B%:5.H0(UZW=*7Q@%%6B .6FJ4R'61/W(
M,.;3YB,Y@T\26MRDM[BG=1GE''8P%P'?E;-E]Z-@ZO/$"&8LV7_

T37@3P]0;0MV\!C_G"N5TK)PLF+5CWY-#&<'G,[$5-78P=LL;#T9 BT7WR M'/IW=$9QF53^BTIL77Q5.J9(0814M#N-0BQBK4.APV#QI\)
[[0920>542.G#%J/O(G8F_.NGA$7 ZI&-=DQ/53F",I6E/C>C.AWLN\#G1R3T-3 MA[N1ZYB'AK-[L>8G0/"H 5U1E*UZP_M34KMCYFFBK+*JEDY?M5;[H
@TV#8_U+5]!F>A*MK(^'CTS2(]\+D* +*/--G MCQ+T%DF=5$1C<.\%W3%,*@+MZIP.[3Y;,N\]4[52,0N%/2#B3XH1VE!B^?C&
MX]'W::6&AXD!/I/G_6E2H8T:4B3VT@,@@0;Q^>GG#Q/[XO3\<_RB8^$J;XNO M]Y:O]Q#CU_\#4$L#!!0 (!N$9UEE/F1,)0\ *;* 5 8W1S;RTR M,#
(T,#D5]C86PN>&UL[5UK<_(V%O[>F?T/WO1+=V8)D$ 2,GW;(4!29@@@P M0'KYU'&,'+0U$BO9)/37KV1LL,&R97.Q@.UTW@0BR>G04<;8\.9 F1K
M!@&Z#<;:)]0GV@C9CK27@$AT+*T)P+''T#3RJ7KA^O2=:VJ%0H_N6T\Z935 MP4AS&]NY+OM_;'C-8?2HE@(C:.C+6M7@S4?
7*M5]MZ/Z5%:7PD:KU.]C0:5?IB7)I MPA+\4\$O5N!?%1NT0[(9"QM33-Y0$_3:P-,B+U1,U6SQ\$!6 M?Z4]LS<#Q"6>UA$K-)T1,&$5X!QT,-
TCRC3/W+L*,DC1T"WC)BO\[,\[,OL- MG4Z>+?QY(*(#S>\%6!-2P\+4(:!/(#+(@3+>>' H1H+1NV' .[073[="93G6R MZ)E#^(&8=S9T9-<- SO(9L-
(GPEJ0$"Y:)P(]J/U7P?.=8O+W 2V#]U4ZCBB M4'M68@>CCQ$@TR9XM[UGI#9[F=8.*87V#M1)FKKL"*O#*6O+Z8[FYUTX_L&
M!=@X35]UVR'09L;;,]UO.E!_AY;]C??DK+A2M)\7M ,C"P'3B>%C\WV=/9>R-M1P?BHIO;HE>B2+G?X<:.
3*W?)6H%;^UC4B+M6BPSNQ8R[;*UVY,]_UFZP%I M \4[[+/W$"[3OB.F("3P90-68[SZ%MK\@;5:E8?+I9)6T%9ML]\;O6ZSU1VV
MFORW8;_3;M9'[,-3O5/O-EK;\)=6:S1T0TL?EH6-T ,M'C=C$]U$5X&F3M]=_M+3]T*'K,W>&4 263?UO7"MT]>E]\6>=T@
T2W\'EONH/S<+%/.2K>$0PG2X M(6)DF3_O;A_N[N[*Y?)MY>&V4JG4;C8$#]A*G80Q,#OVG^&9=#:+-PF>1JO0 M>QI.(STF8T#8_/1*BR3I !B P7FW
L$$KIH3)4SH3DU M1(_=&\78;;,YDQB3!1-?P&:PR)FPEPC)8^M6,;;Z\I,QT.&Y]S7C@PMQ,SYX M(C-
J2M0\$VZS(O4HKRA&^0!0FT"#A:9\2.EB9,3R+ "]N$+ER@5(J((HZ5R\M MAS[<*=B B](5WYA17^KG*R5,K",XQ;W5Z6YM]P M^R(.\#-FU$^9>?
)P]5TE<^!QCT@5M3E"D;_^,X:7^D<"-\!J:()D,3YL[B@-M0H3N.A>5!=H=-MGS0!F>4NP<2OO$2458C$E&Y%K/5+P9,*B&8&8L$>[=.>Q
MP0)/IQ@E,KI9[)SHE,*F:) ^LC)=P*4E?A^,V:N@S;'.QHBB^ %;7?GNWO0QCU@ M 9 A7L])J;$0S;N&TVE12OO['XN;BNBPST?
9"9[F5%F0F=AMXC>RV\2'(_;C MM=4=#;7>L];KMP;U49L5T.I=7O*U/VC]PJJU?VUIG=XPCWWDS&FO/7A]KD.+ M)R='.!#$>7;SI%-
H"/I'ZE9RV2)!63CDY?R>0*(N2[Q=LG(TN%^4*M4;W+? M79>1P?!&2GFPB9.P0F@6MND,C\DU5\@ST]72DSG,F:TIP!,P,0$KC("VOFRB M,W
0Z6319MIV]UFPFHP()MI'&]F !IO+P=YXCG;W/$4INB$DR' ?E9R"=7K M@R)/*RJQH)4B87B?8!-0ZLKR#(3]=+/8&5$!4U1-SL$[MCR A##;C%CK(^G
M$$%JE,(B5[<2X5/"5#I3E #O G"X1-Z7Z#]J3A M4)N9-6'6;3G\+E=^U)'\]/Q9/CS.T%-94N5*MWIV>(>P+MW2_/]KJ;?9+,256 M;OF]]9?.2S;1FS
2=B]%%LCKP/<@GU$XLP/LP#WD]=! MQ_]A-N^=7H\#?YB'*>A,).QBZTSY;A6MSR.SG:?'&C*^- M5G,S[S9G\3Y"^094]"VY6-F&N]I%?
8HF%G<<=VXJE8=:WK:Q(S.I1B8/\%'7 MZKW3HL]PF?J,6J#?*'+.)$GC/>H!Z"Y&KHMB(1"+"EQE1/$44>SLN9+%G)B\ MS2EKU 0LJC6@[LT_ZE-
,;/AW%,42-$YT9Z9AO9:-8&WZTE#,]"0:9/"\Z!.}5.LG98 M(=.(:GO=-M'!]%%9YM/"AF&ZYR^ .19TR.V'FW3^^\A]YVE1XQ54FO&MRO54I7)9PW?$,-
NP;^%>8TT35R"U>RL M#]]6Q,G,G(8G@:IXY$9VW002T8""AJ+L)A!9]2EZW,%_%?<(UPVF,Y@-IP1 M%*7/DNHI:$,[,AB10\NDA ,=D1 LE_@R,L?(@!L C-
T3T_X;N8(OXXI:/$E1 M_9P9WXLN$EV 6B,+WV&#C!U&EH@&%+0194<66?4I>O)Q &9>?^$;"=8OKA > MJXHN'H9<57C*+,O7M@&DPI[A-$S_0UWD?
ME(H]=,W&I,*OJ]OL!FXO>"A53 M\IS930M;U=V+P2"E3:G#U !Z9N"N1/'2>'R]BR_DQ*.NI\Q$(\N+U=VS^7" M=\
<]MNJ>O^).J;U\!=]F!BE+$V',=PQU[N';87SZ+OI(W!>I@#MP+;CG2D9; M7X 8D I3C(GUSMDJ=E/"839&'FA@D
C2DRM>FBVDT(*B^RJ7\]*>&0RK]M!. ML^+5 +<)Z0Q3W7HAV)GQF[CX9F+W]CXP7E^P(#"L /V_53T)CSSU8H2HMTY'70 M, ^)<8 M3AX ^@%I;4-73?
Y*%$OV9'FMXET_LA:,?>@/VMU&NU_O:$]OPW:W-1Q]]<:H M_6M[]{=[Z\CP[?6U/OB#GR\?ME^Z[>=VH]X=L3*-WEMWU.Z^;/U>I[UHMX;|
MF#]33]/16#/X+V MJ?:,#)VLN5Y7L8H\"A[1CFWE<9A5I0G4V'A*R8*86^ZHX MF;KAKGC/NN+F('9;'C+*X657A*('OJ?4(6?^2=4NP18RZ4"-&Z_6(T
P4O5< MM/Q]5I52=7M Z?2Z+X51;_"J-5M/H[7CUY9W5>7@_R4F,Z& _=3?;,Y34*7< M^]NF2K<[D"P.15UG4'Q^>[@T9^O")T];
A25O5T7V$CGVT1WI\^MVQKE&NRE M=8Y?7;7P;K<1&ST=]PHM+W:J3_FD1R!S7!7%>U%4'TH-YZ@WS02EE[AU]:X
M"5&3"8JB._G"YO6&I.7!;S#V3_!+],*(>B?$YVZ85%W"]<_8+#/6P%V(7@_" M[DV^0FX3:YXDN]E0):8("_F&)JN4H;*F2%6N96)50K:ZE&:O_-HEP!&9DA!
M\L-)L&C.,?ZK;CO$71L*[M%::^-_@ Z&7UBB:A+MJFPZ=;R3*/(L"B:)>P$ M]P1F?W+XV(-%^=5LC5V4=0@!*S?'Y.MH= VJ9[K?!,ZE>:7LXL1[
M0V.OP.0GH@V^ZA(ME$7YA;UI0=-@00!,8A:#TV=&>!N?)^GOY MT/W_'E^BNFK^/B!Z?VN>G M58.B;E\68\(4,ETK804Q]UEZN 0]B4.O:+XV#;1G.-
_5>?K-7+"!".$K>H)2 M%EO=M -9DYF$VKI06TG6P6&.^1QWQ(E+3:5MYT(-)1Z_HO>CI_*8V""[&'=8 M,Q=L(D+XTL>#1--;[WO^SSL3X*?_ 5!+ P04 "
;A&=9H!/|04W #< M5P, %0 &-T__N^SL_^^G-T, NPG&X#B@4^ %X-@\ CC]6"!MUI/#3X#0F 8
M#BX)#%9@,'AW\?;#VXNW'W\9G)W]C==QZ46T#$8#7MG[M^_V'T99=1C]-GCW MJOS7_<7[W\>?/SMW8???ODPN/N\I_M,65O"*L(0HN^_L?
_=T_8&%"**?G^S MCN/M;^?GCX^/;Y_N2?@6DQ4M?/'3^9[P34KYVU,$"]2//^UIWYW_]^>;N;\& M&^\,HBCVD'\LQ:H1E7OW\>/'<_[U0$J;#^(#;9Z;7\
[3CY0T@K]%O*D;['LQ MUT\EA(&4@OUVMB<[8W\Z>_?^[*=W;Y^B8,]7"4&%G.A7]*_.2.AO_S(8I#HA M. 0SL!QP]O_#C"9TRS%O]_NF L_NL\IO;!
M+&^$40 0-2/Z0X1#&#"[.7R-ILOI%A NKVB(*-%F2\":%H /X 9'T9L!X^'+ M;%)@W-_%,,+DGM7PUL>;_CX?Q(8 M[_K!KVRP$_!7,/)#"'"4$T#$$TB;O"
(AHXUSJ5R#V8%A+MWKU=Y#$+5" MVF'S'0NE;#83%%-N(^A_]<(MC"M77GOH&8@H@W]O/U\0C#M&IF<|!KR]MA2
4/L]12[W"_>8307M*N3VI4VSN081! -NQYX00M,=FT'U/KMM$QQ!EX "C9 M_W.Y&R51C#> +&AM=*S[!/"*>-LU](=TV=D*;+.6^H';O1JU*NX8S
U&JP4@ MFRMP'|^"">,@Y&'E;&'OA)X*3;2M$^K7W#*MS7=5JH&-P=,6[@3%?"_+U+\U$ MT'UDVP6+3KU=ZPG0'4X[KD^JZ)A!JENVI[@#9+
[V2+N5D:PN)%T93%.Z*J%C)2%24(64_<,@HL1R7'K$WS.: M_7@J"A!MO+<@(7C+_N$\G-,%__(\HS]_A'2R.D-T\L6/@(A;/$5SNNT-"3G4 MQQH\RWZAP-
Y].'OW[NP]WV__ZVE;&O+6FW4]%'@D8'V%ST/#)QA=X8T':<]? M>DD81W66"=J52=6B;^\%RUAZT3V79A*=K3QOFYD';8_]A549'0T%@&!3MOU2
M%:E&*.WY^'EF&_/$(Q1LLEV[30 W!Z5[8=C,T975.>B)_<@[.#&#ID5UA[CFE]('!#M+NA[UD;C*^VW3;/ #"Z 2'O*8 M-7 L/LB5'Z3#V>
SEW!4D]N.1V0E_Q_?KRX&)P-CC737_:5#VCM@[3Z :M_M#^O0 D.UQQ5BO]!@R)S\+F#0>C]E?CL-Q]H<_CI[#T(NBZ9+0!QEO^W9"[QZ$
MO[^H/_CW8DDM$J<9^_J,&J=0"T32C&*20O@CF8Z)$68M-/OJUT2O*DG M:US%1!+1)O VW6'LBV7C3)L9*17 $=5O&EP/%GB@YA83NMJZ_4V'EA&1.&
<5 M]+>C1=!?_K@C.$C\>$KF@#Q 'PA,7T96L@85H5DX;!.6,1);5Q)JP(FIFYJ MZ1]BQ1K-&[-Q.;_,M"OY-&[=A[XX]P'=Q$ L,6\AG= ,1)2F$&7-?D'1%OC\
MA%E]X%),,3(5=1L#KQ(NUFC?J(5+&-Z;N)+1]DV\R6(F]62SXUV,N$]*8T$C M*E.[J)&5LH#^.A!7EVD9(*T4K1>YLA5,A?
S!B[V%CICY_&)'RG1GW67OI0L M3&V%_G T$?K+'S=@Y85C%+,CGG)W$%"4S$%"TSOG:7-">S[]+.3YE"IU:IE MA,6-&3-+(7?,"$5LX#_1_@5,,T&)J^=
LIW<#JW)@EM+7 MP=OA %TI?*S)B?GA6<9Z?F!6LFR]D\ >F0W]T*@X9B1T2L-1UK"!N(C%[?> MAOZX(!Z*/)^?
ARK[3&5!N0RTBG;1BZJT@^LR9:5#25 4NI06]U;[U@@CNH>) M4]_R#$;?+W>7 /GKC4=47:RJF-P]J%'0"3'LF5+[12N*U1!#N6#;KE9#1[@> M9\;
]6S64@C]5 X)KG:YBY:K65X!ECBJ7 .]2NCC[G8=J*<*58RO!I4 M E#VH[[7A!4.S_>GYCL@Q5%CBPQD=#%*28S!"1=#!18D'INI;1"6$KJ-IY; MI5BQ1N-
&W;8B;O<^6R675]>%8? G98A'#EYC<@L>/Y;]%BV#[SC059\RO0[,R&0N>K0?[7*,/UGR#X@BB+W-$QY8*]"ST47>[& M3X#X,&*7^'PP8]MYZ:>,0^U;
[+ZE/O2C;JNU[]7$\6] MXS?O*.U=8 47:S^",KZW73 13I?'.R22[:V03K@5E%+:0O0-QNL9"- .4 VNX M76#%:7;#&O2D4%U'FVURE7IP8ZZ,[I\E,/9;Z
;LV]U8/WHDJ/"P%FCD&^-3 M*F=F_"&[@+U*=UV7NR/-G;=C?^.,'[E' 1L"F2NDP93?KJF;Y)3!IZGZ4OF)(97*UCU3F,C+[J/H2XA"N(=2Y_
MB$K40]WA&8R&&LK706364R"(492?0 MG,.ZGWTD4L2J-HT;=)')O T[-MZG;K9#N/(^2UVEMU=8HL(+*BWC#FX-YZ^D
M3%WL7;N!JQ12\@4K.++D$)9 *'N%%:Q;[DP/(#T%]MA;E0D5YB,BM0YN1#6P M8KXDK_*PL;J@)GA9T?8=2*$-7)<;"YVGS'ZQS^BP;;7CI$[("0K
$P@6>!)% MR2'G6)9Y3-Z9] I+;4R_N&.']8P5TRO<2##=1#5UB!NPJ7QCJD+*]9]>%8 M#,A0=L[H#,!7EVD9(*T4K1*W,44=L[H,&'0]F-"C156+KK%&
(!8D6+Q@V\P&+>BDNL6376 M3\Q; /BJ,5&%BI7HI,H64MI&IC1B :4>NNX,6B5>7-FZ<>,6L)LW<0F;QL]) M94$DA6_"D\!>
C5TN!7N%DZ^RCENQ^Z7B08+6S%ZSGARJ"]@QZZ3D^_M(/&. M.;'B(0K8NF3!+=A:5]S4T2L!]B'IE79)'Y=I72[*J^G,ER;/_.61U M!5^M'A!
[J7N.F:FE\3%26N$(JZ0VA0ZL3CF0I_&1T8K1]:@[2>.C$#+6X,%. M*I\RTX=T/BIFK6K'4\L,H M BQR-[T/SP(.%>9=HP:IJ=2LPRTY'?
FK7%C5K*6)O&3UM.UZS=2,6_%LO./6 M IGOU@W V74=X"@JO$)UN;OUXH2P/=KASTIG@G8%\OUUK2JL"REC3NUKD)?0 M%$.I3&L/0Q-
%86WVS+L;:N I."#4.(S[K_;/$/-[<12*Q'TM(Q7Z=U7$%)%) MO==8RFUXW?BO-:2,=7@PZK^6,[UW7ZN9M3LL>-<%69\DGA\G7>?51-.1)R
M^\6J8C4VE/'U9R.6@>N!,N_GZ5,*!:^1!GJK8],,Q)#P@W06)U(1!R4F MEMJSG-P)H,I.+". O ;:[3ELI=ZS'A_%^)F,\WT54#%MVM:!5G#UG7M$Q1*0*
MOX&8V &(%3X2$;$VS"X](TII8QT>+++@_1$P7'1TR9NTFU=_-4ZH1H.1,:%*1 M$77B# &I)L
.4V5H!AS)VC>?'*,BO$C&J%639[UONLPEPU%8O9!6:A=2:AO; MFURRGR$*;JE)'/^2>]LD4EZ0KEF+?/-3OYZVG:E*=;@5=\:[F@1.83M2'X;Y M.T$@VL?

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|>&IXS!-.@A#9]B#T#L7U.<(!84P1)E11&@_P4+]TFMJGHU_NN3)UR\Q1H,MZ !U3]PA\'73Y">,@/]K/<1A(M*HJ8%QY/[7IBBHDCFG1$\%1-M1&?A)92-BP4*XWKXN8T>"]PJ)OC,"856XR?V*D;E]*2@-ZZ47]HH10'$,17-_M0 2H(-;T#U_1 3G$/*M1QK9T:E*6<642JK2^XFRDQ.28UEA_IY,B9^ : $6J MM1,R5Y9[M713AN&8.N8@I-6M/@%$4874A(;!ADHVXN_#/P!U;](M[,KRH);J M=,$YIM 21MT)RYW50RTU"7"XJ[\TW8?\(99,)WE*XUKY2R?+ASP$QQ1RBQ$N MLJG93L4;3Z. <<<67]VD99&H <4]T$Q8" *"YPFX=Q"V3;TRO]R@I0VT;+;WOH M0'1,I=>8 +A"HX00=J\[%WWVB8J+#2"78$EIY/ZF6C6XLHQLI.!;2(V<*'V& MD4\72AX",(D*.$1G2RIJ5Q:)M113BUV*@C*7 YIK'C.FKO M;H8HH5P?HZ32+I_2T8[/[B]2W%1H$'EDQR=_"I>= U'AAAQP.DU()\H>6S1N M-1_:+)!Z%863AD8Q9#WADFY\Y6YG*;5Q!7]LKV !#,>40Q=N1UL^ M"SS"FPU&\QC[W](H]A]C5?UIHUF-=D]P/OFNB>AWXS2WF==SJ.+TV/L>T M7+CHD<[B=#J?+NG:K,(MJU72O#9;G<)K87),@X75E\X*U!UO:PWCDZXWG=,' M#X@6(&/,[M'1N1WB@/Z=L+1I5R#]MRK6I8.*S6N^W;%6!Y"? D7G(_";,RV+*_B@Q)#LZR7G4E9>Z1/0N;)F49K6R0QUBL&^ H9! -/F[SQ(M5U4C;PMC+U3GJ%*7<24T1%LQ%7@<4)+O)YLD9.L%V5I6K3#]\JZ$C^@K3Q^; M?47.0$QA@&!_)J#4FHS8E8@1;17)@-C7Q^OEYN=QN5F^(2KIJ4SHRGRDJ[$R M L<<#;IG12ZYXV+#P',I0F@%J7!&,079Q M-W6KS8"/5ZE.OGIA(MMU]]^L*Y.#+4>!)%B33(HT$]S^L> M<. CJF:3T@I;U<)H8-@;J+<+F_!(\B7S9IE7U>=[,T03T/-:937$,JE@H_MKWM;NJ@1_!Y&X0VU9B.+UWHL*F9Q)XW@JC8Z.SRB!9TG4"?7[L M2ZF&CQX)^""U-29+ -E+O$U64GK5/K.0]O: GX=AI/;=O674J?>91=1W@-@Q MVW@-(C,?S?]"HL*>13AQ*^=;W?#A'F.]KF#$SDJ2] 96-%W>T=&&DG!CN6+' M8*'NRPL??[YX=_%N<#8XUDE_N1S.)SQ M1SI"M_/Z V=_> 9?^NI I)?0D@JR|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|%Y!2H]]Z[] M@J5Z/"Q1FM\67O36.4K@+*|:KB'RD ^]4&O5)J.VKYWN=^U*@/;WEL\G\ZE> M0O+7S*<"!;YF/GW-?/j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

"=L(ZHA M4D(I;G;G\G!XC7*'R;B#4OIK/.G4(MPUPGBGPGX6CHW1,?+.@.5]0TG=<. T M@0'UM8(%QP*FPQI2FR Z6>4G&U .OZ?A--?"F?;$+_T,O= <)!["&0]BK*6+X M><26'0&3&2R3S%8L-17P,S!R$H.@ \#7,-+G_?"^6L M5#@M%ZC2BEK;OTL6@2F'@2^\VF)+< C&_'B<0P HS<'+>4HJ^=0SI:X[:-BU M'!VV,.>@N!0,&"1IF0*E3TQ5)P[V\CS\ZY2%J')V< O":%G6R//A?5II!_^F\!:L >>5%4-M11\Q:60$6Q<46Z=I7%Z(PFM5YD"KGNU0KO0SCXQO@_=AL2Y8%+"P1GKP3V&J M]RT:U#K6G/45'10_%08]SP4BC'[[SI{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

*[ZU7QFSS8A8&=U7.> M49D/^NJE?'/8D1Y*J);^8@ (GGRP/+U1&#:5MF>W:H/_*,&3 M:V]OG)^JI6*VWN@?G9\D#W<$GU][>N7 [HZ0X:XD3\;!0KMN7A]{$ MIT&MO;U_728E3W[(5Y1*[KYQ=Z8:]7R_DUM_>^M*TCNW^6NKNTVQJJF-X:Q_MEA^69O"DO\\/#]SBO"A"ZDR#FOUS @+8B0BDZH7DL#NY-BK-UG&K}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|LWL_\T+<+0Q]P&'61- !5E=5;PPPCQ8& M#:L[.I8 G!7=*N@U8IW=UBWP!HIR*J)/ B]M,@#(!G .HQ3*]+1R24.)CW5# MU\DSQVZY]J/6PO\A[=;OF%6GCH^YDA!"E&RGY\+RB1<_/1C*NC^OWU?MVSQS> M'!VWCT_=1OX*Y;J4R&2ST;GOH*.9%2H-X_RF+W; .L1YKA'NV4>E$)4_I;&M M&R$O/&CVRVA"X^7/ W<[N8\BZ K+_;]<2?DTCOQD62Y=5-U+KSBR'O/[>.+_\HL*7DN+#C7%[7PM(. MU!BE]T/P_@TO2^//K%]LBM8\GFW^03;'ZYY&.,M#TDC=?8:)LBM8>6(S#RGH?<&V]&":V2^"[3@ MF46O4V8 [2I? >Q*&\3I\82F6+\0DKCNS5C6H0R%#,[PTO{G(EX)]Y1E34:-8[*SKL-J]=='ZAIR\?(HJYW<5.3R;-00'YZ\H7-)A{E)42;5&"])8IT M96-F5?EQVQ KXB4BS,USI-% {0ZPXDOV:|W[+/5]^*2PZT%'7(/16C *M1Q$^ M+TB\%ZBE;EN)0TXQ(L)%'.TU$FU/"_1*9 MC#]:VYL.!T52%G.UXMV=IF:/>[>1EI/TS@@)VS%L>,!-)ZO]5)D-DP-7]&;Y MXQ-[:BE5N;^I9&.SN"P!Y=1[YW"H2${1;4\YSMIG%V+RRKFNW@ZEY/2)AC3$ M7$36TIEX2*\C]"^96]X]-4%.DMN'_? E5E+>X:#@MX_,Q&MA>3>UG#9OV|< MM>2C;GTX&=X>/C4.RX_CUKMO#+Q>\64.+V>&X? MR! #>)N02X/.T23Z'FM K_L<;TYO/;.9E3\E#)=*^& MS@X.[XSSM%C6FK?)8ZE4*ISV?[?H"7,V]1[6?N,9PV#ISKR.+E]?M:O56B?M MG)[DRY49]WMBE2^KR9NU7->* A:=>$>"9U?H/>;-_;0Q'X$<<]@^*IG>WDPY4 M"Q.!600K<9X5^X#65IIA2?J:O-YGLLXKTWH+B^UE(JE3$+6L"@50N$==[72F M3. [<9'MB#))5;]Z^>,"F^L^7RO%NT.[MK5^@->[+EE9NXF--LN1D4[QPR.= M#X7CT[.-9EK)UL5I3VI9N|KUEY%.GG(;TNQM.^-FXJ_RV6'&3$W&IZ-2Q7O MYMI]4"[FK4EZ2PKJN6AH6%>-KK7ZX'I2GPW/[A7Q09--[4G&+I#/W-_[T-Y!G^CLVAS'\ESBTC?PNY>YD/>+VHE2!EP*;|" M&N&5LH 8#9WX39R6+CSXMQKP:)I%*YA?6FS]>H0?9&.[]*L+&SNX>$1(F\+ MM_N) /W5Y?YOC+]_94GUCOX2?#N^6[8O\[7YNTDT7)MDZ-XJ V?"X<3D=AA=69 M2C4HXB[0LPQ[B-[]-#9T=9&)Y@GN$IK"0(R>X28V4+_P*O)'-"D.'U/&Q\E^ MT/4J-@PZ L@'C+&;R- >ASE585[!^Z^]HW"_=']?>G55$1CQJ=HESP9Z2_%UU]8II,J@ZNI;/]X"]A0Q@[YY?\CO*DS,+XY=IXODQ53N M[PWCTD.W2T/+8P*E!W3HP\S_.XG3VW^Q:\IH2;]X0YC?[UZZEZIT095X[NJ]-MU(^>"AYZ\'T7V7]SV'VJD(T1L1>(D&)$[.4BI%2N$&-B'S 1RZ9]040LF_8# M$;%LVBXF_NO:;,IN0,D(EC/(\RAYR9+],3@47M&"47A/^^'-I/C2N5\2SI^' M_\(;\,^/#*X3?DA',]R3$^54(?.9>%_N\$_6*B%Y0;,7K),0$^T<0P_M8Y?S! MC;)>I(@UB,0DLD8B>@_UH)(FBD)B$;FW(K*P*B&?Z]3S,93-_U)^([QHT"# M\8+?* 4FZ/*1_#D:\4A#&6OS*6TV\59A%ARD7/Q%__HZJ$]'J?:_-==>IO,TT+EF>1A^_P1"7P?,?[9Q5.8M[N-90UQ-\POAO&]Z MJ? WI:Y.$[QU<]G*.\,/*!UI]9Z@=#*]JSBR=M.#HPKN7Z_<#A8QJO4R5R M62F1S:W?:X[Y/^;_F/]_@_\EF1F57D^X)H3FY.&S.RI4Y(M+PN F^OZS-3N+XT* (=:U5G1E<^IA%]DYPRIM?OWC[]O W,G>_NS7[.=YL M4 4>8<9>=%SEHJ(^U8;SW'2MF6D\3MIGU=S =96\?3[#Z2 YRKAR7DS(Q?4NFU_)_\22 MO\? &'Y8=#.6-C?;72IG=I8#6@1"1Z_H]N;/CPVT00BAX7ML_=*\MAC+CO@CY MD\YWLN>Y@WFC,K_*C$O#6\N9/98Z.30<,FDI42SFUX3/SYA[ORSW?D 91LSG M^V-A/,_HF?/+8>'QK>K>#,BC>5:^R$O48'0R.=3R=RZ?4H]\^O'*L(QCCF MN!6R%+%("":;A+5@^RC#9M6>P1Q[1SK-= <6;OV\9":I:I/BOS^O!\)O>,DTE% M+]5G>KUUZMDH! ZRY7XE_WC^ M,%2:95UVW*OKHNES35F&OU#,)7+9],96*Z;/?^E5\'_:"#W[W/MRK:^]Z1M M.9ZT[\;3]K^HI.V.ZI:[/9ZN5Q'3$M:)T-DI5.L%C.=GJ016W29[9=OY$)-3)Y:!TJCH2GDX.*367_2?.C41_IQLUEI=LFE.G,F]G'^,FJ. M=G=6? CINM(NSRDU'>TQ;N6R-R*6HF=?-9O7PWFL^'HK)SFU2.=3+LF',HF9> MYR5U2FL?7NL564]JOV=7A4_WZ]&SBE,#: M77MRXHQ.)O:%/6XG3Q^31Z=WCZ69.8,G?Z8=?!+3/NLEI(XS#YNNO#O.I*Z>_(MK5T?,"Y4VL>@^D:KO\%[H\YZI.;;=')6]PFFM4FLE* M=G@VZ^? %,;JF&&M/Y K91%Y>+R5X=X+Q10/U8R1.;FL2Y]LG C9;2U^@,"D6 M*A\K5.Z(8K=F5H0LL2JWHT/KZ# G3LYZ[8Y2+N?U3+\C,UF2E[.)K+P^^.-W M96Y:&U:. M9FJE?%Y[N&W<9I7S$F;)]# 1B(5$)KWISM;7-7.*L9D3FSFQF,;'@DF?1EDY MDX%;FI^?5NMB>;[<'*8/*[C>Z-Q;1RC279_KP= E%C[5!)O+$UG] <9QK;7E[6]XGO$ MWZ%?P$:IU39/B5:Y5&%1TLC_"M^A)V5GLYS1O7QNJU<9T<'F9->LGX\ZQ10 MA!5!@DF)='K=,'O__>)]M_OGGV^HY,U\6,/,Q)A>O* MF>A6>[*NWG1;?=S8*UN!?87[@CNXBW'$+U6XF%IED9L1+2;#ZQ4X\3ITNR(A M(G0N:3H-6JFH/HX*3# MP$EWGLKB3=]_N96KFP*ENZ7ER'KP1./C'^XE=*#R=MNN-V1FIZ$WK M)G?YU[^Y=#H2. F<[CU&BIL"#24^%E9ON]3UX;"Z;$C>\'0*I#0Q.CU9?.J2 M*_.2E7AF=D!*4B0IE<9YH],TVY>BC6MO MQO8- WY>);?/*WR7]L@5[E$+8SVJ6.'CCV4=7FE2G9SI;67B/4Z'W*0YO)H.>U.O//N@BZOA^^]T M/M8*5Q60LPJ4JPJJY^Z#U"HMX;S>;.]- RI70/"Y=53Z5\PL!XQ\H#N#,L!P' M;\D*SH!>H062UG2\!Z6M?M4+6W_TP3<).&$?$WD=('Y#^^%V09W2Y(-<]U4"GAXL!1[!V*R]?Y M-'F+(M8PEG8S Y940/^@48P\XE @P9Y=X"(\D^,"C0L*/*VA/,BO-VC9Q>/N6'N;)^6:B<].1. M=[:/F,T.BX=WHZ=1522M1O'RVFB/KRYF-(LM2<5HS.JF"D82L+)B^%(*!-)& MMWG9M%9E34RK1.U(F72ODTDK-MV8XBY].=3*$KYC.DF,D7E*5&0B<@U.4+Q01"994#NJ-ZC@-O NE>,A5C[H!. M3!?XCS['19&D@!QP?X* <$A9;1,$DY?]QA,56J2;R-XN(/]A^ZH."@Q(0*. MH\|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|+\,:(H!>_9P8R94 WE,%_';.OZ$GXYABZ$^_M>>P@^/[/>$N!!R@@*E?'T9%W/T4W8-_8@S]5 M_"#%^+,)G0+"+7G*3(!KR44 !KA3,![M$$&M1-YLW#.Q)"SW,]9.HI^QF\ M@)N!N](P+_0MUZH(T.9H1FR0W[H+KTS;,'\ M]6]]2NRI3F;_^]_NSC8(**?! ,S:(" Y#;O@6[E4] &>#+U'DACX!8Q2ZT#U MC3_'?QZ)T'0P4*OB!["K{JO!-5[$\(E?)%'>_IB;-#Q XDA1!\CW/Z,AOP9:CPM4)11[!]J6HF%8VO"E6DIH M@@*D&# (P9N7.+$$?HC2T1TV4B3QT3PTN M=/0900'@+5M1]1!=6;"(Y]DD$'PT%P"2!(G"($3SEY'77@DBR%!&((,L6 B4 M/#,$J+0&0E)1E*!U!UA"*4D61IM#QA2T7<|VX1JF!)+H*)/^20' @0CE4#5R#=L M4TCK3%;TR"PAZ#V4^@EN*^~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|K^,M(X6".9_* O#0*$OZ1 4X]O%W!PMFT MI@E5'YJEAA'LC- [)H35(K+80H8=561XQ,,2B#@#%?GWY".!'DP*&3BW^^[#+ M86G0FW9_S] ;=GF(2H/3H4&.ZN?!*O9H$L[O&4 C="_% T.[K+(#<*'E>N' M$A 4MH%_DU@^6H+?H!O!H:DGI# O@0:Y?,>1OB@,^P6@^2T:JK=H-3CE)GJ: M?X2!'R1;,A>H!*3[X_51U"'<=L1N&Q,\'(K06KP%/1TY G;7CJ7 M6) [M5Q^!68DMO@,"\YKL(LVN_,RGE&(_*)8M,NQ?L'XUXX[8K[]E*1 MAQD7#95>VT=IZUA\YN;&\}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

M"!V4CF,7K1&)4R/?/D07IT:VK%#S^42VN,6@=YP;^;ZD4HAS(W^PX-USN/U! MN1$I(69SB4<'HG3(]ND*GG[GM2W):AOG!^Q_9XK<69D;X.+*
<69D4\@\D2Z MB72A$&=&OG-F1!+%;2JL.#42IT:^=F]DD"A(8J*0V6]^<-=9@;V@AUT#82\$ M9)P;^7]YD;+EN-@$O&]9FH,>]A9G2+Y]H"*
[.D&RY%#DAB85$/A_G2.(^,DR1?3/;N.=S^H"1),@&@2Q0+<9(D3I)LD:IRVVP>$B=)OEZ2I&I;`MCH.72'JZ&^=(]CC&.=(-LBQ;$(N2(F<%-*
*\>^=8YDFPN)<[6#AUG,/9,-.XY7/9A:L8^PB7./>SO%(U/`M%ZIQWN#KY0VNB$,46QT(BJD)&ID2POJ/B!GG$/8Y#!?G$#;5ER8*62DAI[=:*
M8QKG$/8.S<6X`]67%%Y[#H2OFD-()_*98D(]QM/3%'YU]:!++#@!420I^8Q.8NBJ*-=%-W7"R`FL8-GWY+Z?Y!=[Z_W:6N`M?$(4Y41>BAM&O<4M^7YDD-
*EF("].=.R-<-QS("W9(^!]-Y^5)*82;2+6[V! MM.LWW0&,-)9'"&M!::UMDC+Y.0KX. /T]3) Y]BVJF=:(]^_LLQX^OE7CFK&*9!7T.-S`M*
O$'!B9S"3F3_QDG?;Y'TN>]A)!+%;=(W':9V\$Y)X#:;?_3/N_DJ'PBG143`M4K&P5;:$S]?(/'S3HHH%.9K>KA./7SU5(_=7I=ADUQ%W!PQ,_/N!:7UR\.*
MWR\P[.7UFCV`2Y$)&7+^C/+]1LF-_^?;9^$FV4$A(V72B>9<`M:ILHCC,5<2>N?>G$]4Z&2<3N;P8IQF^6R.N=Y*#&&<1_O`L0E713>&'83G.*
M3\$RA9YE$SBX1L22V'[LP?WG4YBV?M5X/8E[Y2\TRZ6$@6Q");WKJG%//CM|A4*
*M\DZZDL54=NL.U[$W]B.+M^*LRE>OH(ZOF/R6LR3FY(24W6IS^.^> ME?F&9 !(BY,VWU`X[CF0ONWU$O!F,NE$6MZ^-[,_P(BOE_RFG[+-*WYQ8NCK*
M)89JQ!4P+10G?3XY\)@& .)97M<@>^&U_.?S$CXI,/E'R,Y$.IU)B$5IZ\5E`M^Q=H^>RAEVQJNP4Y.TKI;(+3W'N6'1-
&8[5M758]I(@84X)'Q5EYG+VG;!^2&&5@Y_W0S-9FF\`M[,W\UU4`%1\`Z0?//'S8%:IDWP2^,SHEKR343]@LA1SN*8J?V$+X[U^Z*
M"RNH;.D90>H"NC"T?W"$_928'G%^[7CG+.ED\]T(,V(301F/;>M1'RDN,>;"_M?X])=%%, "MB#:#@#@C\OTV(,
(+7#AR!@..H"4TR=LFH2VPA+28$690S"4%Q M!-4:C14;OGO.+TO B$Q-F-E$<$K%L-E^DB:^;]3 M`C.6R@/%[,,N](C*1AWVK+ITTZ$=*]VY(/U-*
*A_WD_D[0+=K$&1,5!_X(8T"% MI=%3X>'I8VQSBX>,>4K@>&?=XV";FJ>Z@J,8"'N`UQI$N^B*8"UD*Y@3"69(T*V!]BQ^@*?3;("'B8 ,+P6;T'2;!':86UH&*
ML+_E_*O'Q]VGA!-30'&],:D)>*CVGK7?S;V?8%Z@&&.#/[JE61; +81E"-7! #]J%S M/M4$/Z!4 _^R"X@/>B-LS"*(0EW* FW#^5A^AX?*
*@XHMAF>DS3I_[_PO_X:%(- MHMBHGP?_+"N9- *7:V=1_/M#3 R5X'U)'[5RQM?"T:J$_I 66@/,1[^\,="= M"G"!Y^3E7.CBJ/]?^^P+ ^R*I6H9E__*MJA*
*0!DPQR=3@Z)-D%T _3"H]V.4R&X+L4BF2_\C^B MEIC_F>50KOUE$X .5\.UEU:E2'2M\`<=A<(45TR%*0*P0>___O4_K7KY>4O*
*M!/PIQI(EP#\"'8Q&%A)T&;X%^G "S"IA[&XD80K#I 367+!;#L3%A\O 7X,J M^Q(L6/4'/B'\'V E_.7/%7@OH6TIILQ>R#YZ9OD/8ZR/,-*J-C9Z;=A63W<_*
MP%!;>^-O'F>5KH[>9J[UZ6G'!+0A=;@BL.,R4P(@D?^33<@%;K"A.0_`Y\1W
MJ(@-0E\1QH9BFJB0R&ALV8H]%QS#FFG6#"T(WX)"A0!/VZ2KP.,JVA1@:(!R MGPL& D#%9L'FD,39KH[@%6=@66#9"7V2*
*!,>3VP]YCVT!W'(PD!W#9U -;P MT"6&#BO YVC(6<:4:/ZW\+=GH)D(^X 5 6MZ#QQ TP4PP1;A@*9'SXFM*
*MIF5WX9!3724.WSC[.0)]XBDV;"!OPOY;OGC5C\I-D] M725;JS^$Y0Z)RO;.Q&39?V CC(LY^5%>X_)WW%2 A'N@FZ1N<#@%G31;#@4'*C)OG"HH ?*
L.6IFU_959[MQ3#QS7R&$C]J?4XKO,AI2&OOD/Z2"W"A)E(Y3JVX7D;T.5K3=@B-_*!ZDW+ M3*J*,P"P6NJ0G@&@0UEKT8-*6?Z- VZ!K0,$PP9Q*
*-80KPR(HH&K8+J++WSN< M\Y86M*VY8KAS2XVP>H>/=#83Q%?O#<^V#) - E T?5KI RBI=0,/E:P^T>&0 M8WCY ;]8"'0]@$]{7F M^YQ^5H+"")A*
(OPR]2-!#!.20%L7/,K/F^6Y8PL1WPE$-(J,B_]!_D(FG3Q4# M0UR<[IF)@8ZWZ0<<<"$0 ?#Q&.7AB+(CK(6V-3N9!2]F-FO0]N#_C:^C/K%_ M#.!&$E[?
$J1T*OLW^V'A[VU&\3]8&;*>`;.=^3XXCGKD]^YFK5J@GQQ=4AF]T M0?'1/D+DI?8D47S/^B]$>(*+6Z-]ERDM^=!:72+,!..,I9R-.&*
M69_];L[80A&FTF0EHV.N4RJ@4_Q?M5/-E!9!N@X 7C^Y7C-J6>2X$NVO[>_ M"<_Q'RDE29@,8T]%OGS-TH ?B?*
*FE'T7LAUK#%!&;X!6VAK<'K_0F>*5_$UYB M;C.\TI'P*CX+K^7HV?=,>>>7CE%><\OK#4UX?;&&4J>#1':92J1 S=?-U\4.4 M1DM6!ZT>"_B2%?JI**
*W'#OGE_R-\P!QOLDO,FXDYEQ+&$<,5SK65LTT^6,+2. MH'4F<6U_8_R%$@/0*R_OB*G(O K6_!2M":U%Y-"_X#3 MBP* B^__U!Z5-,;>-*
*).GW_14(K[UA[T(T;A+NZ8U0R[*M'EOR2'9L[Q,#!(H2 MQB# P2%9^^LW,ZMPD90HR>"IBIAQ2Q11J,K*\\NLK!;;>:,LB8\-6SWX&K2 MQG,/+]EKFJU?*
*+:N4^[*_^Z+UW'O[0.J6T>17=>N*DI]22LLSC))&#T#]MLWP MON(A:#+>*<-]/*MP=%Y.EV21)I0>D=B21=EGCEDUH9=0CHYZMCG]>(_'_@+6T*
M>S0OZ]=<82G&4[$488KV!TLYI .0G>F5U9KIQZ_];N[HR)3L#R=PPH@.HKOB MX ^6J-L'[7\':D&G@U7[PPQ=]X75>]92+ZR0%;K5"/OF>LY4_VAWC-
)2,WJM M9UJK?RL=VBUT:&5!S'KUS6M^HET4PH0Q_V]^E13@^ ?9&ZF(NHB!M^QJB,:% M!1UIA,U>DO)8);%&L'GK"=.Q/R;2=5N_[$U<#+CX-J;G3A?
AP6\]83]6$QZK M;YE=D$IR;4K2E81.Z-TEEST5E72L=4'5 Z^L#04BFP._9Z] M#'C7$6Q^0TNWSNJ6+7&+P)@-1M2?IZKN1]XWO?
SNU9MCJ(]E[CZVO48;]BSX M0NL97?O:6\854]NN7;O> 75O>OG=2X^-=ZA:>P"&2[6ZQ6IUBS'Q74; O]%U M1^4EO1(&WV5$]NN88/]H^8>%2-
SU3R+QO@GYR M.LSK2,A\X]LZL'OI?8+,NW%IM\Q/_YAZ<7D7J 3.)<0C@?-'VB[5,?JJH7<:-MSTOL?!]8P^W>-]\RKI'"56+GJY(>4W4M2W5<1\+G4K/.|
(9N]3JMKI+X^/3NTHAX<2)(8N5>NSPM!!M3J:IEJ&+D%TJ5MG=>M @NA;#Z)_3),L
*MPR+T<9A+#%W"5#N*H>L#U;0MU36Z+!9BVW=593*,7L=.A820M]D]MY9"%WO MJ]I 4_N6;-BR5\I)E]7G6X^@GTU9ZN7P2H7]G+(XV_$.Y-*
MH7+;,#/O55WQ. M5]VQW@[[GSY'8'N?=U2"TL]#66V^O_TLES+N2^W+%
*M@1*P;Q8ETPF+)>0K895=A7QMU=%=5;,Z+6.3B.^&L3*WRYRA1'QWFHEW%_'5 M5<>L3W,]OT(E49A[7^Z7D<>;4/-N/XFS(D(T M6&+*
*$E;970SXJ8U$3,-63;O;4KW]W?NMA%^>V"A+-@J1BF\/\.2G*C[7[]M] ML]O;!R3PO M[#WS<>9'&EF_[[H'3%RR*X(6J;?/-[8(>?M56[=VN]U>A^#A\P7"-*
\T9 M:_76]TX#$LU[8%]=:S[]@M(W[]M'W0*6$B@?87M]Y*Y FN)K;\<8MJTQ&\8 M>]_T\E=P5%I7-==6;4W>D"F/T<]!6+)'B=2MZX+W-*
[W\5;2A4%UKH-K(;H^& M/T?\?_^80[=D@EF#[$P2?I4?).$TF9;B1Q/]3(F*[7Y&X'Z&N$MIO=8-M6[I M]CWHOY$Y@5V$Q9ZX[Y;9&W2XXS(KL_Z;]NS*
D^4 T.?J,Z@KPX,MUL%!,# M6[[S?;>G=;KE,C6PBJXK5&I/[_Q47HO$P!O9>446G^YPU?T=ZY6=5W:V1'35 M.RJA]N>AK+:P4GX-RNHY N#*
*]O:42NU[!"D[BG*4LR\OZ&%6)F6R[\BN69)OX M<9?;KCPU!.];JJN9$GF^TW#LX*8:O2Y3"<\76-X++MZ"OBM/9&-=LU7',20H MO%?*
*2>M9$O/==LSWHQ?&RNLHR;(W2A(KXR1E,'/%+]*4Q?ZMD]=>G'E^M[4; M6T8#B.T\!R#XB=<%##35=+N^GF9?*
=WXK$9@GGF'KOJ/AENVZ5'O/$E)^(%Q@`MFJKK=ERH)K'GG=A[H^=T[KAO^;[O'D#])S)(B$T4;$1^6Q84[7US] M-'<-F4(W.F2?*
4.WY99+_/O9Z[YM+ZQ^XE%)6X6)2_#\&>D^KBV>8A_/UC<,%2G;ZC6H&(==ML](_W[L_$!?@?.]4>4VXV2_S3W8 MHA7LP#^++
*_'M\W%SA"=_Z4*U0SXQ@-]S6XF2[_>,.04V+@HN'_V1$J;?_,Q5!QDDZ\],J>I&(!R@U+F>)-IVGR,YQX M.8MNE9>&]VI]'7.?>&Y!R:^8$H9*
*(8,S\[\S*V8%A=-5T`1U45`M&-5^U5..KKSXDF$YU_Q)C! F[.']Z98N/KOZ2]%M3Q&\PAMVPCR#PL^5S(N0^$"P69(XJF591!*8 M])-)/SN]J?9-*
YY&C+]6SH?:U045G70="O\$9V" M,&45%5K?&+QZ%,_-L=P#E];,/<']F'IQ7B8\%W&.ZH \/59HES".J;]6_10! M50)VGWSJ-=^8)O#-MZLPJQ_!U04@,F)#
*<7X1PZ-2.%@&\H2WXETB/?:[*5ZW ML2.,.F-'/];8RO=KFHS#? =MR8='68=+6NR4%ML0^CGF,/I<_\'NOP0^,6W! M@*@_7^K*
*XD\P&24[U:\5>KZ'U`">5S*?R;'0+CKNK^FF!FAJ_5&CF2?(B >#`MA&F@_*OPTAP>H9=/(R^.\<5L,DU2+[U5LBBY"9(;5.FE'4*1@@%2-O+@ZSZ#*
*M/P%50'G:?*A'0)\(%%"![@7(3YE?PHNPJ2?,#>,D$*!478[\<7/[\"+(/)@',, MMA+L7QGA1847P2/,>$8'.DXAV7#'&"&<<4%K VD^NLV3BR0=P<*N0Y]E8F8LM: GSVR"\+O^%?TJF]"/FI>B87_W6=CA-Y. R=-5>K20,\1FV,BGEQ[!*CWRQ M_-"#=.@3-GWRKIB"^^^##/L+WC,$=2_VWYEIK5/_ 3Z(D?5=&7@TB7'"Y-*
*"CX MN&0'(V"5'P?>&.;YSHMNO-NL#.H&/<,JH[IW5?2&9%/LW@",G7*5L_/N+?_]V=G2W\A;;;[%SC0$7L37\%?@CJW;6:^[NO2Q,-#Q -+F:*
MK2!B_6&;^'-4Y7^5T-5_C=]0_@M4 CI'Y9H;>K6W3&S&K>"'_Z(AN]V6E0=L M&= 9=!-ZG^]1M273"6R05+8P%+151W>]YS9CS9;/MM\#QTU7'-
+IV)R&NT!R=)?$!.N$*;@7RJ.WA"D)25SA?YL!)^ W@1[&A\0R*_X!!S8J@GFW>6 3XH&OYL2&+R+" M$31?BO!GP_-K>W#8C.*
(:WLEPGO\J0B'G(_HCT1$T7_L1]#%S[H%F.;R$OWTR M =J-$,UC4?C!LMA+-6U!YV;#[,V M'H8^9SS"EMAF+,\CUM!IR/$LS;';"Y #?2![9X+93:ZS&UH#
*M%45(HC1F')Y\;G"YF_C'!8O 0EZJRD<6$ZB#!#H,)] -LSPE=;C+DE0M[[*Q M/*^]O/O%B%]VW[D<\7ND[QD66?()ON)ZA]5NX^[P?-DWAZRGL5@U>U.(*
*_)]Y M$?P9R(&D*@6OY9$MM*Q"0385[!!B?^#J %T)K'$>8>GR>B)^, MQR#?W$=L38I[.5DIX&3-Z M(72!>=;&@!?6"ZG6KIR)OB!BD?*
TZ28@A2.AQ"Y@<'\H8 M6/$:+13Y*R(1_M)\&:8:P%UCP*'!POR=<#KY;'@"K802T3*B_"&STP_H5%Y[M<$<]+B(B0C.
(%X/O>EML3V;S!=13[G/94^Z#R&0>E9G,;XV>4E#T]+W(E]^222Y72__#E"M/>&C@ MF<;H]&7%,O!)\3P/ZG6%M':E"SDF32?3;FW>4@J99%TW.#8*
*999>+Y?3 K. MW $XCGZ8+S*XKJV:EJAMX<5=URPKRGB/XC.D M#(9Z0*0,D7Y**3S "'+G'9X'PY$OM&..KO]RHZ5WX]"C\]*PX7&;Z!:)MG+ M^V;P4G=*
*[?04V*A*@+!:*#1[/9%8O&91A*D404)7XSBW/X[8LR]GRJ;!:HU<3# M$B+OV@LC%-2>\KZ.OA\>W1RA_Q??XB'70+%-U7_UF YXA)DR+5*D>E[ZF!<0*
M5BN'ERDC:%I%_Q!]"BR4NV0E_H0[R?<)O4F3O$D:KP2FR(E!% HZ#,6+(G MS@.(N6V^YG*&/XF5/XN8U7 'L)W 1A(L4WII:!4'8'W3093 B-*
*7&4OW30KB% MNV% I.N0\G*QR.5%%(7Z5X+B=C6ZE_,LKP<"0\ Y4,\U.L9(>%DPD+0D]W MBI?*
PZ?))\N;J<3$WDX=YD5,&#^MPJ.R9@Z#%Z)]8<4N)^XA")L$Z)94>$;$8LOT'5\V2^^U@7(62B00#S.P;_CH. M4YBQ6'=;<=>B*@95R?*
L)_B>^!PI21KMCS0.0#S_\.(?NRE0G%6:$E6!A;-J M6 NR#[(C^3](ZWX;F!(Y7&/!FE%2.1L6,55ZUT%!A ^X&96XUZ4^6@DV)\,
*MN.YV!VD,L2>*F!=E";;>O4MB/*!06KHB,$0EX;8-"[(UB14S$DXKO*# MW>) H%2R JF7B4$N,>+$&!WTPP0L.0DU$*TE$S 281@H1DCW3\R+@'N/8#Z!*
MUU/^)@F&98J*. VFL^'E T:1=(?.:Z1_I0F$>5,>+ &&UBD,P'9;FS379X% M=VVNY!)ZNM$S*N4H1$(5D7REHAHVM^&G;S\2)NJ'LA)DWMWXJ4:X.#*
M:51X=%VX.I5@-OW% MG-)P:+>PCP#'$ -ZX2-F'I8,8;T9=\"K!$N983ILKP/CP<9"E)NDB(<2*
*MC.1"UD.^=&K_*&DY*S!0BXV0=.4+_P<-757LY!5X0@Z!.5[SV+ES,\3*L4S%GG57AR#3U]F<$FWM;8(M/VUM4>U!U)O54TY*+FY0$54V2I!@FH"6>0/$*
L$0Q9.TKPWB^H*K,5M<3%$._M>4 67R:D\NO%"HQL7"R[''E?F!>#-$>LM;A2[V8X(-GIR!K6+IHU6L)%XO*
MW8TY%8:%;X1572!DF&4/PJB@I[DPEBP'6B>YA<%OFQ\1_,8N M0Q\?%]? N)DB25?G&)?$X6V"_#.9A7&UXRQER9A@>""V[V&^'2:.#P6.1TA:2*
M.T@VDW,[T1^^! 805IB-BTB0$C8"XS#O.DFWS_8@OI-BO1W0_&P4B;JB+H&& M1^:5A<\'\]2W8E02L0>2-*
*]*Y7AJ2DD3TJ(:P=NS]1GS,AJ&BB(%#?)YX M@7+L91#(?D7$F.6H%FM'KH2^DP'93"(J3#@H=>1QHD7#*P**X>N''GF/)#$F9)XP810 MJ'0;_!-*
\0]:KO9_4KZE.?Q<.;JNZGV[4JD4R1%EJM. ^Y4IQC> ! X,F-R62L^S[G%I@ M9P]JBB 2E(JH2OABL5%K5D:O;[\23Z&SAN[QHKGA>\VC?W?
*]+/(!1K631<5E=5@ZYQ)B_BH. MMW"-QF&U1@*H/LP)O#;!0E,(Q_G!X$4^ ^%?)?%%]4D11F2L2,:5UZ[1,U^]M$>2"!41)&G"*-1$;!/5N2LL_5]5FB1.*
(C>1SB854KPLG%,>%6-\E4=A7.>T M:*N(_EP1S"O0!I#1F*HX=Q>Q7-3J\$BW'+:NCYFO6!+S6EH!9;U$Y]M3^P6M70V4+%8I@N?>N*#@60?*
H0OH>=5X@-MB_3%6"AB\ME^YDPXO@TE2T:TY937RISG;2M?N(GBF7IQ_[,:IB:SFS*[^V$=X,87ET"2,G/@-MS)RR:JX\A"7Q6(L;^](P+'")YG4_/W_7F.*
(?C8EP,+"V! V-3\ZX-LE%&;Q M'8!OMA92ZO85!:MW<_9>'Q0EOI>7#&6*X=IBH5P$RZQ6Q) /[R^*TZ0D:LU M9;0FK[&F=8*
#=R_D(P%!F))B:,PI/^[N%/HB]YQCS[.UWXL0ZK)H?/$IF"9<`M_D"8O,PS+2H^7W1R=@91GP/0EV+FJ#2V#36G&GM^!
*(TCCEFK?)5A+R^SX<27[M_GJU2$\8K7BDCWWH- MFHHP:R(`;#+%<"P3T3&P\/]YY:$Z44."&XU']K*Q5YVW:Y:+E.?M2!5@JY-4*
*MH.U%1N=6N7U9"*I2!48+PFT P(U $>TCI@4HAUQCS@(9C1,05T>#J/-0>U*`MZ5M@F S#M-%Y"5'O'42]H:-AHT5F5)P",\(R+RR_/?3]TG_["F+OET?*
*YCF%X M5+;@&8S6=BP,+196G?@%96O*S)M?3M;K)SMM3I:5DT6M+I U#N50P1='I,X9 MEP$ZB#-1=.W@[VO;F`[:,?I*&/S^8FC;OC/V FHEWD=$A8/-*
K=IX(U\P];< MH:\-O&EZ_IP9%G:T&:6ZS!ST!_;QMPV64>\U"*#Y7_%RKX %SS4++/6]{WN MCT4U5C0WVIMZ=ALC/D0#5:%*4+%'6:W'ISFMI@GV!-N;*
*<8L)$2%^-8P1F^*N M2*N1!BL'K%5)2CH$#*T)BCS5P%P78?U$5SBK'Y?FB0Y] 2-TU^;$];\+#\]?X M $]VH?*
W6_#)]I/_V1N4M#'Q$J0*53Q[<(_@Q*R98V?M_^#-WRG$VHMF;,.@ M".M6IUA$$H[#&M6^.#ZJB_>*2*A/7'_6:TC7G>1#-Z1)PK+R +T=,.)4[]@V*
MEUU0MT72,&N=O>%52Y-)@:=)ROB_,M%-5P/?<`3>TQC&@^TBA7)&2$C*]/I M;W6;$/$WOG<8?4Q3+.Y4">?_/1&@_&
Y$ST2_FTDOI9=52:Y[6&/YE$I3_(`R,V'O/B)>HE4VX%7LY=K_`D(N7MQN<&%0W MO0/=?LUX"E:W`_;8O9X0[D:YB&7% M8JH]^R=0A(@?LR+AGP@*
*1X_=Y)(B%LI7!*5.E7AV(,$E!]G?8"08K"2\6#[`M86+Z.GRS3(]UK\;HI]\M"<6YG MXJ0A$[QGE/@V1DG+7@@DJ(I'J>MH)O+^6,TZ7??31!&*
<+0P5]2J@&+M9%%N#)9RCB97\=J;<>/LJ9=RW?5#C M("(B)APQPL&^=0A,D)3CKB.DG]7B?:M$X0\A^W/?5Q\W^2Y)?'YL+E0$NX$U-BQM8
]]TQ\/+68$0\\(J.%@Y'A]W7!M9]1O!;M? M#\`_G9P,+;<_],+@U>>@VE[P%_&:2DG)SWEI-NGXW/EY/3#V?F7PV\G9Z>- MT![C89TZ[WWEA^^*
9MG0=MV!8:XW1C2:,,K>4VA:2F->&PL]/E_^\'TY+%Z# M_Q)NS8^74;.B,+Y.HFONV37ZJ(%5X\AR1$N9UDL!SR3,>(X#K\%]<$PC^(>LI#H6K3?.O\^-
*+]JJ;9I&#=BI:,[B"`J;.1(')XYAAKX?#W3RI$Z;G-RZ&KQ4>-J-'X5"M+2*S)QHG>,B6Z> M29GI?:B'LXG/B04T@.SZ=%)=*X4IF"7"UQBHEM7*=IFE?,_%*
(;B\3/D(+E/. ML)\=&D\\@3291LDM8ZH(0[BO&"$4\'C8OR?+1;A" 4-!L01V_"S2O'W,3%4^ M>S?^_ ZY,!<:DZE1X+D U9.J'T!DS^"_*
8IR&/X+!%%>>K,4^$T PH(T.X:ETOR3D4 M7H@L9]QJ8*H98JN/L]UT"N]NK$?>1@QQ5C7ZX64"'DM&P<\8/RSW!IZ$Z&;$

*M4YEWY%N\K*QY%0)1U7I?8K$Q!/]Q<#W3'<,S'3"-NN\/+43]7(>W*A_7KA@]T'J&=&P)+\$/(!P]P*

M%J;%2Q96E6E9V#YF='+Z*]@!Y415:'$GAVJ)RC;7*$2U5"2S@]^=6ZKJW:EN MB$=W<[VS"#+@"]Q"Y2Z.CW @K@EUBZO"'>%$TW&LD1UX0U>SP

74Q_IP9'C! M4-<<9GG]OCX>L3D^-{[*:C8C_}\L3-"EHR/*6<{!'@#UURQ:[B$Z8V>TIP? MM6X@IL];VAI^O6T+(,.^@._M?

&L8]"%6&!C6H#]:D+Y\S\9>$>79]VD27S!PQ-*:^$/'.OK]_D99Q>PIV105 MG*/")]E@$&.6WS;RPL.!.["US?*!U5-P;@]?7#-KO=[]GT]+KYP>#ZC@_.7.:!S

*CF/8 M[E!S+&UHL9$U'.G,&#J#OC/N:X'FLM$%[PZ;-@?ZD/T0(;?DJ$[-#7^BW^6 MG8X._O)&W\^R?O+IG]?#PWYZ\T+AR_C\1?@3*9"

PQ6/O2AC+Y38F\!RF!^\ MP[R>KHUL_3!-#X-D"C'-A\BI?$%[=>]EZ?#Z+/M:7$T&X??;8?)WXZ\X\CY> MW@!+_^UM:8;6@!HUN5K&%K_.G0_?

3B\^6%\^LL9_?7YSX/)&:PAV8XU-!?P M+9W$^>S\M2^G0?_[SX;'T[\XU3_])?^Z6,&\X^W8_XS>[!P"=_W+)_GNM_ MQM___K$X^6X&'RSC_/#%?

[/9)J/76:Y1M^=#WR=XY]7H!']R;&CW#===P M._5%EMK^^\]#R3MQ>DHYP=Z;JX"?HC=SXL=2@Y"TH_:(O&G&W14_-"?BP*L$ M?R"7^9R-

6ZSI%7G2YDOZI,4Y\XPS+\YY"O\/]@6QE.J9!05 !?QV5(S@]"K=5;G,TY*'=%02K78H)V824G'-84;=#TL%_H\6+943IF>

MTW^U\HDO"4S*88]@=J,TA&$^X6D>G#$."0;L0(R+'(=MBN;_;=FS!R[>U7NN MOOW;^IYE?

AK2B<=Z>6^)ESOA9[1]V[=J,#SZ3K'R0_W*>S'G=N[1W]SR-2"@_M_@%\&]-3{Q@W5[\UW_T?_RJ2_+>E,^!?^^V%<(O\/$L.,$C17%/[R7[J6J#W MKO+)?

5KD@8M\ETO0[LAQE*1X:3@E]_Q-MY3/_M"5@CZK%S$J/SCB6,7R,O[LTY:5W)]*99PM0[%=NWCY&53:]]{>)@ZNL3AR,D_M_E@T^>6YE?*VJ?

GRW&:C;7U_?5"/>@C_T\,Z:?.+D3T.V;2^7G()U_PZ-.YE_M(P^/7[]C-AM>9K#T#1CKV7(D#*T/ADRMD*&YL\N2!GZ)1DRI!U:GPP9^VN!_M7,U9(D/_N<]")

W1&H5H;PW1R"EOTY]DK77[,;8'RT+$J/\HBVK/JW-BG[WXLL"[_M?U[_]'+KASQ53Y>LWRU7

M]\A#:O4E@_"N.U]&V2(Z24>5V1=XT_=5$@6,UUD"\%=,\&!CF_M0*T2NPJ&J\0)Z'+3(;81HU[_11]'V95_G?$$%96I[V#'I+5D$IOIM\9)W/K]HMFP;?"]-

'SI&WQM:8^8-1^,Q-QR/^X&M:XX_LK165<,%RIO/_']<]B#U[25>_Q_M;X41X$63=.@U;'7#X3UK1'L4;/*:8\)6*R\:EU=24+N:LH$5GCPL\.("&@],

M^E5";6FVJAYTM^N:Z.LV2.H:?/]'.11/+_!:%"K_)N"'O[\P7BPEA>7V7&,+_M2%O<]#__79V<7;^Q_'IMPOEZ.S\Z]FY:'\P>CQ$)AE@.QE@%:38099XCW#-

M.^44[P)"H*?/<9Y'00%F;PL6\L?MNT=-VG)ZAK']-8AOL]?*URMLC3U5OO8(_M/=QI?EN5"MH)'MW4XMN\OITEC:?>A+V3K"Y9O1-

6W_3ROX5Y!.Q\1Q=-R=:2_MK7>2K5_?4_,SFS+98:[N.%6V?9S;\0*WA#N?O,0=Y%<9M^U_W(:WOBI_]K"7_M5>C%X4XSG#3[,G"[+W"3O"YY?

1]3*IE:LO5.LO7K187F6-K4N_#O_MCD"NK'U;2R$1_^)T:ZJ;=FL:^UU39:V@IJ!9%<_++FEIE:V/]AJF^4*LZR0._M[]C#J@LD1TEP"_^YRB?1?__4$L#!!0_(

!N$9UGUPT_CO_<_)\I_8_M_8W1S;RTR,#(T,#DS,'AE>#$P9#$N:'1M[5I[<]JX%O\]9]GIMIT!;_AI_M$D,S0XC;9BU24$W)\E-

%7@"TH4CLZ9BL#C6492N*)"L#B&,\&"_M*05HV/5W]4;SL&[7:J<=I-4K'N*I_XV&=60U[68+[!.G<>P[VW_M9O7YH.?],73S;8>?

SRXO>E"]6=;U0<^RSKWS?*)5MQO@"9)*IAA/26Q9;K\"_ME4BIS+&L^7Q>GQ_4N9A:WLB*5!*WK)AS2>N\"BJG'3V"_RD)3CL)503\B_A)_MU?O*9^]#

{1A7**9B>MJQRN]\[80'B]-.P&Y_]D5,WU<2{J8LK2F>,0=VIMKX_MI(73=],MJ/H+?D@H6OFZ;U9+]_MER(A]GOX12"ZBMJI&839&XUO";7*_C69^H7>

<;.R8T\#IG.2<&@--_M>!S@6O'IY@/!B=(P[=_CE,W+'7]?"E:3=:_M<#GH?ZQYIN@*+OH]E.]B/R[*=S5T^V,C(_PON_]7*=<=_(Z@*%>&.1X>D#E

MH74GWSFG?\ZD8N$B'V(I1A?E'+S+=N6WUY_@O%QUQ,D_)_M/2XR+H@.4E4@<(YQ:DX$!7\U#F]41$$'PJ.]#(2SKVQ@Q_NH7SQ;\WG,A?.K_M:?

[NS<8LI$=&PVFB_K4)"6*KP(T&+_M4!#0TXVCMH0N)O_,SA)_QA1J4PZSU'-,7%Y5"1PD6J(8>2&84Q0130,J6_N_MB00>0H&@ID90XV1?5*5Y?;J>(,3"*

@A04,,_BA7R?R#!"@BFTUB"C3)8KZ@_MU*AD3=6_A!FB3,XFD@6,"*;7"""!AB'D6]2VKD"+WY?.0T&1"Q9+,&2[(%$1_M4>BJ"\0?,"EGNJA&_^^E",,0]'&\-

[I?;UE^R#?]#ZRIXVA_?!B/W*:9@*1_?_M'3W01Y?\C*(U@1BG4XX5MG$/A/:?&)B,C3+M'6B'334OPYZQ083U7<(_M3GW93.!5:CROBZ53(#?

BV12CF+H7P3;]%BQ!\N47'HCT+]FZ,K;K3$,3*?M\YBOL-BHGMA'%0N%DL%YQ/O(VQ9O3&?7WAKV%9K6UN2]/#<@/8F0]#JSQ9PJ@

MG$F&)/2V>)#/&Q)PJ(E]C:!^>H,H:NOW64KAG:F.CJJ:XCV2[YY%*;EO[F[U5'U\%NY;[;V+^N\!*#7?%;0R.SV(CR\^]KO>YY$+

MP^Y'%SX,+B\'U^/[Y^L2#EA;@#]JTR:U([Z9Z9]A]>*Y[L?0

)^2(1TNH_MBSY<7WA]=SP&/[1?K>NJV*74VWI;PE*!D0TU_M+A&>]RO_RA[*NR2H)2TX%W481BR.60;#.O0B_=/'"3Z2^#*3V24)W_M@%5=J.\U4'^"]

6#U-.O(WT/2O=(EE[$:_BN.3WI\\T@#)E/Q78P6N:P4)XT_M7\2Q]X_K[Q(!%M?>%F^ZV)J[F?LVYEH8S_OF=7K_M-!MOT/RHUM/W]IEN._L>:S-

9^0N'YE7&T_\!4$L#!!0_(_!N$9UG*?(2:_MP_@_+4Q_8_8W1S;RTR,#(T,#DS,'AE>#,Q9#$N:'1M[5M_PDWL%Q%<'XXJK$]MKX;O=/,2_8G8?1K*0!P?

1#NJ;.+C^S%]:#_TDD?G_>'?UP,_+_7U^\^G/99K1$$_]KK!\'Q\-A7_M[#=:;;3;4/#/22I7Q-_@&9S562ZS-PR"8S^?-^5Y3Z4DPO_P2.TWW@U0I(YJQ

MC6M'AU2"3\'CH\.IL)Q%"==&V!+>UZ^%)XP_25MI4'!T&R[]>=]3BQ=%A+&?,_MV$4JWM:F7$]DUK_J#_=:N>VB98#J>S*WC;F,;1*V6ZV?NSF/8YE-

&JD8V_!5_M\^!@?;3E)%F5*3^U4(N46SD3U>EUR@67(:YDOVXU59AMC/I7I_M(GP^E%-AV)F8LTLUY=GSNB_!?F.D_R/0-

:9GQ:UM\%1.T#GIVO7S_M#U'"Z+?=\0\TXNC.B'/AYC92:8S*P6TB1]*RO7:S?1B,L&CY-U_Q_F"%KNCX_M.;7Z@\OAZE9__2B]X$-?A_TKX>G_QRP\Q/H.KC<

M(D4OKB^OKGMG0S8\AY[]]VS?PO8KS]DE]Y,O>V>"J/W)TGTHH&-11A_MIN::H\B[R0.H5@ZPA,,;?LS1E/(!;MFH:TC)T*R%BP^+5CMI-MQ"!C:OSVB8-

M3UG"9X)I,9-BCE!N$VG8;P77_&VZ8)!'1)J1YVM1\([;AR58],%N\%BI@*DK^X!H3T,_M8@5%,@6VB!&YS!C/%JS(K"X$-_<5=%02^.!LBC#%@(DH8::@

MCW7[N=_"B[(0E,)4&/(O6WC>-+4PN(J<@]9M#_15CF@->%F6T]"[##N2;(+3W_MXX)$,GD/+>@7.9JG,_VUWB-Z$E_VM1_3PSO;_\NR@TW]3-

25F2TY&;DZ-_MQQ*O#ABGC&OA(_A(2=IC0(4)0_LM34+B)#:%BR_7BR_98^OP2V2[VPB6_]^]:)(>$2A5.Y.F&*C0Z@(>=2>/\-J1$YOJA3&CM

M\:M1PY_@_,HEWUBCL5Y&%*J4\/[0Q:A4QNZ7AD!A2RB"C7*.8&Q2#D%)TS+*:%F/&CA^5.5]N%D)$@0\0/M_M1;R+%QLM9?

2#6X#@WFZOWZRW<#69C(F<^!&90Y,W,"4B-Z3C7_=+_$*_M"Y)\)%-I%T2"'AN6K-=!VZ'6&]X=T4IZX,+?,3FAO$!";[_71-JB"'!V"KA$

M82(R<+$4QH,:D9-5D@B2(&\@L%Z9(P3M3&2CB41;;R*#&4\+YW$)/V(\!E.7_M,^R\>81QKRC7$R*(?WVU,<>+P]Q1X'IZOXNV)];@H

M*C2AJT(Q'NEUJHQ%.9V1HR\#"+___=FC[R:A9D6@R.4Z.Q"QBT5N_F6<6+!4

MWHBT/#VZ)U__JCE50\D.^\"UJO_T1S9'8S'2ZNIKSTC.>HJOZDSNL_VF)5LU+GSG57^Y5G[=:O[_M\/.+E/[N"_TU^%T;UK;"Y\ZLO"

]A])"M:C])?/<0J1]]9YM_59]2P"6;G7)_MX?));YD[SV;.6^_G.LY:;T5D["DRPNM%UT727N@X#N0/E]DIF]WB/4BQ"W\$_M#N8TN!510:>:[-SGW3NH;?

UD[C!;?R-^6]1SROC/1*]H+8]N)EH564S45NEP_MZ7@KU^SO5I0$E[+M5&:B4;XO777U>G]94KW=?_]F_SGRD<8(N?!-@X^12(1]

MIF1<;OO!0;.SOXH1OJSEOFK@OX_@ON!P]!=02P,$%_@_&X1G6=$GC]RY_M"_NS$_!@:!C='-O+3(P,C0P.3,P>&5X,S%D,BYH=&WM6W]S&CD2_2HZ

M4KM0JH:!["1>+%Q,*YX*I&]-J[;_5/_"$;GF=&LI_%SGWY72P,,?Y_XJ4V._MW.$]XQFD);6DU!VO97'XCT9CF,4\"T7$WH\^?F"1"HM49),%6G"+TKFT,1NI

M/.<9^RBTEDG"WFD9305C[5;S=,/=>=5L-1I'A^AK4#9269>UV\&;H-/J[+/6_M+]WV07=OGUU\9"^N1X.73OKX?##ZXV+HA[VX?O?A=,,]C2#XU]X@"

(Y'QIYB_MQ]EJLY'FF0%6]HPG03_\JI%;;&W>#8+Y?-Z<[S65G@:CRR"V;,(?)$H9T8QL_M5#LZI!)\"AX=':,"-_TA8:1-Q=!@L_WK9L8H61X>1G#%C

M%XEX6TNYGLJL857>W6OEMH>6_:KOR=PVYC*R<;?=:.OW4RWD4R6S:2,3$=E\U_M#P[615I.XU69\E/K:I%P*V>"^]T&B;"Z^Y8V;AW?

X#'6N;+=A.5V<;$IS)9_M=)^/9"H,.Q-S=JE2GCVO^Q+|-4++R?.>DS;R/P)=8WI6W-H&3^04G9.N/3__M+NH8_;8[_H%&'-\9<2[#DZ/3D=]$>GYV=;I-?

Y";;NX/#T;G%[T/[^3T], ^'0%T?@)=AY=;I.C%_MJ>75=?]LQ$;G;/C[X'W_D]#UA^,V.7?UAR%K[_%&>_|%?QFT7T7:;8MT[U^Q_M_O'YQ6AXS*K3N!H."

ULK]7!@G]'?;_(H$;OA^RJ?_FN?S:\;IS__F'XAUMV_M_*?3:GU#$_MW8:R<+#ZA]FF=70C,C/W:9!^YECR3=18*3"

MC96.A'Y;:]4@DB2E7UR]FYR'Y3M::/Q&RPG_J,>0)Z5>3D5XY=X\EE8TJ*'H_M9FJN.8J]JSR_>N4_2WC\/U-%NQ2Y$I;!'EVHG0*%M#XC:D)&RRLNE)Z

M#'P;-E_:0IS"4V\]W8#V,G_0V"&A=M39>B2\X\;1.98NV_T6,Q$@?G4/".UA_M$"DHDBDP1HS(9<9XMF!%9G4AH#GHH*.3P_=G*=[@&!(VX2&*-

%,IN(%57NZ!_M0"9"80S7"Q))^8W_N)4^#+4PN0J<@]9M#-15AF@_>%F6\J"[##N2;(+3W_MXX)_,GD/+>@7.9JG,_VUWB-

Z$E_VM1_3HSO;__.R@TW[3,R5F2TY&;DY-_M)A*O#ABGC&OA(_A(2=IC0(4)0_LM34SB));"Q9.;I_=(FC!1DD_[#85K

^_>EDDD'#)PJL7XJ5KZA(&>O.ODKAR_MYFV_^F?D?"NFX:%*NCQEH(8;:7)GI_E&HHG>MQA($_G[JQ@_\9<4K?=9G_L_M#_H_"!?X/X_6.G&2D!?

FZ4V('(P%D%>.Y.F&*C0Z@(>=2>/\-J1$YOJA3&CM_M\:M1PY_B_,HEWUBCL5Y&%*J4\/0Q:A$1NZLS11C(R.)C(LF(#TK64$%+_*(*M0HYP3&(N$4G#

M!\2:\;"%YT]5VH>GL2!!Q_^T_M%]$N7FRTE/$/9BE/]KH/#.;I_OK)=@-;F\F(S($;E3DP<0-3(GI/-L)UM,0K_M+$CRL4RD71

)>FQ8LEX';8=:;WAW1"OI@8M_M^6$\)@K<%>$&D+0\)#9*>_2_MA;G(P,42&_]J1$Y622)(@KR]P'IECA"T,Y&-)A)NO8D,9SPIG,!.MIZ4!]JO#S$'1WBE

S:U3P*[D]Z>WB^BK*375!F+7IT3[[^57.JAI(=]C\%K%?_HSFR.QB/EE937WM&0%S@=[C+A'S@3]B=@MBB2P#(=;!!)22@%P%<2D%5&.A?\

MAAB%9[J.4SB.[H[KET>,7P3I.GGTITN/^&8>H:$1*]>\$?XELT<38!AXJWM:_M8\!I3)%B&;!*;C)E#'OTLA//5_*;[_M[TV)X+IG"3*;J60FB"ID?

%K^$TJ7[EVD>:(6_K7S6'F?SN_8!_#\U<2GBOWF_M!J3]G4NXW!;J7"$1^:,WEVXLHTAD$"#M6WO(04G07Q.@:T9NA=_6Z)92;6D"

M92_>$AJA2A*>&]%=/E3U>(W!8W]%@:XGT8)@J>]>?FJM45Y>?:*2RDVFSUJ2

M6EK._B_5:?]#9%9]GD.6'79&38X'6./W109W6[S$HVZMSYSBK__*S]NM5[_M^/E%2G_WA?X;_*X-;UOAN[)"M;#W)?/<0J1]]9YM_59]2P"6;G7)

MX?);YD[SV;.6^_G.LY:;T5D["DSPX%;782!WJ-S^R6RU6[R/*7;A#\G!G4Y6_M+.K<9]X[K&W]9.YP6W\O?

EO4<\KXSUBOB"T/;Z9.%5E$Y%;I[M+U5B[:WZTH_M*2[EVXG,1*-\7SKKZB7_LJ1ZQ__^MP=R9"2-.;+AFP:?P!*Z?*9D5&([P4&S

ML[^*$KZLY;YPX+^5X+[F#,R9#$N:'1M[5G[<]HX$/Y7]NBT36?P"TA*_M#,D,<9PI,RE0,'?MC\(66%=AN;((<'_]K?P@I)>TTTZ3)C=A!C_TV/UV]4F[

MEKI_&(:?Q"0):03O@O>7$(EPM:2)@E!2HK!TS50,@4A3DL![*B7C',XDBQ84_MP+'-(J-1')JV89QV4997=A*)"XYCO;4:=J,%]K'KM-UF"T;OX6 :>&_RUN=#

M+_@T\@NUH^G99=^#FF%9?S4]RSH/SHN*EFD[$$B29$PQD1!N6?Z@!K58]=2U_MK/5Z,:Z,H

+*QA;L5KREL6%R*@9J:AVVM4E>*4D.NTNJ2(0QD1F5)W4IL&%_MT<86BBE.3[M6=2_:SD2T/>U&[_HRM>7TI+8DO8]LM.2]*

()0N#*T[ER#\UV^]H(LD6\!*Q.%;:ZDG"AV1;?I\/:DAIT2Z_M,Z'BSM<*;NN95OWF(E'&G"P9W]JO_I:D&0SH&L9B29+7]:(:$[QF5;/ZZD[?._MV#\41:-

YBFZ403A;H'"-M5/8[V(=Z+_3*!ZTQMD-C6N:VS83(,)*?Q.S&5/0_M;)A.UYJAT])[@!@B8:G]2_:_M^MXTZ/_I(T#$ZH\?

$\KI>#++M#0((AN"T86I.3,^$B>_E#G6:A_8C:MN;0.]_M_K\

<IC'7:$]MH\>$.P/39_A!03O?)CTQF>]@3\QAA\O_4_0\P(0EX&&PJN.5T3GX&QJN]+H'P_F._>LY2$Y3OVD/B/JD&XTCI"PDM?YF[%T-%9QTQ1

M0W>D+FJ4!(N*];R-+BT55)3^-4-:!BZ,'THL73U\G;U85JARS-QJ2T7[1OPV_M._'2X<.*2)PX?_MCBD.(9$C@0L@EYAS&!Y@+F9/F2]$*.!

(APR84B;:G'O,51Q&A6*:<(T#>_$IW#@^B-SMN(L\D_MAE]4X&\P@T@P^2D)ZAPW6QT@273M04MSP$%"DMUJWL6XN:>0?K?J6+JV'3E3M6L@S3

M.L[4UHU9%-$$&[QZT6[8S4[7T@V+H*2SV)RW)S6=!->JZ5!**6:%$0K.29I1_MMWK8QW&$RN.B)NKL5P\A.N%F;FU?,[[,K'7)7J)\/:M0!'+SME6E!]HJ8;

MR_1G$;RP\\)##PR(3_=IE"W"'66IFUVQD9F?GF2-=BSU/G2=CSE-,N_>VW_M9W8]!7N>$KONV,Y)MI3L.?@EQE-Q)OI8X.5@BFLI=

[M.)/R\D&*51'KG24BW_MBNM[!ZTW*\K])[U7S5E"C?*[R@3V#WC+DOWSW:]/CE.RH,9,4O+9(-'%I4NN_M!(O*D6^WS49KEX(497;^*5"<2.='W*?_E!+

P04_";A&=9#Q;SFFX%_M_1(_&_TU9^W/:.!#^5_;H_M]#6#7T!28DAFB_-3;A),P9F[_BAL@745EBN+$,ZOOY4?A+1-7!.DY";,X(>T_M6GV[^TE;2]T_#*.?

Q"0);01O@XMSB$2X6M)$02@I45BZ9BJ&0*0I2>""2LDX_MAU)H@4%<&8ST'0:!Z9M&"==U.65C43B@N-8;ZR&W6B!?>0Z;;?U!L87\.HR_M\%

[GTF>^%[P?]XMNQY>GYT,/:H9E_=7T+.LL."LJ6J;M0"!)DC'%1$*X9?5'_M-:C%2J6N9:W7:W/=-(5<6,'$BM62MRPN1$;-2$6UDZXNP2LET4EW216!,"8R

MH^JX=AD,C#9***9X/>E:U;V0G8EH<]*-V!5D;L/I<6U)Y(EAA*IV!13U<&6_M%E0_

MK%FD8M>Q[>>=E$012Q8&IW/E'ICM]DV19(MX6R8*TUQ).5'LBFK=_M.UI#3HET9T+%G4\[^%++M&HW%XDRYF3)^,9]&;_ES6!$US_12Y*\K!,^H

M9/.7G5PZ8_]25(WF*7]M#,+9_I5KK)W"?A?K0/^=1O&@>YS=ZG%-<]MF@D=8_MV;^.V8PI:#;.1M>:H=/2>X_8(F&IW,'X+5A>?Q(,!T.O%PS]$?

B#/8(VG@Q'_MWG#<.X?!<-3#1WSR!XBU/]DGE)>3Z65O%$##@@].&2W-J>B9,^U[N4*=Y8.\1_MV-X4>F?^..B:P2[N"NV1??B_8'!H^/@#"-

IV8=J;G/9&_;GA_WW>?P\]+P_Q_MAX9MW^.8^F>5*3;?? 7Y>"6S%<&E0HE=#M!0STDY!^I_B"12/6:D.Z(5T+H_M>FV)BBE.B9R1A&:&?\WI!GJAJFRLP[

.8XINA#]-N"'1J8S3\T9>S.@1HFID#/T?P:>D*F01/=9AYA*_ML_RFD#M2*BZAK5<@,?_M&'F%]C-.829D1:5QS:YA(\[+27S[GJ4D+-^QA<1_5

7C2O<1$E[Z_M-'>ZC6TKZ<<4D7>9D0G+=D/P5_M>0VHWCEX%;W>4IF&*XDK,VKH7V/"D6"N5/+9.6]V.D"2Z,:KEJ:,E3/M?TPX_M^SNCV?

A=?/M>@)IN+$%*+?/I!,F2*,(2)!1+(%N%|:\C(V%:22HIGE7UQT0_MS+ZQ8[0'9SNL2)&(63$7SK>S($**\L10$TU+K7A!6Y'28A+,OC9#FG=P\U=Z

MO8JDKMQREV68*W*F-F[,HH@F*/#B6;MA-SM=2PL6*YU.C?.@'-=T9EVK!DVI_MI1@[1B@X)VE&W>IA%\=H$C_M"_$T:G>-0U&-M[81?M_\W_7"/7*

[U'F&A'%?/`..[0Z,Q%7!LS<%S;XTVNX$-MWWA@X-7FSZ_!+K5-H_:#PS\9WA],^#N@U:[&N*?]M13Y'_?A/+U;^OW@3_U-M)Z?]43 %SY^,_4G^F;W]5'FBXI[;\ZBH>(]!>R+@'A#PFX8]/.=.-^Z/^?{@-M>:=,2ZN/V_0:,L%9!,_L_/?-@6&W=.;/+E.(.\1:*[,^VV]I6NQI[#P*>Q[3 MY/TYRYX8MO_V/":&W;%!_$2TQV#/K=VGXK1U7^#E8(IK++=;3R3\L)!BE41Z-M^TE(MUK<=XYP;U>4FU!ZJYNSA!KE>Y4.[!X=ER6[)\>?GDFG9$&-F;3D@T'F-M.+.ZY$JP[(Q\NVTV6ML\["BS\YV\XJP[/SP_^0]02P$"%.4"-;A&=9-M?6+!V]85-"QUP-$0-@-$-8W1S;RTR,#(T,#DS,"YX-M&UL4$L!-A0#%-@ &X1G6:*0>ST%-M-P-W%<#-!4-(-!+24-&-T&UL-M4$L!-A0#%-@-&X1G6987,;MG)@(-"F@9-!4-(-!."4!-M-&-T#,Q9#$N:'1M4$L!-A0#%-@-&X1G6=$G MCJRY"-NS$-!@-(-!NEP#-&-T#,R9#(N:'1M4$L%!@-+-L-[-(-/1P-P-$!-end-XML-66-ctso-20240930x10q_htm.xml-IDEA:-XBRL-DOCUMENT-0001175151 us-gaap:CommonStockMember-2024-07-01-2024-09-30-0001175151-srt:ChiefFinancialOfficerMember-us-gaap:RestrictedStockUnitsRSUMember 2024-08-14-2024-08-14-0001175151-ctso:CertainNamedExecutiveOfficersAndSeniorManagersTwoMember-us-gaap:RestrictedStockUnitsRSUMember-2023-07-07-2023-07-07-0001175151-ctso:CertainNamedExecutiveOfficersAndSeniorManagersMember-us-gaap:RestrictedStockUnitsRSUMember-2022-08-10-2022-08-10-0001175151-srt:ChiefFinancialOfficerMember-us-gaap:CommonStockMember 2024-08-14-2024-08-14-0001175151-us-gaap:CommonStockMember-2024-01-01-2024-09-30-0001175151-2022-01-01-2022-12-31-0001175151-us-gaap:RetainedEarningsMember-2024-09-30-0001175151-us-gaap:AdditionalPaidInCapitalMember-2024-09-30-0001175151-us-gaap:AccumulatedOtherComprehensiveIncomeMember-2024-09-30-0001175151-us-gaap:RetainedEarningsMember-2024-06-30-0001175151-us-gaap:AdditionalPaidInCapitalMember-2024-06-30-0001175151-us-gaap:AccumulatedOtherComprehensiveIncomeMember-2024-06-30-0001175151 2024-06-30-0001175151-us-gaap:RetainedEarningsMember-2023-12-31-0001175151-us-gaap:AdditionalPaidInCapitalMember-2023-12-31-0001175151-us-gaap:AccumulatedOtherComprehensiveIncomeMember-2023-12-31-0001175151-us-gaap:RetainedEarningsMember-2023-09-30-0001175151-us-gaap:AdditionalPaidInCapitalMember-2023-09-30-0001175151-us-gaap:AccumulatedOtherComprehensiveIncomeMember-2023-09-30-0001175151-us-gaap:RetainedEarningsMember-2023-06-30-0001175151-us-gaap:AdditionalPaidInCapitalMember-2023-06-30-0001175151-us-gaap:AccumulatedOtherComprehensiveIncomeMember-2023-06-30-0001175151 2023-06-30-0001175151-us-gaap:RetainedEarningsMember-2022-12-31-0001175151-us-gaap:AdditionalPaidInCapitalMember-2022-12-31-0001175151-us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31-0001175151-us-gaap:CommonStockMember-2024-09-30-0001175151-us-gaap:CommonStockMember-2024-06-30-0001175151-us-gaap:CommonStockMember-2023-12-31-0001175151-us-gaap:CommonStockMember-2023-09-30-0001175151-us-gaap:CommonStockMember 2023-06-30-0001175151-us-gaap:CommonStockMember-2022-12-31-0001175151-ctso:TwoThousandAndEighteenSuccessFeeLetterMember ctso:WesternAllianceBankMember-2024-09-30-0001175151-ctso:ExercisePriceRangeOneMember-2024-01-01-2024-09-30-0001175151 srt:ChiefFinancialOfficerMember-2024-08-14-2024-08-14-0001175151-srt:ChiefExecutiveOfficerMember-us-gaap:CommonStockMember-2024-03-29-2024-03-29-0001175151-ctso:NamedExecutiveOfficerMember-us-gaap:RestrictedStockUnitsRSUMember-us-gaap:ShareBasedCompensationAwardTrancheTwoMember-2023-09-18-2023-09-18-0001175151-ctso:NamedExecutiveOfficerMember-us-gaap:RestrictedStockUnitsRSUMember-us-gaap:ShareBasedCompensationAwardTrancheOneMember-2023-09-18-2023-09-18-0001175151 ctso:NamedExecutiveOfficerMember-us-gaap:RestrictedStockUnitsRSUMember-2023-09-18-2023-09-18-0001175151 srt:ChiefFinancialOfficerMember-2024-08-14-0001175151-2023-01-01-2023-12-31-0001175151-us-gaap:EmployeeStockMember-2024-09-30 0001175151-ctso:ExercisePriceRangeOneMember-2024-09-30-0001175151-srt:OfficerMember-us-gaap:RestrictedStockUnitsRSUMember-2024-09-30-0001175151-srt:ManagementMember-us-gaap:RestrictedStockUnitsRSUMember-2024-09-30-0001175151 srt:BoardOfDirectorsChairmanMember-us-gaap:RestrictedStockUnitsRSUMember-2024-09-30-0001175151-srt:OfficerMember-us-gaap:RestrictedStockUnitsRSUMember-2023-12-31-0001175151-srt:ManagementMember-us-gaap:RestrictedStockUnitsRSUMember-2023-12-31 0001175151-srt:BoardOfDirectorsChairmanMember-us-gaap:RestrictedStockUnitsRSUMember-2023-12-31-0001175151-srt:OfficerMember-us-gaap:RestrictedStockUnitsRSUMember-2024-01-01-2024-09-30-0001175151-srt:ManagementMember-us-gaap:RestrictedStockUnitsRSUMember 2024-01-01-2024-09-30-0001175151-srt:BoardOfDirectorsChairmanMember-us-gaap:RestrictedStockUnitsRSUMember-2024-01-01-2024-09-30 0001175151-ctso:ExercisePriceRangingFrom0.84To1.08Member-2024-01-01-2024-09-30-0001175151-srt:MinimumMember ctso:ExercisePriceRangingFrom0.84To1.08Member-2024-09-30-0001175151-srt:MaximumMember ctso:ExercisePriceRangingFrom0.84To1.08Member-2024-09-30-0001175151 ctso:VestingUponEarlierOfChangeInControlOrOneThirdAfterSecondAnniversaryOneThirdOnThirdAnniversaryAndOneThirdOnFourthAnniversaryMem ctso:CertainEmployeesMember-us-gaap:RestrictedStockUnitsRSUMember-2024-04-02-0001175151-srt:ChiefFinancialOfficerMember-us-gaap:ShareBasedCompensationAwardTrancheOneMember-2024-08-14-2024-08-14-0001175151-ctso:SeniorManagersMember-us-gaap:RestrictedStockUnitsRSUMember-2024-04-02-2024-04-02-0001175151-ctso:CertainEmployeesMember-us-gaap:RestrictedStockUnitsRSUMember-2024-04-02-2024-04-02-0001175151-us-gaap:RestrictedStockUnitsRSUMember-2024-09-30-0001175151 us-gaap:RestrictedStockUnitsRSUMember-2023-12-31-0001175151-ctso:SeniorManagersMember-us-gaap:CommonStockMember-us-gaap:ShareBasedCompensationAwardTrancheTwoMember-2024-04-02-2024-04-02-0001175151-ctso:SeniorManagersMember-us-gaap:CommonStockMember-us-gaap:ShareBasedCompensationAwardTrancheThreeMember-2024-04-02-2024-04-02-0001175151 ctso:SeniorManagersMember-us-gaap:CommonStockMember-us-gaap:ShareBasedCompensationAwardTrancheOneMember-2024-04-02-2024-04-02 0001175151-ctso:EmployeeOneMember-us-gaap:CommonStockMember-us-gaap:ShareBasedCompensationAwardTrancheTwoMember-2024-04-02 2024-04-02-0001175151-ctso:EmployeeOneMember-us-gaap:CommonStockMember-us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-04-02-2024-04-02-0001175151-ctso:EmployeeOneMember-us-gaap:CommonStockMember-us-gaap:ShareBasedCompensationAwardTrancheOneMember-2024-04-02-2024-04-02-0001175151-srt:MinimumMember ctso:VestingUponEarlierOfChangeInControlOrThreeYearsFromDateOfAwardMember-ctso:CertainEmployeesMember-us-gaap:RestrictedStockUnitsRSUMember-2024-04-02-2024-04-02-0001175151-srt:MaximumMember ctso:VestingUponEarlierOfChangeInControlOrThreeYearsFromDateOfAwardMember-ctso:CertainEmployeesMember-us-gaap:RestrictedStockUnitsRSUMember-2024-04-02-2024-04-02-0001175151-ctso:JefferiesLlcAndB.RileyFbrIncMember-2023-12-31-0001175151-us-gaap:RoyaltyAgreementsMember-2024-07-01-2024-09-30-0001175151-us-gaap:RoyaltyAgreementsMember-2024-01-01-2024-09-30-0001175151-us-gaap:RoyaltyAgreementsMember-2023-07-01-2023-09-30-0001175151-us-gaap:RoyaltyAgreementsMember-2023-01-01-2023-09-30-0001175151 ctso:UnitedStatesGovernmentAgenciesMember-us-gaap:GrantMember-country:US-2024-07-01-2024-09-30-0001175151 ctso:DistributorsAndStrategicPartnersMember-us-gaap:ProductMember-ctso:AllOtherCountriesMember-2024-07-01-2024-09-30-0001175151 ctso:DirectMember-us-gaap:ProductMember-ctso:AllOtherCountriesMember-2024-07-01-2024-09-30-0001175151-ctso:DirectMember-us-gaap:ProductMember-country:US-2024-07-01-2024-09-30-0001175151-ctso:DirectMember-us-gaap:ProductMember-country:DE-2024-07-01-2024-09-30-0001175151-us-gaap:ProductMember-ctso:AllOtherCountriesMember-2024-07-01-2024-09-30-0001175151-us-gaap:ProductMember country:US-2024-07-01-2024-09-30-0001175151-us-gaap:ProductMember-country:DE-2024-07-01-2024-09-30-0001175151-us-gaap:GrantMember country:US-2024-07-01-2024-09-30-0001175151-ctso:DistributorsAndStrategicPartnersMember-us-gaap:ProductMember-2024-07-01-2024-09-30 0001175151-ctso:DirectMember-us-gaap:ProductMember-2024-07-01-2024-09-30-0001175151-us-gaap:ProductMember-2024-07-01-2024-09-30 0001175151-us-gaap:GrantMember-2024-07-01-2024-09-30-0001175151-ctso:UnitedStatesGovernmentAgenciesMember-2024-07-01-2024-09-30 0001175151-ctso:OtherSalesMember-2024-07-01-2024-09-30-0001175151-ctso:DistributorsAndStrategicPartnersMember-2024-07-01-2024-09-30 0001175151-ctso:DirectMember-2024-07-01-2024-09-30-0001175151-ctso:CytoSorbSalesMember-2024-07-01-2024-09-30-0001175151 ctso:UnitedStatesGovernmentAgenciesMember-us-gaap:GrantMember-country:US-2024-01-01-2024-09-30-0001175151 ctso:DistributorsAndStrategicPartnersMember-us-gaap:ProductMember-ctso:AllOtherCountriesMember-2024-01-01-2024-09-30-0001175151 ctso:DistributorsAndStrategicPartnersMember-us-gaap:ProductMember-country:US-2024-01-01-2024-09-30-0001175151-ctso:DirectMember-us-gaap:ProductMember-ctso:AllOtherCountriesMember-2024-01-01-2024-09-30-0001175151-ctso:DirectMember-us-gaap:ProductMember-country:US-2024-01-01-2024-09-30-0001175151-ctso:DirectMember-us-gaap:ProductMember-country:DE-2024-01-01-2024-09-30-0001175151-us-gaap:ProductMember-ctso:AllOtherCountriesMember-2024-01-01-2024-09-30-0001175151-us-gaap:ProductMember-country:US-2024-01-01-2024-09-30-0001175151-us-gaap:ProductMember-country:DE-2024-01-01-2024-09-30-0001175151-us-gaap:GrantMember-country:US-2024-01-01-2024-09-30-0001175151 ctso:DistributorsAndStrategicPartnersMember-us-gaap:ProductMember-2024-01-01-2024-09-30-0001175151 ctso:DirectMember-us-gaap:ProductMember-2024-01-01-2024-09-30-0001175151-us-gaap:ProductMember-2024-01-01-2024-09-30-0001175151-us-gaap:GrantMember-2024-01-01-2024-09-30-0001175151-ctso:UnitedStatesGovernmentAgenciesMember-2024-01-01-2024-09-30-0001175151 ctso:OtherSalesMember-2024-01-01-2024-09-30-0001175151-ctso:DistributorsAndStrategicPartnersMember-2024-01-01-2024-09-30-0001175151 ctso:DirectMember-2024-01-01-2024-09-30-0001175151-ctso:CytoSorbSalesMember-2024-01-01-2024-09-30-0001175151 ctso:UnitedStatesGovernmentAgenciesMember-us-gaap:GrantMember-country:US-2023-07-01-2023-09-30-0001175151 ctso:DistributorsAndStrategicPartnersMember-us-gaap:ProductMember-ctso:AllOtherCountriesMember-2023-07-01-2023-09-30-0001175151 ctso:DirectMember-us-gaap:ProductMember-ctso:AllOtherCountriesMember-2023-07-01-2023-09-30-0001175151-ctso:DirectMember-us-gaap:ProductMember-country:US-2023-07-01-2023-09-30-0001175151-ctso:DirectMember-us-gaap:ProductMember-country:DE-2023-07-01-2023-09-30-0001175151-us-gaap:ProductMember-ctso:AllOtherCountriesMember-2023-07-01-2023-09-30-0001175151-us-gaap:ProductMember country:US-2023-07-01-2023-09-30-0001175151-us-gaap:ProductMember-country:DE-2023-07-01-2023-09-30-0001175151-us-gaap:GrantMember country:US-2023-07-01-2023-09-30-0001175151-ctso:DistributorsAndStrategicPartnersMember-us-gaap:ProductMember-2023-07-01-2023-09-30 0001175151-ctso:DirectMember-us-gaap:ProductMember-2023-07-01-2023-09-30-0001175151-us-gaap:ProductMember-2023-07-01-2023-09-30 0001175151-us-gaap:GrantMember-2023-07-01-2023-09-30-0001175151-ctso:UnitedStatesGovernmentAgenciesMember-2023-07-01-2023-09-30 0001175151-ctso:OtherSalesMember-2023-07-01-2023-09-30-0001175151-ctso:DistributorsAndStrategicPartnersMember-2023-07-01-2023-09-30 0001175151-ctso:DirectMember-2023-07-01-2023-09-30-0001175151-ctso:CytoSorbSalesMember-2023-07-01-2023-09-30-0001175151 ctso:UnitedStatesGovernmentAgenciesMember-us-gaap:GrantMember-country:US-2023-01-01-2023-09-30-0001175151 ctso:DistributorsAndStrategicPartnersMember-us-gaap:ProductMember-ctso:AllOtherCountriesMember-2023-01-01-2023-09-30-0001175151 ctso:DirectMember-us-gaap:ProductMember-ctso:AllOtherCountriesMember-2023-01-01-2023-09-30-0001175151-ctso:DirectMember-us-gaap:ProductMember-country:US-2023-01-01-2023-09-30-0001175151-ctso:DirectMember-us-gaap:ProductMember-country:DE-2023-01-01-2023-09-30-0001175151-us-gaap:ProductMember-ctso:AllOtherCountriesMember-2023-01-01-2023-09-30-0001175151-us-gaap:ProductMember country:US-2023-01-01-2023-09-30-0001175151-us-gaap:ProductMember-country:DE-2023-01-01-2023-09-30-0001175151-us-gaap:GrantMember

country:US 2023-01-01 2023-09-30 0001175151 ctso:DistributorsAndStrategicPartnersMember us-gaap:ProductMember 2023-01-01 2023-09-30 0001175151 ctso:DirectMember us-gaap:ProductMember 2023-01-01 2023-09-30 0001175151 us-gaap:ProductMember 2023-01-01 2023-09-30 0001175151 us-gaap:GrantMember 2023-01-01 2023-09-30 0001175151 ctso:UnitedStatesGovernmentAgenciesMember 2023-01-01 2023-09-30 0001175151 ctso:OtherSalesMember 2023-01-01 2023-09-30 0001175151 ctso:DistributorsAndStrategicPartnersMember 2023-01-01 2023-09-30 0001175151 ctso:DirectMember 2023-01-01 2023-09-30 0001175151 ctso:CytoSorbSalesMember 2023-01-01 2023-09-30 0001175151 ctso:JefferiesLlcAndB.RileyFbrIncMember 2023-01-01 2023-12-31 0001175151 2019-06-30 0001175151 ctso:JefferiesLlcAndB.RileyFbrIncMember 2024-07-01 2024-09-30 0001175151 ctso:JefferiesLlcAndB.RileyFbrIncMember 2024-01-01 2024-09-30 0001175151 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001175151 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0001175151 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001175151 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001175151 ctso:CytosorbentsEuropeGmbhMember 2020-04-01 0001175151 ctso:CytosorbentsMedicalIncMember country:US ctso:OperatingLeaseInitialEarlyTermMember 2021-03-01 2021-03-31 0001175151 ctso:CytosorbentsMedicalIncMember country:US ctso:OperatingLeaseFirstYearOfRemainingLeaseTermMember 2021-03-01 2021-03-31 0001175151 ctso:CytosorbentsMedicalIncMember country:US ctso:OperatingLeaseEarlyTermMember 2021-03-01 2021-03-31 0001175151 ctso:CytosorbentsEuropeGmbhMember 2021-01-01 2021-01-31 0001175151 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001175151 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001175151 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001175151 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001175151 ctso:TwoThousandAndTwentyTwoSuccessFeeLetterMember ctso:ThirdTrancheMember 2024-09-30 0001175151 ctso:TwoThousandAndTwentyTwoSuccessFeeLetterMember ctso:SecondTrancheMember 2024-09-30 0001175151 ctso:TwoThousandAndTwentyTwoSuccessFeeLetterMember ctso:FirstTrancheMember 2024-09-30 0001175151 ctso:CytosorbentsEuropeGmbhMember 2021-04-01 0001175151 ctso:CytosorbentsMedicalIncMember country:US 2021-04-01 0001175151 ctso:LoanAndSecurityAgreementTrancheOneMember ctso:AvenueVentureOpportunitiesFundL.pMember 2024-09-30 0001175151 ctso:LoanAndSecurityAgreementTrancheOneMember ctso:AvenueVentureOpportunitiesFundIiL.pMember 2024-09-30 0001175151 ctso:LoanAndSecurityAgreementTrancheOneMember 2024-09-30 0001175151 ctso:CytosorbentsMedicalIncMember country:US us-gaap:LetterOfCreditMember 2021-04-30 0001175151 us-gaap:LetterOfCreditMember 2024-09-30 0001175151 us-gaap:CreditCardMember 2024-09-30 0001175151 us-gaap:CargoAndFreightMember 2024-07-01 2024-09-30 0001175151 us-gaap:CargoAndFreightMember 2024-01-01 2024-09-30 0001175151 us-gaap:CargoAndFreightMember 2023-07-01 2023-09-30 0001175151 us-gaap:CargoAndFreightMember 2023-01-01 2023-09-30 0001175151 us-gaap:ProductMember 2024-09-30 0001175151 us-gaap:GrantMember 2024-09-30 0001175151 us-gaap:ProductMember 2023-12-31 0001175151 us-gaap:GrantMember 2023-12-31 0001175151 srt:MinimumMember 2019-06-30 0001175151 srt:MaximumMember 2019-06-30 0001175151 2023-09-30 0001175151 2022-12-31 0001175151 ctso:CytosorbentsEuropeGmbhMember 2021-01-31 0001175151 ctso:StockOptionsAndWarrantsMember 2024-01-01 2024-09-30 0001175151 ctso:StockOptionsAndWarrantsMember 2023-01-01 2023-09-30 0001175151 ctso:SeniorManagersMember us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001175151 ctso:NamedExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001175151 ctso:CertainNamedExecutiveOfficersAndSeniorManagersTwoMember us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001175151 ctso:CertainNamedExecutiveOfficersAndSeniorManagersMember us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001175151 ctso:CertainEmployeesMember us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001175151 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001175151 ctso:SeniorManagersMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001175151 ctso:NamedExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001175151 ctso:CertainNamedExecutiveOfficersAndSeniorManagersTwoMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001175151 ctso:CertainNamedExecutiveOfficersAndSeniorManagersMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001175151 ctso:CertainEmployeesMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001175151 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001175151 ctso:SeniorManagersMember us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001175151 ctso:NamedExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001175151 ctso:CertainNamedExecutiveOfficersAndSeniorManagersTwoMember us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001175151 ctso:CertainNamedExecutiveOfficersAndSeniorManagersMember us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001175151 ctso:CertainEmployeesMember us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001175151 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001175151 ctso:SeniorManagersMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001175151 ctso:NamedExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001175151 ctso:CertainNamedExecutiveOfficersAndSeniorManagersTwoMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001175151 ctso:CertainNamedExecutiveOfficersAndSeniorManagersMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001175151 ctso:CertainEmployeesMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001175151 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001175151 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001175151 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001175151 2024-11-05 0001175151 srt:MinimumMember 2024-01-01 2024-09-30 0001175151 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001175151 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001175151 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001175151 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001175151 ctso:EmployeeOneMember us-gaap:CommonStockMember 2024-04-08 2024-04-08 0001175151 srt:DirectorMember us-gaap:CommonStockMember 2024-04-02 2024-04-02 0001175151 ctso:SeniorManagersMember us-gaap:CommonStockMember 2024-04-02 2024-04-02 0001175151 ctso:EmployeeTwoMember us-gaap:CommonStockMember 2024-04-02 2024-04-02 0001175151 ctso:EmployeeOneMember us-gaap:CommonStockMember 2024-04-02 2024-04-02 0001175151 srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-03-29 2024-03-29 0001175151 srt:MinimumMember ctso:LoanAndSecurityAgreementMember 2024-09-30 0001175151 srt:MaximumMember ctso:LoanAndSecurityAgreementMember 2024-09-30 0001175151 srt:MinimumMember ctso:TwoThousandAndEighteenSuccessFeeLetterMember ctso:WesternAllianceBankMember 2024-01-01 2024-09-30 0001175151 srt:MaximumMember ctso:TwoThousandAndEighteenSuccessFeeLetterMember ctso:WesternAllianceBankMember 2024-01-01 2024-09-30 0001175151 ctso:CytosorbentsMedicalIncMember 2021-03-01 2021-03-31 0001175151 ctso:CytosorbentsMedicalIncMember country:US 2021-03-31 0001175151 ctso:CytosorbentsMedicalIncMember country:US 2021-03-01 2021-03-31 0001175151 ctso:CytosorbentsMedicalIncMember 2021-03-31 0001175151 ctso:DistributorsAndStrategicPartnersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001175151 ctso:DistributorsAndStrategicPartnersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001175151 ctso:DistributorsAndStrategicPartnersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001175151 ctso:DistributorsAndStrategicPartnersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001175151 ctso:DistributorsAndStrategicPartnersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001175151 ctso:DistributorsAndStrategicPartnersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001175151 ctso:TwoThousandAndTwentyTwoSuccessFeeLetterMember ctso:ThirdTrancheMember 2024-01-01 2024-09-30 0001175151 ctso:TwoThousandAndTwentyTwoSuccessFeeLetterMember ctso:SecondTrancheMember 2024-01-01 2024-09-30 0001175151 ctso:TwoThousandAndTwentyTwoSuccessFeeLetterMember ctso:FirstTrancheMember 2024-01-01 2024-09-30 0001175151 ctso:TwoThousandAndEighteenSuccessFeeLetterMember ctso:WesternAllianceBankMember 2024-01-01 2024-09-30 0001175151 ctso:LoanAndSecurityAgreementMember 2024-07-01 2024-09-30 0001175151 srt:MaximumMember 2024-01-01 2024-09-30 0001175151 2024-07-01 2024-09-30 0001175151 2023-07-01 2023-09-30 0001175151 ctso:PrepaymentMadeOnOrAfterFundingDateMember ctso:LoanAndSecurityAgreementMember 2024-01-01 2024-09-30 0001175151 ctso:PrepaymentMadeFromFirstAnniversaryToSecondAnniversaryMember ctso:LoanAndSecurityAgreementMember 2024-01-01 2024-09-30 0001175151 ctso:PrepaymentMadeAfterSecondAnniversaryMember ctso:LoanAndSecurityAgreementMember 2024-01-01 2024-09-30 0001175151 ctso:LoanAndSecurityAgreementTrancheTwoMember 2024-09-30 0001175151 ctso:LoanAndSecurityAgreementMember 2024-09-30 0001175151 ctso:ScenarioTwoLimitationRelatingToMarketCapitalizationMember ctso:JefferiesLlcAndB.RileyFbrIncMember 2021-12-30 2021-12-30 0001175151 ctso:ScenarioOneNoLimitationRelatingToMarketCapitalizationMember ctso:JefferiesLlcAndB.RileyFbrIncMember 2021-12-30 2021-12-30 0001175151 ctso:JefferiesLlcAndB.RileyFbrIncMember 2024-09-30 0001175151 2024-06-28 2024-06-28 0001175151 ctso:LoanAndSecurityAgreementMember 2024-01-01 2024-09-30 0001175151 ctso:LoanAndSecurityAgreementMember 2024-06-28 0001175151 2024-07-26 0001175151 2021-07-14 0001175151 country:DE 2021-09-01 2021-09-30 0001175151 ctso:CytosorbentsEuropeGmbhMember 2021-04-01 2021-04-01 0001175151 2024-01-01 2024-09-30 0001175151 2023-01-01 2023-09-30 0001175151 2024-09-30 0001175151 2023-12-31 iso4217:USD shares iso4217:USD shares pure ctso:Distributor ctso:item ctso:segment iso4217:USN utr:sqm P0Y P0Y P0Y P0Y 0.005 0001175151 --12-31 2024 Q3 false P5D 11600000 594000 P5D P5D true 0.0025 0.0025 0.005 0.0025 0.0025 P3Y http://fasb.org/us-gaap/2024#PrimeRateMember 690709 10-Q true 2024-09-30 false 001-36792 CYTOSORBENTS CORPORATION DE 98-0373793 305 College Road East Princeton, NJ 08540 732 329-8885 Common Stock, $0.001 par value per share CTSO NASDAQ Yes Yes Non-accelerated Filer true false false 54679569 5685328 14131137 160246 49663 6632590 6057072 3247756 3680129 1031694 1834485 16597368 25702823 9269899 10056354 6483958 1483958 11651563 12058896 3801223 3958603 47804011 53260634 2338143 3802170 2500000 431997 373636 5660051 7870149 8430191 14545955 12568745 12896659 13805985 2542857 34804921 29985471 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 100000000 100000000 54500613 54500613 54240265 54240265 54498 54240 308441887 305196874 -156925 529321 -295340370 -282505272 12999090 23275163 47804011 53260634 8586274 7709085 26381455 23681183 26521 44931 62649 55285 8612795 7754016 26444104 23736468 777593

1056831 2627212 3944696 9390388 8810847 29071316 27681164 4108773 3203981 10716394 10600421 5281615 5606866 18354922 17080743 1851230 3749197 5619040 11632416 823914 1103475 2325351 2957738 7002718 8104392 23151118 24358417 9677862 12957064 31095509 38948571 -4396247 -7350198 -12740587 -21867828 -588153 -33670 -774903 -105662 2650309 -1809652 680392 -733997 35000 2062156 -1843322 -94511 -804659 -2334091 -9193520 -12835098 -22672487 -2334091 -9193520 -12835098 -22672487 -0.04 -0.04 -0.21 -0.21 -0.24 -0.24 -0.52 -0.52 54453006 54453006 44373969 44373969 54340583 54340583 44024483 44024483 -2334091 -9193520 -12835098 -22672487 -2330743 1655674 -686246 654792 -4664834 -7537846 -13521344 -22017695 54306415 54306 307514758 2173818 -293006279 16736603 781881 781881 -2330743 -2330743 41444 41444 194198 192 186692 186884 -2334091 -2334091 54500613 54498 308441887 -156925 -295340370 12999090 54240265 54240 305196874 529321 -282505272 23275163 2344671 2344671 -686246 -686246 53290 53 11741 11794 690709 690709 207058 205 197892 198097 -12835098 -12835098 54500613 54498 308441887 -156925 -295340370 12999090 44193696 44193 290199035 1328313 -267476845 24094696 1086163 1086163 1655674 1655674 162078 162 632232 632394 7962 9 15920 15929 74773 75 220211 220286 -9193520 -9193520 44438509 44439 292153561 2983987 -276670365 18511622 43635715 43635 287000021 2329195 -253997878 35374973 2486679 2486679 654792 654792 590348 591 2106528 2107119 82355 83 213224 213307 130091 130 403811 403941 56702 56702 -22672487 -22672487 44438509 44439 292153561 2983987 -276670365 18511622 -12835098 -22672487 111422 32143 132351 58014 96268 -160999 1180717 1067797 137780 166321 313414 475621 107272 14459 2344671 2486679 680392 -733997 628510 603286 -429004 -471822 -504530 -1370510 -1135 -3165684 1047700 -12085642 -15247725 215158 442618 330079 357696 -545237 -800314 15000000 5000000 150000 697950 -11794 -2050417 213307 9163844 2263724 21226 -1205 -3445809 -13785520 15615095 23832026 12169286 10046506 771875 275575 690709 198097 403941 1. BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements include the accounts of the Company as of September 30, 2024 and December 31, 2023, and for the three and nine months ended September 30, 2024 and 2023. The Company's condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X, and; therefore, do not include all information and footnotes necessary for a fair presentation of consolidated financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States ("U.S. GAAP") and should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2023, which are included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments, for a fair presentation of the Company's consolidated financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The results for the three and nine months ended September 30, 2024 and 2023, are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period. As of September 30, 2024, the Company's cash, cash equivalents and restricted cash balances were approximately $12.2 million, including approximately $5.7 million in cash and cash equivalents and approximately $6.5 million in restricted cash, of which the unrestricted portion is not expected to fund the Company's operations beyond the next twelve months from the issuance of these consolidated financial statements. This matter raises substantial doubt about the Company's ability to continue as a going concern. As a result, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company continues to pursue additional milestones related to its recently announced Avenue Capital Group debt facility that would increase its unrestricted cash position by up to $10 million. If these milestones are not achieved, the Company will need to raise additional capital to support our ongoing operations in the future. Meanwhile the Company continues to evaluate other traditional and alternative sources of capital, including additional less or non-dilutive debt financing, royalty financing, strategic or direct investments, equity financing, and/or combinations thereof. There can be no assurance that management will be successful in these endeavors. 12200000 5700000 6500000 10000000 2. PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Please see Note 2 to the Company's consolidated financial statements included in the Company's Annual Report on Form 10 - K for the year ended December 31, 2023, filed with the Securities and Exchange Commission ("SEC") on March 14, 2024, for a description of all significant accounting policies. Nature of Business The Company is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. The Company, through its subsidiary CytoSorbents Medical, Inc. (formerly known as CytoSorbents, Inc.), is engaged in the research, development and commercialization of medical devices with its blood purification technology platform which incorporates a proprietary adsorbent, porous polymer technology. The Company, through its wholly-owned European subsidiary, CytoSorbents Europe GmbH, conducts sales and marketing related operations for the CytoSorb device. Basis of Consolidation and Foreign Currency Translation The consolidated financial statements include the accounts of CytoSorbents Corporation and its wholly-owned subsidiaries, CytoSorbents Medical, Inc. and CytoSorbents Europe GmbH. All significant intercompany transactions and balances have been eliminated in consolidation. Translation gains and losses resulting from the process of remeasuring into the United States of America dollar the foreign currency financial statements of the European subsidiary, for which the United States of America dollar is the functional currency, are included in operations. The Euro is the functional currency of the European Subsidiary. Foreign currency transaction gain (loss) included in net loss amounted to approximately $2,650,000 and $(1,810,000) for the three months ended September 30, 2024 and 2023, respectively. Foreign currency transaction gain (loss) included in net loss amounted to approximately $680,000 and $(734,000) for the nine months ended September 30, 2024 and 2023, respectively. The Company translates assets and liabilities of all of its foreign subsidiaries at the exchange rate in effect at the condensed consolidated balance sheet date. The Company translates revenue and expenses at the daily average exchange rates. The Company includes accumulated net translation adjustments in accumulated other comprehensive income (loss) as a component of stockholders' equity. Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The following table provides a reconciliation of cash and cash equivalents and restricted cash to amounts shown in the consolidated balance sheets:
<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-

space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:65.84%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5,685,328 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"> 14,131,137 </td></tr><tr><td style="vertical-align:bottom;width:65.84%;margin:0pt;padding:0pt;"> Restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,483,958 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,483,958 </td></tr><tr><td style="vertical-align:bottom;width:65.84%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash, cash equivalents and restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,169,286</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,615,095 </td></tr></table> . Restricted Cash The Company’s total restricted cash in the amount of $6,483,958 consists of cash of $5,000,000 which is restricted in accordance with the terms of the debt agreement with Avenue Capital Group (see Note 5), cash of $1,467,458 that the Company is obligated to maintain as collateral for the outstanding letter of credit with Bridge Bank that was provided to the landlord of the College Road facility as security and cash of $16,500 that the Company is obligated to maintain as collateral for the credit limit on the Company’s credit card accounts. Grants and Accounts Receivable Trade accounts receivable consist of amounts due from direct customers, distributors and agencies of the U.S. government and are presented at net realizable value. At each balance sheet date, the Company estimates an expected allowance for credit losses inherent in the Company’s accounts receivable portfolio based on historical experience, specific allowances for known troubled accounts, and other available evidence. In addition, also at each reporting date, this estimate is updated to reflect any changes in credit risk since the receivable was initially recorded. This estimate is calculated on a pooled basis where similar risk characteristics exist. The Company has identified the following portfolio segments: direct customers, distributors/strategic partners and the U.S. government. A fixed reserve percentage for each pool is derived from a review of the Company’s historical losses in relation to the total pool. This estimate is adjusted quarterly for management’s assessment of current conditions, reasonable and supportable forecasts regarding future events, and any other factors deemed relevant by the Company. The Company believes historical loss information is a reasonable starting point in which to calculate the expected allowance for credit losses as the Company’s portfolio segments have remained constant over the Company’s historical evaluation period. The Company writes off receivables when there is information that indicates the debtor is facing significant financial difficulty and there is no possibility of recovery. If any recoveries are made from any accounts previously written off, they are recognized as an offset to credit loss expense in the year of recovery. The total amount of write-offs was immaterial to the consolidated financial statements as a whole for the three and nine months ended September 30, 2024 and 2023. The allowance for credit losses reflects accounts receivable balances that are written off when management determines they are uncollectible. The allowance for credit losses is measured on a collective (pool) basis when similar risk characteristics exist, and measures the allowance for credit losses using the following methods: Direct Customers—The Company measures expected credit losses on direct customer receivables using an aging methodology. The risk of loss for direct customer receivables is low based on the Company’s historical experience. The estimate of expected credit losses considers historical credit loss information that is adjusted for current conditions and supportable forecasts. Distributors/Strategic Partners—The Company measures expected credit losses on distributor receivables using an individual reserve methodology. The risk of loss in this portfolio is low based on the Company’s historical experience. The estimate of expected credit losses considers the past payment history of each distributor. U.S. Government— These receivables are related to the Company’s government grants. The Company measures expected credit losses on these receivables using an individual reserve methodology. The risk of loss in this portfolio is very low based on the Company’s historical experience, as these receivables are supported by approved grant award contracts. Inventories Inventories are valued at the lower of cost or net realizable value under the first in, first out (FIFO) method. At September 30, 2024 and December 31, 2023, the Company’s inventory was comprised of finished goods, which amounted to $1,430,325 and $2,155,457, respectively; work in process, which amounted to $1,049,319 and $838,871, respectively; and raw materials, which amounted to $768,112 and $685,801, respectively. Devices used in clinical trials or for research and development purposes are removed from inventory and charged to research and development expenses at the time of their use. Donated devices are removed from inventory and charged to selling, general and administrative expenses. Impairment or Disposal of Long-Lived Assets The Company assesses the impairment of patents and other long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. During the three months ended September 30, 2024 and 2023, the Company recorded impairment charges of approximately $64,000 and $183,000, respectively, and during the nine months ended September 30, 2024 and 2023, the Company recorded impairment charges of approximately $313,000 and $476,000, respectively, related to the impairment of certain issued patents and pending patent applications in certain specific jurisdictions and the abandonment of certain pending patent application costs in the ordinary course of business. This charge is included in legal, financial and other consulting in the consolidated statements of operations and comprehensive loss. Income Taxes The Company has not recorded income tax expense or income tax

benefit for the three and nine months ended September 30, 2024, and 2023 due to the generation of net operating losses, the benefits of which have been fully reserved. Deferred income taxes are accounted for using the balance sheet approach, which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that a future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership. The Company follows accounting standards associated with uncertain tax positions. The Company had no unrecognized tax benefits at September 30, 2024. The Company is accounting for an uncertain tax position of approximately $2.1 million for the year ended December 31, 2023. The Company files tax returns in the U.S. federal and state jurisdictions. The Company utilizes the Technology Business Tax Certificate Transfer Program to sell a portion of its New Jersey Net Operating Loss carryforwards to an industrial company. Concentration of Credit Risk The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation ("FDIC"). Beginning in April of 2023, the Company joined the IntraFi network, and established an Insured Cash Sweep ("ICS") account whereby all cash that was previously held in the Company's money market account at Bridge Bank is swept daily in increments of less than $250,000 and deposited in a number of IntraFi's 4,000 member banks. This arrangement provides FDIC insurance coverage for all of the cash balances previously held in the money market account, which represents all of the cash and cash equivalents held at Bridge Bank. This arrangement excludes the restricted cash balances. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances. A significant portion of the Company's revenues are from product sales in Germany. Substantially all of the Company's grant and other income are from government agencies in the United States. (See Note 4 for further information relating to the Company's revenue.) As of September 30, 2024, two distributors accounted for approximately 31% of outstanding grants and accounts receivable. As of December 31, 2023, one distributor accounted for approximately 19% of outstanding grants and accounts receivable. For the three months ended September 30, 2024 and 2023, no distributor or direct customers accounted for more than 10% of the Company's total revenue. For the nine months ended September 30, 2024 and 2023, one distributor accounted for approximately 10% for each period, of the Company's total revenue. Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance in ASC 480 "Distinguishing Liabilities From Equity" ("ASC 480") and ASC 815 "Derivatives and Hedging" ("ASC 815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's own ordinary shares and whether the warrant holders could potentially require "net cash settlement" in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance, and will remain as a component of equity thereafter. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. The warrants issued upon the closing of the Company's December 13, 2023 offering and the closing of the Company's June 2024 debt financing both met the criteria for equity classification under ASC 815. Accordingly, these warrants have been classified as equity as of September 30, 2024 and December 31, 2023. Shipping and Handling Costs The cost of shipping product to customers and distributors is typically borne by the customer or distributor. The Company records other shipping and handling costs in cost of revenue. Total freight costs amounted to approximately $89,000 and $140,000, respectively, for the three months ended September 30, 2024 and 2023, and $267,000 and $341,000, respectively, for the nine months ended September 30, 2024 and 2023. Effect of Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, "Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity's Own Equity (Subtopic 815-40)" ("ASU 2020-06"). ASU2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity's own equity. The ASU is part of the FASB's simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASU's amendments are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. The Company adopted the provisions of ASU 2020-06 on January 1, 2024. This did not have a material impact on the Company's consolidated financial statements. In December 2023, the FASB issued ASU No. 2023-09 entitled "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". This ASU provides guidance related to additional disclosures that will be required related to income taxes. The updated guidance is effective for public entities for fiscal years beginning after December 15, 2024. This ASU will result in additional disclosures in the Company's consolidated financial statements related to income taxes in 2025. In November 2023, the FASB issued ASU No. 2023-07 ("ASU 2023-07"), "Improvements to Reportable Segment Disclosures". The guidance primarily will require enhanced disclosures about significant segment expenses. All disclosure requirements under ASU 2023-07 and existing segment disclosures in ASC 280, "Segment Reporting" are also required for public entities with a single reportable segment. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. A retrospective approach is required to be applied to all prior periods presented in the financial statements. The Company plans to adopt the provisions of ASU 2023-07 in the first quarter of fiscal 2025 and continues to evaluate the disclosure requirements related to the new standard. On April 3, 2024, the Financial Accounting Standards Board (the "FASB") began a project related to the accounting and reporting of government grants. The FASB has decided to pursue an International Accounting Standards ("IAS") 20 accounting model. Under IAS 20, a grant relating to income may be reported separately as 'other income' or deducted from the related expense. The FASB expects to issue and exposure draft of a proposed ASU in the fourth quarter of 2024. The company is evaluating its accounting and reporting policy for government grants relative to this project and the requirements of IAS 20. Nature of Business The Company is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. The Company, through its subsidiary CytoSorbents Medical, Inc. (formerly known as CytoSorbents, Inc.), is engaged in the research, development and commercialization of medical devices with its blood purification technology platform which incorporates a proprietary adsorbent, porous polymer technology. The Company, through its wholly-owned European subsidiary, CytoSorbents Europe GmbH, conducts sales and marketing related operations for the CytoSorb device. Basis of Consolidation and Foreign Currency Translation The consolidated financial statements include the accounts of CytoSorbents Corporation and its wholly-owned subsidiaries, CytoSorbents Medical, Inc. and CytoSorbents Europe GmbH. All significant intercompany transactions and balances have been eliminated in consolidation. Translation gains and losses resulting from the process of remeasuring into the United States of America dollar the foreign currency financial statements of the European subsidiary, for which the United States of America dollar is the functional currency, are included in operations. The Euro is the functional currency of the European Subsidiary. Foreign currency transaction gain (loss) included in net loss amounted to approximately $2,650,000 and $(1,810,000) for the three months ended September 30, 2024 and 2023, respectively. Foreign currency transaction gain (loss) included in net loss amounted to approximately $680,000 and $(734,000) for the nine months ended September 30, 2024 and 2023, respectively. The Company translates assets and liabilities of all of its foreign subsidiaries at the exchange rate in effect at the condensed consolidated balance sheet date. The Company translates revenue and expenses at the daily average exchange rates. The Company includes accumulated net translation adjustments in accumulated other comprehensive income (loss) as a component of stockholders' equity. 2650000 -1810000 680000 -734000 Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The following table provides a reconciliation of cash and cash equivalents and restricted cash to amounts shown in the consolidated balance sheets: <table

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:65.84%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5,685,328 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"> 14,131,137 </td></tr><tr><td style="vertical-align:bottom;width:65.84%;margin:0pt;padding:0pt;"> Restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,483,958 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,483,958 </td></tr><tr><td style="vertical-align:bottom;width:65.84%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash, cash equivalents and restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,169,286</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,615,095 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman', 'Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:65.84%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5,685,328 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"> 14,131,137 </td></tr><tr><td style="vertical-align:bottom;width:65.84%;margin:0pt;padding:0pt;"> Restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,483,958 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,483,958 </td></tr><tr><td style="vertical-align:bottom;width:65.84%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash, cash equivalents and restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,169,286</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,615,095 </td></tr></table> 5685328 14131137 6483958 1483958 12169286 15615095 Restricted Cash The Company's total restricted cash in the amount of $6,483,958 consists of cash of $5,000,000 which is restricted in accordance with the terms of the debt agreement with Avenue Capital Group (see Note 5), cash of $1,467,458 that the Company is obligated to maintain as collateral for the outstanding letter of credit with Bridge Bank that was provided to the landlord of the College Road facility as security and cash of $16,500 that the Company is obligated to maintain as collateral for the credit limit on the Company's credit card accounts. 6483958 5000000 1467458 16500 Grants and Accounts Receivable Trade accounts receivable consist of amounts due from direct customers, distributors and agencies of the U.S. government and are presented at net realizable value. At each balance sheet date, the Company estimates an expected allowance for credit losses inherent in the Company's accounts receivable portfolio based on historical experience, specific allowances for known troubled accounts, and other available evidence. In addition, also at each reporting date, this estimate is updated to reflect any changes in credit risk since the receivable was initially recorded. This estimate is calculated on a pooled basis where similar risk characteristics exist. The Company has identified the following portfolio segments: direct customers, distributors/strategic partners and the U.S. government. A fixed reserve percentage for each pool is derived from a review of the Company's historical losses in relation to the total pool. This estimate is adjusted quarterly for management's assessment of current conditions, reasonable and supportable forecasts regarding future events, and any other factors deemed relevant by the Company. The Company believes historical loss information is a reasonable starting point in which to calculate the expected allowance for credit losses as the Company's portfolio segments have remained constant over the Company's historical evaluation period. The Company writes off receivables when there is information that indicates the debtor is facing significant financial difficulty and there is no possibility of recovery. If any recoveries are made from any accounts previously written off, they are recognized as an offset to credit loss expense in the year of recovery. The total amount of write-offs was immaterial to the consolidated financial statements as a whole for the three and nine months ended September 30, 2024 and 2023. The allowance for credit losses reflects accounts receivable balances that are written off when management determines they are uncollectible. The allowance for credit losses is measured on a collective (pool) basis when similar risk characteristics exist, and measures the allowance for credit losses using the following methods: Direct Customers—The Company measures expected credit losses on direct customer receivables using an aging methodology. The risk of loss for direct customer receivables is low based on the Company's historical experience. The estimate of expected credit losses considers historical credit loss information that is adjusted for current conditions and supportable forecasts. Distributors/Strategic Partners—The Company measures expected credit losses on distributor receivables using an individual reserve methodology. The risk of loss in this portfolio is low based on the Company's historical experience. The estimate of expected credit losses considers the past payment history of each distributor. U.S. Government— These receivables are related to the Company's government grants. The Company measures expected credit losses on these receivables using an individual reserve methodology. The risk of loss in this portfolio is very low based on the Company's historical experience, as these receivables are supported by approved grant award contracts. Inventories Inventories are valued at the lower of cost or net realizable value under the first in, first out (FIFO) method. At September 30, 2024 and December 31, 2023, the Company's inventory was comprised of finished goods, which amounted to $1,430,325 and $2,155,457, respectively; work in process, which amounted to $1,049,319 and $838,871, respectively; and raw materials, which amounted to $768,112 and $685,801, respectively. Devices used in clinical trials or for research and development purposes are removed from inventory and charged to research and development expenses at the time of their use. Donated devices are removed from inventory and charged to selling, general and administrative expenses. 1430325 2155457 1049319 838871 768112 685801 Impairment or Disposal of Long-Lived Assets The Company assesses the impairment of patents and other long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. During the three months ended September 30, 2024 and 2023, the Company recorded impairment charges of approximately $64,000 and $183,000, respectively, and during the nine months ended September 30, 2024 and 2023, the Company recorded impairment charges of approximately $313,000 and $476,000, respectively, related to the

impairment of certain issued patents and pending patent applications in certain specific jurisdictions and the abandonment of certain pending patent application costs in the ordinary course of business. This charge is included in legal, financial and other consulting in the consolidated statements of operations and comprehensive loss. 64000 183000 313000 476000 Income Taxes The Company has not recorded income tax expense or income tax benefit for the three and nine months ended September 30, 2024, and 2023 due to the generation of net operating losses, the benefits of which have been fully reserved. Deferred income taxes are accounted for using the balance sheet approach, which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that a future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership. The Company follows accounting standards associated with uncertain tax positions. The Company had no unrecognized tax benefits at September 30, 2024. The Company is accounting for an uncertain tax position of approximately $2.1 million for the year ended December 31, 2023. The Company files tax returns in the U.S. federal and state jurisdictions. The Company utilizes the Technology Business Tax Certificate Transfer Program to sell a portion of its New Jersey Net Operating Loss carryforwards to an industrial company. 0 0 0 0 0 0 2100000 Concentration of Credit Risk The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation ("FDIC"). Beginning in April of 2023, the Company joined the IntraFi network, and established an Insured Cash Sweep ("ICS") account whereby all cash that was previously held in the Company's money market account at Bridge Bank is swept daily in increments of less than $250,000 and deposited in a number of IntraFi's 4,000 member banks. This arrangement provides FDIC insurance coverage for all of the cash balances previously held in the money market account, which represents all of the cash and cash equivalents held at Bridge Bank. This arrangement excludes the restricted cash balances. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances. A significant portion of the Company's revenues are from product sales in Germany. Substantially all of the Company's grant and other income are from government agencies in the United States. (See Note 4 for further information relating to the Company's revenue.) As of September 30, 2024, two distributors accounted for approximately 31% of outstanding grants and accounts receivable. As of December 31, 2023, one distributor accounted for approximately 19% of outstanding grants and accounts receivable. For the three months ended September 30, 2024 and 2023, no distributor or direct customers accounted for more than 10% of the Company's total revenue. For the nine months ended September 30, 2024 and 2023, one distributor accounted for approximately 10% for each period, of the Company's total revenue. 4000 2 0.31 1 0.19 0 0 0.10 0.10 1 1 0.10 0.10 Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance in ASC 480 "Distinguishing Liabilities From Equity" ("ASC 480") and ASC 815 "Derivatives and Hedging" ("ASC 815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's own ordinary shares and whether the warrant holders could potentially require "net cash settlement" in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance, and will remain as a component of equity thereafter. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. The warrants issued upon the closing of the Company's December 13, 2023 offering and the closing of the Company's June 2024 debt financing both met the criteria for equity classification under ASC 815. Accordingly, these warrants have been classified as equity as of September 30, 2024 and December 31, 2023. Shipping and Handling Costs The cost of shipping product to customers and distributors is typically borne by the customer or distributor. The Company records other shipping and handling costs in cost of revenue. Total freight costs amounted to approximately $89,000 and $140,000, respectively, for the three months ended September 30, 2024 and 2023, and $267,000 and $341,000, respectively, for the nine months ended September 30, 2024 and 2023. 89000 140000 267000 341000 Effect of Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, "Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity's Own Equity (Subtopic 815-40)" ("ASU 2020-06"). ASU2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity's own equity. The ASU is part of the FASB's simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASU's amendments are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. The Company adopted the provisions of ASU 2020-06 on January 1, 2024. This did not have a material impact on the Company's consolidated financial statements. In December 2023, the FASB issued ASU No. 2023-09 entitled "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". This ASU provides guidance related to additional disclosures that will be required related to income taxes. The updated guidance is effective for public entities for fiscal years beginning after December 15, 2024. This ASU will result in additional disclosures in the Company's consolidated financial statements related to income taxes in 2025. In November 2023, the FASB issued ASU No. 2023-07 ("ASU 2023-07"), "Improvements to Reportable Segment Disclosures". The guidance primarily will require enhanced disclosures about significant segment expenses. All disclosure requirements under ASU 2023-07 and existing segment disclosures in ASC 280, "Segment Reporting" are also required for public entities with a single reportable segment. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. A retrospective approach is required to be applied to all prior periods presented in the financial statements. The Company plans to adopt the provisions of ASU 2023-07 in the first quarter of fiscal 2025 and continues to evaluate the disclosure requirements related to the new standard. On April 3, 2024, the Financial Accounting Standards Board (the "FASB") began a project related to the accounting and reporting of government grants. The FASB has decided to pursue an International Accounting Standards ("IAS") 20 accounting model. Under IAS 20, a grant relating to income may be reported separately as 'other income' or deducted from the related expense. The FASB expects to issue and exposure draft of a proposed ASU in the fourth quarter of 2024. The company is evaluating its accounting and reporting policy for government grants relative to this project and the requirements of IAS 20. 3. STOCKHOLDERS' EQUITY Preferred Stock In June 2019, the Company amended and restated its certificate of incorporation. The amended and restated certificate of incorporation authorizes the issuance of up to 5,000,000 shares of "blank check" preferred stock, with such designation rights and preferences as may be determined from time to time by the Board of Directors. Common Stock In June 2019, the Company amended and restated its certificate of incorporation. The amended and restated certificate of incorporation increased the number of shares of common stock authorized for issuance from 50,000,000 shares to 100,000,000 shares. Shelf Registration On July 14, 2021, the Company filed a registration statement on Form S-3 with the SEC, which was amended on July 20, 2021 and declared effective by the SEC on July 27, 2021 (as amended, the "2021 Shelf"). The 2021 Shelf enables the Company to offer and sell, in one or more offerings, any combination of common stock, preferred stock, senior or subordinated debt securities, warrants and units, up to a total dollar amount of $150 million and expires after three years. On July 26, 2024, the Company filed a registration statement on Form S-3 with the SEC (the "2024 Shelf"), which enables the Company to offer and sell in one or more offerings, any combination of common stock, preferred stock, senior or subordinated debt securities, warrants and units, up to a total dollar amount of $150 million. On September 26, 2024, the Company filed Amendment No. 1 to the Form S-3 with the SEC. The 2024 Shelf was declared effective by the SEC on September 30, 2024. Because the Company's market capitalization is less than $75 million, it will be subject to baby shelf rules which limit the amount of securities sales the Company can make to one-third of its public market float over a 12-month period. <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Open Market Sale Agreement with Jefferies LLC On December 30, 2021, the Company entered into an Open Market Sale Agreement (the "Sale Agreement") with Jefferies LLC (the "Agent"), pursuant to which the Company may sell, from time to time, at its option, shares of the Company's common stock having an aggregate offering price of up to $25 million through the Agent, as the Company's sales agent. However, as a result of limitations related to our market capitalization discussed above, the Company may offer and sell shares of the Company's common stock having an aggregate offering price of up to approximately $19,700,000 from time to time through the Agent. If the Company's public float increases above $75,000,000, the Company may sell additional amounts under the Sales Agreement. All shares of the Company's common stock offered and sold, or to be offered and sold under the Sale Agreement will be issued and sold pursuant to the Company's 2024 Shelf by methods deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, in block transactions or if specified by the Company, in privately negotiated transactions. Subject to the terms of the Sales Agreement, the Agent is required to use its commercially reasonable efforts consistent with their normal sales and trading practices to sell the shares of the Company's common stock from time to time, based upon the Company's instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company is required to pay the Agent a commission of up to 3.0% of the gross proceeds from the sale of the shares of the Company's common stock sold thereunder, if any. There were no sales under the Sale Agreement during the year ended December 31, 2022. During the year ended December 31, 2023, the Company sold 2,656,464 shares pursuant to the Sale Agreement, at an average selling price of $1.76 per share, generating net proceeds of approximately $4,532,000. In addition, during the year ended December 31, 2023, the Company paid approximately $61,000 in expenses related to the Sale Agreement. During the nine months ended September 30, 2024, the Company sold 53,290 shares pursuant to the Sales Agreement at an average selling price of $1.03 per share, generating net proceeds of approximately $53,000. In addition, the Company incurred ATM activation fees of approximately $41,000 during the three and nine months ended September 30, 2024. Stock-Based Compensation Total share-based employee, director, and consultant compensation amounted to approximately $782,000 and $2,345,000 for the three and nine months ended September 30, 2024, respectively, and approximately $1,086,000 and $2,487,000 for the three and nine months ended September 30, 2023, respectively. These amounts are included in the consolidated statements of operations and comprehensive loss under cost of revenue and selling, general, and administrative expenses. The summary of the stock option activity for the nine months ended September 30, 2024 is as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.99%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:66.99%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:66.99%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;width:66.99%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> Remaining </td></tr><tr><td style="vertical-

align:bottom;width:66.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> Contractual </td></tr><tr><td style="vertical-align:bottom;width:66.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> per Share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Life (Years) </td></tr><tr><td style="vertical-align:bottom;width:66.99%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> 10,548,174 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> .</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.01</p></td></tr><tr><td style="vertical-align:bottom;width:66.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,687,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 0.96 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:66.99%;background:#cceeff;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> (1,018,794) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:66.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (706,609)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 5.40 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:66.99%;background:#cceeff;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">— </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ceceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#ceceff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:66.99%;margin:0pt;padding:0pt;"> Outstanding, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,510,137 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 3.54 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> 7.06 </td></tr></table> The fair value of each stock option was estimated using the Black Scholes pricing model, which takes into account as of the grant date the exercise price (ranging from $0.84 to $1.08 per share) and expected life of the stock option (6 years), the current price of the underlying stock and its expected volatility (77.8%), expected dividends (0)% on the stock and the risk free interest rate (ranging from 3.60% to 4.65%) for the expected term of the stock option. The intrinsic value is calculated as the difference between the market value of the shares as of September 30, 2024 of $1.50 and the exercise price of the shares. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td colspan="11" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options Outstanding </td></tr><tr><td style="vertical-align:bottom;width:56.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> Number </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.7%;margin:0pt;padding:0pt;"> Range of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> Outstanding at </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;width:56.7%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> Remaining </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> Intrinsic </td></tr><tr><td style="vertical-align:bottom;width:56.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Life (Years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:56.7%;background:#cceeff;margin:0pt;padding:0pt;"> $0.84 - $13.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,510,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> 3.54 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"> 7.06 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 1,892,822 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:56.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.83%;margin:0pt;padding:0pt;"> </td></tr><tr><td colspan="7" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options Exercisable </td></tr><tr><td style="vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;"> Number </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;"> Exercisable at </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"> Intrinsic </td></tr><tr><td style="vertical-align:bottom;width:56.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.66%;background:#cceeff;margin:0pt;padding:0pt;"> 6,164,466 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:17.83%;background:#cceeff;margin:0pt;padding:0pt;"> 33,555 </td></tr></table> The summary of the status of the Company's non-vested options for the nine months ended September 30, 2024 is as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> Grant Date </td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <b

style="font-weight:bold;">Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"> Non-vested, December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 5,205,736 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.89</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,687,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> 0.67 </td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> (1,018,794) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.81</p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,528,637)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> 2.30 </td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"> Non-vested, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,345,671 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 1.08 </td></tr></table> As of September 30, 2024, the Company had approximately $3,540,000 of total unrecognized compensation cost related to stock options which will be amortized over approximately 35 months. On March 29, 2024, the Company granted options to purchase 380,480 shares of common stock to certain executive officers and certain other non-executive officer employees related to the Company’s salary reduction for stock options program. These options will vest in full on January 31, 2025. The grant date fair value of these unvested options amounted to approximately $249,000. On April 2, 2024, the Company granted options to purchase 1,214,400 shares of common stock to the Company’s employees which will be awarded based upon each employee’s 2024 individual performance evaluation. Once awarded, these options will vest one half on the first anniversary of the grant date, one quarter on the second anniversary of the grant date, and one quarter on the third anniversary of the grant date. The grant date fair value of these unvested options amounted to approximately $830,000. On April 2, 2024, the Company granted options to purchase 922,147 shares of common stock to certain of the Company’s employees. These options will vest in full on the first anniversary of the grant date. The grant date fair value of these unvested options amounted to approximately $594,000. On April 2, 2024, the Company granted options to purchase 110,000 shares of common stock to members of the Company’s Board of Directors. These options will vest in full on the first anniversary of the grant date. The grant date fair value of these unvested options amounted to approximately $71,000. On April 2, 2024, the Company granted options to purchase 556,000 shares of common stock to certain senior managers of the Company. These options will vest one half on the first anniversary of the grant date, one quarter on second anniversary of the grant date, and one quarter on third anniversary of the grant date. The grant date fair value of these unvested options amounted to approximately $380,000. <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt

0pt;">On April 8, 2024, the Company granted options to purchase 131,339 shares of common stock employees related to the Company's salary reduction for stock options program. The grant date fair value of these unvested options amounted to approximately $85,000. These options will vest in full on January 31, 2025. On August 14, 2024, the Company granted, in connection with the appointment of its new Chief Financial Officer, options to purchase 80,000 shares of common stock which will vest as follows: 41,000 options upon the six - month anniversary of the date of grant and 13,000 options upon each of the first, second and third anniversaries of the date of grant. The Company also granted options to purchase 215,000 shares of common stock that will vest only upon the achievement of certain milestones pursuant to the terms of the Company's existing 2022 - 2025 performance pool in place for the Company's management team. During the nine months ended September 30, 2024, 78,000 options were awarded to newly hired employees or to consultants in connection with their employment or consulting agreements. Change in Control-Based Awards of Restricted Stock Units: The Board of Directors has granted restricted stock units to members of the Board of Directors, to the Company's executive officers, and to employees of the Company. These restricted stock units will only vest upon a Change in Control of the Company, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan, as amended. The following table is a summary of these restricted stock units: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:40.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Restricted Stock Units </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> Board of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> Executive </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Directors </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Management </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt

0pt;">Employees </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Intrinsic Value </td></tr><tr><td style="vertical-align:bottom;width:45.47%;background:#cceeff;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"> 346,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"> 779,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"> 1,697,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"> 2,823,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,134,085</p></td></tr><tr><td style="vertical-align:bottom;width:45.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 175,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 156,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 331,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:45.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (330,750)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (330,750)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:45.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 346,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 954,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,523,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,824,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,236,000 </td></tr></table> Due to the uncertainty over whether these restricted

stock units will vest, which only happens upon a Change in Control, no charge for these restricted stock units has been recorded in the consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023. Other Awards of Restricted Stock Units: On August 10, 2022, certain named executive officers and senior managers were granted 288,500 restricted stock units. These awards were valued at approximately $563,000 at the date of issuance, based upon the market price of the Company's common stock at the date of the grant, and vested (or will vest) one-third on the date of the grant, one-third on the first anniversary of the date of the grant, and one-third on the second anniversary of the date of the grant. For the three and nine months ended September 30, 2024 and 2023, the Company recorded a charge (income) of approximately $(67,000) and $27,000, and $106,000 and $214,000, respectively, related to these restricted stock unit awards. On July 7, 2023, certain named executive officers and senior managers were granted 250,000 restricted stock units. These awards were valued at approximately $883,000 at the date of issuance, based upon the market price of the Company's common stock at the date of the grant, and will vest two-thirds on the first anniversary of date of the grant, and one-third on the second anniversary of the date of the grant. For the three and nine months ended September 30, 2024 and 2023, the Company recorded a charge (income) of approximately $(234,000) and $(13,000) and $102,000 and $0, respectively, related to these restricted stock unit awards. On September 18, 2023, a former named executive officer was granted 45,000 restricted stock units. This award was valued at approximately $89,000 at the date of issuance, based upon the market price of the Company's common stock at the date of the grant. These restricted stock units vested (will vest) as follows: 25,000 on the date of the grant, 10,000 on the first anniversary of the date of the grant and 10,000 on the second anniversary of the date of the grant. For the three and nine months ended September 30, 2024 and 2023, the Company recorded a charge (income) of approximately $(1,000) and $9,000 and $50,000 and $0, respectively, related to these restricted stock unit awards. On April 2, 2024, the Board of Directors granted 343,000 restricted stock units to certain senior managers of the Company. These awards were valued at approximately $328,000 at the date of issuance, based upon the market price of the Company's common stock at the date of the grant, and will vest one half on the first anniversary of the grant date and one half on the second anniversary of the grant date. For the three and nine months ended September 30, 2024 and 2023, the Company recorded a charge of approximately $41,000 and $81,000 and $0 and $0, respectively, related to these restricted stock unit awards. On August 14, 2024, the Company granted, in connection with the appointment of its new Chief Financial Officer, 65,000 restricted stock units. This award was valued at approximately $63,000 at the date of issuance, based upon the market price of the Company's common stock at the date of the grant. These restricted stock units will vest equally on the first anniversary of the date of the grant and the second anniversary of the date of the grant. For the three and nine months ended September 30, 2024 and 2023, the Company recorded a charge of approximately $4,000 and $4,000 and $0 and $0, respectively, related to these restricted stock unit awards. Additionally, certain employees were offered a total of 213,000 restricted stock units as a condition of their employment. These awards were valued at approximately $517,000 at the date of issuance. 40,000 of these restricted stock units valued at $149,000 were forfeited as of September 30, 2024. 33,000 of these restricted stock units valued at approximately $231,000 were vested as of September 30, 2024. The remaining 140,000 of these restricted stock units will vest upon the earlier of a Change in Control or in three or four years from the date of the award, whichever occurs first. For the three and nine months ended September 30, 2024 and 2023, the Company recorded a charge (income) of approximately $(23,000) and $(186,000), and $8,000 and $0, respectively, related to these restricted stock unit awards. The following table outlines the restricted stock unit activity for the nine months ended September 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> Grant Date </td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:74.94%;background:#cceeff;margin:0pt;padding:0pt;"> Non-vested, December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"> 430,505 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.31</p></td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 548,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> 0.96 </td></tr><tr><td style="vertical-align:bottom;width:74.94%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"> (297,169) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.23</p></td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (40,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> 3.73 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.94%;background:#cceeff;margin:0pt;padding:0pt;"> Non-vested, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 641,336 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"> 1.31 </td></tr></table> Warrants: As of September 30, 2024, the Company had 4,352,130 warrants outstanding. 2,706,561 warrants outstanding are related to the Company's December 13, 2023 offering and these warrants are immediately cash exercisable at an exercise price of $2.00 per share and expire on December 13, 2028. Another 1,645,569 warrants were issued on June 28, 2024 in connection with the closing of the Company's Loan and Security Agreement with Avenue Capital Group (see Note 5). These warrants have an exercise price of $0.79 and expire on June 28, 2029. The number of warrants is fixed, however, the exercise price may be adjusted down if the Company raises equity (excluding sales of equity utilizing the Company's at-the-market equity facility) at a share price that is lower than $0.79. These warrants can be exercised into common stock. 5000000 50000000 100000000 150000000 150000000 25000000 19700000 0.030 0 2656464 1.76 4532000 61000 53290 1.03 53000 41000 41000 782000 2345000 1086000 2487000   <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.99%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:66.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;width:66.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> Remaining </td></tr><tr><td style="vertical-align:bottom;width:66.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> Contractual </td></tr><tr><td style="vertical-align:bottom;width:66.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> per Share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Life (Years) </td></tr><tr><td style="vertical-align:bottom;width:66.99%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> 10,548,174 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> .</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.01</p></td></tr><tr><td style="vertical-align:bottom;width:66.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,687,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 0.96 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:66.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> (1,018,794) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:66.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (706,609)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 5.40 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:66.99%;background:#cceeff;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:66.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Outstanding, September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,510,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 3.54 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> 7.06 </td></tr></table> 10548174 4.49 P7Y3D 3687366 0.96 1018794 2.69 706609 5.40 12510137 3.54 P7Y21D 0.84 1.08 P6Y 0.778 0 0.0360 0.0465 The intrinsic value is calculated as the difference between the market value of the shares as of September 30, 2024 of $1.50 and the exercise price of the shares. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td colspan="11" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt

0pt;">Options Outstanding </td></tr><tr><td style="vertical-align:bottom;width:56.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> Number </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.7%;margin:0pt;padding:0pt;"> Range of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> Outstanding at </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;width:56.7%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"> Remaining </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> Intrinsic </td></tr><tr><td style="vertical-align:bottom;width:56.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Life (Years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:56.7%;background:#cceeff;margin:0pt;padding:0pt;"> $0.84 - $13.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,510,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"> 3.54 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"> 7.06 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 1,892,822 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-

right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:56.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.83%;margin:0pt;padding:0pt;"> </td></tr><tr><td colspan="7" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options Exercisable </td></tr><tr><td style="vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;"> Number </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;"> Exercisable at </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;"> 5eptember 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"> Intrinsic </td></tr><tr><td style="vertical-align:bottom;width:56.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.66%;background:#cceeff;margin:0pt;padding:0pt;"> 6,164,466 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:17.83%;background:#cceeff;margin:0pt;padding:0pt;"> 33,555 </td></tr></table> 1.50 0.84 13.20 12510137 3.54 P7Y21D 1892822 6164466 5.48 33555 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"> <b

style="font-weight:bold;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> Grant Date </td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"> Non-vested, December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 5,205,736 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.89</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,687,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> 0.67 </td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> (1,018,794) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.81</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,528,637)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> 2.30 </td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"> Non-vested, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,345,671 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceceff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#ceceff;margin:0pt;padding:0pt;"> 1.08 </td></tr></table> 5205736 1.89 3687366 0.67 1018794 1.81 1528637 2.30 6345671 1.08 3540000 P35M 380480 249000 1214400 830000 922147 594000 110000 71000 556000 380000 131339 85000 80000 41000 13000 215000 78000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:40.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Restricted Stock Units </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> Board of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> Executive </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Directors </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Management </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Employees </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Intrinsic Value </td></tr><tr><td style="vertical-align:bottom;width:45.47%;background:#ceceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"> 346,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"> 779,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"> 1,697,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"> 2,823,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,134,085</p></td></tr><tr><td style="vertical-align:bottom;width:45.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 175,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 156,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 331,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:45.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (330,750)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (330,750)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:45.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 346,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 954,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,523,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,824,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,236,000 </td></tr></table> 346500 779500 1697500 2823500 3134085 0 175000 156250 331250 0 0 330750 330750 346500 954500 1523000 2824000 4236000 0 0 0 0 288500 563000 -67000 27000 106000 214000 250000 883000 -234000 -13000 102000 0 45000 89000 25000 10000 10000 -1000 9000 50000 0 343000 328000 41000 81000 0 0 65000 63000 4000 4000 0 0 213000 517000 40000 149000 33000 231000 140000 P4Y -23000 -186000 8000 0 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> <p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> Grant Date </td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:74.94%;background:#cceeff;margin:0pt;padding:0pt;"> Non-vested, December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"> 430,505 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.31</p></td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 548,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> 0.96 </td></tr><tr><td style="vertical-align:bottom;width:74.94%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"> (297,169) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.23</p></td></tr><tr><td style="vertical-align:bottom;width:74.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (40,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> 3.73 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.94%;background:#cceeff;margin:0pt;padding:0pt;"> Non-vested, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 641,336 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"> 1.31 </td></tr></table> 430505 3.31 548000 0.96 297169 3.23 40000 3.73 641336 1.31 4352130 2706561 2.00 1645569 0.79 0.79 4. REVENUE The following table disaggregates the Company's revenue by customer type and geographic area for the three months ended September 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"> Distributors/ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"> Government </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-

space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Direct </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Strategic Partners </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Agencies </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> Product sales: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 20,705 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> Germany </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"> 3,180,863 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"> 3,180,863 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> All other countries </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,937,580 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,473,647 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,411,227 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> Total product revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"> 5,139,148 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> 3,473,647 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"> 8,612,795 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> Grant and other income: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 777,593 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 777,593 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> Total revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,139,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,473,647 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 777,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,390,388 </td></tr></table> . The following table disaggregates the Company's revenue by customer type and geographic area for the three months ended September 30, 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"> Distributors/ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"> Government </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Direct </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Strategic Partners </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Agencies </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> Product sales: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 44,933 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> Germany </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"> 2,937,431 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"> 2,937,431 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> All other countries </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,267,051 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,504,601 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,771,652 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> Total product revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"> 4,249,415 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> 3,504,601 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"> 7,754,016 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> Grant and other income: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,056,831 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;">. </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,056,831 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> Total revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,249,415</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,504,601 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,056,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,810,847 </td></tr></table> . The following table disaggregates the Company's revenue by customer type and geographic area for the nine months ended September 30, 2024: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"> Distributors/ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"> Government </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Direct </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Strategic Partners </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Agencies </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> Product sales: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> 36,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

*Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> 98,719 </td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> Germany </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"> 9,497,184 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> 9,497,184 </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> All other countries </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,361,933 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,486,268 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,848,201 </td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> Total product revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"> 14,921,836 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> 11,522,268 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> 26,444,104 </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> Grant and other income: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> . *

</td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,627,212 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,627,212 </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> Total revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,921,836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,522,268 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,627,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,071,316 </td></tr></table> . The following table disaggregates the Company’s revenue by customer type and geographic area for the nine months ended September 30, 2023: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> <span

style="font-size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"> Distributors/ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"> Government </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Direct </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Strategic Partners </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Agencies </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> Product sales: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"> 9,443,787 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> 9,443,787 </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> All other countries </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,263,375 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,974,022 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,237,397 </td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> Total product revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"> 13,762,446 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> 9,974,022 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> 23,736,468 </td></tr><tr><td style="vertical-

align:bottom;width:46.49%;margin:0pt;padding:0pt;"> Grant and other income: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,944,696 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,944,696 </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> Total revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,762,446</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,974,022 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,944,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 27,681,164 </td></tr></table> . The Company has two primary revenue streams: (1) sales of the CytoSorb device and related device accessories and (2) grant income from contracts with various agencies of the United States government. The following is

a brief description of each revenue stream. CytoSorb Sales The Company sells its CytoSorb device using both its own sales force (direct sales) and through the use of distributors and/or strategic partners. The majority of sales of the device are outside the United States, as CytoSorb is not yet approved for commercial sale in the United States. However, in April 2020, the Company was granted Emergency Use Authorization ("EUA") of CytoSorb for use in critically-ill patients infected with COVID-19 with imminent or confirmed respiratory failure by the United States Food and Drug Administration (the "FDA"). Direct sales outside the United States relate to sales to hospitals located in Germany, Switzerland, Austria, Belgium, Luxembourg, Poland, the Netherlands, Sweden, Denmark, Norway and the United Kingdom. Direct sales are fulfilled from the Company's warehouse facility in Berlin, Germany. There are no formal sales contracts with any direct customers relating to product price or minimum purchase requirements. However, there are agreements in place with certain direct customers that provide for either free of charge product or rebate credits based upon achieving minimum purchase levels. The Company records the value of these items earned as a reduction of revenue. These customers submit purchase orders and the order is fulfilled and shipped directly to the customer. Prices to all direct customers are based on a standard price list based on the packaged quantity (6 packs versus 12 packs). Distributor and strategic partner sales make up the remaining product sales. These distributors are located in various countries throughout the world. The Company has a formal written contract with each distributor/strategic partner. These contracts have terms ranging from 1-5 years in length, with three years being the typical term. In addition, certain distributors are eligible for volume discount pricing if their unit sales are in excess of the base amount in the contract. Most distributor's/strategic partner's contracts have minimum annual purchase requirements in order to maintain exclusivity in their respective territories. There is no additional consideration or monetary penalty that would be required to be paid to CytoSorbents if a distributor does not meet the minimum purchase commitments included in the contract, however, at the discretion of the Company, the distributor may lose its exclusive rights in the territory if such commitments are not met. Government Grants The Company has been the recipient of various grant contracts from various agencies of the United States government, primarily the Department of Defense, to perform various research and development activities. These contracts fall into one of the following categories: <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;">Fixed price – the Company invoices the contract amount in equal installments over the term of the contract without regard to the timing of the costs incurred related to this contract. If billings on fixed price contracts exceed the costs incurred, revenue will be deferred to the extent of the excess billings.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;">Cost reimbursement – the Company submits monthly invoices during the term of the contract for the amount of direct costs incurred during that month plus an agreed upon percentage that relates to allowable overhead and general and administrative expenses. Cumulative amounts invoiced may not exceed the maximum amount of funding stipulated in the contract.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;">Cost plus – this type of contract is similar to a cost reimbursement contract but this type also allows for the Company to additionally invoice for a fee amount that is included in the contract.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;">Performance based – the Company submits invoices only upon the achievement of the milestones listed in the contract. The amount to be invoiced for each milestone is documented in the contract.</td></tr></table> These government contracts have terms ranging from three months to four years. The Company may apply for an extension of the term of the contract in order to complete its research and development activities but would not receive additional funding during the extension period in excess of the original contract. See Note 2 regarding the accounting policies related to these contracts. The Company is evaluating the potential reclassification of grant income and related costs of goods sold to net with research and development expenses. In summary, the contracts the Company has with customers are the distributor/strategic partner contracts related to CytoSorb product sales, agreements with direct customers related to free-of-charge product and credit rebates based upon achieving minimum purchase levels, and contracts with various government agencies related to the Company's grants. The Company does not currently incur any outside/third party incremental costs to obtain any of these contracts. The Company does incur internal costs, primarily salary related costs, to obtain the contracts related to the grants. Company employees spend time reviewing the program requirements and developing the budget and related proposal to submit to the grantor agency. There may additionally be travel expenditures involved with meeting with government agency officials during the negotiation of the contract. These internal costs are expensed as incurred. The following table provides information about receivables and contract liabilities from contracts with customers: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"> Receivables, which are included in grants and accounts receivable </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,845,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,846,271 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.33%;margin:0pt;padding:0pt;"> Contract liabilities, which are included in accrued expenses and other current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 837,592</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,573,141 </td></tr></table> . Contract receivables represent balances due from product sales to distributors amounting to $4,528,972 and $3,270,724 at September 30, 2024 and December 31, 2023, respectively, and billed and unbilled amounts due on government contracts amounting to $316,261 and $575,547 at September 30, 2024 and December 31, 2023, respectively. Contract liabilities represent the value of free of charge goods and credit rebates earned in accordance with the terms of certain direct customer agreements, which amounted to $51,192 and $196,322 as of September 30, 2024 and December 31, 2023, respectively, and deferred grant revenue related to the billing on fixed price contracts in excess of costs incurred, which amounted to $786,400 and $1,376,819 at June 30, 2024 and December 31, 2023, respectively. The following table disaggregates the Company's revenue by customer type and geographic area for the three months ended September 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-

align:bottom;width:45.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"> Distributors/ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"> Government </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Direct </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Strategic Partners </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Agencies </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> Product sales: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 20,705 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> Germany </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"> 3,180,863 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"> 3,180,863 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> All other countries </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,937,580 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,473,647 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,411,227 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> Total product revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"> 5,139,148 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> 3,473,647 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"> 8,612,795 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> Grant and other income: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 777,593 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 777,593 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> Total revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,139,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,473,647 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 777,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,390,388 </td></tr></table> . The following table disaggregates the Company's revenue by customer type and geographic area for the three months ended September 30, 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"> Distributors/ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"> Government </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Direct </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Strategic Partners </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Agencies </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> Product sales: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0pt 3pt 0pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 44,933 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> Germany </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"> 2,937,431 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"> 2,937,431 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> All other countries </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,267,051 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,504,601 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,771,652 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> Total product revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"> 4,249,415 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> 3,504,601 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"> 7,754,016 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> Grant and other income: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,056,831 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,056,831 </td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"> Total revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,249,415</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,504,601 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,056,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,810,847 </td></tr></table> The following table disaggregates the Company’s revenue by customer type and geographic area for the nine months ended September 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> <span

style="font-size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"> Distributors/ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"> Government </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Direct </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Strategic Partners </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Agencies </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> Product sales: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> 36,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> 98,719 </td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> Germany </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"> 9,497,184 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> 9,497,184 </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> All other countries </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,361,933 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,486,268 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,848,201 </td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> Total product revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"> 14,921,836 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> 11,522,268 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> 26,444,104 </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> Grant and other income: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,627,212 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,627,212 </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> Total revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,921,836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,522,268 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,627,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,071,316 </td></tr></table> - <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table disaggregates the Company's revenue by customer type and geographic area for the nine months ended September 30, 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"> Distributors </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"> Government </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Direct </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Strategic Partners </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Agencies </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> Product sales: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> 55,284 </td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> Germany </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"> 9,443,787 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> 9,443,787 </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> All other countries </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,263,375 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,974,022 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,237,397 </td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> Total product revenue </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"> 13,762,446 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> 9,974,022 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"> 23,736,468 </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> Grant and other income: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,944,696 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,944,696 </td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"> Total revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-

space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,762,446 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,974,022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,944,696 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,681,164</p></td></tr></table> 20705 20705 3180863 3180863 1937580 3473647 5411227 5139148 3473647 8612795 777593 777593 5139148 3473647 777593 9390388 44933 44933 2937431 2937431 1267051 3504601 4771652 4249415 3504601 7754016 1056831 1056831 4249415 3504601 1056831 8810847 62719 36000 98719 9497184 9497184 5361933 11486268 16848201 14921836 11522268 26444104 2627212 2627212 14921836 11522268 2627212 29071316 55284 55284 9443787 9443787 4263375 9974022 14237397 13762446 9974022 23736468 3944696 3944696 13762446 9974022 3944696 27681164 2 P1Y P5Y P3Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;">.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:71.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Receivables, which are included in grants and accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,845,233 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,846,271</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities, which are included in accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 837,592 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,573,141 </td></tr></table> 4845233 3846271 837592 1573141 4528972 3270724 316261 575547 51192 196322 786400 1376819 5. LONG-TERM DEBT, NET Avenue Capital Group: On June 28, 2024 (the “Closing Date”), the Company entered into a Loan and Security Agreement (as amended, supplemented, restated or otherwise modified as of the date hereof and from time to time, the “Loan and Security Agreement”) with Avenue Venture Opportunities Fund, L.P., a Delaware limited partnership (“Avenue”), Avenue Venture Opportunities Fund II, L.P., a Delaware limited partnership (“Avenue 2” and, together with Avenue, the “Lenders”), and Avenue Capital Management II, L.P., a Delaware limited partnership (the “Administrative and Collateral Agent”). Under the Loan and Security Agreement, the Lenders have agreed to loan to the Company up to an aggregate of $20 million, to be disbursed in two tranches: (1) one tranche of $15 million (“Growth Capital Loan Tranche 1”) on the Closing Date, with $4.5 million funded by Avenue and $10.5 million funded by Avenue 2, of which $10 million is available to the Company on the Closing Date and $5 million constitutes restricted cash subject to release to the Company prior to March 31, 2025, provided (i) the FDA has accepted Company’s application for review with respect to DrugSorb-ATR De Novo 510(k) and (ii) the Company has received a minimum of $3 million in net proceeds from the sale of its equity securities after the Closing Date. The

restriction will be released on a dollar for dollar basis for equity raised between $3 million and $5 million and (2) a second tranche of up to $5 million, which may be disbursed at the Company's request between July 1, 2025 and December 31, 2025, provided that the Company receives FDA marketing approval of its DrugSorb-ATR application ("Growth Capital Loan Tranche 2" and together with Growth Capital Loan Tranche 1, the "Growth Capital Loans" or the "Commitment"). The proceeds from the Commitment were used to pay off the existing outstanding debt with Bridge Bank, and will additionally be used for working capital purposes and to fund general business requirements in accordance with the terms of the Loan and Security Agreement. Each Growth Capital Loan shall bear interest at a variable rate per annum equal to the greater of (A) the Prime Rate (as defined in the Loan and Security Agreement) plus five percent (5.00%) or (B) thirteen and one-half percent (13.50%). Commencing on August 1, 2024, the Company shall make monthly payments during the term of each Growth Capital Loan of interest only during the initial 25-month period following the Closing Date (as may be extended to the 30 months anniversary of the Closing Date upon satisfaction of certain conditions) and thereafter to maturity in equal monthly installments of principal plus accrued and unpaid interest. All unpaid principal and accrued and unpaid interest shall be due and payable in full on July 1, 2027; provided, however that if the Company draws the full amount of Growth Capital Loan Tranche 2 by December 2025, all unpaid principal and accrued and unpaid interest shall be due and payable in full by January 1, 2028. In addition, the Loan and Security Agreement required the Company to pay a non-refundable commitment fee equal to 1.00% of the Commitment due and payable on the Closing Date. In addition to the non-refundable commitment fee, the Company also paid financial advisor fees and legal fees of approximately $640,000 related to the Commitment. These costs are being amortized over the loan period as a charge to interest expense. During the three and nine months ended September 30, 2024, the Company recorded interest expense of approximately $58,000 related to these costs. In addition, the Loan and Security Agreement requires the Company to pay a non-refundable final payment equal to 4.5% of the original commitment amount. This final payment has been accrued and included as part of the debt discount. This discount will be charged to interest expense over the term of the loan. For the three and nine months ended September 30, 2024, the Company recorded interest expense of approximately $132,000 related to the debt discount. The Capital Growth Loans are evidenced by secured promissory notes issued to the Lenders by the Company. If the Company elects to prepay the Growth Capital Loan(s) pursuant to the terms of the Loan and Security Agreement, it will owe a prepayment fee to the Lenders, as follows: (1) for a prepayment made on or after the funding date of a Growth Capital Loan through and including the first anniversary of such funding date, an amount equal to 3.00% of the principal amount of such Growth Capital Loan prepaid; (2) for a prepayment made after the first anniversary of the funding date of a Growth Capital Loan through and including the second anniversary of such funding date, an amount equal to 2.00% of the principal amount of such Growth Capital Loan prepaid; and (3) for a prepayment made any time after the second anniversary of the funding date of a Growth Capital Loan, an amount equal to 1.00% of the principal amount of such Growth Capital Loan prepaid. Events of default which may cause repayment of the Commitment to be accelerated include, among other customary events of default, (1) non-payment of any obligation when due, (2) the failure to perform any obligation required under the Loan and Security Agreement and to cure such default within a reasonable time frame, (3) the occurrence of any circumstance that has a Material Adverse Effect (as defined in the Loan and Security Agreement), (4) default beyond any applicable grace period or cure under any other agreement involving the borrowing of money in excess of the Threshold Amount (as defined in the Loan and Security Agreement), (5) any judgment(s) singly or in the aggregate in excess of the Threshold Amount entered against the Company that remain unsatisfied, unvacated or unstayed for 15 days or more after entry thereof (to the extent not otherwise covered by independent third-party insurance), and (6) if the Company becomes insolvent or starts an insolvency proceeding or if an insolvency proceeding is brought by a third party against the Company and such proceeding is not dismissed or stayed within 45 days. The Loan and Security Agreement includes customary loan conditions, company representations and warranties, company affirmative covenants and company negative covenants for secured transactions of this type. As of September 30, 2024, the Company was in compliance with these covenants. As additional consideration for the Commitment, on June 28, 2024, the Company also issued each Lender a warrant instrument (each, a "Warrant") entitling the Lenders to purchase an aggregate of 1,645,569 shares of the Company's common stock for cash at the exercise price of $0.79 and expire on June 28, 2029. The number of warrants is fixed, however, the exercise price may be adjusted down if the Company raises equity (excluding sales of equity utilizing the Company's at-the-market equity facility) at a share price that is lower than $0.79. These warrants meet the criteria for equity classification under ASC 815. Accordingly, the Company has recorded a debt discount and additional paid-in capital of approximately $690,000 related to these warrants as of June 30, 2024. This discount will be charged to interest expense over the term of the loan. The Lenders were also granted the right while the Commitment is outstanding to convert up to an aggregate amount of $2,000,000 of the principal amount of the outstanding Growth Capital Loans into the Company's common stock at a fixed conversion price of 120% of the Closing Price (as defined in the warrant) or $0.95 per share (the "Conversion Option").</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company's and CytoSorbents Medical's obligations under the Loan and Security Agreement are joint and several. The obligations under the Loan and Security Agreement are secured by a first priority security interest in favor of the Lenders with respect to the Company's Shares (as defined in the Loan and Security Agreement) and the Company's Collateral (as defined in the Loan and Security Agreement), which includes the Company's intellectual property, pursuant to that certain Intellectual Property Security Agreement, dated as of June 28, 2024, by and between the Company and the Administrative and Collateral Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Long-term debt consists of the following as of September 30, 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Principal amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 15,000,000 </td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"> Accrued final fee </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 900,000 </td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"> Less unamortized debt discount </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> (1,455,858) </td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"> Less unamortized debt acquisition costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (638,157) </td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"> Subtotal </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 13,805,985 </td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"> Less Current maturities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"> Long-term debt net of current maturities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,805,985</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Principal payments of long-term debt are due as follows during the periods ending September 30:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> 2,500,000 </td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> 12,500,000 </td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,000,000 </td></tr></table> Bridge Bank: On June 28, 2024, concurrent with the closing of the Avenue Capital Group financing discussed above, the Company paid off its existing outstanding debt with Bridge Bank. The following items survive the termination of the Bridge Bank Amended and Restated Loan and Security Agreement and related amendments: 2018 Success Fee Letter: Pursuant to the amended 2018 Letter, the Borrower shall pay to the Bank a success fee in the amount equal to 6.37% of the funded amount of the Term B Loan (as defined in the Restated Loan and Security Agreement) (the “Success Fee”) upon the first occurrence of any of the following events: (a) a sale or other disposition by the Borrower of all or substantially all of its assets; (b) a merger or consolidation of the Borrower into or with another person or entity, where the holders of the Borrower’s outstanding voting equity securities as of immediately prior to such merger or consolidation hold less than a majority of the issued and outstanding voting equity securities of the successor or surviving person or entity as of immediately following the consummation of such merger or consolidation; (c) a transaction or a series of related transactions in which any “person” or “group” (within the meaning of Section 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of a sufficient number of shares of all classes of stock then outstanding of the Borrower ordinarily entitled to vote in the election of directors, empowering such “person” or “group” to elect a majority of the Board of Directors of the Borrower, who did not have such power before such transaction; or (d) the closing price per share for the Company’s common stock on the Nasdaq Capital Market being the greater of (i) 70% or more over $7.05, the closing price of the Company’s common stock on March 29, 2018 (after giving effect to any stock splits or consolidations effected after the date thereof) for <span style="-sec-ix-

hidden:Hidden_GUTVIa4l10arIueiLeoCKg;">five successive business days, or (ii) at least 26.13% more than the average price of Company's common stock for the 365-day period ending on the date of the funding of the Term B Loan. This obligation terminated on the fifth anniversary of the funding of the Term B Loan which was July 31, 2024. 2022 Success Fee Letter: Pursuant to the 2022 Success Fee Letter, the Borrower will pay to the Bank a success fee equal to (i) 1% of $5 million if the Company draws down the first tranche of the Term C Loan and is payable only if the Company's stock price equals or exceeds $8 for five consecutive trading days; (ii) 1.5% of $5 million if the Company draws down the second tranche of the Term C Loan and is payable only if the Company's stock price equals or exceeds $10 for five consecutive trading days; and (iii) 2% of $5,000,000 if the Company draws down the third tranche of the Term C Loan and is payable only if the Company's stock price equals or exceeds $12 for five consecutive trading days (together, the "Success Fee"). As of June 28, 2024, the Company had drawn down only the first tranche of the Term C Loan. Borrower may pay the Success Fee in cash or in shares of common stock, at Borrower's sole discretion. The right of Bank to receive the Success Fees and the obligation of the Borrower to pay the Success Fees hereunder shall terminate on the date that is the fifth anniversary of the funding date of the last Term C Loans made but shall survive the termination of the Loan Agreement and any prepayment of the Term C Loans. The termination date of this Letter is December 27, 2027.</p> 20000000 15000000 4500000 10500000 10000000 5000000 3000000 3000000 5000000 0.0500 0.1350 P25M P30M 0.0100 640000 58000 58000 0.045 132000 132000 0.0300 0.0200 0.0100 P15D P45D 1645569 0.79 0.79 2000000 1.20 0.0095 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Long-term debt consists of the following as of September 30, 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Principal amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 15,000,000 </td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"> Accrued final fee </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 900,000 </td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"> Less unamortized debt discount </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> (1,455,858) </td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"> Less unamortized debt acquisition costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (638,157) </td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"> Subtotal </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 13,805,985 </td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"> Less Current maturities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"> Long-term debt net of current maturities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,805,985 </td></tr></table> 15000000 900000 1455858 638157 13805985 13805985 Principal payments of long-term debt are due as follows during the periods ending September 30: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,500,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,500,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,000,000 </td></tr></table> 2500000 12500000 15000000 0.0637 0.70 7.05 0.2613 0.01 5000000 8 0.015 5000000 10 0.02 5000000 12 6. COMMITMENTS AND CONTINGENCIES Litigation The Company is, from time to time, subject to claims and litigation arising in the ordinary course of business. The Company intends to defend vigorously against any future claims and litigation. On March 5, 2024, Danielle Greene, a former employee, filed a complaint against us in the Superior Court of New Jersey, Law Division, Mercer County, alleging breach of the New Jersey Conscientious Employee Protection Act ("CEPA"). The complaint specifically alleges that we violated the provisions of the CEPA by allegedly terminating Ms. Greene in retaliation for complaining about certain business practices. We dispute these allegations and intend to vigorously defend against them, but there can be no assurance as to the outcome of the litigation. Royalty/License Agreements The Company is party to various royalty and license agreements that require the payment of royalty fees. Royalty expense amounted to approximately $354,000 and $537,000, respectively, for the three months ended September 30, 2024 and 2023. For the nine months ended September 30, 2024 and 2023, royalty expense amounted to approximately $1,594,000 and $1,643,000, respectively. In addition, the Company's license agreement with Purolite expired on August 6, 2024. Royalty expense are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss. 354000 537000 1594000 1643000 7. LEASES The Company leases its operating facilities in both the United States and Germany under operating lease agreements. In March 2021, CytoSorbents Medical Inc. entered into a lease agreement for a new operating facility at 305 College Road East, Princeton, New Jersey, which contains office, laboratory, manufacturing and warehouse space. The lease commenced on June 1, 2021. The Early Term commenced on June 1, 2021 and ended September 30, 2021. The lease also contains two five-year renewal options; however, the Company had determined that it is not likely that they will exercise these options. Commencing on September 30, 2021, the remaining lease term will end in 15.5 years. The lease requires monthly rental payments of $25,208 for the Initial Early Term, $88,254 for the Early Term and initial monthly payments of approximately $111,171 in the first year of the remaining term. Following the first year of the remaining term, the annual base rent will increase by approximately 2.75% annually over the remaining term. The lease also contains six months of rent abatement (months 1, 2, 3, 25, 26 and 27 of the remaining lease term). In addition to the base rent, payments of operating expenses and real estate taxes will be required. These payments are to be based on actual amounts incurred during 2021 multiplied by the Company's share of the total building space (92.3%). The landlord will also provide an allowance of approximately $1,455,000 related to certain building improvements as outlined in the lease. In April 2021, the Company provided the landlord with a letter of credit in the amount of approximately $1,467,000 as security. The Company has determined that this lease should be treated as an operating lease in accordance with the provisions of Accounting Standards Codification ("ASC") 842. On April 1, 2021, the Company recorded a Right-of-Use asset and related lease liability of approximately $11.6 million, which represents the estimated present value of the lease payments at the commencement date discounted at the Company's incremental borrowing rate of 9.8%. In addition, due to the six months of rent abatement and annual base rent escalations during the remaining lease term that commenced on September 30, 2021, the Company will recognize rent expense on this lease on a straight-line basis over the remaining term of the lease for the difference between the rent expense recognized and the required payments under the lease. In September 2021, the Company extended its two operating leases for its office facility in Germany. These leases require combined base rent payments amounting to approximately $12,100 per month. The initial lease term of both leases ends August 31, 2026. In addition, the Company is obligated to monthly operating expenses of approximately $3,000 per month. Both leases have a five-year option to renew that would extend the lease term to August 31, 2031. There are no provisions in the leases to increase the base rent during the renewal period. There were no lease incentives and no initial direct costs were incurred related to these leases. In January 2021, CytoSorbents Europe GmbH entered into a lease for 1,068 square meters of additional warehouse space. The lease commenced on April 1, 2021 and requires monthly payments of base rent of $7,784 and other costs of approximately $239 and has a term of five years. The lease also has an option to extend the lease term for an additional five-year period through March 31, 2031. The Company has determined that this lease should be treated as an operating lease in accordance with the provisions of ASC 842. On April 1, 2020, the Company recorded a Right-of-Use asset and related lease liability at the estimated present value of the lease payments at the commencement date of approximately $594,000. Right-Of-Use Asset and Lease Liability The Company's consolidated balance sheets reflect the value of the right-of-use asset and related lease liability. This value was calculated based on the present value of the remaining base rent lease payments. The remaining lease payments include the renewal periods for both of the facilities in Germany and do not include the renewal periods for the United States facility. The discount rate used was the Company's incremental borrowing rate, which is 9.8%, as the Company could not determine the rate implicit in the lease. As a result, the value of the right-of- use asset and related lease liability is as follows: <span

style="font-size:0pt;visibility:hidden;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:70.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:70.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"> Right-of-use asset </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,651,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,058,896 </td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"> Total lease liability </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,000,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 13,270,295 </td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"> Less current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (431,997) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (373,636) </td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"> Lease liability, net of current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,568,745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,896,659 </td></tr></table> The maturities of the lease liabilities are as follows for the periods ending September 30: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,685,727</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,725,524</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,766,416</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,808,432</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,851,603</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,024,373</p></td></tr><tr><td style="vertical-align:middle;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,862,075</p></td></tr><tr><td style="vertical-align:middle;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,861,333)</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,000,742 </td></tr></table> For the three months ended September 30, 2024 and 2023, operating cash flows paid in connection with operating leases amounted to approximately $547,000 and $633,000, respectively, and $1,684,000 and $1,801,000, respectively, for the nine months ended September 30, 2024 and 2023. As of September 30, 2024 and December 31, 2023, the weighted average remaining lease term was years 11.9 and 12.7 years, respectively. 2 P5Y P15Y6M 25208 88254 111171 0.0275 P6M 0.923 1455000 1467000 11600000 0.098 12100 3000 1068 7784 239 P5Y P5Y 594000 0.098 <p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;min-height:0.0pt;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:70.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:70.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"> Right-of-use asset </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,651,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,058,896 </td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"> Total lease liability </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,000,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"> 13,270,295 </td></tr><tr><td style="vertical-align:bottom;width:70.6%;margin:0pt;padding:0pt;"> Less current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (431,997) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (373,636) </td></tr><tr><td style="vertical-align:bottom;width:70.6%;background:#cceeff;margin:0pt;padding:0pt;"> Lease liability, net of current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,568,745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,896,659 </td></tr></table> 11651563 12058896 13000742 13270295 431997 373636 12568745 12896659 The maturities of the lease liabilities are as follows for the periods ending September 30: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,685,727</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,725,524</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,766,416</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,808,432</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,851,603</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,024,373</p></td></tr><tr><td style="vertical-align:middle;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,862,075</p></td></tr><tr><td style="vertical-align:middle;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,861,333)</p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,000,742 </td></tr></table> 1685727 1725524 1766416 1808432 1851603 14024373 22862075 9861333 13000742 547000 633000 1684000 1801000 P11Y10M24D P12Y8M12D 8. NET LOSS PER SHARE Basic loss per share and diluted loss per share for the three and nine months ended September 30, 2024 and 2023 have been computed by dividing the net loss for each respective period by the weighted average number of shares outstanding during that period. All outstanding warrants, options and restricted stock awards representing approximately 20,328,000 and 14,119,000 incremental shares at September 30, 2024 and 2023, respectively, have been excluded from the computation of diluted loss per share

as they are anti-dilutive.</p> 20328000 14119000 false false false false

""R[6]CFO@E?FQ\-YN^5G>T<;H-A"ND*1#Z!7*"]T&EE"=-O M5'T">$6\[1KZ7ECU3E69UHV590U5E-ZL*F.R]&Y5.FSFV9&_6R6G=6#MIV5>*
M!SW(H72KAPCX;U?XX=QGE\'(+E5%]LM1$]D?_O@R/UT6Y#[87IMIF0N?X7-, MVY3FU5@B3?;:]DQ;6YJ,Z=>'!5N'AS<9K%\?&'PI#PQ.MSS9-EIQ
YDPX7CA MV"/ACMW7D\=3Z95S8@37?N],#Y.1@X$B[7U85\1HL&_H2)+8))(,V9_O5"F&GOO/4+81#TX7]@U_MFGT,C]+5+B:UO1*H<[-*
(C<3.:IBEU,,A#%CBOC&>1XUR:Y$3NI69':-C8D< MDCO:D&Y.5,0.#%(ZUJ720]\[E%'.R?V9=D2?90WQY6LN-;WM=4C/>HJ'1DHP*
*M9C+FY5@8)P1OP:?-_5I/_F5Z%S8B#>5?!N/84E8\H-Y4A)-7EK(;5JX)JCAO-M*R86IU[(WD>]+>A8'7&&9P"!1R\A09/'1BU%%DN[$J(>F?Z+$-*
*T3*TG;D1E7(J$UI4@-M](@9*DR"RX#R-A@@E7DA'@/T3,'0-2_A,RUZ%K';<5E;@2K1[W=FN)DP;NF/<*
*M#.^SPRO!,*A9QKB&)&_225Y^Z/!LD..RC%M%6WN!GKW_%ZRUOHP-M1VU>5]TY2J2@G%85?R5BNOP2I?;>T=))K0'%.>://(8LOY.VGE-MY;]^,?,JJ-*
*=#4D1G9+URS(PN6.=F>Y#;4A>K5]2\FMH[/=MA=*S#%#@GPILL;-M#TF?GAR_2C&"#VM-@T/2G#8W]:K89:%768UW!]3TE#-MJ(;7(-7VI]1GZ]K,:*
[8C]TD;T(YUZ'+KV>/PLM-%&;'YP^_N_"9UVY>_10>M&_?(Z2[G!D?1_E6QVA?/Y0OE+.7-MN6ZF_G@;CP;S/\^G(VM7BZ?^VL0)"&=-|*
*<>84HX@+WT(NA?[M*T;#P+A^K*-M>8-Z;.P040P#&"8Q? #'9YG'3WZ84-U>4S.G;&Z3F+^3)H"R$U>@N#S1:XMN-M78YO;$J%K6V?*
\K(_>XBYJ[SL45W.@7AJ@YVLVF),/"O$<_6ERTJ6/E7_G+/B-M90-U-=LAVG6-]/CL@1J7_6XG')!**Y.33E=5R&YXL!ZD0I+/^N/S,TW(U'($
*M4AY>=U2W*V"*]!G?V;_NZ?;A;_]?U!+-P04"-;A&=90QV:-M2_=Y-3(P<-%0-&-TKDE3))SG)S.PD>^_=DFWY1#NVY;%TDLT[!6J*)B&)-Q2I(2G[>/[Z*
MAP]^&$#!SX9\7M7NG1RKN1$-=C<:0/W__7YX,'G#8N9'_'U^]?_?]5PC[-M=N"X_NX_OCK%VXN_?O6__O,_[=-_!\N+O(/X>,M<@+*
[=,!^C.P06S%VT(L;-M[]$F.!XM'}WA,'0]#UV&KK/#"+W__MU?WWW_[]<-_HXN+_V0T+]VQX-0^8L1^-M>/<^_>$J(1?X/Z/W![_']_]\/T/?T(__?
S^KS__^;-HX2Z%NR.L;=TF0,_U-M__B9_I\G.AXB(OK1?WRUC^/CS]!]]_+R\N[S4^B]"\(=0?[^Q^]2P\XY,-^?-M(<$_?)C"OO^N_]S=*
[NV]_A@7;A^%%N^G6-1,B\[S_]]--W[%<"&KD_1PS_-M-K"MF$UZ(U](''D'_=9&"7=-_7;S_X>+']^\^1T[*5XVM!N')KTZ<(12!__P=*
M__&K__QO"/$Y#@,//^(M8N+]'+\>\7]\%;F'HT?IL;-M0IP5#^^%X7<4_SL?-MQY3WGRCO[_]">?^-R9]NK2?L?84HQ,?'I52"GS(;"
<)W@W.WHYI9YY#]N2V7-M1:1I.=T0(\>=V"UB%GCVZ%]NR7^5N,:?8^P[V$GYIH04ZL?&&;9!"6>D-[M$-MU/&$H3UN8A2%8VP_6X7/'_G8)=Y!/H?*
*%_0_V!20?_SC*B!N;OX4Q:%EQRDE-M)L-_?"7X_;L2/Q1L'I:9LD(]4/^LT'.!.(].R-NXQA?>'PZ.?HV# Y")I+A-M-L&/__">/!&7)19#'-6GT,:M/D:1,]G\\-&)QR*
*0=*7_L7'I5?_>9VN#I;O-MH(4?N_$K6OK;(#PP7_?OW^5$Q_[<*2L:0E$@3?EGF(\M8C'}UL7?)Q_4]<'E-M7YK"0'S7OY^L,,:A]_](CT$H,F@I).S7EC!>_?*
*5,#_=$/(A5X<,'"%X"-5X-MP*$;,.O?N2:KET*T"ARL6@B9KBI%"0A,)01P&'P".7&]?#]Z?"$0X%<=1-8A9"Q-MFBI"]??)%4#,0.W#)T$AA4,*
<.H@6"#$8Y(<7LUS^^&48-M(-40,2%3@AP64>#I%6'IVT%(G-[;G*QCLCQ=!2<_-#E^O-D>N%PU8D&JBP5!9-M:Y0H0$JBP9>,ITJH,\2041"BA
*"B%*97M(WU>>F0Y<[=NOS4KV&]D<)#*E>-#-M$&6UD@-#*922&YDJ$214Q@);L>:,.0R8E2O[GUO7Q>ZFL0EA(O5$P7]89-2"0-MOD@YD>E*-CE+_P-*
1'+3R-7Q-PL$5^<!5N-E>_"8IBY-&Z$F=<:&6Y&"P.E+E-MHU%#-)=D2@*F':P=7$5/H3!L^O;\EA'!FZ-GDA$$"I+!1968X3,-*I-%LFD*
M>&"Z\O!$L>7J/^Y1&26+-@0W0&R'[0]TI0<+]C(-"51HWA.(@@31[U4A\W#[$E-MT9#RST-W;0(6LXNVPF-3W[/5!]]]:::$4)C)/RS-6O
*>]H$O/S&K@\!!8!FK-MZ4>N_C[YAQ8S4/O8#-PQ.(#]QQK;IY"HV_L?GC9N[(FLN0X"\\%EK*8?O/K[-MY!]9J"E-"HI2-M6*!3*M3&&(_YM=O5&O)3N,422-*
*2&3AD:*6HI5;./;RR8KP+PE?E;7(|"OKFO<9P_?(]P&\?Z_PH+]"#U$*,T*K-^6YUV>-M(M?'D7RUJ4!!JH"0X;(*E$"-5%#*
*@TP%&"A*8:=7@<4!ASNR@'T(@Y=X?Q4<-MCI8O]P82:$B54-I05@TA*)"*'B1J4]*@C@.2I-W,8>>UZ3JI2!0)V&@-V*-MSRA-0+F,&@M2CT$AX3X^&?A*
,T("^X_UWB(3L3K%]!46W4C+8VPE$NBV14.<-MRN9%@0&UA6ED2;J189B(H#-B$$C-C[I#1;?&=+VXD6UYOV,KE#\GD(,"W6PUL)[=5EM;US?\FV7:&O
*'T)WJ:W0YU>0]{(1I6G#=ZD>M6>L7J(-MLKJ_7MRO%]>(_-=Z=;N\GF_(R!GM_/[JP5;_{)8;-.&;.+&>]JE=K^P\7F\7C-M';I>7&YFZ'ZQ@37'>13A.&]{8*I*
<&8H9K=H@F4($/,3L5-/;AD0^I2"05N=-M'M/K-7C\PQE-SI*T%+<&"ZV_$N;K:EP!!-1F(2<2I9YEF4Z&:;>>$"GS'.=G-M6&V_L]+]W"?H_RS^>7?*
*+8^P%LWC*RL,7UU_]ZOEG62;-$U<,&MH)5S1.K00-M0:RE!6=UQ2-(K,:^X\"^@Q9,4HI($8"V)X&$=.F_X%S=.!UQ.9]I8'H$=N8-M<$1V2O>:.JF*
M3X_0C]_/$*NX2\G]VY]^FOWE+S]2MW)-"'*_]PS@1U@K7/K/9$"\)7,CF0F-MRR!P5B9BM6A5Q=]!K*C.0$W%,A:F*_FTH)?*
*%P.O%@\A/EJNL_A\Q'Z$R5*X-MBO:H-M?*4)F(AVL@>R&!F#-OPZ^SMC-OB-&WOX#:W>1GYD%0]BR]/>O95(B1NGM-M0Q@<<1B_/A-^8V*7=*-TI(?*
$\M!&C0*Y*#2+4EX-Y/!-RT-30P+OR%%FB"'Q-MRN@IF@GA4@^9F#-X%\97"#.)K3SB*-Y=.\;L2.&>;.*32WATTDA$;&P##?
CC"+>PT&Y=L"2R@DU(Q7W).(D-8-MIR3GI.Z,2D<5QJS1[44P0=$YP\K=?RA@_RT-?"807F^8,2Q@O(\H8'/293O*
*MUK6>7,^-71R171Y[=+D//(=8&MWQO-:3#ZZ'-*W%,$HHKKXH(803OFZNF"-M.7!V_D\V[\.OU?05;SF_7-XN-*
\O%&LWOK]%ZL[KZVR^KV^O%X_IKM/C[Q^7F-M=V-L3R_C3(5@A'UIY)[)H:%M2"^:]JX!@8"I::W%2"0J(P$EI:2[#@_5,Q'T*
*MDF2JP/#I,6+V18DQ94C0E!@1*_)DF-3;E+O*;D(<.33P2A#XNPT.#]?XJ2$K-M3-@)Z/OEC)>4Y5BLA-IVW%GM!]-MA:&-]1U()#F-*
+H'],I2]!G7EZXN9E'\DA%$PZ8T^7TU>U-3-MQ3#@G%W,4O-!>X8W]D*G;_J=!&->(,UA8$5B%;VW(<[;M>4@L,A+(@=&%ME-Z-MCL".HX!9]_<__?
@]LW#Z%QI<)D)%;294PFDA>]Y(VA9Y>HOO)AZU_':8-MHWD-)ZG:P9JQ9I^::D(&BJR;&A.2974YN7DWHUK72+/-XR\B92+HI3\O%RP
M71Q92JD/&514O0]JVG&1]B&-6<=#>L="AAP'M3@&-KYQT.:]G,UHC'Y+@H'F
MR]]F/:/BZ(9+X28DDZ+IYIM614!MSM5Q1^$JP6CV;FK(D'30XZ5&_$^@!-=NZD?5-+WJMVK7&-G50-MV!P6&!(&-L1_T(%?*
<\1G3]"GC/!T.)ZFSD1P.+CQ@:WB]YVKP<+++?9MN=(]-M.0!K2C0+4]HD(0>']1_1Q$_]W#W'X.4CBC@C[_PU'/K_J%O]H.8H[]\"UW%*
MKF46EIEY5^TRK0S+K6J=;E1$^#K-I9K'<>@^G6)ZPXSB-#U8DZ:+:!67&T!._MX(R1!T(&D[",YXBIBA8)(4&?
P\L8KSQ_KX)!/7<7\R%Z_.TATS8>#'B&EE%T-MP@[XT\,.8A#[Y.@?_O^W???OY^A/\^^__Y[^O]1Q#N56*=X'X3NO[#S/Y$?*
*MI']UF>#\=#EO94)+I$B*]!A6.:70SD59%*P&!ANKB5BN!FA%&+"TIK,Z$,'+)-M^^*89%"=!*B;TGMN2#)C^O.?9G\FO_]E_8_,0,@_?_C3H[.?*
*_O+G)AM3U2]J-MF=D,$5)'S+IA>@/VENF4">DXK*RXY3U8KK/TKZRC2_9UD]\@A0:,A50+4$]&-M%((/"9$,J>*E?(6;0B((CUT<)*
*G0^9%#^GS2Z_IA,ID#&7RL*7M\WWDA(T(ZZ?E2*U-M>?P-?5&M8$KSL;5H[^R8(KX/34[P]>?5*W0T/7-O1-M-RV=A&VM&EM0P!FR]J>0[U*\AEAM*
*W(#C;$CALCNO\SYFGM)*W+CA/Y\)) M!LM03+I])$'=*F3=N1QVDOV-0]:N7NO>28YLRGUDDWCR*TH9I@&WEFK6]&X*
MB5YR"LD%]&!&]&+&C+C:'D)3+]XWK$T/T/"N,$(G8^7T+\'E2658F6#3/;HNT-M)JB.9(KER<216UP5PP!+$I/4K'<<+#^6(1EF5IE3W)W:K2-:S8R9?
1/$+5YK@-MN3_#?*_;5:UYCH'?DK>8A13!+(=0%J/)&7!H8QQ!D1UM)V!$>D-_:4H)"N:9-MQRK/EF@Q!24LLPQ%(%"3M110C#&9&D_:=E/--
*!X.LB56%"@(=?4^7-M=X%;-MF$9DS;79_VF@0>?6M=P/U:/53-WV#2FCN1N^@I2:NSTEAA$6IK//4X!#6Y3F-MCJ&L9:9M[_K*8]CVIR:.G&-R'^M5[?*
*+Z_EF04O;D_^Y6]QOUFAU@U8/-MB\?Y9DD-6-W[J]7=P^/B%X*V_'6!,E?K]0B:%H5Q0O.5KK9Y@!0[6NK'$A2[HZ)3D261V*73QP#NN5%1_8-*
N'UMYOM!-MB^,>98VO7N-@'81/:SJ-T+D8$"EBA4L9T6)!3!PY8>ES-C>T1P)![1"2+RG-MK]>V07A@9%&((/5Y",0[8;S:AB2)"=*
*IE%CF/EI*ED&:XCE[,CV&&[-U@@PW6-M88-,4,9L9GU5-#C3$W/2P^[X*TM(F],4:94S:H2UM6);;Z&>)-AD6#?/$M9KG\OKL,*
_2:6\2$8.WC8.;T,&S'.'#MN82+&Z(CM)0D-MY?(1PZ2>%G&FO7_+_"F)DDZ4P.V@B^"4VE#!M*;VO,ITUM$-MIQ.EM-+
*(892:C.4T4,I00.*E@PW!_P\)N3TH"^*HWBU_1-$3O%H=!UX\IP)-M.0+D)7&3&.4K8ADTT-6QFAW!76K&'@LRE.(1=80H%OCE<$=QC#"(#V$010]A*
ML)66Y"E!0.YX:HR6=S89ST-[GLKX@KT#@4-[-ENQ+6(W3&RQM/5(' \T>$+)<22-HP4#E$-B8$-UG9V"(PL'G#NBP-M?8MWEC=#6]>W?-LEK!>ZA
9^=/)B\/S--?8(N=E7?IG%V-L^&9AOBPE-H'O08.4T_B^SH-YFA)^SCK1OSN4Q\7+BD#38K%;_6R@QQYAA)TII-E-H:L(,(N2N(:94(-M&+8;T8TSC=I]:.TZS-
AM:.\R@+?4NHSSLU#"J-M=-X&]J15/A1J72IE;HIN-_)/?^)7'0"(?$2K([?!WY09C\QT(9C)-T\./W7-M%JIH#8U((+:AR56]Y%
(!+S.6!/5;DTZ^Q_!&9#BKDBS)]TW736CY$7$29"']8+D^75\IO\9;-R#-+6E&-L[<.-M@A;-K@4ZB/6UYJ^FG-D%E))
!1J($LGZW#PQ2@:DC/07FLO%.M@@(N8VF0,[-MG8,X)SE:OZ=&]G8(RSAX!25/$1%Y$9HH'3]9@&RQ'TY*%P*JQ-/J0K,:!UHH-MFJ93'(JHM*
*MEUT>*E(6UGXR5\@W-89$'CF9SMIQJ?KGXAHJ^P@AZ_='(ZLX#A:?";+<1-Z-MKF^%K\L8'R(R)S;-%0W8,7X:7DL#]Q%'A"Y-,NI$ULN;C#(<8(F4$>41[*
*(+-M1ZUYHC8?%N7CI

```
<9&3\D3WKF^3X\0)I]8<96U=.1D%L]*4C]GD/(?[W&R(+,T(3>A K_AH<9^3[20_&?^6M)W M!'<9UYEM-ZQ9_#[F/5M^>=GB@IJFY^LH*+5B,H5]%I
K*.K*TXD9(J2'Z">2] O"[CU6X<[RDQ[8Q.5%@>%^O%_6:^ M6:[N8'X@MV\UEJU0(<#K?+$91^>70(%;0Q$[]5;Y:_+S>]H?G^-UA_O[N:/OU-
-6R\_W"]OEE?S M^PV!N5I]O-\L[S^@A]7M\FJY6)]Q]%$XR?&=M;OSW:UKDYU8?3:IHV!^8HQ% MK1,;9QK3])CRP<*?
#CR<7Z346)Q_35:_/TCT40352LWP:9EO 6^:0JG$+)9 M]P3(!JFAE+NZ1A;POTY+>% 2I8M'4US@(?\3/V3YB^=69U2(CWH+D^_71S=6 M^92>7Q?
71/5K\H,).J\ D1+@-ZI^MG4@F X:S)#7[1;L1 M0X)8B8J5FI;G&YF:'[Q0968XI5=YN]XAS^;TQ*OR7FW)6*XPBK= M?
3L*YJILDV,M$.$/Z8MD##U=&49PF\U.E4Y.&!9N0812L7>)+ P)=B4S-2+TRPVZ':U M7J.'Q2-:_S)_!#X2J[+?
Y%L5\.8HC]*C2H&-4)\F=Y/"TQI0B&&8Y$';2C.P M-4B>"=U;,8EV5MO+4^3ZQ,>SY)57_G]E^MX&$>C14"NQLK=#6EAP3XA:L%?3
MIL*.+M@B*T_1.C)T]O:=TZ>_IR/P!*Y7]"=#?01.A%G5A$&?DO^%=PU#"5GX M8F/XB&J.W$T08G?G7]$ZY3YA,K3\R&,_:OB-'L2 ?
$EO\3/_TID2G,_IR7(G M/_24/NVP:[FI6SX\LI/Q49PS .6EAIZB>D9N0A&E)%&!9N;5#'%G0\]&]LZG MW;3 UV^A1Y25(IY*[]@2%
[82B[9PU7(KC8A@-54T.6M5B]:T@&,H>>N%,D5U M,4VTP5J-0^$DV648R!1 M@D,?[ZSB/0Z39SM$/!L349X\K/0 FKAPIMY*N*)-
:R&"&&\+SNH%5"@N,T"& MG;Y-BU".#V>)&KE2?63_P(L04>$%8D,7^WPF3B,(&TX:F\$ARW^]12C7 17# M A4$53$CJ R:@!N\9'44";R/U_)PM-
R0'L"LPK0/#NTK[N]NW6?LS*,(ZVX; MNY$"-)\>HI=,JP,=&+/KS&A=?S-2* A12HP>DK"\7T8/<8(F&RW(A$"O>W9P MP!OKL^ZZ)P.'7/?
4(I37/3$LT+JG8D:P2%!P1.!-MJ&N,D&O?%=4T>A3*7I8 M^^A&?UR%V'%C^E^R;:D* S+EN%&0ME72BAX0LX#YUED59TAB[9W$:NK**Q<;;=
M6Z0QS'B]=X]'7F_^%\MW",+N*HA:F'5+ D!FWDG,S.Q;8<.Y@0YL=G(+M_^) M[5E1Q.I)I>M-E(S.3O'VR?C(I@S,D)NV?T0O>\R.-QD1^B.BR8_\][0 ><3J
MR9-M$>V.&Y9^#!BRRX/#*"UUE3(:O4-+&2=;C/E84:$ &(6@?_.#6,[#K-A! M(8&*T!-AA4G!*^"SB__H9.]3J0AE^BL9FR 1-FF?
7_J'&N\O>Y=@971S&E!N M=P@]2FD@0@2E5! C8ZAG'E1JJR8U[!F'K\4JKZ%@4_^T^95XG0\?7BW^U*JAU@B9/!6:2#Q\_;L].*I4ANR1'64,,S>8^?D
MX=56?&5=ZW!9!]G0JS)UJ#;\(%#AW%C3E8=\0X\ &!:.(TK] MMZ.GE66&DW MQ>.\PS'P<1(DV6FBB59#6A$@6& TT4RFX] G 2P;9RY(RV%_K.;O"
$_L4$- M<-DPD\B:EU"/XGINMEOIKX3 Y4:S660OM"ZMB$P6,3/L1TQ&5MYQ=:3_&27] MXUZ5*\20A $+E XV+:7*I;VIPI0T'8AMP3:'D+MXHO10D>
LZ7:4T)RE[1=? MS7%!X\]-P>WP1DD!IY+VM7HUW"'0OT;S4[P/0MI)]Z/OX+ P&P]$VNCR=?$9 MA[8;X0?B)O$CF8#^CF6 @0UV/(--:RO'U'M4,QW70&
(IC5?AY-CP*!\?G2@# M)>>'& \S]/2*4C80XP,Q1L[0(4XQYZY/PBX_1= 43WD?L+:\V.&E(;J% M4WI$3/!@;<05>R,="L">19]%I<9F9)
(J#N<0\0PD.MW56_[KUQ%K*9W,0A+L MF&*Y8E\F:H$Y?[%"9]"=4NM13+#]02>L3:C2<@@CXY).,G0,0L0M9A$;#LX+
M:;P3F7X2A:UKC?)03PV34#H3*TQ+#WBY+("+K]KY]U3#(Q3^@A:-$"G)G3(*8&_:JBW6J+/CH@#NG6M M)]?3#2PZ40)]!=%5\,KKB+9DH%Y-=.-3],)
T-QHQA^KL;4YHV?>*CS<-%3N ME9,WZOS>V$ZGR$M(T@KUK#-4^DO$9\].6##FH(1V.%GZ)$Q@N22-M;EU$$W8 M$C2))0[L95C
X;F:+:6B5IKL%*B8N/0.++)#B)AB9W>T#";S"_S]<-9=J-T6 M7I>,"3;83F2Q1>K1 +;/-DPJ53<"E1=BT\7J/<:$'7G.^;7=:0&FU?87/LF>
[$H)+DNW'L68N+!_D MZPB%[FX?7P3;BU.$+RQ6[('%CQX=-@L>7Y.\@B!KML%^A\I^'7B*)*U$9BBA MB1C1C)2,'K_]5 M2-L//,)#0,5_QG/Z-
'V'TTYW]\1L)#^SBM?TSB'P>0)_8S YW$ F;(.&GC;Q M1FFH48"W4L.*H;2\TE"H.!9;<\EH%[8,!!4'3%R5W#]UM],HC LV2OZ5VR?Y
MQS]8GN7\LQM5YK7RV_16(&2.*F[IATEU33!RO08P3]&E$%!?\PX?GG HXSW] M%?"+EADL?5/^$\Q7+8XM^Z[7P<%R?8
O>V=]=@^G@_3;5GZ'^;I")M/O6_IQ M\B\L&+WVC1,8](E#046++=DU)K:SCFYL>>Z_V$')K>OC98P/U76E!9X1D9=: M*$D@)4:"CHM47*G#G!
(F^D1Q$4,VZ?RXG7R7\_5RC58WZ.%QL5[<;^:;Y>I^ ME+9BPF?('\(@BGZE#U5$YT/-.%!-PC2%R7N!-2 MOS2XJQ^.IM5;6)%KH[' M,"!>V(HQ?
W:D?!\.UKJKFZC2KAZ(H:)?E>^L)CA&[2M7[?W^CLEEP/NQIBH& M\_C*"L-7U]^)?$AG*G K;D>!B^MO2Q(@JW$G'IOZS$@Z[_!^7 MV.
[;64>R3B]].Z3'IDO_HQ^6F'[D5R>;@-Y&WU@V.ZT5^:/6)(!6\8ZB9HMZ M2WRX-;X3HPU+OIO0I*4>3P6J?#4Y!I'+@N3TOBT.6+X!VB9C0,4 PTS%LB!\
MD0YW/X^YS"S=)"4&&2,,+W?]H\N^]1AN*DMN25LAIZ\[B&M=GPX'*WQ=;==Y MF=)"?3M:R\
[%P@N484D#N;6!IR9S=P/1A7.#@PK04/;7];=!>$BZUSX%IQ@= MLW2LI[1%>?I\B$4N$>> %;TIEM>MU \F7$#YSG'G+T]7RUJXSXOSL\[GIS!&
MJ<9D,LJ(MTA]>EY.I>RQR]LM*>CBF:2SHE%4NM<&<<0G1,QU5+GQKN':Z%U]4Z5PNNY M9G
X+6L2H:A=,E@0K5(S4],F06M0Z&N^OI*$AC0Y31ZWWA"]$KV44YJ$)B[D MN60+X0VIS5;P597XV$P@S=X]@4*^HCU:,ACZJKH=F&#-
AHA07.H@874#@8-P*=P$1Z2;$]/6W.@07PP(&WBKF2^&V M"! FR)9S(D@V);#L'C>!AK:%080 UG?6GCY-V5&=D D 35=RG9)S6M0,#HN
M8:.N&PPPR_4RX]2KQ+SZN$L(:HJ2* ZX!' &*(HZQ*ZJBA%'6;7< M*1=/,2AD&1$YZ^4Z(74XH$(@,D8$E3XH*'M/P]7&D'6SAP@F.$6RE#OJ +$&
M!NT,ZRS7'6$. ^@$JTS('""%,T6=VW,.7/.]5-53$?N) &KN4O9+I5NKT'! MU&F7L%'?%9<+PAH1^Y69IZ> ROA/#FZ*LM1%D*M,#FN XE29:5*?&:
(8HYZ_ MW@:63\]^L,U*;.3GKDT84.4VM03)BVHJP0%+9VKP)4C7.1)FV(/= MXFN#(PYCHCUN1Y#67 [2&91=9F,4W MLP_Z/NI64KED>/)G^TZJ-
D4#OI6Z';US-:NG&X MUT#G^UJJ:?:&?#%U.U4M&[4WG6#2'I?W5\N'^2VZ_+A>WB_6:S2_VBQ_76Y^ M1_/[:[3^>'WR:KE8C^&V
M;P)ZL>#SF@7V:Z$VX@>RIM\&4;3X;'LGAPB\L3Z+9K M!2#GVTW0S+^V0X=S MH5WXK#]UX(_NGS )\C"*K<_4HK><,K(3TBC.:1-G2@M 88>Y ?
I0._GGC@R* MOO'(L-_2=Q,!L2/Z9_)'ZG.)Z05DXQ$1<4##PT$F+2&"4BK%.J/H YL'2NG; M&PBQT,<$?A@MY-4K(R'G<'"VLK2?R:TA!3QJ?FJ3H<=A]?
Z)7I*LMORJ]M'QA"U 1 M%-"AM9SA[&"Z#@)W^"SCI?;5.2#KH<:?:3T16+"+LPYL*\# =L9B*F:X96!((WM3HWBF]?? &9MBRT Q)]^&#ED=O+L=JB(K )
MYM?Y(QA6H^8!A_0/U@Z_ERSN:A2#JM0(1%&6]2G FU&GIL:01J&:&GF E];K*]E8/3O6<6#_ ML0\\AXA &4J:)XO62"DH4*S7P'H6[DG@X"(^)4/R-
G+QWHJ1@R.;Q!PX0E&! MRM>L!Q-<:XR6$A6@$0#&J'I-!(6ZW\+G S^2PIS3)9CLB]D=XX*,%A,$@1 >RYT+69V*1A#K=AW$>C+'$
MIHD66N.M&3F]':39K*[^]LOJ]GKQN/X:+?[^<;GY';B]ZYZHWZ5%U.^*;-"Q M'S$]*[0QOWS-01ZL5_9@\,4*G=61-39?G6)6^LCU=X^!Y]T$(?
U1$FB,-1A@ M(]E1IZ_4?7:4D6!:UHXH2MWD**6+)TH*%8=#A?'0TRLJPB5C(C;H#"7#DO_( M!T:?Z- H&1OZD??
T,PI\I#2@P/S$;/R)3<=Y$\ZJ/&DC^2D^R+F[J*(44WFG M&>*CCNN6CCAT V?A.Q.Y)N5,EJ3'OI/>.[QB:Y)I6,=6&!LW$4]XY_KLR?1D
MTS'E8J4[$>>]6'T@@'&T]!^8HK&PQ6Y\(M\BE7FDB16.=+XN2C%Q0[HH MP3!GZ:*D^8+DI_+A/(=9CX+^E.J^_TM+OI,F.UB5H=
(H^QX@S)@<&KSO 3W6KE&6YX,U>?H>7K MM )%W2^<0->A_D'^Z--_'E=43=,@..^&<*FMV3ACO]IQR@=UKBUY.$\/VTG( M<=VL\-+LS?
O:83[$N5RX-PN6V9N.,76['*1_4Y;;DX3Q=;B5HQTAM,PIL&N=(C)'/($6CF@ MF4ZROT2CGC;GXZ," V_G_J[+_-96@T=\2-
JJ704^PSR1^;IUMQA]\SNV0D5+ MA4%F2:/,)<0\):CI8DF?31NP.#PU3\)3Z\/V3 ,*"K#!X>$'U>>8FA/@A01F MXFO+R[1LP"TZ$'("7GR*?
3#ES0S?:\3G&/F^3U:@9;@[SN0<7;)+D4U'Y;N8 MPA14L1EXR7/7; 9'@(5SS!!=[+B1IN-& L>=^NU2R8>$1;1,CU;,\>.B]?0,
MOM"E^@M=IE_H\OR_4$,I(4,_TQ WOR.MJU<662@\SXCEM#LO9[J*]IW\P1;/ MKHR<[YK93V+Y<9"5,,@P@5Q#^[_Z=?[WQ?R'_LT:\D-V,$<*?
K$!QKETY)V-,HG^.XS1@?"WI[LK&A%U7CO$E#L(\=Z!:OO;]B7U5IBGW26 MV(RQ_%;I2UE8!_XFPUSLC[2B)E=@!JRG73DYT]6TW\0/MI9V8^-\5]
(^\DZT MY4Q8[+:A.==U<(3O,L1&L]>W..Q6CK'T\3,6,%[,K+V:Z!_29_ MP%6P&R/GO [VD7C@'25.F?G_=Y3&?=GA=I098U_>CG+@;Y*1.^_DE$*6C>9\
MR%J'@7!ROLDI/29^R.24#FR<97)*9SE'KAV5<650^J01'Z/32_UI"/2 MH&FU%2]<[*_1_!3O@Y V1_[H.SADG4WX)#T0.:/+UW(]&#]_HDY<4PT*Z&XG
MFPD9Z2=)[9^6>W7='QGB.9]FQDD(EK?BS2:QB#GH@,((=TIU.V-8IPOJ96 MGX!KUM%M^,F6CW26IM8T<0.9FFR8XMVZZ/88/G H_32K$NY\O$=
M%O1W:@8'.D;7$"$[Z5; PAU&-S(EZ".<'=*FA[_HR#2&[>/H(2W4^6M[880Z M3Y#0)XX&VK!R.">T()[*VFW._9@;V39K4W?:"OO[>B-@B=;?
&^;^L2.N/[> M@C?/A9G2,VF]VU'\A>^LMOP^J5.]AR&'?2.>33&EH_DXP9CG[^VD0DWH]\A? M^:E\
F(T6=:D&SXAKSA;?""PV19.+B3>,+:D&_$"TJF^7L_ MH4"3>C[&01+^,1[>DLO3FUXN/"_Y1EJ,S?GYP4_'H]3>\':D&_$"TJFX2OMH5(-PE^I_@PJM'?B&]L
MGN#1W*1\Z//WF$VR3>H\.3/4=11?IR7\O"5'VGK6DYDI3HL5HS4Q0':O@G[\ M?H:H@S/ H]8R)3O.47UN5/5V+]-"79>61Q]3M\O;AF+1M(1NV$_5G.D-
PY]! M*>"0$S#I4B!8 ,ZBQ+C97ZSK!+[!U6.8:K0 W'TI:\8 56LG9^T+6"F&JFX[
MW2)Q9@^+3/EPBGG4JMI^%JTL"K.V)+/B^I%K_VIYIPF:*U?',^V<9L!)'*F! MB(#6]&/? ))W:^VX5X9\48N=E,/"MGXGS/J L/4@'. MJ$6CF^;
[1IO@T<^HZT,;Y!='D@WHC+K SEL^H]:>]61FBM/RUL^HZW.C.J69 MY$RZ-4MOY#RAXZ<8[1"A)3_G?W+02>!IY@N=X1ERIUHMY6W#
M!'6@:@.:YIF'G,:1JCI51C/(JPXGSG0UFHP\%)AR9O-3 =VIF+K:$G7ZEZ]7 MGA5%FJ62ZAA&U#F2"2(I4E0%AZXP).9'71Z(!2[$+AF6&?5\&"N).+<-3Y8E
ML'#:I&2^J$="0! -4G!2TQVN)IGB&/3$MHT4AKZ0[;&JW ?^,XY(1)R>F/#P M_#'PO)L@I( C+6L_GX\8UX^N3?6=NY:3U_T^AO8"70F^!15@;U
MT.>]4NC(-LW*D;4LR7B9;"WYB4^XS\XYIUE).LW[,$TMP9WFK]/%QN*ASM<= MJJ9N2-\G&N M8HY,/._N\::0S4$D::C;;@6:D@O3'M>-
/N%#/C=NR8)!C^U&EG'4[0#G*._: MK;LK,&$K /XA&.";.8FIWA6 !_X=&'H#&X'.GV&22TF#_3*@N'!7E^?CK4WZ M/&_JAA/*3VN/?
KY.N>4$#W\U^C;=;2O9)KE_2+<:+]I-^'6\9'P$+HVX8.] M@/GHNW'TN/XH; FKB0/GG+2$*;H4)0*((]#@2- >-L5)GE%!J9
MINHO!9I4Y1NXJ&D#@Z49.3GT>,WMV^K%;VZ\?\0>6S^BO7OAH11OHH5$]K5!Z.7O"*C7AJ MW>6^\#[P^>G)XI\G$B4M?;+'.]%?
BW6/>=;VT%>5K88^P]2##E,[2+Y!BW'/ M*\F@M6!C'*W2K*2D1"1G Q7XJ)1"Y[R8DN\&,^7BXS#6WIXV@$C:#)F3\6;6 M+&7MF!HGRNP+O?K$T-
5SL[>2B8NR^GCE M_)S7)>%@ H^QO-77-,0#W9CPE]\K2LM9EE9 4U8^L[Z2S-=79M+8%?(\9]/$ ME7386"/)UIPNN,D&?%,:L\HTCKPE2T9[*QNQDC@
VZ^FC.6Q#S;!IM:<5.UA MI4XR&4\-M4U&'/1-.3?!=([LX HCOA4G5Q,)P-$5>#"C&,K44VQ(BG,ED6KQ MFI3:(8O;B MW[@WS)Y'/.H50I^0B3,,#GI-
]R#!0B<.SBMXZ"$BX*G>>955-^*[G.N]O_Y$ MC'/YWW[\-^UJ1T@#:#OX6W6P8R<$=/6MIER._[^N53!,62*](O@O)E5N'%N
M^*L]%+WIM;AX4R:XD!MFYJ?H6 "XLK:8 ZWU],P7DNPB%FPM$7#P%I<3 MZ41/LZ+4AG]CBXI$/L!U)>/HBUA:=.>_.?'CW!<8W9EX7'\LZ,@7L-
3HEQ0W M(E.@'9=O<32,@X)DT^"_ MZ0N+J:O)%[N$G-^Z\65D:KSU5D;FS]Y;:7+4\O[-O-7U2VB,--9'@DB9^-(6 M6V/:+'5,NC!CX34F.>/\VS--
<,]FWBK1FK^WN$IT_$@021!?VBK127]#TBB^ M^%5BF ]H0E^3T>_*Z$-Q\U:(=LR]Q>6AR^>9-)U!B[,WMC"T%QT^"8(R^\4O M"-
\.$/*9EQY5A2MMK]9=%;B5?A(I=E83Y[,2:L0X!QGLQA%9R:'!G$P3>S4 M=(&-D9KE;XZ=>OZ>!GC@ZQZ5!.28;I5$Z=1OS(,92">@(O:1V#W;-
X'G[HTA+$Z%/6;"1DIA=1R:'4PV1:>;?U;3FKCTO=2L/Z0:1=R M&>:[<4U#Y H[']/P=AP/R)_U%2?Y-,GWF,QX'_&S&Q%-6VT;W! K&\E^VQ#-
MV=7]>HTSA$E.HO]4J1U+=_J&.:.^@M2,)(M>XCU&F#7E_3I"=G X!#[O*(Y> M]JZ]1R_!R7-H6!_B?Y[<$#M)E&_%L44VV
[:4L>7L$<)5A9/H8LTRC<./K<* M?YJ.A59;K4AREM26Y2#)L,:YX\%GD O-%2CFD"WT#/AZE9@VNUE(IHK)4FPS
M7[VAD,,#7D(V"5&Z%Y0!PUS5J;F16RM7ND\4U(S#<\90N7F\>/-3 @0_=!"P M+3A1*$!!'A?4V&C4CR$ZUTO"R9+W?"1,N/[NADSQ]^_^^J=-
\/[=]W\5]CQN MB0L4 +85+HOL=!'A0K9V' HJR1\)6^S2G49CKD^6N@._P3_BD(99M%,6";LJ M$4,R$J)#
(3H6A:&C0857/>=!5SSHIM13RCK<0A1A^]TN>/[.P2Y?@\A_Y$L/ M^<<_;O'.\A9L+R"(5X00T_L2!:/48PA^GG1YD8Y?TP &A3C8X%%'\\?F PNC
MB_K/,)]9Q&+ZC8N_3?Z!ZX/7[3OYKB-&"_\;[,5XY6/%7K8.!+5IE;&[TZK M$(#;4#$KM>^[V;L1.O#7[2S%)V*'JRDZ(OA@.TA-$8]\0MM5-\8#'[A43\H)
M.]82V](2$NZ84<%X\9Q1 9RT"CE0ZX;R4DCK%KWY7_,U6/S$C2O'@4@X-6C MQFYM]<@@X%>/"BNM5P^"#[UZ-
(E0Y!7:S+HQ'K\$T^\8KO8NIC>\]BEVG_%J MNW5M+-\^**%A]A(: J0;"P7HY+N,1E[J=U84 V4H*,&!UO5!A1EC?5ECWR6; M(\NW=D0&^1(CA@-
:951,9PN-" ANK9%SH[O<1(P".B0DH%:<%H*LRQQ#VV)/ M]D?)IN0'G/?6 3M5#Q'-?4?7.KO1@&^K6EZNKBWF3$[_F'G L[-"060NS(E.)"[TA A M
MC2DJ8. A@Y"??A$!3DD"+_=ZHJ6K>09MA)%V$B&;>* 3^AO7MWS;M3RM$WH9 M-. )O5J T@F]&!3FA%[%B^10.T,Q96D:5!C8_
9::I6X1,7+NQ($7#Z#@-%B M'D/A9Y#\A=KXPJ*V=/$QX>EOB9O5N\\]O,Y30F3") ML'LSPA9R)_8X0W$B'WBN8;-,L@/P3A1,MDGA<7<'=$-
MLNFD4MLF#3BH'4[J MFD6.D[\UK$62D?]NDR4:1EME7=B6=ID3,-4RJQSVL$U*ZIQ6S&;9ZQ9*4:8_ MP;ES??
=P.DC/;"J_PYS2")E,SV5*/TY^$B,8O?:M$QCHY:4EN]/K8E9)9VUC MWPK=0'"6HH"#T4TETZF."H$FUU4%%W7?G(",=\C2I P) Q_]Z(AM=^MB1WC(
MT@ +I!1-S&>*(0.<7CG4G$@59(8*&*/6'TB6S(_'P%]8H>?B<+6]VM-H8>E? M!7Y,Q%N%9*^ZV;NA,]\2/[C&Y#LY<]]WR:H>6>%K^NO*YT#Y+W/?
R7^\(;,: M[PN_RF\E#6 *Z +4 ,DK=ZW@',%=ZQHB>K<;Y.?D/#BRI&2<1(* M4@2:Z51#VK)ID6)!W8F;JA?I$3YE#"6,^UNI&NRSW6D!OK+M
MRW3'O/$ >=E@*$Q&H[\[F#L_)%PXU,9G5$X*S\W6#@T]'_!),ZP3'Z:+)NY^MMFMLGT(W=G%T97D> M=BY?JPU?)#?VO:F"-[GH.R&-
/3;U29K3;;,MSVTZ)^4=]W+JB)-'3Z]GTH2S M]P1E8A*/D?;93;KOCO(:D/4#8^7\?K6\$YZ?XGT0NO^2]*940$.]"FP4('\9 M* 4%?!W8P%/=@'@#-UY
DJ&@' ?=!$G7UJCP5[#G@8/*!OI*L*TD\]TNQ#M^ M!$0+@Y-XB#4Q&\.$L[$>\7Z3:(0(;=2JS,QK6P
MX,R]!7L*G3I8GUEZF\50V6EXOF+&>XL&F#YMX?,Z*DEW:?3 MFA%!F&MGQ'ZQ_%?:(/+)]7FD3@\["_TB9T2',8&G%),_)/4G:+FVTU,0.A23 M_.K@I[C
```

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f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`9W[MR2)8V8]HCS%OISY#MF=%D:MU MZ>..* URH=S3BQKSD+=*)]@?JA&1D-\.)2,_]&Y M@-JY&JAXD_OI>QR/Z*5;4C?11W>:(#T/W8JTH?ZY@PRBRN\G/V;643I0S,*8 M]/C@%? DX_A+=^!"SW.S$Z=W'Z@VY\$%GK7"$E6KA\Y3.?8!SX*E ,Q3SH":Z5!JPNDZE S16(=2 MX7!4AQ*_!(8ZE*99T'(H1#R#'4J3B"J"\@- L?'OK^C309Q'WC66S'8#@=6 S M.%RDVR1",=R5P8+$Q&IFZH:"?8=L/>^M Q[OH6!/U>$\"M\.ZJ.914HBD914 MJHACC&K5F;JK&,VY)ONJY,PBQ9RA1/<&>7HH>Z;#;L=_)5[U%.+5\1B$,7T# M3]:[FY/OW+X[*I[MZ*)"/>-I)UK^K$;* OAB#E&\V9+-T> (J2$;*1#$8BGZ5(*F*8ZE1]+(DD5M%P: M|%F:9T%0'!=RQ1"]O Q@#R$^\GJ:=Y:#5_XJG&^)N'18HF375]P%!M;'!2@EM%

{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`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{6UX,^7I"Z}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`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}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l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`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

06.'Q2%L7TCG0QL%WB+B6OBI)<8957 M0*0.,$]@28!\5MB*&+ZW&7TT -?!7B26_(?W?%CX017Y6K.V(HZ+29_:(,/?BE7X M1]?"'"#T2D_6[|CVWKW[XQ\5;ISV|/,X]_Q M?>?8]OX)O"G0[:6%O6U\K,.[)\) J.7;*HZ"YA07#0$Q]X&*#8'P?M5VPG_" MY4A&H'H[<1X40C08^<$K=^=9QMX63B.!L\'>+=>_@^-M",WYE(I,KTU/$9_Y M1B9LV]\M]XU"(O2YKS;? V:',4P|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|FFCS19)B-U4!PL"2_4-TW?Z#GP12\.+:QU:V)$\9A(>QO MLHD!3>GK0VUG#F("WCS10>B? S(+^NT2MSC$LE+!R81%)H24 @HW[+$]U\,] MSYQW,\O("AFE[M.6]&+IY-L$E4':?RN3B_-1";E0ID,'- \\C2S2UV7>J[+D#_9\RUCW)N!5DMQ31[>]&]OVP\O@DK M#J(3""\]'"%A]9'#KT0%\Q],QWI-%^GF&VAM.)8$.M24\>J[R/'KVG_.=>/3P M@QWS\,6S)T]=PF:V$0T!#PVRP=;! Y,@*$5-J>82,7X]9;6@REKU&/8VU"II MXQHO=0*\|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|50C26F9(SK(?P.1 MV+;OO-EWCP?)BP/1%+M!+_4UBH*PIP Z;KY:+2.%B#\Y7ZUW3\7'N/U/W@V-OERGO8S5?0,5XTQ]N-W+&-(QBN(CWS4'9S:9.%.(=!>E-3AR?M%,$Q@/N[*<&Q8D.=57;%4A M^607$I*M74JW"NEA\CS6_Z;D$R9 MI^ =NGZD\@+I9YZM_^'_G?@W??:2KS;U!/Q4:*KF,HS M8-_XU],U+7SNW#ZD5'!I^^1%09H#[4UC$ 'YZB!BF? S7.W%M MH0TN.H1ZV%\K8?=:,B;48@\7%40<4?^NQVBQ,$??1\)/|_G M>Q*PMW(RS&'30$0<^>]P& 2>K9#F*]+&;R.NLOMN[S:9"TU9TI#ECR@C]IZG MJ70X)9+:?7-$DOVEYEIL?,KA$#] >:H>60(87LO$]TH[G;(6G=YK,P@G)!RUF M@C\>B'U==] ^V:]S?@*9+AC0D";H>.,*A+8SKN8=7WM\ [BYOI6AE3/)1'/DZG] MBW#IAW=A!)3LPDHIH$"LFMYR-W6"WYM.0V=5M\21_DHNG^W^4YW0>)25_YR/ M/OYC@K_? 7]\DEK_ZA_%WS0G^%O7>.>^0Q.K+^"31G_M.F&.BT34DU#3 @ ME3\?5))>BA# #? *?9CTR+Y<8Z?,+:+\,@<'CAEB+'ICE)5MKVDEY,S2\0JQ M=W2R:'0W<;C.'UD+VUG[[9?8473I=A2'SW7@X7OR[RJ*"C=N1/3#&%.9#=,¦ MC^\NNW=WTIX'BLV$9(ER%O=H.Y_T2VQOTE.98*0!)V/A91&3 MN&CNLU)#.5 M!6LFQ.@ +Y29"#RWG='OP$4[+]MOFA ;EQ\TZP]RE@1BX=8 5JCQQ'Z)36(U M#EB)ES7DJ3I=4$H>E)^D*07,,? DT?:]VW/^QM@:YTS*I> M099B(F:04/P'/ M?]KSE;UU-9QSQ1AB7W8 K-E6Q\\^T='L&7AH/B#/R2SU6P!D 1Z)ZrFR\%+, MV%3,F/]$VMFA? RM+C8(&%.=&&>FEL&A57@1^0UL8[%E&7L>/2K2 !2P+>)%D M% #X40IDNI@2"E7!+G=BQ(M%NUG1R?D =__)B66[#N=8IE:F>_[*,$]"40)AV0Q&!G B5\'ZX4N#&]%!"_V MNYSPY?0M#F"Q+%)L9#\#.'3,=WU]W["^G> M7Y2OQ M$[[XA(7B4$ A'E_*)S0M*:>7^ MHGM_V9(DYH2A7U)BH5O(:-S7YF)]R"[A]BT<(!>;(H&E0\#^5NOFXC+I63V8 M?/\^FG\? CN>S3G_\B/X^GH_&WX;CP6@X;]25.D]PEG=;3.W\Z%TFC]650E[2 M?#O+VYJQ=GP<7'9O+AM,-EA1^8E)H*(2A,1T:6#E?X(6], S? ?&",%H+7$D MJK[K L]!0&>A?]E`]PSQP>!H06IZ,2#!>F]!%5M<'1;$+F-@R2%OHE,K4C% M$5ZH,O&$6BLR<65]IS33V_67#@#*_O&$6BLR<65]IS33V_67#@#*_<,JT/A>4:AOVU$BE\6?1@"1K396]",E@ M7.(%J4C"=Q'AI0TUKCS"(1+F0,N?2<)"+>5&/IK$R2-/:%&HE_4] 0.:6^(H M>IL^BCX/^[.&SYS/ *T7@/H!+[EX$]=,?F=\.!Z!JSO0IU+>4]Z<&G&N7G7O M]B5(N5&$3NS*B%$VX7NT E^ &=*DO\'X!NREHVU64-=,@H<5L:S$J-$C$?<; M8).U<13!,MG7S#-7;EFI4&3'((§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`M?[>#3L(=)_ARQ\2?[IC1M_1\>2T_-_VT =FF2'H(N2Q2U?5)?L^&'86\)I[MN2'@CK#UV.? +Q!WS=LZ_A/(R2(F?YEL.[<7U\1MW^%#'7O1\58@ ML='#/YRW>OQ,H7L>1P?HQRT8(_#F/X'Y#KI;EK?*?[7)WESK9P*N@@M]SM=0 M7E=*_>!(4?.? =D5ZA:V<#*ORY!7ZR*\%9$+:9'$\RFTGKN"[[MWMO<*$(DHL M]*V?/*YK),4\V5MRD"BV9DZ*4$2!Y7LB6'^?X#N/&0HW+2-T90?& M\$-'17.? H95J2VU&,4E=]2%CIKFY:5<] 5=0+20)BUR<7BMFSS*7=9N:Q\|[MMEWW!3BS%5(LUWY+ITZ;SR<=YXGLUGG93CMS'[M3X>-6H^'FH-]2/8B4F1I M)U7Y<7MUT]@HG>DK8&Q_,%DDN_:@N5!_V.&,D;;E9Y7-2[+'W$Y\!-QW>[<7 M&KG;9#>0$WA?X1:G(R9=H:0+7K4>9HLAG=[TP-T!1- 2GY4S?.M$PK4)OX M_--=L)6._%FD4BA0/A_WC07 M_-?_!U!+ P04 " ;A&=9EAR]:7?R.-8N_/W\'MZ[W^=T]3I%;D\8G*JNLXPQ.Q@P9OKB M)6P!QA-X ,RO/!*!]#*2!!*3T$-5P$*6]K[V]"WI[_^[,HW$ CJN9EO__3=^ M@_T[2W%5C5K_-[_LR)7*OW|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`O+B^3 M8NV)YCP@V*]JZ.54=EK2S7RSXI)K>59OLQ\A&"1'E>%D5I8DHD)+,=!IP+S! MOIM@=TH|BBS>I> ?:21AZ@% M'@J%D<7=)$':-K]"7QR28%D? 3]/6N&/H)K()N7&6L?P^PDP8 -+[3$O[,D QA M?-M/)6]08TOF?1Y,G0HV,NUZ;79@:JG/#\EPHSY,ILM6A:^,>T63-46QRX\W M(1GQ;$QV9?63K$;*9# <26UV7X72$I_2NZ"9YL2-5RM;RBYF=<^J^-*(JH!-U MJDP-K;R@@@MAM@@MS79JP$*3=\E5(E,.(R)MV2GGN6&IQ;SHYA=G M6S)"1M*)&>'H! <88X69C*?67XU>R+5=FOZ[!5PN_T>Q+A6>2 VM6YJL6*_M6+13S9K ;'-*T[GA0.Y4VLM";]Z\BO8)5/FBH(AKEUG-I0*G$%-CF//YYE?; M;="':5]M!T.SRE50&YNRYU ;.JZK\%3?U&=:UPE%'! P_U31+,WWSJ42#B$8* M',V^9^UV*A+B&0\<0PN=<&X2]E>RHB4UVQ"\ M !\..A[0K)TW\!! &]8&,W@ @18;&**$MUV "&'OMD1I^UL>3NBE6AU-]?-SG\B;?B[_&'^FT7\8-*M!%HEAH9P#9T3-A_$&><'7U MM8"M:@,+16HH1/6=,!\W1DP*6VQ)),N:8[:[LX(N%,5T8UY>6+[TB$2'G7<0 M.,#00+Q'D1Z:?@NQ.N1,%'^X&GK"6^%HF?4*2- 5[M*H0>S.A0:P53#W755 M07'_J;KK7RC",V'XCLV0SYS >V=N]X44$]M.?7>SB-FV6575PNZ!T0";BJ0' MS#0/&%T0PLTKN:X/#R,XT6BMQ22>6DITF12:=]Y0=V5$,IK!TACS6$/\/BQP MB=;GPC#1_>?OL([HUHU*A-!4$U%=T6U8??/? 7ZZ&Q"ZL%XJ^FT3%7B%\DKM* MJ9N5JX;+=K\?]!E]=&W?B3Y%)5VW6W)&L[@C9_I%]+[7/)14U_?F5([6M6RR MV$O)-4Y-(NIL1P*C]:'=)TT-/X^0]D!$5(!/%MIQIMIH9FJ)M)2NA(M1:4;GGO:9Y:9;__ME?]3Z8YM^_GWS%/[NQW8WD]U/3 MGD6JZ6]4'G"\4#E'"S1)+)W$[N9X_^R.? NI>4R9)8O>OV#S9?=Z]Y/31U9!I5?(6/L:0NXY9 ;V>=]Y_D^2OD(IF'.7QB] MR;#*BY5LKMH=C?62Q5X0IJ.D[SLI]\T 3T:..GT,X!\T/8VFCNPUL=74VP\G MA?P)\ZP %O.]*6[!%LJ1IS6J07]W?'^+<%.1"H,.P;L#YK&V2UYKX\]L,S MDC'7 #-]LHG(7Y*TBX+UV5V3./K57^>>O)PG>#<*<09=@>2]? XVF9JY9:3M+% MM6ND]09$X%\6:6T1$9GONQ)?0N[FL5:YF+?2O(;QG-%HP-.# (>@.GW'.PZRG%:+.9S7M",G9//IN_S^3P=M6,]1Q;8\"H+HF*)7"4TD@J]J6S M^<4I?W-N*XIO^D98W"'X^{B}S1PX"0FY@"5+L! QJT.KW:-MDFP< Y; [;RG7:.,FN@=783^LUT.AT#_KZL MT], RU0]<>%@6LMJ.D9C J9"[$*PR]#IL>#VT3]]%.3FJ>F[8R1@17 MI>N7+N QT.GG04&%JCO*M%GI873 T#U67'5ZPSA$-.>;_-Z6S9-8M/)(-89M M2AWS0K4B3RF]T:Q)E^[$?*I%(P^CT"]C\,LFK9$;V"21R2QY+3U)PZ1*]-CR MQ2NV+S!IL6'WSDMGSDC=I3\;9+!DSZ+RGF1S&>SB{0OMFDGAL$N6CV15A?* M96^6;8LX-B\8"NXQ0\LJ7S&+/UFKGR4; <5JE+M)MS>8G7D\7)2U;X;.SOEVX M=./]-4H]'MP^6]>KL!/0/MOJ2]U:(]G&Y]U,:W3QG/]RG7Z6W-.)=+]T:)29 MTKC"2$1Q1%6& (IO5G5UU^MOX>XXX]+0Z?>YT74TD]2D?L 4?E-@T0_2ON:?+ MV?:1.CW7G@VZHB,3$NWH9;$TRS6^ OG?Q>+ <%)+\%]9F6QL_(/MDH598=6%UT,I>NZC[5HA%G2D:\E<$O MFS1O34W:V=+2Y$&K629'D-.PRU\H_0*3%AMV'VW3AM6&G2JW6P.,YM@JMJ:) M>7UQM6FQ@L'IB@8[_?1\)@.VA-CAO&?'24:%]ZDOFL18/QJWQXS-4LE9L/ M/ FZ&!1]}2UP2A51OG+ULI,_'K.5+A5I]/=Z,9TNYYI'QEHFE=RE6^7/8FM, MTO^/N7#69*%T8D1E<;) JK#'Q@F-Q6&[)K9$-UTN:>M+/ M@+E7*D*R&ML:2MCKH MK:5*4YFVU[SA-COQ-5&G)]$67"_0Z)3PBL]NLY-OH)W.2:]8FHQUG2AC+< P==M0R5E@KF#P?V'(V#P<-?[B? 91D_44131G_((O9-P:.MZY,=&1O$3B$= Z,G"?1Q,QD'A^XA@,DDP1P)X/VF)P P(^.9NW->[C^\PZWV+7ZZ+&7!3*=\?E7T?G*@G7;^B@Y*)Y_F?*$4K Y"?

QY*G]< M#$YZ%L;1;]UC[/T[W\#9LPEAE 3!,\<(X8.F5R%\Y]#A^F 9%%V^R//FJ-M7 M@URE;XQBMPIV%<)CA2#\'OU5",^$<+#D:5$2E9!5U4%;8S+ (A^U3\,B#?1W@N M$;J;%-XI@L]ZMP3A2N8Y'@SM:LW)S8?]Y26IZD\,/@]37/OQY.E27.3!(3:D MS#)6]]G#TQV):'%\IB;T5(V.PY;/AS)P;$*&/-WH^:\W9/ M$\IT <=$U^0)1JNG,.*2M.U.^3TQN;BG=Y\MQ_F*?&X@JBFAG9HT^&0;= 8# M*J7[]=@!X=OD F!@87',UQ@U)RQ;=)%@/M${]=BOGKT#L(46N*/LXRK(VHH P MRFD.5#S;<;D)T!P36"? G!#P=F%0D@P,Y-LE&TS&8BE^^^A?P=S+]+DB\(BZ MGYIL;KKJ 1BW+KTN#Y_6SR92/TC.:\D*JA4E/P EKL)D.U;?P&R^QL/"T[+7%@I+"DDVX2 MM9'*T!=P,/_#63^W#/,M+\58IV*_;UTK?&I(91*C>FJVUM-)++HXJKC-C-U+ MQ6_;7:B\JE:M(MN[3Y.:JZXX@O.S4LT/\ 969\2;WB[ZW]*@#S7*96GK5E) MK(8VM&'>-LGRQ5O:\/;P:WM=U- _YZWL@@7;$\U1V9$"1&BMZFL96D+Z+C M"79/!6O3Z/X):ZGW#_.V[WB3O:=;?'[^E>XIH=%>4LUZG_=I,Y6U)PNC%L2N M"B$4@2<9M\7KEW/N_2)YY/65#WA^^=[RH;BC_Q$G3'Z=[<{>CQ;JLZ-",LCS_|&1]-,QD-6+@-F*C%^/" M^D\I(/H(.Y-"7PH\L63RP*\EN^- B,B>L8Y>4BB$[3[^(??*WY[UG'9QJMWAE MP.,RW^!!C&N5!V)3ZZ86JXNS2N=QH4Y^6L*Y8X[S;Q6_,$_N_%X4 M%"'M,JNY5. 48FH,)WS]BK ,98 .^S7\F5(E..(QJZV2GG MN6&IQ:PNJHSA*GZ?G'&[+.';A>GWB(^-WYDW]+$E\SX/IDZ%')EVO3:[.,/W MB+X_4.RN3F?|Q6[/X[35=1E.1WA* [XINDA<[4]5LQ:Y(ZBIX5W?S6XC>_3A] MAIC,)W-CA_=]7JHP%'39BRKQO<K>#W\(RIU?8>]U4^OZ]X]"&|GN] MBE:3FM4QO3? %"HQ;3A:T['(,+D)5G*:2]ZHJKJKBF(5P%6IR%8Z!P4?#OI?) M,AR-4+?0K1H*:ZG9FY9FP"_=$J6LI4Q:U[STRU.6.FFG29%HRL,J'SL%BO1 M#&\? S'"'+LM>G>#$+X>D7=W3ED?OAP;JV@&K)\L)R_:$!6=>%GIL-:F'J.U&=_M_Z%ZM0-@('*-D0H(Y[A3RLQ@X#4R%:.^'":D"K8NRHL)B 'D",TH%W0_ M42S\D&%HHAN.W4KB]_3PWBXS.2V,AX=^> H'"HQ$#_4$QYK20,.V[LN&7I6: M[!#A>QY%X^]#1VWBKK>K"LC0I]*?%62:>AZ(_*TG'T?2< MLG3 C? -)4SC99_AXE:^=?(5'W'RZ% G#)(T3>FK,5UPY6W(6/LG&+U_SBA3= M4^XJ*U=9^9"LW'MJ"[O:RO+%@JX7Q@TF5\P.AT-PE8POE(RK3_;I76"4EF,FQ+W;6ZA5[5[O\%NRI*TU>KW,[.CK^^/XWF] KH"SCM8@++>= MR62I:M7.I:$%3N'Y-\7>&R %,C@Q3],U7@+|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{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|[.K_+_&_QA6 M=+R3_W- (8>)4+1>E+K\6_Z**[?ZL4MRQ)#_7UZU\<9383$NY\-<14OR1+_+ M\L,"/1WD+I#19SL5]C,\[C>=[,I7>PVSF"^INEE@R&)AS626G0M4S6O'\4G9BAMV? B!;RJP6L\89)T:F7FJ69_F[OUKJQHA1K M*@VD@"OY1(TMIKOQ/-ST;A;__HE.N]R?QCFX$W4V?K9+]H";I=1$0WXE6+X*D0QKFV&VQ=| M+^I+&.WV^C2@(TZ_[/!TQWLU4%]MJ(+L_#GX6';?>"$[L-N8P==X%5*KJR@_D=M!{/#4+$%PUL)E.A^$D3D*H2MR5*.R"'*+3[-ITQ:2E;G1D].+@RC M%SL@AC;U2;K<;=QX3)9G47,\[/?IN;^_[@6"?L\%NW=AM0Y,Y/VLD+B'8B^, M1BCB?[BQY#V0K1EDD:F)W!H3<] (TJ4QR%;L7RQ352Y!]@3I7Y'XQ/($_TD)*X[*4D*:@S,RJ9L5C-B!WRKD@X?@/<9T;_ M0,^L,;ZZ&/')$KM6^&*CM(AGX?@/C_Z_=+/>N[!ZKNB?F7*3;7- (EWE!J.1R MJVIQZ/0O+D[Z.=`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~04BD_BZ#RE!$M? #^Q&TN3_?]V 5XEX*4+W>[/X04]+5I6U&DLD4'5R[.%';2 MX'6S0\'\;,("PKIT5_O1-*^ZXWA$5.JIR,*:,13,[,SZ=-FLL<3BTBW+IR+B MZW0$)6? N/,F[O\)>YR0H|O<7TQ@OXE5],TM.Q+]0]K@6WULLR\V]=! MKAH DZK:5#EV9OEK]IVND/TH9'?&|G%!R'OQNE:!07H=SL.Z9%LL+\>_S.W.J3* MO6)-\ENT2LQ8(UN\]%VET9TCSQ/JXT#>H_];-] XG,"FDP2S)& WF]ZVGLL M7UI]VD$R!X=>R7(]QP_G>]^0]S:PHI*QZ&*$@!TI,% (:VY_CV7Q'6Q1A!@NZ MN.=DS>QXDHTE.M^U4G4T!A^3;ZNX7Z;?*;'W63=LOG1KV0?1I&K32G4L22W, M;`]Z=" M"UTEEK;Z779>>_70T? 7!5_#5P(4>^/;%|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|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

MY0@GD21O2/)Y/_'WT9U0I^CD!1_]|]O"G.V\7E]#WL;8;#!Z_OEVN|'S#:(} M0/%;HV|KWF;_%P3)*$8P'7?%$1L67LT'2^63@Z(S/&F;/:/,+Y\(Y6('T"E M^K9V, (37"F3\.]4A&TEEA,-?7-O0M^7F_@\H?WJN/B,SOSN4"N<&$;"?Y>! M4HI#-T?4U3Z65 0[+;=SJ7&WN2D[#*N9$1M%SU;T/Q/_/W:#*87AB!IS$ A@^_M##=()**MYQ_*>IY.EWQC|FT5T48/W?$.GZEB,*V/ZY@Y:Y?KDY%B=D@6\0ZY M/%Q;%#[,E]-HKWCQY>'20ZBPSK+JL!,Y? JL1'Q289QU!D,FV.VL!*J<;O0: M"[^_#+6IJX+Y0|8EMF>U)C8GMYXU+W;IX<8GU*0_V!-2LM2P% LFAD%"F4!% M3X0W?2/[!Z.:NC DW'"NL_P/? 1HL3X$;;1-0$, S4(MSB$X:<$NC$9#\QQNFTFHZ"ER:,*F,P?7&'\QT'S6*S>RM4X!{P?'<_PZF6@88O MLQ.=YH"87%>L63?+_OJG'Y{G\M0>K.? G_&B+U]Z.KD=3K]L7(2HA4A!(3,WS M$+:.@@<#BV%9HKXP@_9'M"A*E4$,!)5H&R@$/),)=4 ^%Z+Z/_2Q.RS?@AAP4 ME@I%J 7'OK$I,Q23[<0? X!,MV@0S"S?!?(HP;49^)Q[0_0_" M_=EQNT?4D*9;&._A-F_XZL3RQGU,DP=+@FP*S5JM^2[XNQ4#8*% MB0@0_!D:"M0=4J? A6,>)L6,OO'[^N86@BMHV?&>NNI6;MB2Z*:))$8FO^]FW>S3?9H .&0P8, M<47.T"0C4R-(RL-,BI(9',,9@&=H@%$/$Y<%WF[H6C^_X 62XZ25,*0-9K?E MY1%V+J.9QBJZJR>1C*\"-V>E.N%FB4=I4VI=|=U9S;,P4 BL$LT/[{[-;K=5 M'&XL,P=5C\XU+,$]*8D5Z,FF;:BS2K=Y@)6.(P)*D%[I-CQB?(6E[KMUG M.'W#I,Z_2G\ X.K38OZFB#%%W:0_H9[B%<%[FV4XNDXD=?/9+&$_Q SB)G.1 MO'A+9O K!.6U;$+D/D7L"EV!L>T$9RIG#-U?\Y%B+_E? =|S21A@BNF5|5[.@Z[X) M \@X0[VH,AD=I\V7;HP=,,]HA>1'X31*4HNOT1Y?6ZMX5>HAW?LK?L"2>>? M#G"NY"S2:S3EMWMV)6;LD M6YA\"]]E!.'+EQIZ-7IMPD)3M4-3B\@6^4(6L!0-&&$,%)YA$39VMT<6NXEP M:XJFOE@$1OX!#E/Q![F(2TAA?2A3&Z6SW DTC!UG$W\@?D5)ID;![G M-K_E0CG<*!9HH2GQ>*Y\52JB3S,MSDO%$F4USSI'IE/S_?A^Y'\Z:?G>@/-M0|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|-'8?@KUJF&[OC,V=)Y)"G?O5'NR.J< R.R.F.3FEW MY13#9(@GSP4[TH%;Q)11XF|7J^^:ZS 'M[7^OV!? E70WPFS/U5!LV&>-@\4 MSW9,G'5;=? M=?JE8?:'ZG0R!T<@+%N39K8E0DNSG7M5*],4D4Z_N_.^%T]1MAS8M/U M? C7=55?'"O=777W5U9>&V1^JJU-"->.]%R=I<5A'>3)++!,9)\|YZD+D9I.W22B M3A-[O5X5=*S ?E705P5]:9C]H0J:YE<3Q${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|;5G)!FJ>GDL'/BZUY5D]1R@QG9?)QGV3. MI4=30D'_&:;J;GJ5?^'WMONJ0VLZP+_S]707CO_<6[X@AOS8/768X0(&80(,3T1R$T@)"0 M0 ,"KOZ31+?=;3],0BHB+7\MG&U4&7E\U169E9FF$>KN4%M:W99B=[_=M.V M!J0,5T9@X<=&7O1:PV8THMB7DP)+RS8 J4E@P M%,DA&RR7=EOML]%3#ZRI5YOEMIBH;>&LWUGD5R-%X=O14P\L*FVK2.FJ6T,Q M3Q8F^&B4HU2!C8?NK>JTBNK>LI;DXH/(CA3?Y M2J,.E0N5EM>)GGI@M=#!W&KH?6DE:N3:2^\+_M;=>9V PTUE9U*[#Q-J##*'(BIH>RA0U',H#A8/D@>BV%9FK MTAW)M#R? YU)"J3!JM4:KPEC&9>)AR^R$'<]3Y87'PXG'E#)+1YH769EXW#(_MTS*5%D67L *VR!NL[!:0'D(M4P|;5G)!FJ>GDL'/BZUY5D]1R@QG9?)QGV3. MI4=30D' &:;J;GJ5?^'WMONJ0VLZP+_S]707CO_<6[X@AOS8/768X0(&80(,3T1R$T@)"0 M0 ,"KOZ31+?=;3],0BHB+7\MG&U4&7E\U169E9FF$>KN4%M:W99B=[_=M.V M!J0,5T9@X<=&7O1:PV8THMB7DP)+RS8 J4E@P M%,DA&RR7=EOML]%3#ZRI5YOEMIBH;>&LWUGD5R-%X=O14P\L*FVK2.FJ6T,Q M3Q8F^&B4HU2!C8?NK>JTBNK>LI;DXH/(CA3?Y M2J,.E0N5EM>)GGI@M=#!W&KH?6DE:N3:2^\+_M;,>9V PTUE9U*[#Q-J##*'(BIH>RA0U',H#A8/D@>BV%9FK MTAW)M#R? YU)"J3!JM4:KPEC&9>)AR^R$'<]3Y87'PXG'E#)+1YH769EXW#(_MTS*5%D67L *VR!NL[!:0'D(M4P|;5G)!FJ>GDL'/BZUY5D]1R@QG9?)QGV3. MI4=30D' &:;J;GJ5?^'WMONJ0VLZP+_S]707CO_<6[X@AOS8/768X0(&80(,3T1R$T@)"0 M0 ,"KOZ31+?=;3],0BHB+7\MG&U4&7E\U169E9FF$>KN4%M:W99B=[_=M.V M!J0,5T9@X<=&7O1:PV8THMB7DP)+RS8 J4E@P M%,DA&RR7=EOML]%3#ZRI5YOEMIBH;>&LWUGD5R-%X=O14P\L*FVK2.FJ6T,Q M3Q8F^&B4HU2!C8?NK>JTBNK>LI;DXH/(CA3?Y M2J,.E0N5EM>)GGI@M=#!W&KH?6DE:N3:2^\+_M;=>9V PTUE9U*[#Q-J##*'(BIH>RA0U',H#A8/D@>BV%9FK MTAW)M#R? YU)"J3!JM4:KPEC&9>)AR^R$'<]3Y87'PXG'E#)+1YH769EXW#(_MTS*5%D67L *VR!NL[!:0'D(M4P|;5G)!FJ>GDL'/BZUY5D]1R@QG9?)QGV3. MI4=30D' &:;J;GJ5?^'WMONJ0VLZP+_S]707CO_<6[X@AOS8/768X0(&80(,3T1R$T@)"0 M0 ,"KOZ31+?=;3],0BHB+7\MG&U4&7E\U169E9FF$>KN4%M:W99B=[_=M.V M!J0,5T9@X<=&7O1:PV8THMB7DP)+RS8 J4E@P M%,DA&RR7=EOML]%3#ZRI5YOEMIBH;>&LWUGD5R-%X=O14P\L*FVK2.FJ6T,Q M3Q8F^&B4HU2!C8?NK>JTBNK>LI;DXH/(CA3?Y M2J,.E0N5EM>)GGI@M=#!W&KH?6DE:N3:2^\+_M;,>9V PTUE9U*[#Q-J##*'(BIH>RA0U',H#A8/D@>BV%9FK MTAW)M#R? YU)"J3!JM4:KPEC&9>)AR^R$'<]3Y87'PXG'E#)+1YH769EXW#(_MTS*5%D67L *VR!NL[!:0'D(M4P|;5G)!FJ>GDL'/BZUY5D]1R@QG9?)QGV3. MI4=30D' &:;J;GJ5?^'WMONJ0VLZP+_S]707CO_<6[X@AOS8/768X0(&80(,3T1R$T@)"0 M0 ,"KOZ31+?=;3],0BHB+7\MG&U4&7E\U169E9FF$>KN4%M:W99B=[_=M.V M!J0,5T9@X<=&7O1:PV8THMB7DP)+RS8 J4E@P M%,DA&RR7=EOML]%3#ZRI5YOEMIBH;>&LWUGD5R-%X=O14P\L*FVK2.FJ6T,Q M3Q8F^&B4HU2!C8?NK>JTBNK>LI;DXH/(CA3?Y M2J,.E0N5EM>)GGI@M=#!W&KH?6DE:N3:2^\+_M;=

M+6>MDCM@9$&SVA'Y,-]^DBA$X@P@'T ^@'Q20#Y?LWR:(OK+|\MS&JXM^%;_M[FS]OG3E\!*WV+;)";$1S'FNHG=64VO02BR?V$!%$!!Z-+AT9]DO")V\QJXC M['D|4G?.KE?(@3FQ+ ^D!R.R#CJ$GPGG^QRXAL M*:,\#L9BK:/RBBA71HYU94,E]$UBH!",))9P55H(6,W(E>,F5[L\&")N^4R" M6/GMQ,JO=\1Y !KXH+/D, WH>KYLY^'BBB--=L*SFD-TIE=VEI1P=A3DT$G1 MU"9(4R8'1A$IQ%O\+F<&QW$(@<^4Z0IX /# ;?+ U\R!BNR;]E3$=;D\%PR6 M8V[>#FM7-@>*K8I>6:9X3 P*@E"@%*;86DQB\V>77T-A$1F0-,BO^5ER9=O/ M&+8221?XC4%B#4BLN9+_) 'B<\KB*L!6U-@DN4VK19!A%L,WP94I=8RR/6M# M-SAN3IM90IPB;J,52DD'4XJB(((YE]X(\FI 7@W(J[FHT^8EH71S"V;N.C/7 M1 5D:O-9N"4:5SZKR<--WC6#69]#1]YRC",-;4;'W<;);S\1""9(B ;)-2"V M#6+;]3@C?L6<(2RNV|EHQHI#$3O;II$"S)2NS#[!J-ZRC'&QP_6KA$ .F|E0 MFK>EI'4Z"I$H!:$("M@'L]@GQ2PSU=L'[,ZI>VFD,/,>5";F9YASMCBY+KL M@VZRZT*1J&_%/FRV-&\EMYIS-F*?V# ^%00R.0R1S+%YU2ZDUO(]IW)U4@1\> MY-'<#74=]@,IO-<<9P?R6.0]RBG/5A)+N5=.C.%VKE&_.V>4[6QLHLK$$8(2$8QR M,;"37!1]5^N%):4=K>Y*-$WYQW/SSCZR3T C^=@!2DHZ9AN"LCQ$JZ'&+B\ M7G(:?VI #6NH3;) %?*|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|V6%&K5*67,%#E!AJO:LKUJTG'%%#+I+@[! M, I1R!E;4#TD,X#ZT"F8;GJ8X:S^B4\SP]C26@:KP3.NYCMLHRYWEZ[#QLR0 M]+M"8!S"&-"H%U1\!15?TW#P.JN[Y-,D@AG+8#PSC)69KZV5M=$(.P,C,2]B M)PH&@00"+2?2SR)G==]\FD4:]0KL-J:F8=;&2WWKUR5U0[1C M%DF<.I$A0M 0CAQ+JKR/U(I_/[?M?KX>#;S-H(HTJ")]04<+O]#B;[,G3VQU MR <=Z'BG$O1S7:Z? [P[X]J:0'<5==]A=6V^2HB":/-/)Z6%2+ZZM|V?UE@ L M7\(U\AXLE^8+$N%Z/8+36IPW:FAV#8^CP%22N[&+)\|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|V+WGZ9/+ $$/4G*UN,D"5Q[?:^OY+=5%_J42OX 3)["1[0-'LHT=MBJH4T%):7C)EM>K(;#Z$B& M[2K_$E"T*@]:]7?7<\@Y>&7UM,GH]^>F 26 ;[X$|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||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|=%$#CIC?&?=T$U#1XD:[.OBL!?MDLC^O%K(MB*WAXTX1KN7R*%N<"95FI*O1T#UIK80U;;#1&W!\3|'\I:%K6'42#]TCM2T- MY\PFHW7$;'?<-O#J=K'8)_6B-4@ M5^!M8B7R^ #I++;RH%A*)K;/:RY5F"BY_F@ADFY'Y45|6Z]/HK'8OA"JC2)6 M7%/=IFD8J^%T92FRHTSBH7M"V(S8A:X7!XY(=AGLAEBK6-(^BU!] MDV3&2KCHM$-NL!N|)P2^WJ2;ZY4[%S>\46![(38RE4@(^+X0M@.$11=.3C;) M_A8S2MM5*\LF0_;2FVT5G$A#G=C]];!%VI,;;S653,@V17> MW2KB?!9IS8%=>UV4O,UBXIABC=/IP7#8H6IT,G1O8GQ[79 I@4-ICIWR!(ML MS&3H_KSZ#$PTO?X$-4N+L-[3X4F@1+88RZ7+?>,#4WU1L-8M ?V M3Z2_H!:Y22GDR 6M!^S6S!/M9.C^Q+!F)S\N=3=#<]@Z9KLB/Z42MY@?V(: M9MCX0IV)(EE0/& _5196(QI[8 \5@W%OSA1=/#)U^C W7M!*1PSCH? NOL GF ME4ZV-AR8_5,+XZ%[LBWPC6J^/%'[HES6%W6+F/<6C78|=$^V2H6Q MJPJO&69_52R:C*B%[7KR GMJ2];GH<]@X18FX6FT-^6+'7+#QD/W9:!LETO3 MJ'95L\;26KTTS2]"E)70 SNIZ BD69V/8)@/>ZV.UI4TM)\,W9-6;U$:"'^RF MZW*E8K9)BX7V.J"2H7MDRQ5=&L]/U]$^YN;S;;LJY0M^,G2?;"4,TWLATIK MRY*[7C6;=+49;:7QV#VR]?'0#TMM3C6S--O#BB8_6.F[YSZ3;>(I_^6!W(5) M%,>RY(6G_7C^X>4A.KY^^>2%C+U4RLX-|LJU)0>^\]JOE7SRRA>U[XK:=P2I M[IO.+/7TALCNU_S4:Y#O/<1^,^'ZTCL(+%]F+9SO1\W3+"9\=_],_S\81I1\[M7VL8R>A--^>O?Y?'GA/WY_AW|/&\D,,3_@X3ASW4+WXO^L=/..:/!^,2|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|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|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|[%)U?4%W MEU;>#LS2=%(;KK(.5T';$@+OFG%!&(9#,+-?,!/(-Z)V^\TR5ZXRG7.=E*,JYE/R-H"S\A^__O MOQ 2_C<&0[L?XG4$>=>7C42^IA0LHA35"<:6E@9..63RGSXO>]DS/1W(3= IU3 MK=:0"24$B3.K"1PB8!@BD6/M!D']O(!WVNC[9C,WM-N%+#,%QJ27)D3M!0 ME"N1HZ%#4EVXSV|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£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

6$ M_9*9)$L028[$34_/;&1<6()>(M!_8;#X$(O@\Y'BS2GDF6-!#GG11$X 14!X M1'6Y]WE$Q[6LQH+.I8VNB(""#8&".6$Y8)# (/&%0>*CZT;^#"5>+Dl.U'-B M35 G=;FCV8TLHS53FO/N6]I>A1C"K#]"]* &IC&M\;;/;=3L)C0M^!_ T 2? M9!@RR?,O59)@V,"P<=.P9P1[7ICFU_.I?Y])Y>&&]I{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|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t%+*/C"4V@"NP8,\[P!W M;6B@"?GBZ&V@.5,[?$H/5?F>L#U+ 2&7&J5EQMSMARVO6=@NY],6M(=Y%*PB M>"Y)"$]V,L\ECDLVW,EV:>:62W/17@>S:6_5L>HBM!M1S/(UAN.'A"RO*PP?MY]+#^.5=,CIA.9[W"W$2P"4E2%>U/2L*;:IW3/NP\"6N_;[VE.BG;+7>Y*33/>LDGR*7FQFDYF3G>|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|<+POJ^P=PKT3="S'STUY*'O M+,_'P"=["OV 76IBYB)_%>WD3VY Z-_0_B!R&=%C|U$!#]\]..?+H(?U,X]MB_#51@W<#YQ5'W+W10D.:9@B(>3?S?9 Q/L/'Q,_1M7H2PBRVE]H1.+_):CP M-_]^0N]';",?[&^'%T8?/?/X(UO4$,05C@2T.N9)A=!I3!CG54$36>@DT< MEB H76>Y'Q$A/H:1#QDPAOO+[T Q.^PV.HUV1JIW.XELH]ULM,5NJ5$/^1(MM(MNH=QK54D[L2KE.%_Y=0X,;^:S8*>:KC7Y'80B6XXC+KJ-1STGUCI1+/)QN MXGZ^B48^@6;<"*=\GET'G3 S)KNS;)%'@2)HEN1X5N$H75 8EILH8\"1BI9F M-(9B-('CP8$1ZM&.*#?6*;6]H56YXI+2TBEG2^NUB*HSGHX459WFI,8>C]OV M&2-K2.V*WH(CV:6Z6WV99<*'76PV(OFRLMH6T2?^9.G*OSY838$(N-`M+>UWABY1!O19XLI[&PU]4#E0,AS0RILS,O.7G2-NAI6RVFDM59SLRH$6%B3^S4)HI_>*T7R74W;C5;M:5 M]7B&1L:>V7.7 S(BE.B4'0#M1F(Y9*T4=CX,I)52M@5' MQN9)M1>;&-O)_V6UNAR<]\L=`>I/$M59T5R"BWJ MV,AR>9WSEB,Z1@291;DR%7/J:NEX-#J?A3O:G5DI.=W(A0A7)AWNCT1ZT)G = M'[KB%T758 J2K"Y,VTRO]%VA#))?%Q(<.K:['SW+U(=%?FLHRTR!7? T2BXT/ M70R6!6%/5+I$BBBW]?VNI$XM.-<30E4>EKE^SF^YLMKO@"V@G<%2W:!+RV-# M:Y/N8K 9%'5ST67*(I&NC[+C%KJ?)C8TXQ4EBFBF [._$SJE:G[N<>NP WQLMJ}3>%D6%S@Y*&MCG9$KV7YTGC@"V5!O2[71G/!F8!9"SFC;7,+.I*2KEB@TU M@I$-=]C:RJ2&0J_X!,9G-&K<,ZZ ME#J$*=UBASNOG&DA7SDV-#MW?'?/TAVH"D1%IL=,,2]#J#[!K7JA(38$=M23 M 6VLZ&FWI/:XC4*?X%:OTDGSZ6R6E@M!DY_U1_M9>Q8.C;& X MV2]LX=8F# M!H7-KOJ94A7.J01CF7+*7&TJ/H+B]ZH0MLM<< M$U.TE(YM63EHG,VDW4JFUDQ]K%1EM5F"'=#TAA%V&8LN1D-] 8C0]M52E_]J9T0UYUY]5EIE/QUMN6MPIR0K,XRV,X=DW!DJIUV UV?&_T%- -.B$O5DQ:4P3KP?P,NSZ[R=*M';]#0 MV 9;;%O%C*DX,[/2XY7]!NRR'AD^-;;#;DV-3"E^,2=SVUV^UMMVUCT'SO6$ M#+@]M=R.:%HB.G6)E/GBTK$<.@)QF9IV_J0W{[7H$0 ;<5PZ[ZY*2S#H;&Y.GU3]OG#X5("^4]K.#167*\^59@3C#7:-M3;$Y:W0D:36NLY;'&+Q,06*=8.Q^]>N>N_('TJID>8KKC.9<(1P;FVMJ''^34M=K98DW;5S;)%E[ENSY^BH;&Y]EN4-FSMZ;D9!!/*JE6RMC,4T="8PF3&?J4V M%]6&W!?6HE$;-;BNW5+8$Y)5JN;&TL!K<@0UR^T#>DEZ#6>*AL;F:@?U7JM8 MF-4DT"7<7]K&5Q9<^-3C7,,XW5UH(PK ;HYEJ4L/_#K^XZ'_P4'_X1#>0.ZO M%OG7CWQF-?"=QPYS^,DC)S?NX\;C#+Y[G-CAA63DW?PVS!P^)4W^9%[,'3SP MOQ||WX'/G%C.YN@9'7].H7#UKRB0LX%T^FT,Y>!P/?++&U$6;"9S"!^,AED*E^_<_E'C%"72=?`M,&A=*5\PCIV3+[\_\?/B<#_A@9G/`7[*GR^&)?YMY< 08<*??B_/Z@?MKS(9J)_$>7M2\K^I83A!C/&C=S[,E_WXIV[8(+& G\^__GW^"/*GZZ:^S$* M8'%%XG3A<'@8[+ @G! $#',8YKZ(=-\U]$C01!+#'1:(M%P3BZF /N["7 +IGTBW)NH403$8\K!HG!8_^L;!]\7U)<+%Q43F#X3D2O7F M@^4BZ@\6_SL&(^\S$R[8[>^#"?67;(=7^0+]{UN!6"PJ5R8J]X/II:4\3Z(#EVO -X/UZG]UY&XUFA;.$&*(D\K>F M0)BN_:84>'F/N"X$^+"6HM]:YE^N6OA\CK^I&\GC[?]J/8K?2?(['+FJ];N?X MG'O3!?GTELX=KRK]^7R-.7LK<>9A*W%&

*(9>,.!3)+6J*8|C8!<8N\(V|P%>Y|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{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|=B>SQO 5TWYP=?/CNX4>017 F4T-#OZP;+KJ=WK#7X,[\]UO6XU^!`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|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

*VEPYC/0,)E8&#>.#R5@\F)L,E[GJVYMCTDA)N[9A[7 MEHCWAACSPGG!;_M4%OZ>F%Q)C?2$4,KRM93OKK9I:I!O^YP58M2=% MW<.Z'*#A_JL*/6F|>T1J'$$[0X#K!Q7><543BKS!57Z) E%O4^2Y9BY2X4U& M:??C[1 YR0Y+$WB/_'1Z4Q_ TJ3"]:L:&V7_XS/T)+OA4PC21Q=P&"O,E#U_@N1!NK/2?2VY2&$PTE+P42CG,-G:Y $D+2C'#8 M&S7H!?HY4#7TL2',W"L?5'-FN)P&^1?./@^TF+0!/UJ!RDY_%H_U)PJ#XX0J MVT3W8RDB*D)JP8YKMF]/-'5PP'\P=L3#.E(63OX>#S_5J M,/%=IEM8%D0Y#O"506R>*

*]TT*PE6_8ND"VM81Z1M_(>/($]MIQ:UK1SGJ@#X>VYB?,>22)?]*I7!+]&/[GUU,@(8$U:$ZLF9T:,KJ* M/KT6FNJHS!1^E(.[G9:A\P&3VK#S[G67@/K).3-36:P&.<[!Z?2S:MYCD^P**=%E!)G2_)EN27"Q#04Z9*7?"H:. M]85*N3A*1PV6LUDM,6<9T@BO:A<.O.7*Z5>8L:B-=1FMJC+">"EPNWP=B$$A M/^CE2KTT%\U$[88TX=B& LS7,S>X,VRC#L!P[FT(& 4ZDSAUR.T-#ED2,S7B M6IP7X-2V0Y9P_-X#*

3K'&7ZZ3X'2OEX4S%%&Q>GP&R:TC31'PG'2_+$&@ 6([9J#P8)BS-@%[" MN15.N29@-S>C'P^Q?^_M, N\M=<>&]Q/?@T,/>AYF1!:XJV%VL.<&WW2N\^",N/HGK)VE(XAO0.P)[M^+/A0E_1B"E'MN&,N"]1PF8&#-_YEWPX2WSZ=3."([SB[Z^4G-Y2IGZ*2D^ M8I<%;\9M1@E69:36B-+9-RDPT[#Z)6&J&[N:N#TRF[=]"B*TN753;MF4@^NT M WPZ-F 2&^"&#R=0#1P@0YVB"[T\4G,SEP[AI9SYGCSKC$5-U6Q4R1NJ(FTZ M3;.J+()D:?6<9CX3XSE0S=XM\57.I4FFOF((COM]I%M6I&AE99,BA3@:DA;D]FVCG_,%.1;<%Z/ MWU+=(<*$=\P1(CW<,2\4DCEEHF0Y8=(=;\K%62?$UF*RPES_!LE%GBPY,9[ML"H?L(2G -8L/A4WGZ18T)VL)\#W;9DHOYZI\G ;[BN%?J4D9A)%@5*?M?DN MHED68WD\;M8,B@N-><+(#6JEF+ZA4F0*)A92IO;C7\Z.KXZ]>O"<%DNY?,#?L.M M>V2[E"+6A=7K\EH.S\]3D(MC8Q?=VZ.@S]7.HX>N>$Y77/=LZM4W R[2B>>Y MS)S,):A.?K:47]\TWDWLA[;PU1;7)?:LEHC.1]T6S2]*DZ%I1(S(= 6+*$Y# MD_Z6B5_8Q@7[Q\&;G4'RQ@J+SW2$_C8=(VM;@\]M(B*7E&QIODS9Q='P^N&6 ME-7,D6JZE"9"S824F*"6YZIB MY[4R-Y,2A)1Z?8[Z5PZKWJ-ZN"ZQ^4Y>R2T&ZRPA9,PQQXZJ,<.HO=8 V2-Y M(TSFX.LLDL\L[T):LXWN/ETD@G,%7HV*0%=EP>AQ0H7G1FR;&H6*=P"2Y<[^ M'E)#=A$OQ/F5,S&8?"W)Z'817D5;F]!0%4P38]W#4GTG=?[@!W3#9TPXLAL8HMFC MU^/)9241HEOZC02^M<]K0<#'^]7OH097$PEMKF(.]+,80]I?R_!U?C.QDTH.=:VRGVP%-_2@)M9L"E MOU.6BI/[G8T(.L6F<"UG5RR#;ZS/8Q3"MA2]\E9S(A@."7S&"TR U,'=!0RM MBH&Y#I,(W=X0:/8N/6'% DJ,,"7+4G<-_B M47]-%]0"18H!U./D[H:.^#H;E_,"VT'@-?]PPM<4Q_H*,W@]3 M%/8 =RY>C;LKL&@9+02)E;E#LS3M 2ZUL3Q=$[#6A\XDZML!9Z1*IT3S1,]O MEJB=1A#[]" ;A=!$K(5V\1%36|=L/(2H](6LG"=+\'2U#@8%$!X]D5Y"&*E1@ M+C8PP;%R;!;CD-P>^.[,=@BF#O7H&2VTN_3&2;&[8(D R.MQ2]^9H2\K4DX8(1Z\3EG#RRF RH-0EV^DJ4.CX GU%@*=4J!* LX+6RWR'V) ML,>,@*:'(T9G".N"N'=M#SNH#:/FWE!\,ZCH*F.[TW P^V-)D M?_L"CS=O[A$X1ZW-'"+.@3-PH!M %)RTYATN.<;)VN$_'U0Z825I.H>_Z=V: MB;LU.| .=XJ|:&X3N5+ \H/|[CSGA5"*5 3]-FK> |K1D,R(.#=H3L,Z*$#M"4CC^3M.<$]=YNOI'$1]KJ=JG.J282.]S>4!GM2&2%@5-0I%I.3LSCA5K-0NF6-#^S6"/(79&[TRC^_P8H\MP_8JO%-=|M49K3D5T+C1H9KE')1^UZL3_>C%<__I#1V-W 0[US M7Q<2032F8C[+M[EMQ>ZLD_EZ]]V06V_?S*(3=-MHL-O8OMW-*SZRTL[8<3R4=OYJ.W\:VH[GZG6?-8;N&%0>N K=@>>N %2ZID-D M!>1./^_-C./-&EOC(TN^D(BG$\GOFI@EKQ63C&;8(D R_

H#62[7.0KI?:R0K'$/-P$M@-Q M.FA64COS4FL+MBF>,RO-4HN2,ROXJ#OJD<.!OSCH4TIO.,C6:%:IM-E0V>JH

*M=#/&]N&C)'8FP3>IJZQJ7DD4<0U_'L*5K>%RG=W3.M9RL68:LF6!;\=V<; :@\6NKZ!I.,)&?*

F43"VX]1#IV^(O[$G!>&\3Z\+B,U$GV/9<"XG$Z/@$OF5X,'#BT.'!7A8&IJ[9U[*Y>)8H O.N(?]S'\[W7\XDWW/71 MM*+H@RYW2)?XT[-%X*

*^R/,3E01>]#%*R_4 M@RSW1Q8@+!L\FWS_HV.%MW#PP0P7:^SUK,_V_>G_J77)IT?_EYR0 M*R<6W^<6>O.0 ?.$]N4>#\H+J*

*:5T!/31XWCX.RU%CR,5$*P'%SPLQC\.Q,2# M%_Y.@_'BY/\V]N(E5 'I4X'=CPVI+%@2?%A'#^7PEYM'.^2UAX'T,)#^Y-Q*DPL82-_GEA85@7P5!?*

*G2#2T^^T__O91= M]'W(CG&_R*J7\KZ^3XL\)#\-Q@]WX?L10AD^+,+0?9^216[Z&XT /VM#@%4 M&'H):^BFS49>L0M7?]*

A]+0C994NZGX$ODRJ:Y"""6K=E42!=[G2U?] VGS2VG MFK76A3%W7[6$TTD6]95DX)_DF6SYUA^+[7&O7UW6XTHFOUFKN69G.8VRYU!W

M0]>IZ'[0]UWTY2$\V@OTG9:74G]=CD2(2CX1@?I92%FK'|\"5-/Y)7Z-49O MHZ=>/K4NYIO<8<Q SV' C+[?R$&,O|N//\QV0

*M/ABVNC,IO8FU<9MFO]>W-N@[[6+\'K\(&ARQ@5Q,Y$*Y$9%)VEF&4[,&M1E_ M:4N#N$U?P=UE,(]!^I@-L4XHFFA&1R-B8RKI9=WHT$H#ZJ,P*

;R@(!,G@PQ) M/F,\'#1F>P#?713XCOD@[MTYC1&)/D6CC^KX9[GI)J@%Y!/U0%^Y0[]$G^@'-M^LH]TB7VQ#Q0"N^0,]%=I]T>2BR.Z4+4&0/@?

EDO+8WPQ7Y&GD_=`4F.=] MB7O;@(L"T;QTSOU=]?+A^!-%?R5>N# 2R8,;CKGAWNJH_+,FOJO*\^CZRR$] M/)C]2ZN^R];4/YCAWC7?YQ35?*

*RV]>.6JZH=0?&D-:>&RZ@;&R6J@B MOT\XX8(%EE<7D#LIKW(4X??A@4M66/Y-3/"MRFP_5&3W0J+"W1?>7;_FX^4^*

*MFW=0=N&).YPONYCKE4%1#RI&?'O:SE1C1([5:TZ7X6@P'*6#=#1ZC6QEK%KN M+ 'P%GF0]/VE@UXB#])):OCBB9!WVY;W4DG4ITKBN=*

*('OU('*E(KF=R&JO A M.<%_!=7'A _.HGY9;[PYD?E$;YPE,@_. M)#)[5,5A(K.?5ABW(Q.Q-\I%%3DS-85T3=_:-+0KHC_^4%0P$HF\-HOYN 3C M!EG-*

[\IC_KR6[]8] Y]M=@W0+<&R3?PDP!P,;QFV= W=\7=GRE^F17SL+\TE MO;-D.&!K_:6M8>^,$/$'(>Z#$ ^)N!-"A)^'#7_0X?,TTU!;P';]_.@/&TH7 MOJ-

YZ>;A7EJ2OJ2D/X\3X/[=9@]>LABN?SESC[ORO3CC I>?Q!-SVT2Q]R6& M/[3D0Q8>6O+!&0\M^4P.^4-)/D3AH20?G/%0CH91975I9?

*M0"MBMRPT[=;DD05(7D\A;K_>";5%NM)P7,U??G+;ZY@*9,-FG4(H?U5]/ MJ\0VO:%7'-EC"&W1SE=7TD<;DWP@>767->A6QV!;V"=SU=XLZ*

*[95U)*IIQD M6BP7FK4-IQ%))$@2D6",NE9%S!T(PHU.]ULO^Q)9Z_A(^LJB_Y%RES<)_\?K M7=XA^D>5+2@4!(-_T!LZA\@!7H_4RJ9+|-AAU2QOK!*

*(U:NM.(X_P$Q-_*8O] MCOTHM'YXJ?H5C>H+G]=?1D+?S\K%F)(HI>DQD/,(I,P:?;XCX!=TN].Z M,9+D2YI[*MU[1MW:LH8S__!X'}B4,;.?*

W'1. Z&OQT[/:N"#4!$Y:S3;MSF0I MS1?C/H.:?@:),!,,Q4]IY?WZ-L+Q<+8?SO;=`__7T SOL01:,2V>F&NDKQ^#[@:HZ]^$!?D^C(IX4E/ M@9->

>U&.Z(OQT(9G('1_UGW9A?&5+R>PX/\!-RWUP)RW0^^&^)%B CF,"2+4-U.0=F"7J2WP$00 \)\;NAKP"&6 MI&X"__I28(7<;[J&TEJ2,92'DK^]U*

*[1D7<:S9U2U"]?T_JIE76K:X$9CS4 MQQK$1?5 HIX<9F7!,/K2:CAM5G-:DI.G9B4D$1N[7AK#2^4(302!77+"P AE M#[X;;*FQ>Q'8K/U,P"^F%4#X)>*

OE@[8!DQC![X'%.1P$EC)JAH82 %AI@.M M"H> D"A'9+P\T)Z')B%3&OX6:0/"KIB2]FE$P=>#:=UP/H+/A3TTZ<,+?! MXV 3KYGX0?

7)^(XC]K^8AM5ORA9$5<[WJ7*$)FMS M;LEE&+/$VE2K3_3&-\@YP59MSC1M272OJ7W50B45ZT?:#6:IV).&D9@-HG1

M!EF0(8TXZ,4,)V@:ABBY3LB#R@.MM$29"T@N7L+'D;:P8 C7=_U@'C& BJ M\^3!@.1(HNG5*7Y(GZ:@0E100Y8MS%40Y_0^0#M MAR|A1H3B3*

ACN=![+41 ME.0 F,O(!K^ ;^<%S8;C46'$W1'T)6J7\X60-H;AP.<@7AK)V')(/;YC1E(PP7+)1)E*)53O5 M7[(__I!TW/>8O*5.9N>&K ;(.U+)=)_<\>/NY_/L"*

G<=_?/?=\5 \W"I%2 M7<@P I>I"(V"/I?K\=0MK8?)D19G\|)$4&;9=4&@Y,U(:;[@G0(9IH.T MGWEV7A/|:6/:7.1V^ MBJ.^5SLA+?

*6(8HFV2T0TW6R*PWEK$N=J/_XPE+\[_; 3+L5]S95^(>[;BH)* M6:VD1;2I9B.WG$4*\>A=VPE%;_:,2DL"8K2MU$E65\;O#Q*DM4"*(B M%?*

4K(A#2W]4I&LB2YTA(D>[1+RIKAS U1E19WK1F[F2B;V')R M0UF$DTG5F,33A 3.XW#X3'C[O&;_Y0D??*I/>[']M.]*

M98]=ICB+D^.=:KXCUG1;!%^)W0^"#Z)N='_M?FZD/_U_#8B|+(\ZX=G2F/5S_#48E)L<"M\;>I[@ =N?H(S=W6",QX.9&X4

*M>TR'ZOS*AE,1:NP%LB*ARD MJ%/4EG/'][7NV;^&]OL:O'>OJH]OFIM9=[T9$$)H4=V*##/<,##N'3FC^=Z5 M?X&S)\%8D(:RAB\7#WM*>5IE#55),&!:*

*[L31A+OT>Z@$K]$KZRQ,+4GO\VS] M.FBC+UJ_B:D[F]/I>,(;#,/U"*S[3/^]^#MF"[M&+8$%4W?KMU!9Y_<-J1 MD2C/>"R%<-AL+$TWZVSB;N/SS<_)-*

=Q7\$,CS\ M"9\(_%\@7?";OX[V^X!L84]ZNO-"_-&9X5VR'&ZNM#'MA+.U:&7%VX5VO=8= MK^1J;0R3-W_@#=@]_2G2?2(ZBF:53%XG)5$-

*Y;LD"TW2XR<9=1TJI/1>@RNT M4ZHV$.9%.KX"3]+'3W9GK=DJP=$U3HZFNRN%Z;;4!'PR>OQD(95*9AI:M*T]?E;=%;D/P*

*M9+T5WS0GI<2&AE,>O#T|_;&^'D\JH;Z1$[A1%13*]-? D<_RDJ&:&:W{Z4|B"M63$:[>RV.L[ )\/$\;/YSK*Z99]=N!+-%AOUHM()OC<&Y]S)DV;7)F.+?GW,*

*MDU$QI\8'Z6J_Q((G3P=EBFHQ6QUF(T0H.QYP6],[K239?N1TT(31[QBZG%D1 M L<: J>*N6Z.[4=/G^0C]0;?:(<(/L05>Z)-QPR-8/NQTR?+6U%>=**

(EA:\L M3)I1Y=D@$X)(,:N)'IT2;I-L2ND-![]D:S2]5-ALJ6QV5;L;8/GR4PK8!^(8D MLM9+3]/7.#5>9[G;8_!8($P_8[L'X4$*IJE)V$Y:R=8$/0?

*L*5W6+'C<0TTD M6V9 S-%V7^!M*P)VE 6U("3_Q?\)!\ Y]K%DI!:#[FIU.X W;$2QFLBMYX 6DMC4X4<5VS+A/@%MBFO.?*TJ6LPO M(I.^GB<**

*[4FW1*PU_)[4(VE]>=_37]N3TY@5%]"=I.%Y25 MS4W&BD+FB;IA90:M62*C.+M7=]RVF,SXQO_:/Z*_MDS:4<8=RIN1U((3S_OWB3,BG*

*C]C#PL%U[X0/2^55LR.,K51]B9OE K?(O/1 MRG E=&_ALF-W+Z>9EF'##\T*3&MO3@3-%R+.EV6BO7ERD><3!;X]B!-QE1:6 M@Q@+_8!7L Q*TG1X*

\6?@_NXK'@2KI0ETY>1L-?NGBA@_5;A82NQG+O]=!' M=FA.Q6=;@9AU^C.SWLCQLO81%03'QHH$+!H(_>8,K&

0]_@R2;V26PH%')HK)%!GT)D_R!2>Z[H#9:Y*H#? M8#3I< !\C80F8DG"[&87GYA$:'*:K$E,/59 TF"NM%^5XO5+Z<^+@LO$NT(V M;Z!)[\B5?*

#03)AKFC"/C5XPKR=@GM -&!>8NX'@"L&O^Y GY#D=[K1]JQ94TF<,:-FM1\)B M8;A?@7PAC T)K=>\)(=Z@@NR!3AU^ R#/M] \L>?Y 22!"X-AB*

*,70TAF@1P M^2*4W#]0;4.&AFH ,4P #'I')+DHCH'-$ M^\3\$SO#:@?.!QC-|>R3&TMOZ,8 \B#XLC'7\4$*U%&8#A1U:1QJ AT=R&DP*

M/@D75E4%#0TOX/%NIELAB;%7@E0L"I7)8%H!TYL-]B;OV:W]C29^\8+A(TT' M[$[1ALK67^?MI0<)#Y(=)%LLT')+8&B@$&

3S"FA@K__<,2ZFJFT%B%_F($W+F_ M.(B["@-35VWK..YZE7 X8)?(,V<_M[K&<5[;_1D!AX@?"@R[W1A7F*Q1]T MN3^Z*

'EYZ+$[I,M#7NZ3+@]YN4^Z(.3E/NGRD)?[I,M#7NZ3+@]YN5>ZA!]T MN4.Z #WV+"3\@RX?HLL;,R\;VW[_!,_=F^[@^AHI'T7W

(XKQNP#R@POQTK>1IATOD>_E MI?A3G/K4-AJOX97+[,_=J5GF);YX3D8"B/V?O8#^'JKX0[N$-<7IOQ?2'2\Y M>/>F6-%E/-X!??15],># 2[' #O$V0?

Q_5[BH3'KT+XCUA-MSD)K\X.ES6= M;F8N? >%|=<9VA_BEKNSO+^>WWB7KL$F0?1_2#95[',J5=I<97 MX99G[M^>_#W>XI2A?1]$\F./SC

*,US_HJC"'+D^92IO[W89V<9AFR9LI#+& (MINB0D]YG|-^T[>CI'J2DH;<58?=5[W*O5C : M)OL4*GNB7BB>1@'YRFAG^BRPV_4MRO3+NE./?*

UJQ_U(E;G/8CV[,97YAIG5E$9\-E)*P M:=3;-8B9^>,/14>#$9]BU(L=:0_Q_+O%<^]?74 @)9U=Y=;29,+/.MG-9",5 M(X1V"Z3|CPFDL0V3=KLW:O

*522ZF(K7P5D>@5?2//[%8_"&0#X&\GD#ZPXN\ M1QJG,X*B[4A7XJ.=^'38*%!;>O7UI'&:EB:-8BV;(!;\,J,1I59=CZZ -$9A MW\)H//:0QX<\?*

*D0>/R)CH4J7WUB-W(P3[%*H/222CT:: M)PF2#FTS54+2NUJKRZUM?8F 8\/ *PZ&*3I(,)%G5-+7NY'/8."A;W&5?F$S MY4LJA??@$_IC"=TLPE9-*

)=KQ[+I.\,GN0%6(0]NO-"[8BL9NBB8DT^P;:R! M\=$>S=2B64B4\UDN9"3CX46F0*5']WX$AM00&!?YS_6LF8?<_1UR=]'062<;MV;929#

[.29'QMEV1R66^?E^.Q'EQ:PWSB_Y0,Y=\:/;:&7&QOU&A W&KCH M,7|$T8>X/<3M3>)VP<"8DEU%)YW1@IAUV4BX'JK%2>.KR!IKKA>M;BK45D*B*

MO-6D);LIB/!H@^&P2#1(1AZR]I"U%V7M(_+3L/A<8I5[\?RF')_3(49C9?46 M+1'>(S\S5L^-93N^)#:P8UULLJZP+=AFA %^)15^R, ^',2P^.1?JL!)JG\6'

MN+[,N-PF?(O4I;1NC'3YDN&2.UO@]2]Z;IBN]Q5.R$?0Q?=D=03/!KOL<[KV M.DQU(>9;3:

(RZ]OM4R&LHEQ/_HI@9>'!#\D^.N&;^Y&9H5BKDD::;H1)-L M@5DEG[(-\ELR?;$?AY9T+[5P6!GA?;BI58%T*I'%.D6(_JZ=:X MT2!K0&RCT)$E@C$?*

1_;70VX?TM"F)7;=AK5,C1[MF8X3?<A*-(__L0C|$,4'Z)X#5&\7!Q)2 E=2^I4!T1F.4SUR:D)9G!? M<:37R&&R59JT!\1"YZ+4<-*

(B1D2ZMQ@#.415=A'2OUG\0Q(?DOBB)'Y$NM, M8JCY?H]00N71@$G(9,^L?KU3CE\5TK-F>SQ2%EF>*.4B26I;A*><4U]'?U_I M^OQXB!,VNK48?*

E)W:V7>0?U=)^E:KYP.9TUVVXZ*3(K\9OR=+&ITGFFN6"! M H+E='20I*(O:" 49?L/ZL3]QWW,Z8I^*4[*O*!?LL6X*BAEW=] =#0LQHD*

*MB>H\NPMVDO-7M\ZXUNS?U*W^A=7]^),RI8"EPX[U0&B Z6H)LF9M K#E5& U MD2"3/-O./K"2536P!'\+@N?EX22@:^HF,!'FD#L#]AQ(HQ!*

(3B!_!F0MD 1S M,'0U&'"WZJ4)7EBTCZ^;.]UT\<*9XUA)RF4*3--"/%QO-'DI:0@/"J(5,. M0FF'K;Q.23L6l.:7<6NXH=*Q$)8%P^B7F50]G9L-*

*=6*Q[,RRMKPR2_3J>GL7 MN_C>4=WV/#;D:(DK+&I&,:[(-2G)?L;>B2-+MEJLMN%>M)-I/E0N:!><>]N M<V EXGI1HFL:TJ, M^92]*T:[I?DDWIIPFSC-*

37N-3+1IC7_\T72?X_(=']Q.NP:&P%H FADL\7DU M/Q',P$"2-/#W(;0-1:C,X:D!"(6N_P3\#?_9%X$]%% GTN8<&8 4!P\.9L: MT@3LB+R4

JINFNYKP7^&)&'-%F3 C,PTXD9D#3XGMVU5H B@@%(/.*/ .+&WY=?QMLA(H68.TQ>"P0QAM,[@,. M)8#86PQ(;O,;L @4X,($!0(@ P+.4/P9?*

+:2#"DPQB4RUTS+9/IA)/HDU /[M7\Z'YH:6J?>3>$EEN)=-Q\G8&>RFMA JRDYB[F "*^G"6R>Z?(]7JIWXHUI MF5Y&-?8#00;XCIQIVI((M@(8Y%5*

*>UU$]KYY-!4TWXP!9,Q7^8S-F:PT#,[' M%9*#27=3%75[!90/R3"^H?$S6N$IT$0Z0\ PE$D*S 'AT$/PL^@TRIH&Y3^& O' MA$<"T/4.2QT-#'|&RB2(E*

UT,<#P/X'"V;D>M/M|^>68D M&T#9"9H&2&Z8@K%QOW#FU2<# "- !Y^_9H2G0/IC9US0NW'[TU=P3^Z?L@9V M4?H%WWHD<;_-UKN0'79O$L>8?

*7(;%C-;13!KS";;:>ED\=V1%U95]2$T%9;W4["[CA46A]N-/-.8K:K\0$[Q><9;[M]H#OZ#)?4'EYF$U%*Q6RVY16%TJ4O@T5BX-*

\913M#@M$B!PLIZU%EY6+SUCH M%Z+B?$JZ54FM6GG-263VF9BN4H^U*T!XI'^Q N^D7@7<<'OC7B13:K4K[$-*

MEHL.DJS!"O/P)'<+XM4JDT&F:$DVE\FLAZV"Q6VK4_;'GS#A'Z&\+O'8T_W M1KQTJ9$W^^W8DFCT6L5"C!QG"N%;$(^A^,Z*4'MCOIT5R(Y&%0N-)B>&?:_ MX I"$&J1OXFX]4QSG/.?C,E;LTPW=L+P-CNU8T#GW[JH'B\&T-H>% M=S]?

*E(.;*_T2V.$I>ZEV)H,BUR@D4L7V:*SD[L0)6\23R>J\W2]Q),U&MOER M5RHW(%M'"'^==,=.V/=AA]MX88G%=E3(*RJGS-@8D1TW-M%" GAA#'-?7MG.*

*M\0I8*QT[1>:S;M7#I;H;E^HR$M3AXS.*63$Q139&4J2T$J1U_MT2=_FO*I|- M1=?+B;Q2-*

*N4N1X2+8DS2H!ZE_,T#QZVZ&BD_P:^Z#"E+,6ME6)%B4@G%VI*I M+-=&?GI34BZ6E5I[EK(W?"-1;FOYM5!LM5? 3/?7@F]UD._/Q|H,(9>K>;_-*

*M.Y.%7TF8O$8HDT)T:=1GZ M4 M+@@SKJ#$,>CG5_>8%C?5GU ERY&O4*C6%.RRI" M?L@RJVK?IHOWX3J%:YM^IF"8':XM=/]U|B;7B<: GJ']06&?*

*\9QD$_/D_V?O M39M45;9UX>_G5QCSW/W>O>-(+7]PUCTK A7[7K'[8B B(@A*H^*O?S-!+2VM M9LZI0M4D8JV:-BF08XQ\5Z0HO%-*

M=3(&]\+LR_G8M\[Q_+T*7EZ4=/S!,.ZO"UI?'G-V1UMB@P+ MYN_6U3U"GMI<*=M<$,LT]Q*S8MU+&45[NOE0GF*_VB\X8^XEQ%6=**2J[%.2+-*

LF6S'ZK#I>G6Z+1C+CRTKF_'+12=5+<8C(N&X6_Y),MY3=R'K%[M<2@US\SFS3%=XNOUCICC" :?!OQ?&B MY_2Z%XL4CFO-

TNU#E4]#R4WK5QCAH3AV,HYZVR*QUB)KX]WPRRYWKK,IGDG MQQ:\).2-:KCB/AL?D/SP%_PY.+XD718M6)$Y>U5G1D!WU;[L%$7_=9>R2@EH*

M(K)U<);AY&@!'IVN_]#'Z@)-F37L[M9ID>W+5/_K=*XOC<00 MR=1-Z_E027I"A%F0/8_]1:6*C(PM6=00<0J>\UG4-Z)G'XI4V2>0EG_.GSD5Y\>/C-*

M%3+TV1< M("#PVF=7]9GHE,O[8 'H;P(+_[M05'Y;^G98K',M!.K 0$ZIG ML$P/EG$<.2N>I^Q#3N1=[?,/CHCBEEQOI0SND740O/BV)@T":,-4AL I^2/*

M@ #'D8..W7%=$[6$-)4] PZ'=:WS1%^.7)*LN2HD*VN-4^H32H(MYKR\F9$ M7(XT<\H"VU"V+'C%\6RIY?*

("IC1')&P>=3YR6$@9R*K=G@@9I9A5V+Z&2L(F M.$?^?&1:V^6&\W8>%]JI3;]?EZBF4_VR0+/63)NN[6+.@GT,+JY)#-TIT^<)6E-IC;]XT&3DD=,X,-M-

*@H8>7'-2J4R&N+21.?=$BL6E[E.4V,4L,U>7+/NU3FO*P[J?$_*Y0BLNV:V M10Z,/%SSU181_&X\(K2A-"XT24ZK]SBDYO1ULL-P(SB4##9\\ MYPCD?C:;N*

ML65\KI9H::EZ @]LP\ D]%O'05(@Y-HJ[1#0%+)VC.7%_8$=/,D2F*0(;"6 M39Y.6]N:2Z5[G%B&O)U&/FP X)\M9!>]-P$U_58NR6UM4+

*J5G(9SXU&C,7+X M):7 YG9O9"F]X1 'NM0AN?%U_N*Y&SX2N6U?1([\"BU\#+ZE]OG[)V]KNW/6LO/[R[2^W2 MDQ8I1]K-EP':,O$,3RUH*

*:FL|X(6>MZ/PR#DI:$Q6(RS)8TFMA*1&8S8NIM M (7D=<]9!!UG-^?-/#\?KYH-!4/%5+,)-S>EH1A*O!@98H|=0&BTEB3. MNUFQOA5W7+/*

*LQLL>;ZM>6DZM1ZN\SME'L:2F:MSR5^'7H6R6%GW9LC2=C5 LB+(0?2ME&=F3\,;+*F M:CA0 MG_-V#EZKUW92Q8D,E$*

*}3Y>9CM8ICW\G/'^[+'%K+=1]_Q@*LAL9FILVI/Z M!O8XH+]8CM@7XW 4ID7*+1<1//UU*R()9K0RHB,(OC(MIF]W(_-*

H7:KKQ8;.11>C1:Z'I2=>O\F%0^;P^\/=CP^Q.9V"?^!>Y)@.T,K!5A2Q,,.^R(@_//K?%MP6AI[D8B@K8M'XKI024+6[Y+0V;J73\C33 MU6 I"(5=

*[\+SEJ+_%*5CH^_%ST&J.;:'W;Z-RMOFM!'ABF5="><8K0\A8<]V M>?(N*@C=]'8LS:D,ZM6+N1PW3KD="AAYY%LIT-/W>Y]^K/-H>>9#$85[+NV/*

M5K69H_7ZD.6'?%WC!2&%C J]!GH0&@CS@->7QF]\RB.URH-:MAW>7>+K'F4BI/M,U=:)4TH;38N8(!,="^_MGA-*

*5RX>2JQ*RW>4$N[HV%WQ^;&0H?+0#9I+?[>._Z%Z@4EF&\#!= "@0PM M !< G-WM]*(SY:Y]:);=EF1#!-:_$8A]E9.P!-:>:.DJK T*SE H&OL3%.I6*

MW9]L(4.!_-CV|!KCWOQ_!V^K1O!H)=O.&/R\F7.="UG=O+M7GX>+[%4O='9 MD.W:@'?

*I!94V9VN]ZD72@*F9QOJD;.NJF&87E8W,TGE%HQ>>C!4HJKSKPO*_M7U567OS$1^>T'(B&[V]]/&(C85KPW5D:,&Q?CZA;)#BWY+G@_S.2&<8M83KI*

*M :6ZD.^P(M'56.YJ?_;=%5_+__8]T4?X"[,)'RWUV&'?C, | +.V>9BRRX6'WJRU%H*ZG5)))).'K,X 24T#3BPB&;ZSOSYN1X4DUIB2YEAV$3.*

*(RQCN*5HW,#YJSMCT0 M\D6BO)[QEK#>A=I3.3>H4^!%K2VH5!;KNW1:EX"P_/&T9)1;OX57?WO%HQB*

M";7,3N5.5FMO:.N[(M65NX6EINSU%KS_B7_Y5MRJM)LE3.PBR$MHK*JR6]-MVI!N&+$#M.(U1^EFM:#1HF0LRU-[UIK#'I1?*
*I8KQ#LSQYE53EK:+!=K>UK'> MC"KF*TPHG;DFU)C,(@-90"A;9@9--2L7[E7 &$)@!]I?04<<;\Y01V;Z^A@ MX[;]_?B-IX;3!-*
KZ\22AS^STS_XD/Z%37@=S;$ER P[;TMJBG]O4ZZ(LNG+S M0H4"JLG$A:)ZO47$:S^9,;DFB=Q^?GYA7@<\8!I(D/;C4"XT)2>2P0W-B2#6
MT94I0@8Y100VDPPD: FK-BU@1=^L\E UD'V%YFEQW]OG^,)?HI\ ,#%@^]%< M-#B 5 (B(2YM^?
GPXO2A:'#M_0/!DD(IJ%D\JT,47<<\+T+T/SDK'+RL&WRl-MW62#&D''.CS7_GY8,.-R3TH:3ZX/SV"<@@5Q(-KA/0)/ M;WT.:F.A_OYA6>J^]/BL&%
(RWB%)OJ?7^,/#A3]+'NBO&AB0I[",\G"02]2-W;LWS-8CTK>4&6),P MP__]@?_XU2T:?6+N*T3LS\O0>WC4\]_)$Q^6CK2(,3=>.S'F1H5(WUIN_D#,*
MY< $146.(3=>.C'D1I-(WUIN_D#(]8N1_K__QFCT;YBZ%4/O-UA"OT6E0!8N M_YY+QF^"[#ZZN??08?
_EB19GDY#W99KIH$%6> ')1)%:6_(R38,8$E@Q>P!RFFZV2 MB$W_L!1N!9"/G|V)M/M9(?3)5Y/|VX5(A@^(K#?;TB U >"Y[2+"UYTJTA/*
*M*2#9^NYWC[D)HYBB(XVV66&1-I3N7*![VOE5$\;Y'Z M3O$$:=X,%6GP;.',(;"Q=[;Y!B T_=XL.P009%4E=2LUREF^3%;,H;TM<:0"*
M(8CZ\0_Q1&#OX$_D;,@/%U<^Z(7X%?3Y",+EP[UHH2@KH;;KBHKJ\GXC&P ; M--Z?SK6:5Q;J2F6B;ZR01LP&"$A'? MU=#
]WOZ4B-DF/EN0-&LHM^RV V!$L:6FBI/-_C2NU=:2=0RI8;,5!'P5-, M$]-3EZ6YWW75Q>Z5V+T2:S>W1IU?T6Y4&VOA+8-IH31!M9B:;)5R"#SHS_>X
*MP#C*_*X'-L?QL;?UPRJQPI/9!2>#UN) G#)Y-;KE/M*BK]I=8QRDYVXBEJNVT5+ M@,CBJRW,;=26MZ0TFGZ:T\288R^6?*
68,^I(90\8VY8W5H4LRG&M(!-"0)]8+ MFZY$045Z7([-;1 MQVJ67AH-40VI3<=L6L6'=B.2)SM_G&+#EC-6K2M:,U7 M&VU2^FXP9LD-*
(!10B&@22Q+$>^[D>+W&/J#8!Q0BT$1#=?JM#)M=+CN;COH$ M+?0F1-&5.EM,+-,EVB-/%/!B0H/(D1UQKA[WD)^RH>KGV/$S(NT@NW\P:Z
MRWGDAL>'+&JL>J7&1O[E7,\;\;1^3_Q,8XJZSC|U-K MP)D=O[3WW]K8]6;"76TTZO2-C."9PU)7S2Z5Z@((_YTK57M$G##IX+/ 7F[*
*M5.$I<<8%J]BG!&>8<%N!V!*01SA[KA)DY;'SLJN^=+.MF*+!&9.V++D6V#@X MQ9+|_7FO%:PW*==5ZO,RFlD@)=SMCMID[A=0"-[K.F."*
*WZNHT^]T+3JN5I+ MJ+.*4=(*S559:H*=.DF3%%A.ER'C%XGWS^-0_6M#'I1<0T[@[+X'^QO';TNZ M:<,%=`X"[W')05+YK#T0*W&D5G--*
*H(D8+OB=N(0[6R((U-%EXM^V+"=JIB,G MJ/\)!BK0@M>OI-VNU>D/*7@"Z!-S163. M%^NIH*2" UL,WYZ%3#GR386G &RAKVEF;N#9 (&&\(J-"]%+C*
%_)U#S `(X M,3=&0IV>-_X7P7@;GLH,!>K?\E;277\/L,&T?'5D_Y7K ,UNY[2Y)M$_G<=8,PI;YRW MPD[6]G8N='9"K[_.;D=TB4FE-V]
*(UL5]EP"5QR]2,@$X!';WT^.]@\;8|$*0 MB*KABGLKY<0KW4GO/4F710O:QI,_S\T! N]S|VB^]V:Q)DX>S/OK:K__0P?0*
*MP8;B1A&1+4$\L^Z_$RTLXDPO*PT[0)_0] MZ_0<_.]\U_/^LP]Z*>Z9Z)C+^W'PE?5#G/!+3,PLN&C_NU//O&VUO7>R3B?H MJ#*
[U3P>"UON1L^(I=]\589^&"";;_'M/Q)FJ83VE :%YHDI]5['%)S^CK98;@1 M'$K]N+;&1?^7HY1,,"@VID8T.V%&)$V+(U&4Q!%.3"B,%66"Q>@? 4'%@UNC
M1W%NF.UTKSL$\U^.5TML5USA(W8UR-SE$Q13&MD]JO!S,RJ^<&ZKB@C?$2] M'CD:XGV%'O%EOL=DT]OFNK[04W#DQ37+'IIVL'6U]>4+&=DS-*
*R-:[6Y&!'3K MGH\T2_56PRP2*RU3YQFA-NK6)@,%C+RX^SQ?'JR1-#] \T1^MQB:6[R-P&M>*
*MW%THB2TUA14SVF]X<(A6QQTK%!R)8.^`5M8LF2V41GVM/Y;6[_)\3-1SFQ$Y M0E^/'/"%5)1/0K-E\T4V:TU9FFQ.:(N1]9*I:J86_:*
[@CP>"%RN)SGEP28H M&ST?.5&PG9-ULXB&ES,#!]G0(?=!-5=K]A)T'AC25%9@>Z*U#:#5'"Q $=> M,+XXPO*=FK9S^;*!]=*
<]>>SI,_B<%V3]%NNTS.N9D9!/(65$-2G/;_-KIEZ/ M5;3LMS9] TTG[>*.U9$EV(+5]%=$G0V+36KO1]^X-M-N\]E*NMIU6Z"[?V"*
M3/-2I98O#&8[OK>FL12F8HLJP8&1%U,BQ5U7K^B+!IKO-EVZ42H.%ALX\N)! MET@7V^2R787WN"DWKNU(9%B$.:47=|^9O48MG6+!MHUV-
*BMQ2?5R1!.,O+AF M+C,:H\[.6O%UR3'E7CXG9H#FLU.*YS)YZ?\8L+9>K=NHV:_"8=>$)\> M;[:USL Q^-YFAWFJ/: %IPE-]8L'6);;V:9L[!1>=!EJ8+?*
F_E&4,O)^V M:]9V#20#0*>#%^8\OV'GQ 8.O1!]R2/@8:@;M#\EK2M2IH(LIC%IT""28FZ(B4P1\6(_'1%*,91D9) M:B)=3$I:%:.\U>C:@HOR-*
*772,4C'O@JI CXS.KOTCN:]]J*_H:2MTZANKD$J M[?:J!*EX'=1%F]*N:O502K@*J;MJ#S"*VA51]2-9S;.E),NM*D.*.X:I/;*661<6-=2FIA.#YKT*
*M+MV8",HU2!V87'%=R$[S0MEKBK: DR8+L.(*I [T.CU>E] L2F>V%4[4B4*W*
MW[P&J591[!CR,%U!/2=3&PK>6.YPRC5(S6S7[=6PV6GQ8C;7I%O@H;O$54CM M+[/B>L5O9IIK$>7QMK'(V)IR#5))UV25!
*(9RPQG7S$R/"%Z'U+R@]]=H MINP*"&TTUV\NNM5J6;$+=/,:I.JM5=/+SHI=C2XT<<4H.L5NMWD- M4B5II=>GF2Z*BOWT=DI-5M5\E1>S77%I-4*
M+64Y:.+A.6C/3M6WR+A- MYVWN&J3VOHJP^Ds]7LKBN-!;9)7<-4A=]2(N<$37<$EL M;&3=M$M!1E6M J8USZRI7*+?XU:K]SGJ8V!#EJT YU[*
*8J4.9VI3F6+79<[JXXPO@J4 MDV:Z5^$+%5%8V*Q"8W@JS>A7@9)#*OU2#FNGM3;2&8GY(3[)53;7@%(?Y:9. M=5;CT-52KF:V';V FE>!LE OM10"FS?1-*
*BMC8[7D],>(<@THE*VY>PJ)4O+ MT'6>JQ'&O-Y1K@'E6A70[1)9@1U2U*>VFA]FM>\!I3M8J5854O5FM"N3?ML*
*MBT2[&_RZ[CF]EQ5ADS(R6F:8RR_;%=TQ:]>!4AR7G/D:F%DH[4[:W=%JP'1R MW%6@G*Q;;+\V7AA:K[!9.7BVI$S=ZT"91EM6O?66[<;X&'*
*_AG!HN3T5&>6<6W'!+>\/.0-E^8E MDIR2(T&<;8F\O1H4=IU-X*U5P94FG//,,.]Q@=WIR+=/11)@K.^D(]_>1#7 MXKM\3>_?*
*<>I>5K5%1;%DQ;]4?;IGQAO'YWGDRBC):KLGR!DDMU0'JZK!*I>4 MOS[NKI3_[<,3)R^4V)^@^^HR806T28R]A+07SH3C+8,@J2*;BB4N9X!)HB6+*
MQ_,5@S.5/W7 XCW.\T/0)O1-X12+,Z]\NY<^PDL_[>|=XT=23S3[9Y[G\W;; MX9#.(?^1(>QQKV9]@[3U=5H^=|45|Y4']{=[W%MW_H+\H4N4C
M%>1/D(R/=O_@@8?&07Q\OCZHG&#([JP)_;^A]5])"7OG;D&B\/D21"";SLP M#'RS8_J^DRC$2'DO$^5+ V5L+|3V0N3LA=@\>!01HK7'Q=K-
*A7:356'/K+'K MF);]U[=4;&*F7S]#_V9!FQT$7/\>VBNL:+ZDT2{]=(P]-*+2;Y]&/RM#X)G M4Y$^"/[C?=]2I2\#UZ'Q.=AZOS"?*
*VXXE.K*B2@%|&J+E&+++U95Q.,>-_E?&< MAN2^G63@B]8A*>\T4*;N=JQQ+:<456G!Y %B. MY8%)C-9FI97F"WE-RRN-5+:0'H_'XB^?*
N_%!7YNBL>^/SMFV#/Z;=.,3ME7-^ M1 \C-Z]%NGQ[/L T8N?F^E781XKX\0^.)AF4NL]!8^&&^;YK8.\6/'X?-N/ M8,+OD(/?*
*3A^,Y2Z6NUCN8KD+!*1DA>EK1/92==I"5-O022+!>293EQ3ID M94?NBRDS3TT[C+$2* .++*0*FS9B>&?T';^8&SEE:V7EP&Y#>_;!%A",OS" MGO;-*
*_$E1#+"$CX;AV8A9?I0BR5H[,\7'_(*T>-WN-]A\6@D7-I&.JA<(4:QI MY>6@Y]A8DRD.X$$3P$8DDAB+)EF;N)^9&/9R"TN3"GO>(>0-1C(L<6^S(&P^*
*MQ_(=RW#XTA;3'5 MK*1YNKHN+9!V>5I3@)XS(>O/*(I+?Z7HB.)TZ8(P.!U!_SHX.+_7V_D9^U MR'+-*""&8&'#RX/U6H?+-7-8K?N?*
UL<(C>$:I?!E>Y0N6FN7X'(A8VDKM6NG M.$4<:W**6.1I(&G3E)H2L!3W5,$DZ18-`[-_IZ"%B7\"=$:B:']5Z#JI=R=
M,R;'-]M#G=7#0M(^5=VL[RWSPY7CB;9 M#2XMR.UE]L5[YKPCA+S/3LO;+)|>M>I:/;W0',U:9$5_GX6.%RD)8E@2Q]_;M:+]R:@,|=^]0#)M8[BM)]V?
*IQ9D.<:9#G.GP4#\,KY7%GH3Q%NIA'6LVVTS4 M2K<9+C[6\V[#%O#ZFL\,JP:3PKK-!@Y/ 28@/&)$*HF1;)S \-T"8"%|-_(X M]*
*M285F=EM!U.3L$LO5JODRW!ZA X--TAB>9%*WK\UXZ%K)6Z+A) #K]SDCJB$!-M"MVNV]6W!]Q'E]S?V/D0;J^-*4'K_BG!B>^^YX9?FAM+*
<"5!U03'OSG2G#H M9>J_P]NO'%^\9YNLL.WWZ(05P\YL>'#8,>SI?MZ9$;OJ[N;]"UL(PM[2WG95 MATV9>'G$RR->'E_3%?Y6L#G0X (%[N7W)_MA21-
J%2_OA[M/([JQ3PQ[B"->LA-/2;I7=8D/76G(1:I-R:BW#%H;I2AH]2/?QB&25*IN*=' M#';A!O3")DRD4>[V(%6K93*$Q-ME;645V04V5AJ2&7)BU488I8!*
*(=LO>B:WF+;88N3;1,B1'9905^3U M8<&>56(HHU"JN2C3!PPCC'F$2'@&&)>(s:]V[4QTA?'0MUFS,)\/>(8 M*^0[3D1KL*WT*&>@8L>Q9'$0(&*U-*
)8D4FB38]PP>WQ/TER,"%D=F M%=]YUK#OM8[66I,Y,![W3=W ":)WQR";J+2])2MPXT@X8$3& M7('"]/P,1.9O^^"*2HR]A+1G7,+QEK)?7CK\-*
)0@TF0#21@1%]L%S[(FQ7YD2>$IQ:GX;9\S,9 M+IOGA;A%?.DV#AQ!=`GJ/"/H$XJF<(K% 0#L5W#PBN^E<#(0?/G9U0H^Y2CWKAD),2,>
MQ(@/LB9B/CR(#Q^E@,2,>!PRO1LBC1GQ,&1Z/XP;,^)1C/@H5R+F1(Q-?Q8C M8FR"B-B;(H()V]LB@@C8FR*"", ^RM"+&?*
*%SC(A<:0_[>M(A!(&&7=IS3HUO M6NCSSHS]=YM@^8Y-??(8$CR\OZ D&XYL19PJ86>W1X$&(22_AXX'#Z_E^,G5 M\ <*_T].63)U^.'__L!__*H08$_L?*
*>?/?D(&QF[]+@3]!_3LLM_HI5GS^#Z2_Y M[C"8V4W5G9C93_/LNZ,F;%&7[=L= ML1?VM&[68O*MGCO?O*3VS08\X3;.>A.3?@=@P^;N#64U"B?=1JG]?*
RRML;3& MTAI+:RRMW^D0\3>%-7(.P3!.ROOF OGXR/;M&EK^.3U8B-,>+,3GFU-^>&#' M_LN?/;)#+/?SPT))'J/NL(Z3DYPKYYB0SQ5B7:)7E:U"2]*);-*
;DA8S@6R. M.CSDB23*>*.3;*^/4@\//1WPPYR$8*)6Q_;%\M=+'>QW,5R%Y%>_.%K1?=0 M=I8C@9609K6(9FJ,@C6MC*93-^2.=T2]MREWI,*
((%;EB5LHJD\Z,48"R QO> M?:CM?,'8RBM;+R\#MPFP1.?T@Z_I3XIB@"5\-S/1LSRHSI"+3867LIP MN!+=>9'AF45RB(<.F79X41"
(W&/'N>I=5VKU;2UTT1S2T7 FDR2)+"XE_# M>@D_=-Z1.D,[0H@4GR$?RW>&E,#3S-0A M!H5%5>^$'$NH(RHUZG9,@V\+3&LV.V?((.*
/1&:UY\1%+]8Z)33]83IS&0K M$3!&C0.H/V='AY=Z>W^C.N2Y11H00["PX>7!>JW#Y9HYK-;]3T5^PSIE$;1AO@=B>1 KH;)9%7=CA&6:@*;*
*YL:2.,TD4>J.-O>W MAQ\BW"JN2&AK!VLDAJI?@:I/G3_X.! KM.=-_:/RB.":8[Z.>;4,OPOY##)# M7\UF!-GM:NHX2V],SL*JTPV@MG_0(86221J-*
*02P&L3]+Q.*T@EC,?)6S\G6D M_"N[6=[;9[/%P2B%-]2)EI%3W4FA4)Z6W)"-!=[*=0M(RFMIO0[^,#1[47/Z*
M"B05S&M(,@R6I"G\FZ8VP(/X#L6PB>6^DG1_N%Z+ M'MKAY4XUU:AJ?0F;AXR/S52U0Q;YABO0J[26,B;FI%511JR?Y)[$R522Q*@X M@2$.@/T9 =XH
*WE(F0(FLQID1JX/,V[7-T8 MEDMCPII#"'J,*R3LI1A#4 Q!<8Y)+-]QCDGXSH\!MF/4PM@=^^76I"X)8G%H MZB%OCX1$M\S=MC=%:6?&$TU7)88\!*
*[9'Z,%@D@Q%)E&,_L*I([#ZPA(-)P%8 MOT\:40T)4.AV[;Z^/>]NN;^QMZ'<)M5A-($]D^)3GSW/3?!VMQ8@F,)CB4X MEN _5X)#KU/_'=Y^Y0#C/?*
MDA6V_1R>N&'9IPX/CCF%/_;51<%7%[84A+VG MO>VK#ILRGU\?\?(ET>\/*+D"W\KVARH<($&]W*VV>&\C,_&FGTW[D]W0YJD M*EQ>Q*
*BTUTN;)CW;Y2@S9)^[:_2E@MDU/8W.=C-EET7L2]DJYPM!1"M88H12=_M9..^C'0A1G3"YLPD<;YV\.46*PR:KJX5%*
*PRNN.IES;RH7NIH@]3,#:X&9R*9FSP9\XK_!Z']D4#@N,H8NS!CIY4_@D>[#@& M$TMP+,&Q!,<2'+:E]44%^_M&$?*
\^5";&%8F/B1P2RVUB8KIC70['>W[@WJB M.-5(^T,^539DNFP30ASL15B#'.Q#@3*9SY5+0Z5-O%!?Y$!FZ"CYF>5K,W%<.4;9QT2*8Y!Y 9E=!NV-*
S6P^_MRZ^*T\IP(_%5DP\Y]P3#,KW"CNEZPFI.28)-=5[/ 'D.."J.O5>^9-F,F"7KIL;0.:$3X'$1+5%1;%D!>X6"0>, MR)@+!\%R>GYW(_&T?_$^)L9>0]KQ*.-*
Y2]@M2E6-.0&%*@W\10S7DQ-(\ MWLQ.R.8$YK_+2\??>&(A$FDP_^2*?;SCUW^>9 0(W],_0(%;B4M;?Z>3 M)$DF,?0K)X[P@M+-*
*($@N3YU3R$#\I>U_'\ZGR?]^LKUH58P!7)P(,GA/0(!\WD,.*DA&T"$OY>FK<+U\VS).H"* MM?SJFGO4]&]\&"J.;5-W'?G51,_-*
Z).!X,O;/I]@+I>_.OZM"8#$C(L"(C\(Q M,2,>Q(C4$QVOB"@PXJ.H;,R(AT$3%?,A"GQ G]"8$U'@1 Q-$6'$!^FM,1\>
*MIS3%"R(*C(B1*2*,B)$!&GR(D>FVC/C9G,2//'V_/6OVJ:1#R#+]R(OV.-:R M/\':KY8^_,Z4_7>;8/V.37WR&!I]Y"IZ?.%<%*@2=O9\%&CP@'5\?*
*=&03!U^^+|_!:^_*B;8$WI?@K"?D)+QV4U."7+HA!:4M1[.H8UC4?BJ M]B9"[%U\"@B1&N/"T.[H>A(:S>GY1U_?4O%)E9I M+YC^DE|?*
*<_O;:*ZQHOJ31(CUTC#TTHM)!E;UY=^;(W*H9XG__AX-"[]_"E2' MQV1?U_K"?#[6U@;T.538QHS_E+[UA1E_]'*,.?W=.>TWQSEG\Z^I(F%7?>Z;*
ML29L49?M&QWJAX4_K9MUKXS&>:5A--RBPV'C^SVXW@2ENVET'8L+E[0V&EPI]- M.T-T7 F'@OK[?NB?7-A#;POL:S&LAK+ZDUE-7*NP(H;HB&.M-*
U4SJUVQRBV9 MD-M-3;] LGF)CD![VI5+B\M>BC1'%&P=R:-)QDL=;]64|\>)1Z=M7NC1G0/ M3K3]2BCQJ>:5]\(/BAPBVJHENWR/ZS4HHI*
*G[6[(^#$C2;251:V6D,>P9:;F MVMWA8 /P _;$I),HBL;X\652 FZD9(1[QL.]# ^"_I2Z6NBAN6O?8<5*E6EH; M$TU:R"!3W!NU9NU26PEWQUGTS-TJ/5;SJ-*
NHY,D5(VD.JX =!_8^3+$?]*Q? M,#SVRF+/RX#V"L+FLHXXR3GXS.1H!:TC8LON>ADQO^6 CNC;UI]0$K]8|)O3]83I MS&0K$3!&C6/@/VE$AY<[?
*7^+.N2Y11H10S"OX>7!@JW#]9HY+-2]3O<1NQQ M-43?3,K1BNZN6VA.9D$!IV1KCJ2#5T"9/(]N\NEN@K8S(C1AH<%-)@L;2*8*(MHV._95U'""7Y"-*
*+5CI/HBP?SW,&R=ZRH;L5*NH^U"N3:9RG(_-0TYV-)92BL% MJPUYC5Z5K&W'&ZZ14A-@&/WC'PQ+DBR=Q&DV!K'?*
*LC+_*2YEI\(K##R"|&Y<,^HT=BX MQPY$N,M"MPM&)UF23>+O'BW|E=,:,_R_@5_+G%CN"X'W!R[&60YQED.5--54-*
V3&O%2GI<8#)]%._O,,7",N1;HY8Z$O! MR&0*QY(L0R%.7H@\SMS#B5)==?45;M<\E)YX(RJ%YQIM)&0=S:DV MRT)6V(H:XB';EBZ*UES=*
0/"$4CM_7$_('+L4X!!]9!(H33&+I_K]2'6G? MQW2:*1@9-+?F;8U3ZIQL4JU9R.IY$5.538QHS_E+[UA1E_]'*,.?W=.>TWQSEG\Z^I(F%7?>Z;*
ML29L49?M&QWJAX4_K9MUKXS&>:5A--RBPV'C^SVXW@2ENVET'8L+E[0V&EPI]- M.T-T7 F'@OK[?NB?7-A#;POL:S&LAK+ZDUE-7*NP(H;HB&.M-*
U4SJUVQRBV9 MD-M-3;] LGF)CD![VI5+B\M>BC1'%&P=R:-)QDL=;]64|\>)1Z=M7NC1G0/ M3K3]2BCQJ>:5]\(/BAPBVJHENWR/ZS4HHI*
*G[6[(^#$C2;251:V6D,>P9:;F MVMWA8 /P _;$I),HBL;X\652 FZD9(1[QL.]# ^"_I2Z6NBAN6O?8<5*E6EH; M$TU:R"!3W!NU9NU26PEWQUGTS-TJ/5;SJ-*
NHY,D5(VD.JX =!_8^3+$?]*Q? M,#SVRF+/RX#V"L+FLHXXR3GXS.1H!:TC8LON>ADQO^6 CNC;UI]0$K]8|)O3]83I MS&0K$3!&C6/@/VE$AY<[?
*7^+.N2Y11H10S"OX>7!@JW#]9HY+-2]3O<1NQQ M-43?3,K1BNZN6VA.9D$!IV1KCJ2#5T"9/(]N\NEN@K8S(C1AH<%-)@L;2*8*(MHV._95U'""7Y"-*
*+5CI/HBP?SW,&R=ZRH;L5*NH^U"N3:9RG(_-0TYV-)92BL% MJPUYC5Z5K&W'&ZZ14A-@&/WC'PQ+DBR=Q&DV!K'?*
*LC+_*2YEI\(K##R"|&Y<,^HT=BX MQPY$N,M"MPM&)UF23>+O'BW|E=,:,_R_@5_+G%CN"X'W!R[&60YQED.5--54-*
V3&O%2GI<8#)]%._O,,7",N1;HY8Z$O! MR&0*QY(L0R%.7H@\SMS#B5)==?45;M<\E)YX(RJ%YQIM)&0=S:DV MRT)6V(H:XB';EBZ*UES=*
0/"$4CM_7$_('+L4X!!]9!(H33&+I_K]2'6G? MQW2:*1@9-+?F;8U3ZIQL4JU9R.IY$ 5.538QHS_E+[UA1E_]'*,.?W=.>TWQSEG\Z^I(F%7?>Z;*
ML29L49?M&QWJAX4_K9MUKXS&>:5A--RBPV'C^SVXW@2ENVET'8L+E[0V&EPI]- M.T-T7 F'@OK[?NB?7-A#;POL:S&LAK+ZDUE-7*NP(H;HB&.M-*
U4SJUVQRBV9 MD-M-3;] LGF)CD![VI5+B\M>BC1'%&P=R:-)QDL=;]64|\>)1Z=M7NC1G0/ M3K3]2BCQJ>:5]\(/BAPBVJHENWR/ZS4HHI*
*G[6[(^#$C2;251:V6D,>P9:;F MVMWA8 /P _;$I),HBL;X\652 FZD9(1[QL.]# ^"_I2Z6NBAN6O?8<5*E6EH; M$TU:R"!3W!NU9NU26PEWQUGTS-TJ/5;SJ-*
NHY,D5(VD.JX =!_8^3+$?]*Q? M,#SVRF+/RX#V"L+FLHXXR3GXS.1H!:TC8LON>ADQO^6 CNC;UI]0$K]8|)O3]83I MS&0K$3!&C6/@/VE$AY<[?
*7^+.N2Y11H10S"OX>7!@JW#]9HY+-2]3O<1NQQ M-43?3,K1BNZN6VA.9D$!IV1KCJ2#5T"9/(]N\NEN@K8S(C1AH<%-)@L;2*8*(MHV._95U'""7Y"-*
*+5CI/HBP?SW,&R=ZRH;L5*NH^U"N3:9RG(_-0TYV-)92BL% MJPUYC5Z5K&W'&ZZ14A-@&/WC'PQ+DBR=Q&DV!K'?*
*LC+_*2YEI\(K##R"|&Y<,^HT=BX MQPY$N,M"MPM&)UF23>+O'BW|E=,:,_R_@5_+G%CN"X'W!R[&60YQED.5--54-*
V3&O%2GI<8#)]%._O,,7",N1;HY8Z$O! MR&0*QY(L0R%.7H@\SMS#B5)==?45;M<\E)YX(RJ%YQIM)&0=S:DV MRT)6V(H:XB';EBZ*UES=*
0/"$4CM_7$_('+L4X!!]9!(H33&+I_K]2'6G? MQW2:*1@9-+?F;8U3ZIQL4JU9R.IY$5.538QHS_E+[UA1E_]'*,.?W=.>TWQSEG\Z^I(F%7?>Z;*
ML29L49?M&QWJAX4_K9MUKXS&>:5A--RBPV'C^SVXW@2ENVET'8L+E[0V&EPI]- M.T-T7 F'@OK[?NB?7-A#;POL:S&LAK+ZDUE-7*NP(H;HB&.M-*
U4SJUVQRBV9 MD-M-3;] LGF)CD![VI5+B\M>BC1'%&P=R:-)QDL=;]64|\>)1Z=M7NC1G0/ M3K3]2BCQJ>:5]\(/BAPBVJHENWR/ZS4HHI*
*G[6[(^#$C2;251:V6D,>P9:;F MVMWA8 /P _;$I),HBL;X\652 FZD9(1[QL.]# ^"_I2Z6NBAN6O?8<5*E6EH; M$TU:R"!3W!NU9NU26PEWQUGTS-TJ/5;SJ-*
NHY,D5(VD.JX =!_8^3+$?]*Q? M,#SVRF+/RX#V"L+FLHXXR3GXS.1H!:TC8LON>ADQO^6 CNC;UI]0$K]8|)O3]83I MS&0K$3!&C6/@/VE$AY<[?
*7^+.N2Y11H10S"OX>7!@JW#]9HY+-2]3O<1NQQ M-43?3,K1BNZN6VA.9D$!IV1KCJ2#5T"9/(]N\NEN@K8S(C1AH<%-)@L;2*8*(MHV._95U'""7Y"-*
*+5CI/HBP?SW,&R=ZRH;L5*NH^U"N3:9RG(_-0TYV-)92BL% MJPUYC5Z5K&W'&ZZ14A-@&/WC'PQ+DBR=Q&DV!K'?*
*LC+_*2YEI\(K##R"|&Y<,^HT=BX MQPY$N,M"MPM&)UF23>+O'BW|E=,:,_R_@5_+G%CN"X'W!R[&60YQED.5--54-*
V3&O%2GI<8#)]%._O,,7",N1;HY8Z$O! MR&0*QY(L0R%.7H@\SMS#B5)==?45;M<\E)YX(RJ%YQIM)&0=S:DV MRT)6V(H:XB';EBZ*UES=*
0/"$4CM_7$_('+L4X!!]9!(H33&+I_K]2'6G? MQW2:*1@9-+?F;8U3ZIQL4JU9R.IY$ 5.538QHS_E+[UA1E_]'*,.?W=.>TWQSEG\Z^I(F%7?>Z;*
ML29L49?M&QWJAX4_K9MUKXS&>:5A--RBPV'C^SVXW@2ENVET'8L+E[0V&EPI]- M.T-T7 F'@OK[?NB?7-A#;POL:S&LAK+ZDUE-7*NP(H;HB&.M-*
U4SJUVQRBV9 MD-M-3;] LGF)CD![VI5+B\M>BC1'%&P=R:-)QDL=;]64|\>)1Z=M7NC1G0/ M3K3]2BCQJ>:5]\(/BAPBVJHENWR/ZS4HHI*
*G[6[(^#$C2;251:V6D,>P9:;F MVMWA8 /P _;$I),HBL;X\652 FZD9(1[QL.]# ^"_I2Z6NBAN6O?8<5*E6EH; M$TU:R"!3W!NU9NU26PEWQUGTS-TJ/5;SJ-*
NHY,D5(VD.JX =!_8^3+$?]*Q? M,#SVRF+/RX#V"L+FLHXXR3GXS.1H!:TC8LON>ADQO^6 CNC;UI]0$K]8|)O3]83I MS&0K$3!&C6/@/VE$AY<[?
*7^+.N2Y11H10S"OX>7!@JW#]9HY+-2]3O<1NQQ M-43?3,K1BNZN6VA.9D$!IV1KCJ2#5T"9/(]N\NEN@K8S(C1AH<%-)@L;2*8*(MHV._95U'""7Y"-*
*+5CI/HBP?SW,&R=ZRH;L5*NH^U"N3:9RG(_-0TYV-)92BL% MJPUYC5Z5K&W'&ZZ14A-@&/WC'PQ+DBR=Q&DV!K'?*
*LC+_*2YEI\(K##R"|&Y<,^HT=BX MQPY$N,M"MPM&)UF23>+O'BW|E=,:,_R_@5_+G%CN"X'W!R[&60YQED.5--54-*
V3&O%2GI<8#)]%._O,,7",N1;HY8Z$O! MR&0*QY(L0R%.7H@\SMS#B5)==?45;M<\E)YX(RJ%YQIM)&0=S:DV MRT)6V(H:XB';EBZ*UES=*
0/"$4CM_7$_('+L4X!!]9!(H33&+I_K]2'6G? MQW2:*1@9-+?F;8U3ZIQL4JU9R.IY$

;GRU9!RMO#6=_?E6? MB8ZYO!\'7U4?$"?\$A,S"^+"?W?JF5?L"RX"?P.Y!"M>#RZ[^0B^_^C'/QVX MJA+F- &7.) /^\A0\92[!XJP3T,$Vi[']T3\>7#<^)?4#7X$F"']&\X(O$_ M"=S_Y7]>T?N,;=@)PN]O&'STQN4/;!%];!I-I^QXC(OR2$(Q:D2F ("'#^01 MBU.8*&$L05+BCX 0X@'-J3<%2;>K*Y8&F(Q!H_G]8#E"C\\HVR?+,#EFF MT4PG/UM3)KI=CI41,<)?CS2L]'8P[C3SJ.MK&N5TRKU%!^GBFQVWX1[34\$\\M%N(2A:9I4FWHC+R8_ZC-DH2[DZD*YT<)J'7PQ>6I*IS"LPHRU MU0*3"\OLIC9$[J<.GX\4>@MUQT^=(M\C)=5=]+4BMX%WOR!3&=M2PV+TM+=E$0X,O5Z9&4\F;"I1J:(EK-,E4CGV58C[Y\X>4'0HK5JEOGN1A&\-ME,8WO$[6MJ;$7U)I@7>'F\+_+"M96B+Y_&^5ACFFF#pD0Q93Z78)J,$*^K*WF MG-.9;$;9M0I/;KMXT%$=T2=:U>NCN#Y7>;'?6-(J[#A_<7>)*DB5;EIG^*#J ME:TZ.IVG 4&9RVMN-)XLDF5.X1===?$BT=FAA"*[)7EY3(11.4L@NBM+]76&> MGN\X:PJ;0%QHHL*%]^3<_G&Z @75S3%EK#:5M UGPY;K4]T-?2+0F]YGBMDP90GE9=I'EQDA-Z_[0HZ "[0?JJ:KA^OH\,OQ M")?F)9*NC)*LMGN" MG$%R2W6PJA] E<$\[J!%S8'^]TZ]5X&_F0P4:UTW-VO2OBJ:F*BV]*B6+(" MS?]$ T9DS 786SV_.H3YVSX$"A-C+R'MM>]$XRUEOQF(?#B].[PMK*O6((%0''IXI$)4#U0[O$6C]/@C1GQ($9\E&;,^)!C/@H6SAFQ..@Z=TTK)@1#X.F M=],18SX\B@\?)8;'G(BAZ<]BQ ?YR#$?'I'@9>[PZ'BX:DJG##__W!_]C5\4$>T+O2Q#V$U(R/KO)*4$.MO6J#;B2'AK7C6\2^:D%YY$CP\'+S1^)D;"[$YD+T5(BA2@&:*UQX6AW5!T MI+6;TTK=O[ZE8A.KM!=,?ZF5C#G^^+3376%'\22+$>FD8>NG%).K^O+OS1'Y M7V$V0/[]/1KVYODJ4!T>DWU=ZPOS^=@F):#/H5E*S/A/Z5M?F/&'CA4QI[\[MI_U&A^=L_IH=&_9^7-MHPA-A=Y!5#? MIHO.#87U>O.[;RZK;W?]BX4URL)ZO9/3-Q?6-]LZQ;(;RVHLJ[\NJY%S!89Q M=/(W%\@0PL^WZW$>X)DY<%L^XK0M'_'Y?N4?GN&V__)G3W&CK.ELUASFTH;M;K92\^%0V91#;AU]\+K8&/?-E+:.H3UKC6:],H3HWHF!7'8I*XBQYO[:AWQXE M'IVU>\/>Y1%"B5N?XOSMQ>[1D>3;M9F-I2Z6NC]:ZAZO$=U#T2G,-Y1HV(RK MR=DM[Z;MFC1'0VZ G"[/1L,)7G!X>E.@EHT6;79]10?V/_Y0T_F"4957AEY> M!N0VO&\36HG0:5A?TYD4Q=!*^'8GH&8Y4>42,V]M4XU!;%1KF@:A"$\+60# ML4=(%:7&M0U!G3.,*3H:XE@&8>^Q^3]=!JAW=0<;0!MZ=960=A\CL[)*=]=O*,8Q(BE.Y;N/T>ZOX%M#71$ID8-BE5E7D)7169 :[C3 M&\|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|=Z$W#7;'B>T&7B\JF,<(7_@2HP#\)$%H#B]));N[RO=D79[%$5'M,Y0AW^$SO-M?C?E%TZ7'U[P'MXI?V-?0_A]J@(I>OKGQ"<_M>'1I=WA9K$?TL!2G2Y;FA:8RR_L?S&\OMP^?W*L<5[ML8*VWJ/4$@QI+R& M!X<6(LL/A&)^-,?L.W)]M@%15M@-1YC>$5K8T+5O.9X8<%G(H MVJ:\E.E)7A-%&I5A:<3-Q^4M-\++04>K'/T0R19)).A4GP\0P%\-<)&'N]B@U M(B<3@VJE#;"#Z:"(JX%4)&*;FRZ!LEQJKP7KE 6CU!VB+-)D0I&!7\#$Q] M@:#@-SR++PJ3CI(^:*CF.#$?=-QP(6<7"'&XUISA.%QQ6&XD=;O_":?C9W&:'+3 M*L1-HJ]2^&4&%W!-]5]:?"-5]{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{Z/O[O$)* M*$_[U20=;+:.>G% K(=.DH"603K + :\FGA+A)+UY+ YBJ#T2L77 'BZ*D M.\='$!5+#KZ&S[K4@18-F((+01$& M-P92?WPV,,"2QY#ADB5/(&*,P8--$NX2B!(.;!4L8C";BR?7P9/]>P0X+"[P M)'!G]8F_%G57WB,\7">.O+#!#F 9X-HBW"+ W5SIL#7L=P7_TE$ M2/] #1 * /H"]67/21TLMI>OX86!=;*!#7.26+D6Z!D_9OV/[03@*VVXQ M/'C_GZ>PMH\35V5 I-=XOI?RA:B!?6#ISPN()A R*`>?"'/ATODT FIW MPT&/.)YN<]AG /+XUP9:F#XY%Z"9+QG[-;6!1G&FB'?"@]>G!BCI85O:)YMD< M*.VF,D8Q'BF0Z+O<5ZBZI?SX!SOHG?L9_8/<=(:B]F2&E>R28U1HKY-._;%8$0>OQO!Y+@?_U!!NB0DF_UZOE#NM=-E0G%DRD)9?G_]:UL7-YH>Q6YW9H%DPOQ+N['H6;; ,8")8)0"HKT]O+/L[M"U@QCK>$.H!N\+:U,%5X2!_@?K(MY]OO/F*KEF_G>ROX(+R%IH3!^T.XE]"7/@_WNMCAQ4'M?IP,*Y] F0^F?AA M[!]$B:-6\ HF#AN=:!@N; I];;>&\PUV'K!_0(#TZ0W(HP/E>[W7*P(J0I4. M;"UJ $T7QK++0}(-!M?#7[*#%@EH &4!G<*Y!043$-V8%VZ%(&WSM>H%5L M3%>? "$\$&,"YS^&NY_JOSQHQP&-I@#*3UB1F)ARH-XO9#G8 2Z4'JCG]Z!MQM:]%.PEI*5!-KH7DT2@\M &;;D@RIQHODE#U\?GV$!5$K=]/41^\@P.!]H M\]F'.QT8Y<$YV"[8;TZ?*U ,X2R,61?H@8)O\PC2K8LW/7' MLFSL-0Y)7;J^.30IZA"IT^)EI?]H\\Z*D)[YXJJ\R955H90L-C2*BM/9<.6 MD[]+\FL0YH]W (L8P+$T]6F"51\S:7_.^C= >M=?=&(3IX1*I8 &DR@(QX4MX1,W"=23%!\,@CYNOO?RP(>]!UL"I\6E+3\?7OQ] P_FL3(*?_G(,9>^8]-_M"$07/\"C/4_5K3RYQM5#)@%Z.%7BX!0|S\8+AA%^'XR_3K_XK4F\"A+XCP<> M_YV '"OAYL>>7H<>7H4!+I;7#7Q1>Q_?Z=H\NOURD-1[X\+?F+"_S[P6JK$V M WOE! A/-E\ QR(4-F"GZ'H 4U#L#VBV.(C?F2H-]7!+5]!9LS>/"'4!1?,X MV Y@V+4L^<6WZ(]5[9/-OCA-C('M!7Y]0WMH>C*9E^4E0=Y+](@W>^%G*XX],1R#X1"?AKHJX/?\&? XLE'2QO&&^:-MO5HC!.3AB;C?(T(D@;G)U@$J#T&Q$R+, O'$_86CR,C8DD4-$:?@.9]%?2-Z]IXHM+/N\8R@\+)@$)%N">F+9?R5>7L*07%|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`ZP39#%DQ M 7BMFY+VX^`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{CUT3NV/.<1=2M3[_@;G6IQF?HGE(4,Z89'QRM@)}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|;)OY/& ."! #EC'! MMDPK.!K;ND4;E5W0;EH\:)A-^"UJ-.&'_I/^XNBPQ.87J2]&Z;6UUDS8*P/5'0KFO.-X(CW:!75;+4N@+W7*A4QO(2N*/(9O6]T/G+PRWRN)] MT#3PZ/U&4WML!'VX3=H")]96(96(V[#MK!9JX-C:G&*8[U7F7BP&[XK$)/E M/OV$:$>6?<7HH-Y;ILM(:M3.*P=D.&FWV\IMJ9.93NX>'L_ FEV_4K&0!R;M MT3;FFUH,JZ-S#0%G=#)W:#@!#L4J/^_)BU8URV?J"%YOX4^IV8^ODS#0{U-_MB8[_LZLX.NL RM]E*SH^WB7N#"=Q?$9UPZ;Y6;})6=+!T;4^/28%<7XCN?;! MZ*_.'@G93U#$.VQ93)"ND+014NK++FZ/I'$=#N7GI#Q_?3Q/#.\W$@?GR'_M7QKM]9O U_2'L_-^NWTECEKWM[EY>U:]42_'?BUY$DM{[IITI[D)NGQ=6>N MC^]*&U6%/R-70=:SL(W/U0^XQ?ZFWJY<%T9WF M!_V#V]FG^_OUSM7$35_.^@M>?U\V-.J5L5V M?@3',7+)=>H9TM%A MO?X;[S@RJQ238%NN'N**%D\:.VQC MB/8Q'8>DT.Z#O6]IE"08-]('';;:A4(A!W@P-:U/A$.%'/(LA!4(:WV0]0+ MH[_*96?:0#4-BQQA[]MCR[!]@5TTOU+6]BY.-L?)@=13;QFJ?%Z)_*:&"W7^C M .\,%*I,%=[%$JD.R6$A[3FI/8^]1{&E+!T6-^)3>(+.D 1S(IB%'R5FL"U%MHW%X8%)_3+):XE_']#^=EG1^HU9OR<&0U!OS!UURGL[5_DZZ-=N8?IN",P3Q M;_H?FO#32$\W%\V1-\#W)^MGWL.<$6_8+_QXI1 %:B"=V]:Y\0#(K0WGA[)2 M+"7)1'ZZ?-.@^_49YV.,H]:-^/JL'[<[I"H$N!.$W*(7GJE%L7.75P7A.5\{O!E37+];<%]'}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`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

*{&'QPPI[P>+K0V05\CJZQ+4[L%X M0>@MM-"[" R=@!4*S ;B=&M[?1>5#>4W1#;P^C+8"]YCZ;7SN# MYB9#5@ –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l_5+KBSZ6F]6A8*4!<>97L.DX;9E3<4;5+ }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|\?=)C,9>'(_*%LFD@ YGS[] MOY,X9O472\YAMOO%O!@G^Z5LC-)U+,- S5[,Q'Y(D$U-B=M/$#_J[U[-D.)O[MNQ.&-\])C_&R&JQ{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|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|$8SN25RX=FYS C3@[&EYFCS./MJ A>RGI_ MN]<:F=/T:??IZ>]PWIX_/#W5]-%]]:_W!,C$PUKHGIT* Z0*LMX8MZ+69C? M4QLT">Q)6R8RY?BHUC&Z=^7A?'C6K?7/YL6S]E) (,_T1ZJ"GGQT_C9V[07M4 ML1I*K5U_N.Z U)%2ZW+G.RF$*!1XT@GAP M?NB-2E7IE^3TV#J1#W]'(SCTT+%*^!1:V:).F+A>IM;NG$S:NM.7>O>U M\6WG#)DT8@;F*Y6"G"Z>:6;;O1+U]IW7:!'[(U69DW]JC&NMWP^>OJ08KCSC2CJ<7MQ4%"U;O+GNS OF M!08,OK5:B(#_<:BUQ[GQ%O7=)_T]U]_> (]2",N"J^:E^()2'?3$MY\>;=*(.G>67*